field_name,form_name,title,element type,version,definition,short description,datatype,maximum character quantity,input restriction,minimum value,maximum value,permissible values,permissible value descriptions,permissible value output codes,Item Response OID,Element OID,unit of measure,guidelines/instructions,notes,preferred question text,keywords,references,population.all,domain.general (for all diseases),domain.traumatic brain injury,domain.Parkinson's disease,domain.Friedreich's ataxia,domain.stroke,domain.amyotrophic lateral sclerosis,domain.Huntington's disease,domain.multiple sclerosis,domain.neuromuscular diseases,domain.myasthenia gravis,domain.spinal muscular atrophy,domain.Duchenne muscular dystrophy/Becker muscular dystrophy,domain.congenital muscular dystrophy,domain.spinal cord injury,domain.headache,domain.epilepsy,classification.general (for all diseases),classification.acute hospitalized,classification.concussion/mild TBI,classification.epidemiology,classification.moderate/severe TBI: rehabilitation,classification.Parkinson's disease,classification.Friedreich's ataxia,classification.stroke,classification.amyotrophic lateral sclerosis,classification.Huntington's disease,classification.multiple sclerosis,classification.neuromuscular diseases,classification.myasthenia gravis,classification.spinal muscular atrophy,classification.Duchenne muscular dystrophy/Becker muscular dystrophy,classification.congenital muscular dystrophy,classification.spinal cord injury,classification.headache,classification.epilepsy,historical notes,Label(s),see also,submitting organization name,submitting contact name,submitting contact information,effective date,until date,steward organization name,steward contact name,steward contact information,creation date,last change date,administrative status,CAT OID,Form Item OID
AgeRemaindrMonths,,Age remainder in months,Unique Data Element,1.1,Remainder Value for participant's subject age when age in years (see Age in years) is recorded.,Remainder Value for participant's subject age when age in years (see Age in years) is recorded.,Numeric Values,NA,Free-Form Entry,0,11,NA,NA,NA,NA,NA,NA,NA,"For PDBP data, use in conjunction with Age in years. CDISC variables: DM=Demographics, SUPPDM= SUPPQUAL for Demographics, SC=Subject Characteristics, AGE, AGEU, AGETXT. For more information, refer to https://wiki.cdisc.org/pages/viewpage.action?pageId=32815150",NA,CDISC,No references available,Adult and Pediatric,Participant/Subject Characteristics.Demographics,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NIH/NINDS,NA,NA,NA,NA,NIH/NINDS,NA,NA,2014-04-01,2020-02-05,Published,NA,NA
AgeVal,,Age value,Common Data Element,1.5,"Value for participant/subject's age, calculated as elapsed time since the birth of the participant/subject. By default in months","Value for participant's subject age, calculated as elapsed time since the birth of the participant/subject. By default in months",Numeric Values,NA,Free-Form Entry,0,1800,NA,NA,NA,NA,NA,Month,"GENERAL/TBI: For children younger than one year born at less than 36 weeks gestation, it is recommended to also collect gestational age. Recording date of birth will give the most detailed information required for calculation of age and is recommended as first choice. However, in some studies recording date of birth may elicit discussions on a potential violation of privacy legislation and specifically HIPAA regulations. In these cases, the calculated age should be recorded.
MG/NMD/SMA: This is recorded for each brain MRI performed. This is a derived field from Date of Birth and Visit Date.
HEADACHE: It is recommended that age be calculated from date of birth and the study enrollment date. However, if age needs to be collected (e.g., full date of birth is not allowed to be collected) then it should be recorded in months and years. This element is recommended as Core for pediatric headache studies.
","Age value in months. CDISC variables: DM=Demographics, SUPPDM= SUPPQUAL for Demographics, SC=Subject Characteristics, AGE, AGEU, AGETXT. For more information, refer to https://wiki.cdisc.org/pages/viewpage.action?pageId=32815150",Age,CDISC,No references available,Adult and Pediatric,Participant/Subject Characteristics.Demographics,Disease/Injury Related Events.Classification;Participant/Subject Characteristics.Demographics,NA,NA,NA,NA,NA,NA,Assessments and Examinations.Imaging Diagnostics,Assessments and Examinations.Imaging Diagnostics,Assessments and Examinations.Imaging Diagnostics,NA,NA,NA,Participant/Subject Characteristics.Demographics,Assessments and Examinations.Non-Imaging Diagnostics,Supplemental,Basic,Basic,Supplemental,Supplemental,NA,NA,NA,NA,NA,NA,Supplemental,Supplemental,Supplemental,NA,NA,NA,Core,Supplemental,Age value,NA,AgeRange; AgeVal; AgeYrs; AlcUseStopAgeVal; AlcUseStrtAgeVal,NIH/NINDS,Olga Vovk,olga.vovk@nih.gov,NA,NA,NIH/NINDS,NINDSCDE,NINDSCDE@emmes.com,NA,2020-02-05,Published,NA,NA
AgeYrs,,Age in years,Common Data Element,1.9,"Value for participant's subject age, calculated as elapsed time since the birth of the participant/subject in years. The subjects age is typically recorded to the nearest full year completed, e.g. 11 years and 6 months should be recorded as 11 years.",Value for participant's subject age recorded in years.,Numeric Values,NA,Free-Form Entry,0,150,NA,NA,NA,NA,NA,NA,"The subject's age is typically recorded to the nearest full year completed, e.g. 11 years and 6 months should be recorded as 11 years. For subject's which are under 1 year old, use decimal points and use the following convention- record 1 month as 0.083 (1/12), 2 months as 0.166 (2/12), 3 months as 0.25 (3/12), 4 months as 0.333 (4/12), 5 months as 0.416 (5/12), 6 months as 0.5 (6/12), 7 months as 0.583 (7/12), 8 months as 0.666 (8/12), 9 months as 0.75 (9/12), 10 months as 0.833 (10/12), 11 months as 0.916 (11/12) and 12 months as 1 year. For the individuals 90 or older, in order to preserve PII, please submit ""150""  and make a note this in the ""general notes"" column.","CDISC variables: QNAM=MHAGE, MHAGE=Age at MH Event, QVAL contains the age with the appropriate unit (years)",Subject's age (recorded in years):,CDISC,No references available,Adult and Pediatric,Participant/Subject Characteristics.Demographics,NA,Participant/Subject Characteristics.Demographics,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,AgeRange; AgeVal; AgeYrs; AlcUseStopAgeVal; AlcUseStrtAgeVal,NIH/CIT/BRICS,Olga Vovk,olga.vovk@nih.gov,NA,NA,NIH/CIT/BRICS,Olga Vovk,olga.vovk@nih.gov,NA,2020-02-05,Published,NA,NA
GUID,,GUID,Common Data Element,1.5,Global Unique ID (GUID) which uniquely identifies a subject,Global Unique ID which uniquely identifies a subject,GUID,NA,Free-Form Entry,NA,NA,NA,NA,NA,NA,NA,NA,Enter  a unique GUID,"CDISC variables: USUBJID. For more information, refer to https://wiki.cdisc.org/display/SDTMIG33/Subject+Visits",Global Unique ID (GUID) which uniquely identifies the subject:,Imaging_Read;CDISC;Imaging,"Johnson, S.B., Whitney, G., McAuliffe, M., Wang, H., McCreedy, E., Rozenblit, L., and Evans, C.C. (2010). Using Global Unique identifiers to link autism collections. J. Am. Med. Inform. Assoc., in press. Published online July 17, 2010. 10.1136/jamia.2009.002063.",Adult and Pediatric,"Protocol Experience.Participant/Subject Identification, Eligibility, and Enrollment",Participant/Subject Characteristics.Demographics,Participant/Subject Characteristics.Demographics,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Supplemental,Supplemental,Supplemental,Supplemental,Supplemental,Supplemental,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NIH/NINDS,NINDSCDE,NINDSCDE@emmes.com,NA,NA,NIH/NINDS,NINDSCDE,NINDSCDE@emmes.com,2014-04-01,2020-02-05,Published,NA,NA
SiteName,,Site name,Common Data Element,1.6,The name of the site for the study,The name of the site for the study,Alphanumeric,255,Free-Form Entry,NA,NA,NA,NA,NA,NA,NA,NA,Enter the name of the study site,CDISC SITEID,Name of the site:,CDISC,No references available,Adult and Pediatric,"Protocol Experience.Participant/Subject Identification, Eligibility, and Enrollment",NA,Treatment/Intervention Data.Drugs,NA,NA,NA,NA,NA,Assessments and Examinations.Imaging Diagnostics,Assessments and Examinations.Imaging Diagnostics,Assessments and Examinations.Imaging Diagnostics,NA,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,NA,Supplemental,Supplemental,Supplemental,NA,NA,NA,NA,NA,Site name,NA,NA,NIH/NINDS,NINDSCDE,NINDSCDE@emmes.com,NA,NA,NIH/NINDS,NINDSCDE,NINDSCDE@emmes.com,NA,2020-02-05,Published,NA,NA
VisitDate,,Visit date,Common Data Element,1.6,Interview or visit date (actually the date when data in the form were captured),Actual interview or visit date,Date or Date & Time,NA,Free-Form Entry,NA,NA,NA,NA,NA,NA,NA,NA,"Record the date/time according to the ISO 8601, the International Standard for the representation of dates and times (http://www.iso.org/iso/home.html). The date/time should be recorded to the level of granularity known (e.g., year, year and month, complete date plus hours and minutes, etc.). Data Sharing Instructions: When date/time data are prepared for aggregation or sharing they should be converted to the format specified by ISO 8601, YYYY-MM-DDThh:mm:ss. Record, the date of interview or visit (actually the date when data in the form were captured)","NINDS: C17409. CDISC variables: VISITNUM, VISITDY, VISIT, SVSTDTC, SVENDTC. For more information, refer to https://wiki.cdisc.org/display/SDTMIG33/Subject+Visits.",Visit date:,CDISC,21 CFR 50.20 General requirements for informed consent A Guide to Informed Consent - Information Sheet: Guidance for Institutional Review Boards and Clinical Investigators Contents (http://www.fda.gov/RegulatoryInformation/Guidances/ucm126431.htm#general),Adult and Pediatric,"Protocol Experience.Participant/Subject Identification, Eligibility, and Enrollment",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Visit date,NA,VisitTyp,NIH/NINDS,NINDSCDE,NINDSCDE@emmes.com,NA,NA,NIH/NINDS,NINDSCDE,NINDSCDE@emmes.com,NA,2020-03-04,Published,NA,NA
VisitTypPDBP,,Parkinson's Disease Biomarker's Program (PDBP) - visit type,Unique Data Element,1.4,Parkinson's Disease Biomarker's Program (PDBP) - visit type,PDBP - visit type,Alphanumeric,NA,Single Pre-Defined Value Selected,NA,NA,12 months;18 months;24 months;30 months;36 months;42 months;48 months;54 months;60 months;6 months;72 months;Baseline;Screening,12 months;18 months;24 months;30 months;36 months;42 months;48 months;54 months;60 months;6 months;72 months;Baseline;Screening,1;2;3;4;5;6;7;8;9;10;11;112;13,NA,NA,NA,The type of visit from the visit types available for this particular study,CDISC variables CMENTPT=Visit Type from the CRF,NA,CDISC,No references available,Adult and Pediatric,NA,NA,Assessments and Examinations.Other Clinical Data,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NIH/NINDS,NINDSCDE,NINDSCDE@emmes.com,NA,NA,NIH/NINDS,NINDSCDE,NINDSCDE@emmes.com,2014-04-01,2020-02-05,Published,NA,NA
SubjectCaseInd,InclExclCriteria,Subject case indicator,Unique Data Element,1,Indicator of whether subject is a case,Indicator of whether subject is a case,Alphanumeric,NA,Single Pre-Defined Value Selected,NA,NA,No;Yes,No;Yes,0;1,NA,NA,NA,NA,NA,NA,NA,NA,Adult and Pediatric,"Protocol Experience.Participant/Subject Identification, Eligibility, and Enrollment",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2014-04-01,2014-04-01,Published,NA,NA
SubjectCaseInd,LBD InclusnXclusn,Subject case indicator,Unique Data Element,1,Indicator of whether subject is a case,Indicator of whether subject is a case,Alphanumeric,NA,Single Pre-Defined Value Selected,NA,NA,No;Yes,No;Yes,0;1,NA,NA,NA,NA,NA,NA,NA,NA,Adult and Pediatric,"Protocol Experience.Participant/Subject Identification, Eligibility, and Enrollment",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2014-04-01,2014-04-01,Published,NA,NA
SubjectCntrlInd,InclExclCriteria,Subject control indicator,Unique Data Element,1,Indicator of whether subject is a control,Indicator of whether subject is a control,Alphanumeric,NA,Single Pre-Defined Value Selected,NA,NA,No;Yes,No;Yes,0;1,NA,NA,NA,NA,NA,NA,NA,NA,Adult and Pediatric,"Protocol Experience.Participant/Subject Identification, Eligibility, and Enrollment",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2014-04-01,2014-04-01,Published,NA,NA
SubjectCntrlInd,LBD InclusnXclusn,Subject control indicator,Unique Data Element,1,Indicator of whether subject is a control,Indicator of whether subject is a control,Alphanumeric,NA,Single Pre-Defined Value Selected,NA,NA,No;Yes,No;Yes,0;1,NA,NA,NA,NA,NA,NA,NA,NA,Adult and Pediatric,"Protocol Experience.Participant/Subject Identification, Eligibility, and Enrollment",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2014-04-01,2014-04-01,Published,NA,NA
AdvEvntOthrActionTakenTyp,AdverseEvents,Adverse event other action taken type,Common Data Element,1.7,Type of action taken due to adverse event other than action taken with study intervention/ treatment,Type of action taken due to adverse event other than action taken with study intervention/ treatment,Alphanumeric,NA,Single Pre-Defined Value Selected,NA,NA,None;Non-Study Treatment Required,None;Non-Study Treatment Required,0;1,NA,NA,NA,"GENERAL/PD: Choose one. If treatment was required, then the corresponding treatment needs to be recorded on the Prior and Concomitant Medications CRF.",CDISC SDTM variables:  AEACNOTH,Other Action Taken,AE_Mapped;Adverse_Event,No references available,Adult and Pediatric,Safety Data.Adverse Events,NA,Treatment/Intervention Data.Surgeries and Other Procedures,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Adverse event other action taken type,NA,AdvEvntStdyIntrvntActTakenTyp,NIH/NINDS,NINDSCDE,NINDSCDE@emmes.com,NA,NA,NIH/NINDS,NINDSCDE,NINDSCDE@emmes.com,NA,2020-03-04,Published,NA,NA
AdvEvntRelatednessScalePDBP,AdverseEvents,Adverse event relatedness scale,Unique Data Element,1,Scale of the causality between the treatment modality/intervention and the specific adverse event,The scale of the causality between the treatment modality/intervention and the specific adverse event.,Alphanumeric,NA,Single Pre-Defined Value Selected,NA,NA,Definite;Possible;Probable;Unlikely;Unrelated,Definite;Possible;Probable;Unlikely;Unrelated,3;1;2;4;5,NA,NA,NA,"Choose one. Record the investigator's assessment as to whether there is at least a reasonable possibility that the AE is related to (or caused by) use of the study intervention.  Definitions for each of the relatedness responses should be supplied in the protocol.
",NA,NA,NA,NA,Adult and Pediatric,NA,NA,Disease/Injury Related Events.History of Disease/Injury Event,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Adverse event relatedness scale,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2014-04-09,2014-04-09,Published,NA,NA
AdvEvntStdyIntrvntActTakenTyp,AdverseEvents,Adverse event study intervention action taken type,Common Data Element,1.7,Type of action taken for adverse event in relation to study intervention,The type of action taken for adverse event in relation to study intervention.,Alphanumeric,NA,Single Pre-Defined Value Selected,NA,NA,None;Study Intervention Discontinued;Study Intervention Interrupted;Study Intervention Modified,None;Study Intervention Discontinued;Study Intervention Interrupted;Study Intervention Modified,0;1;2;3,NA,NA,NA,"GENERAL: Choose one. This CDE is only appropriate for clinical trials and should be removed from the CRF if a study does not have an intervention.
EPILEPSY: Choose one. If treatment was required, then the corresponding treatment needs to be recorded on the Prior and Concomitant Medications CRF.",CDISC SDTM variables:  AEACN,Action Taken with Study Intervention,AE_Mapped;Adverse_Event,No references available,Adult and Pediatric,Safety Data.Adverse Events,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Safety Data.Adverse Events,Supplemental,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Supplemental,Adverse event study intervention action taken type,NA,AdvrsEvntDuringStudyInd;AdvrsEvntSeverScale;AdvrsEvntStartDateTime;AdverseEvntEndDateTime;AdvrsEvntVerbatimTermText;SeriousAdvrsEvntInd;AdvEvntMedDRALowerLvlTermCode;AdvrsEvntCTCAELowLvlTermName;InjElapsedTime;s0:AdvEvntOthrActionTakenTyp,NIH/NINDS,NINDSCDE,NINDSCDE@emmes.com,NA,NA,NIH/NINDS,NINDSCDE,NINDSCDE@emmes.com,NA,2020-03-04,Published,NA,NA
AdverseEvntEndDateTime,AdverseEvents,Adverse event end date and time,Common Data Element,1.7,"Date (and time, if applicable and known) on which the adverse event discontinued/stopped","Date (and time, if applicable and known) on which the adverse event discontinued/stopped",Date or Date & Time,NA,Free-Form Entry,NA,NA,NA,NA,NA,NA,NA,NA,"GENERAL: Record the date (and time) the adverse event stopped or worsened. The date/time should be recorded to the level of granularity known (e.g., year, year and month, complete date plus hours and minutes, etc.) and in the format acceptable to the study database. If an AE worsens, record an end date/time and create a new AE record with a new start date/time and severity.
EPILEPSY: Record the date (and time) the adverse event stopped or worsened. If an AE worsens, record an end date and create a new AE record with a new start date and severity. Record the date/time according to the ISO 8601, the International Standard for the representation of dates and times (http: //www.iso.org/iso/home.html). The date/time should be recorded to the level of granularity known (e.g., year, year and month, complete date plus hours and minutes, etc.).",CDISC SDTM variables: AESTDTC Start Date/Time of Adverse Event,End Date,AE_Mapped;Adverse_Event,No references available,Adult and Pediatric,Safety Data.Adverse Events,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Safety Data.Adverse Events,Supplemental,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Supplemental,Adverse event end date and time,NA,AdvrsEvntDuringStudyInd;AdvrsEvntSeverScale;AdvrsEvntStartDateTime;AdvrsEvntVerbatimTermText;SeriousAdvrsEvntInd;AdvEvntMedDRALowerLvlTermCode;AdvrsEvntCTCAELowLvlTermName;InjElapsedTime,NIH/NINDS,NINDSCDE,NINDSCDE@emmes.com,NA,NA,NIH/NINDS,NINDSCDE,NINDSCDE@emmes.com,NA,2020-03-04,Published,NA,NA
AdvrsEvntDuringStudyInd,AdverseEvents,Adverse event during study indicator,Common Data Element,1.8,Indicator of whether the participant/subject experienced any adverse events during the study,Indicator of whether the participant/subject experienced any adverse events during the study,Alphanumeric,NA,Single Pre-Defined Value Selected,NA,NA,No;Unknown;Yes,No;Unknown;Yes,0;9;1,NA,NA,NA,"EPILEPSY/GENERAL: Choose one. If answered Yes, at least one AE must be recorded.","CDISC CDASH: AEYN. There is no relevant  SDTM CDISC variable, the suggestion is to use AESTDY - Study Day of Start of Adverse Event and AEENDY Study Day of End of Adverse Event.",Has the participant/subject had any adverse events during the study?,AE_Mapped;Adverse_Event,No references available,Adult and Pediatric,Safety Data.Adverse Events,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Safety Data.Adverse Events,Supplemental,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Supplemental,Adverse event during study indicator,NA,AdverseEventTrackNum;AdvrsEvntSeverScale;AdvrsEvntStartDateTime;AdverseEvntEndDateTime;AdvrsEvntOutcomStatus;AdvrsEvntVerbatimTermText;SeriousAdvrsEvntInd;AdvEvntMedDRALowerLvlTermCode;AdvrsEvntCTCAELowLvlTermName;InjElapsedTime,NIH/NINDS,NINDSCDE,NINDSCDE@emmes.com,NA,NA,NIH/NINDS,NINDSCDE,NINDSCDE@emmes.com,NA,2020-03-04,Published,NA,NA
AdvrsEvntOutcomStatus,AdverseEvents,Adverse event outcome status,Common Data Element,1.8,Final status of the participant/subject related to the adverse event,Final status of the participant/subject related to the adverse event,Alphanumeric,NA,Single Pre-Defined Value Selected,NA,NA,Fatal;Not Recovered/Not Resolved;Recovered/Resolved;Recovered/Resolved with Sequelae;Recovering/Resolving;Unknown,Fatal;Not Recovered/Not Resolved;Recovered/Resolved;Recovered/Resolved with Sequelae;Recovering/Resolving;Unknown,30;1;2;3;4;999,NA,NA,NA,"Choose one outcome. The outcome of an AE may not be captured at the visit during which it was first reported, but must eventually be captured to provide a complete picture of the event. Entering the outcome of an AE may be deferred until the AE is resolved, or the participant/subject completes the study. For AEs that have not resolved at the time of a study visit, the outcome should be marked as ""Not recovered/not resolved"" on the AE case report form.",CDISC SDTM variables: AEOUT,Outcome,AE_Mapped;Adverse_Event,No references available,Adult and Pediatric,Safety Data.Adverse Events,NA,Treatment/Intervention Data.Surgeries and Other Procedures,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Safety Data.Adverse Events,Supplemental,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Supplemental,Adverse event outcome status,NA,AdvrsEvntDuringStudyInd;AdvrsEvntExpecStatus;AdvrsEvntSeverScale;AdvrsEvntStartDateTime;AdverseEvntEndDateTime;AdvrsEvntVerbatimTermText;SeriousAdvrsEvntInd;AdvEvntMedDRALowerLvlTermCode;AdvrsEvntCTCAELowLvlTermName;InjElapsedTime,NIH/NINDS,NINDSCDE,NINDSCDE@emmes.com,NA,NA,NIH/NINDS,NINDSCDE,NINDSCDE@emmes.com,NA,2020-03-04,Published,NA,NA
AdvrsEvntSeverScale,AdverseEvents,Adverse event severity scale,Common Data Element,1.7,Scale of the severity or intensity of the adverse event,Scale of the severity or intensity of the adverse event,Alphanumeric,NA,Single Pre-Defined Value Selected,NA,NA,Fatal/Death;Life-Threatening/Disabling;Mild;Moderate;Severe,Fatal/Death;Life-Threatening/Disabling;Mild;Moderate;Severe,30;4;1;2;3,NA,NA,NA,"GENERAL: Choose the one severity that best describes the investigator's assessment of the intensity of the AE. The five severity grades are from the Common Terminology Criteria for Adverse Events v4.0 (CTCAE). Severe events interrupt the participant's/subject's normal daily activities and generally require systemic drug therapy or other treatment; they are usually incapacitating. Consequently, a change in severity may constitute a new reportable AE. Severity is not synonymous with seriousness. A severe rash is not likely to be an SAE. Likewise, a severe headache is not necessarily an SAE. However, mild chest pain may result in a day's hospitalization and thus is an SAE. It is helpful to define the severity categories in the protocol or Manual of Operations to obtain consistency in reporting across sites.
PD: Choose the one severity that best describes the investigator's assessment of the intensity of the AE. The five severity grades are from the Common Terminology Criteria for Adverse Events v4.0 (CTCAE). Severe events interrupt the participant's/subject's normal daily activities and generally require systemic drug therapy or other treatment; they are usually incapacitating. Consequently, a change in severity may constitute a new reportable AE. Severity is not synonymous with seriousness. A severe rash is not likely to be an SAE. Likewise, a severe headache is not necessarily an SAE. However, mild chest pain may result in a day's hospitalization and thus is an SAE. It is helpful to define the severity categories in the protocol or Manual of Operations to obtain consistency in reporting across sites.
EPILEPSY: Choose the one severity that best describes the investigator's assessment of the intensity of the AE. The five severity grades are from the Common Terminology Criteria for Adverse Events v4.0 (CTCAE). Severe events interrupt the participant's/subject's normal daily activities and generally require systemic drug therapy or other treatment; they are usually incapacitating. Consequently, a change in severity may constitute a new reportable AE. Severity is not synonymous with seriousness. A severe rash is not likely to be an SAE. Likewise, a severe headache is not necessarily an SAE. However, mild chest pain may result in a day's hospitalization and thus is an SAE. It is helpful to define the severity categories in the protocol or Manual of Operations to obtain consistency in reporting across sites.",CDISC SDTM variables:  AESEV,Severity,AE_Mapped;Adverse_Event,EPILEPSY/GENERAL/PD: Common Terminology Criteria for Adverse Events (CTCAE) v4.0 (http: //evs.nci.nih.gov/ftp1/CTCAE/About.html),Adult and Pediatric,Safety Data.Adverse Events,NA,Treatment/Intervention Data.Surgeries and Other Procedures,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Safety Data.Adverse Events,Supplemental,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Supplemental,Adverse event severity scale,NA,AdvrsEvntDuringStudyInd;AdvrsEvntStartDateTime;AdverseEvntEndDateTime;AdvrsEvntVerbatimTermText;SeriousAdvrsEvntInd;AdvEvntMedDRALowerLvlTermCode;AdvrsEvntCTCAELowLvlTermName;InjElapsedTime,NIH/NINDS,NINDSCDE,NINDSCDE@emmes.com,NA,NA,NIH/NINDS,NINDSCDE,NINDSCDE@emmes.com,NA,2020-03-04,Published,NA,NA
AdvrsEvntStartDateTime,AdverseEvents,Adverse event start date and time,Common Data Element,1.7,"Date (and time, if applicable and known) on which the adverse event was first evident","Date (and time, if applicable and known) on which the adverse event was first evident",Date or Date & Time,NA,Free-Form Entry,NA,NA,NA,NA,NA,NA,NA,NA,"GENERAL: Record the date (and time) the adverse event started. The date/time should be recorded to the level of granularity known (e.g., year, year and month, complete date plus hours and minutes, etc.) and in the format acceptable to the study database. If a previously recorded AE worsens, a new record should be created with a new start date/time. There should be no AE start date prior to the date of the informed consent. Any AE that started prior to the informed consent date belongs instead in the medical history. If an item recorded on the medical history worsens during the study, the date of the worsening is entered as an AE with the start date/time as the date/time the condition worsened.
EPILEPSY: Record the date (and time) the adverse event started. If a previously recorded AE worsens, a new record should be created with a new start date. There should be no AE start date prior to the date of the informed consent. Any AE that started prior to the informed consent date belongs instead in the medical history. If an item recorded on the medical history worsens during the study, the date of the worsening is entered as an AE with the start date as the date the condition worsened. Record the date/time according to the ISO 8601, the International Standard for the representation of dates and times (http: //www.iso.org/iso/home.html). The date/time should be recorded to the level of granularity known (e.g., year, year and month, complete date plus hours and minutes, etc.).",CDISC SDTM variables: AEENDTC End Date/Time of Adverse Event,Start Date,AE_Mapped;Adverse_Event,No references available,Adult and Pediatric,Safety Data.Adverse Events,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Safety Data.Adverse Events,Supplemental,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Supplemental,Adverse event start date and time,NA,AdvrsEvntDuringStudyInd;AdvrsEvntSeverScale;AdverseEvntEndDateTime;AdvrsEvntVerbatimTermText;SeriousAdvrsEvntInd;AdvEvntMedDRALowerLvlTermCode;AdvrsEvntCTCAELowLvlTermName;InjElapsedTime,NIH/NINDS,NINDSCDE,NINDSCDE@emmes.com,NA,NA,NIH/NINDS,NINDSCDE,NINDSCDE@emmes.com,NA,2020-03-04,Published,NA,NA
AdvrsEvntVerbatimTermText,AdverseEvents,Adverse event verbatim term text,Common Data Element,1.7,Text that describes the adverse event word for word as described by the participant/subject,Adverse event verbatim term text,Alphanumeric,4000,Free-Form Entry,NA,NA,NA,NA,NA,NA,NA,NA,"GENERAL: Any untoward medical occurrence in a study participant/subject that does not necessarily have a causal relationship with the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a study intervention or study procedure, whether or not related to the study intervention or procedure. Each AE should be listed on a separate line. Any worsening of a baseline condition or reoccurrence of a baseline condition that had previously ended for a time should be listed as an AE. Events, such as nausea and vomiting are considered two events, and therefore should be listed on separate lines. A participant/subject may experience an unexpected AE. An unexpected adverse reaction has a nature or severity of which is not consistent with the study intervention description (e.g. Investigator's Brochure for an unapproved investigational product or package insert/summary of product characteristics for an approved product). The unexpected AE must be reported, whether related to the study intervention or not, with as much detail as is available. See the Data Dictionary for additional information on coding the adverse events using either the Common Terminology Criteria for Adverse Events (CTCAE) or the Medical Dictionary for Regulatory Activities (MedDRA).
EPILEPSY: Any untoward medical occurrence in a study participant/subject that does not necessarily have a causal relationship with the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a study intervention or study procedure, whether or not related to the study intervention or procedure. Each AE should be listed on a separate line. Any worsening of a baseline condition or reoccurrence of a baseline condition that had previously ended for a time should be listed as an AE. Events, such as nausea and vomiting are considered two events, and therefore should be listed on separate lines. A participant/subject may experience an unexpected AE. An unexpected adverse reaction has a nature or severity of which is not consistent with the study intervention description (e.g. Investigator's Brochure for an unapproved investigational product or package insert/summary of product characteristics for an approved product). The unexpected AE must be reported, whether related to the study intervention or not, with as much detail as is available.",CDISC SDTM variables: AETERM,Adverse Event,AE_Mapped;Adverse_Event,No references available,Adult and Pediatric,Safety Data.Adverse Events,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Safety Data.Adverse Events,Supplemental,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Supplemental,Adverse event verbatim term text,NA,AdvrsEvntDuringStudyInd;AdvrsEvntSeverScale;AdvrsEvntStartDateTime;AdverseEvntEndDateTime;SeriousAdvrsEvntInd;AdvEvntMedDRALowerLvlTermCode;AdvrsEvntCTCAELowLvlTermName;InjElapsedTime,NIH/NINDS,NINDSCDE,NINDSCDE@emmes.com,NA,NA,NIH/NINDS,NINDSCDE,NINDSCDE@emmes.com,NA,2020-03-04,Published,NA,NA
AgeDiagnosRemaindrMonths,NeurologicalExam,Neurological examination age at diagnosis remainder in months,Unique Data Element,1,Remainder value for participant's subject age when age in years (see Age at diagnosis in years) is recorded,Remainder value for participant's subject age when age in years (see Age in years) is recorded,Numeric Values,NA,Single Pre-Defined Value Selected,NA,NA,0;1;10;11;2;3;4;5;6;7;8;9,0;1;10;11;2;3;4;5;6;7;8;9,0;1;10;11;2;3;4;5;6;7;8;9,NA,NA,NA,Use in conjunction with Age of diagnosis in years,No references available,Plus months,NA,NA,Adult and Pediatric,Participant/Subject Characteristics.Demographics,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2014-04-01,2014-04-01,Published,NA,NA
AgeDiagnosYrs,NeurologicalExam,Neurological examination age at diagnosis in years,Unique Data Element,1,"Value for participant's subject age, calculated as elapsed time since the birth of the participant/subject to time of diagnosis in years",Value for participant's subject age at time of diagnosis in years,Numeric Values,NA,Free-Form Entry,0,120,NA,NA,NA,NA,NA,NA,Enter the subject age in full years. Use in conjunction with Age of diagnosis in months,No references available,2b) Age at diagnosis,NA,NA,Adult and Pediatric,Participant/Subject Characteristics.Demographics,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2014-04-01,2014-04-01,Published,NA,NA
AlcConsume6MoreDrinkFreq,BehavioralHistory,Alcohol consume six or more drinks frequency,Common Data Element,1.2,"The rate of occurrence for when the participant/subject consumes six or more drinks containing alcohol on one occasion. It is noted that the meaning of &amp;quot;drinks consumed&amp;quot; differs from one nation and culture to another, so the most common alcoholic beverages likely to be consumed will be defined as well as quantity of each that constitutes a drink (approximately 10 grams of pure ethanol). For example, one bottle of beer (330 ml at 5% ethanol), a glass of wine (140 ml at 12% ethanol), and a shot of spirits (40 ml at 40% ethanol) represent a standard drink of about 13 g of ethanol.",The rate of occurrence for when the participant/subject consumes six or more drinks containing alcohol on one occasion. It is noted that the meaning of &amp;quot;drinks consumed&amp;quot; differs from one nation and culture to another.,Alphanumeric,NA,Single Pre-Defined Value Selected,NA,NA,Daily or almost daily;Less than monthly;Monthly;Never;Unknown;Weekly,Daily or almost daily;Less than monthly;Monthly;Never;Unknown;Weekly,1;2;3;0;999;4,NA,NA,NA,"GENERAL: Choose one. Response is obtained from participant/ subject, family member, friend, or chart/ medical record.
FA: Choose one. Response is obtained from participant/ subject, family member, friend, or chart/ medical record.
STROKE: History can be obtained from participant/ subject, family member, friend, or chart/ medical record.
MS: Choose one. Response is obtained from participant/ subject, family member, friend, or chart/ medical record. Unknown includes the scenario where information is not documented in the medical record. Current Guidelines for MS is incorrect: Choose one if currently drinks","Note: This question asks about ""drinks consumed"". The meaning of this word differs from one nation and culture to another. It is important therefore to mention the most common alcoholic beverages likely to be consumed and how much of each constitutes a drink (approximately 10 grams of pure ethanol). For example, one bottle of beer (330 ml at 5% ethanol), a glass of wine (140 ml at 12% ethanol), and a shot of spirits (40 ml at 40% ethanol) represent a standard drink of about 13 g of ethanol.",How often do you have six or more drinks on one occasion?,NA,No references available,Adult and Pediatric,Participant/Subject History and Family History.General Health History,NA,NA,Participant/Subject History and Family History.General Health History,Participant/Subject History and Family History.General Health History,NA,NA,Participant/Subject History and Family History.General Health History,NA,NA,NA,NA,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,NA,Supplemental,Supplemental,NA,NA,Supplemental,NA,NA,NA,NA,NA,NA,NA,NA,Alcohol consume six or more drinks frequency,NA,NA,NIH/NINDS,NINDSCDE,NINDSCDE@emmes.com,NA,NA,NIH/NINDS,NINDSCDE,NINDSCDE@emmes.com,NA,2015-09-24,Published,NA,NA
AlcCurntUseInd,BehavioralHistory,Alcohol current use indicator,Common Data Element,1.5,Indicator of whether the participant/subject consumed at least one alcoholic drink within the past 12 months,Indicator of whether the participant/subject consumed at least one alcoholic drink within the past 12 months,Alphanumeric,NA,Single Pre-Defined Value Selected,NA,NA,No;Unknown;Yes,No;Unknown;Yes,0;9;1,NA,NA,NA,"GENERAL: Choose one. Response is obtained from participant/ subject, family member, friend, or chart/ medical record.
FA: Consumed at least one drink within past year. Choose one. Response is obtained from participant/ subject, family member, friend, or chart/ medical record.
STROKE: History can be obtained from participant/ subject, family member, friend, or chart/ medical record. In the U.S., a single drink serving contains about 14 grams of ethanol or ""pure"" alcohol. Although the drinks below are different sizes, each one contains the same amount of pure alcohol and counts as a single drink: 12 oz. of beer (about %% alcohol) = 8-9 oz. of malt liquor (about 7% alcohol) = 5 oz. of wine (about 12% alcohol) = 1.5 oz. of hard liquor (about 40% alcohol)
MS: Choose one. Response is obtained from participant/ subject, family member, friend, or chart/ medical record. Unknown includes the scenario where information is not documented in the medical record. A current drinker is defined as consuming at least one drink within the past year. For MS: If ""Yes"" is answered, skip to question 3 History can be obtained from participant/ subject, family member, friend, or chart/ medical record. In the U.S., a single drink serving contains about 14 grams of ethanol or ""pure"" alcohol. Although the drinks below are different sizes, each one contains the same amount of pure alcohol and counts as a single drink: 12 oz. of beer (about %% alcohol) = 8-9 oz. of malt liquor (about 7% alcohol) = 5 oz. of wine (about 12% alcohol) = 1.5 oz. of hard liquor (about 40% alcohol)",NA,Is the family member of the participant/subject a current drinker,Medical_History,No references available,Adult and Pediatric,Participant/Subject History and Family History.General Health History,NA,NA,Participant/Subject History and Family History.General Health History,Participant/Subject History and Family History.General Health History,NA,NA,Participant/Subject History and Family History.General Health History,NA,NA,NA,NA,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,NA,Supplemental,Supplemental,NA,NA,Supplemental,NA,NA,NA,NA,NA,NA,NA,NA,Alcohol current use indicator,NA,NA,NIH/NINDS,NINDSCDE,NINDSCDE@emmes.com,NA,NA,NIH/NINDS,NINDSCDE,NINDSCDE@emmes.com,NA,2016-06-15,Published,NA,NA
AlcDrinkingDayAvgDrinks,BehavioralHistory,Alcohol drinking day average drinks consumed range,Common Data Element,1.2,"The counted number of drinks containing alcohol consumed by the participant/subject on a typical day when he/she is drinking. It is noted that the meaning of &amp;quot;drinks consumed&amp;quot; differs from one nation and culture to another, so the most common alcoholic beverages likely to be consumed will be defined as well as quantity of each that constitutes a drink (approximately 10 grams of pure ethanol). For example, one bottle of beer (330 ml at 5% ethanol), a glass of wine (140 ml at 12% ethanol), and a shot of spirits (40 ml at 40% ethanol) represent a standard drink of about 13 g of ethanol.",The counted number of drinks containing alcohol consumed by the participant/subject on a typical day when he/she is drinking. It is noted that the meaning of &amp;quot;drinks consumed&amp;quot; differs from one nation and culture to another.,Alphanumeric,NA,Single Pre-Defined Value Selected,NA,NA,"10 or more;1 or 2;3 or 4;5 or 6;7, 8, or 9;Unknown","10 or more;1 or 2;3 or 4;5 or 6;7, 8, or 9;Unknown",1;2;3;4;5;999,NA,NA,NA,"FA/GENERAL: Choose one. Response is obtained from participant/ subject, family member, friend, or chart/ medical record.
STROKE: History can be obtained from participant/ subject, family member, friend, or chart/ medical record.
MS: Choose one. Response is obtained from participant/ subject, family member, friend, or chart/ medical record. Unknown includes the scenario where information is not documented in the medical record.","Note: This question asks about ""drinks consumed"". The meaning of this word differs from one nation and culture to another. It is important therefore to mention the most common alcoholic beverages likely to be consumed and how much of each constitutes a drink (approximately 10 grams of pure ethanol). For example, one bottle of beer (330 ml at 5% ethanol), a glass of wine (140 ml at 12% ethanol), and a shot of ... more spirits (40 ml at 40% ethanol) represent a standard drink of about 13 g of ethanol.",How many alcoholic drinks do you have on a typical day when you are drinking?,NA,No references available,Adult and Pediatric,Participant/Subject History and Family History.General Health History,NA,NA,Participant/Subject History and Family History.General Health History,Participant/Subject History and Family History.General Health History,NA,NA,Participant/Subject History and Family History.General Health History,NA,NA,NA,NA,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,NA,Supplemental,Supplemental,NA,NA,Supplemental,NA,NA,NA,NA,NA,NA,NA,NA,Alcohol drinking day average drinks consumed range,NA,NA,NIH/NINDS,NINDSCDE,NINDSCDE@emmes.com,NA,NA,NIH/NINDS,NINDSCDE,NINDSCDE@emmes.com,NA,2015-09-24,Published,NA,NA
AlcPriorUseInd,BehavioralHistory,Alcohol prior use indicator,Common Data Element,1.4,Indicator of the participant's/subject's alcohol consumption prior to the past 12 months,Indicator of the participant's/subject's alcohol consumption prior to the past 12 months,Alphanumeric,NA,Single Pre-Defined Value Selected,NA,NA,No;Unknown;Yes,No;Unknown;Yes,0;9;1,NA,NA,NA,"GENERAL: Choose one. Response is obtained from participant/ subject, family member, friend, or chart/ medical record.
TBI: Choose one. Document when the behavioral history was collected so as to determine whether this information was obtained prior to study enrollment or later. Response is obtained by report of the participant/subject or proxy as soon as possible after visit/admission. Substance abuse directly before injury may have contributed to the incident causing injury. In general, substance abuse may indicate increased risk taking behavior.
FA: Consumed at least one drink prior to the past year. Choose one. Response is obtained from participant/ subject, family member, friend, or chart/ medical record.
STROKE: History can be obtained from participant/ subject, family member, friend, or chart/ medical record.
MS: Choose one. Document when the behavioral history was collected so as to determine whether this information was obtained prior to study enrollment or later. Response is obtained by report of the participant/subject or proxy as soon as possible after visit/admission. Substance abuse directly before injury may have contributed to the incident causing injury. In general, substance abuse may indicate increased risk taking behavior. For MS: If ""No"" is answered, skip to Drug section",NA,Is the family member of the participant/subject a past drinker?,Medical_History,No references available,Adult and Pediatric,Participant/Subject History and Family History.General Health History,Participant/Subject History and Family History.General Health History,NA,Participant/Subject History and Family History.General Health History,Participant/Subject History and Family History.General Health History,NA,NA,Participant/Subject History and Family History.General Health History,NA,NA,NA,NA,NA,NA,NA,NA,Supplemental,Supplemental,Supplemental,Supplemental,Supplemental,NA,Supplemental,Supplemental,NA,NA,Supplemental,NA,NA,NA,NA,NA,NA,NA,NA,Alcohol prior use indicator,NA,NA,NIH/NINDS,NINDSCDE,NINDSCDE@emmes.com,NA,NA,NIH/NINDS,NINDSCDE,NINDSCDE@emmes.com,NA,2016-06-15,Published,NA,NA
AlcRcntUseIndPDBP,BehavioralHistory,Alcohol recent use indicator,Unique Data Element,1,Indicator of whether the participant/subject consumed at least one alcoholic drink within the past 12 months,Participant (subject) alcohol consumption past 12 months,Alphanumeric,NA,Single Pre-Defined Value Selected,NA,NA,No;Unknown;Yes,No;Unknown;Yes,0;9;1,NA,NA,NA,"Choose one. Response is obtained from participant/ subject, family member, friend, or chart/ medical record.",NA,NA,NA,NA,Adult and Pediatric,NA,NA,Participant/Subject History and Family History.Epidemiology/Environmental History,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2014-04-09,2014-04-09,Published,NA,NA
AlcUseFreq,BehavioralHistory,Alcohol use frequency,Common Data Element,1.2,The frequency of consumption of alcohol by the participant.,The frequency of consumption of alcohol by the participant.,Alphanumeric,NA,Single Pre-Defined Value Selected,NA,NA,2 to 3 times a week;2 to 4 times a month;4 or more times a week;Monthly or less;Never;Unknown,2 to 3 times a week;2 to 4 times a month;4 or more times a week;Monthly or less;Never;Unknown,1;2;3;4;0;999,NA,NA,NA,"GENERAL: Choose one. Response is obtained from participant/ subject, family member, friend, or chart/ medical record.
FA: Choose one. Response is obtained from participant/ subject, family member, friend, or chart/ medical record.
STROKE: History can be obtained from participant/ subject, family member, friend, or chart/ medical record.
MS: Choose one. If ""Never"" is answered, skip to ""Have you ever been hospitalized for an alcohol related problem"". In some cases, response is obtained from participant/ subject, family member, friend, or chart/ medical record. Unknown includes the scenario where information is not documented in the medical record.",NA,How often do you have a drink containing alcohol?,NA,No references available,Adult and Pediatric,Participant/Subject History and Family History.General Health History,NA,NA,Participant/Subject History and Family History.General Health History,Participant/Subject History and Family History.General Health History,NA,NA,Participant/Subject History and Family History.General Health History,NA,NA,NA,NA,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,NA,Core,Core,NA,NA,Supplemental,NA,NA,NA,NA,NA,NA,NA,NA,Alcohol use frequency,NA,NA,NIH/NINDS,NINDSCDE,NINDSCDE@emmes.com,NA,NA,NIH/NINDS,NINDSCDE,NINDSCDE@emmes.com,NA,2015-09-24,Published,NA,NA
AlcUseRelatedHospInd,BehavioralHistory,Alcohol use related to hospitalization indicator,Common Data Element,1.3,"Indicator of whether the participant/subject has been hospitalized for an alcohol-related problem (i.e., esophageal varices, delirium tremens (DTs), cirrhosis and others)","Indicator of whether the participant/subject has been hospitalized for an alcohol-related problem (i.e., esophageal varices, delirium tremens (DTs), cirrhosis and others)",Alphanumeric,NA,Single Pre-Defined Value Selected,NA,NA,No;Unknown;Yes,No;Unknown;Yes,0;9;1,NA,NA,NA,"GENERAL: Choose one. Response is obtained from participant/ subject, family member, friend, or chart/ medical record.
FA: E.g., esophageal varices delirium tremens (DTs), cirrhosis, etc. Choose one. Response is obtained from participant/ subject, family member, friend, or chart/ medical record.
STROKE: History can be obtained from participant/ subject, family member, friend, or chart/ medical record.
MS: Choose one. Response is obtained from participant/ subject, family member, friend, or chart/ medical record. Unknown includes the scenario where information is not documented in the medical record.",NA,Have you ever been hospitalized for an alcohol-related problem?,Medical_History,No references available,Adult and Pediatric,Participant/Subject History and Family History.General Health History,NA,NA,Participant/Subject History and Family History.General Health History,Participant/Subject History and Family History.General Health History,NA,NA,Participant/Subject History and Family History.General Health History,NA,NA,NA,NA,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,NA,Supplemental,Supplemental,NA,NA,Supplemental,NA,NA,NA,NA,NA,NA,NA,NA,Alcohol use related to hospitalization indicator,NA,NA,NIH/NINDS,NINDSCDE,NINDSCDE@emmes.com,NA,NA,NIH/NINDS,NINDSCDE,NINDSCDE@emmes.com,NA,2016-03-07,Published,NA,NA
AlcUseStopAgeVal,BehavioralHistory,Alcohol use stopped age value,Common Data Element,1.5,"Age in years when participant/subject stopped ingesting alcoholic beverages, including social drinking","Age in years when participant/subject stopped ingesting alcoholic beverages, including social drinking",Numeric Values,NA,Free-Form Entry,0,120,NA,NA,NA,NA,NA,Year,"GENERAL: History can be obtained from participant/ subject, family member, friend, or chart/ medical record.
FA: Skip if ""Alcohol current use indicator"" and ""Alcohol prior use indicator"" are both ""NO"". Can be obtained from participant/ subject, family member, friend, or chart/ medical record.
MS/STROKE: History can be obtained from participant/ subject, family member, friend, or chart/ medical record. The age in years should be collected or N/A (Not applicable if subject never smoked) should be selected.",NA,Age quit drinking,Medical_History,No references available,Adult and Pediatric,Participant/Subject History and Family History.General Health History,NA,NA,Participant/Subject History and Family History.General Health History,Participant/Subject History and Family History.General Health History,NA,NA,Participant/Subject History and Family History.General Health History,NA,NA,NA,NA,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,NA,Supplemental,Supplemental,NA,NA,Supplemental,NA,NA,NA,NA,NA,NA,NA,NA,Alcohol use stopped age value,NA,AgeRange; AgeVal; AgeYrs; AlcUseStopAgeVal; AlcUseStrtAgeVal,NIH/NINDS,NINDSCDE,NINDSCDE@emmes.com,NA,NA,NIH/NINDS,NINDSCDE,NINDSCDE@emmes.com,NA,2019-10-31,Published,NA,NA
AlcUseStrtAgeVal,BehavioralHistory,Alcohol use started age value,Common Data Element,1.5,"Age in years when participant/subject started ingesting alcoholic beverages, including social drinking","Age in years when participant/subject started ingesting alcoholic beverages, including social drinking",Numeric Values,NA,Free-Form Entry,0,120,NA,NA,NA,NA,NA,Year,"GENERAL/MS: History can be obtained from participant/ subject, family member, friend, or chart/ medical record.
FA: Skip if ""Alcohol current use indicator"" and ""Alcohol prior use indicator"" are both ""NO"". History can be obtained from participant/ subject, family member, friend, or chart/ medical record.
STROKE: History can be obtained from participant/ subject, family member, friend, or chart/ medical record. The age in years should be collected or N/A (Not applicable if subject never smoked) should be selected.",NA,Age started drinking,Medical_History,No references available,Adult and Pediatric,Participant/Subject History and Family History.General Health History,NA,NA,Participant/Subject History and Family History.General Health History,Participant/Subject History and Family History.General Health History,NA,NA,Participant/Subject History and Family History.General Health History,NA,NA,NA,NA,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,NA,Supplemental,Supplemental,NA,NA,Supplemental,NA,NA,NA,NA,NA,NA,NA,NA,Alcohol use started age value,NA,AgeRange; AgeVal; AgeYrs; AlcUseStopAgeVal; AlcUseStrtAgeVal,NIH/NINDS,NINDSCDE,NINDSCDE@emmes.com,NA,NA,NIH/NINDS,NINDSCDE,NINDSCDE@emmes.com,NA,2019-10-31,Published,NA,NA
BldPressrDiastlMeasr,Vital Signs,Blood pressure diastolic measurement,Common Data Element,1.4,Measurement of pressure of the participant's/subject's blood against the artery walls during diastole (the relaxation phase) in millimeters of mercury (mmHg),Measurement of pressure of the participant's/subject's blood against the artery walls during diastole (the relaxation phase) in millimeters of mercury (mmHg),Numeric Values,NA,Free-Form Entry,0,300,NA,NA,NA,NA,NA,Millimeters of Mercury,"GENERAL/ALS/MG/NMD/SMA/EPILEPSY/STROKE/DMD: Record the diastolic blood pressure of the participant/ subject. The standard unit for measuring blood pressure is mmHg, which is approximately equivalent to Torr.
TBI/TBIACUTE/TBIEPID/TBIMILD/TBIMOD/MS: Record blood pressure from the blood pressure monitor or measure manually by sphygmanometry. The suggested range is 0-300 mmHg. Add date stamp for when assessed.When hourly values are documented, we recommend to take readings at a fixed time point, for example the last minute of the hour. Exclude values which may be influenced by artifacts. Add date stamp for when assessed. The injured brain is often not able to pressure autoregulate normally, adequate perfusion may be more dependent on perfusion pressure; lower blood pressure and low perfusion pressure can aggravate ischemic damage to the injured brain whilst conversely a high blood pressure may lead to increased intracranial pressure and carries an increased risk of neurogenic lung edema. Hypotensive episodes before and after admission adversely affect outcome. In patients with severe traumatic brain injury, routine calculation of the cerebral perfusion pressure on an hourly basis is recommended. Pediatric-specific notes: As a minimum, vital signs should be recorded on admission and further, on a daily basis during the acute phase after injury. For the Core datasets, we recommend recording the average and lowest blood pressure over a given period. In the ICU environment, recording blood pressure on an hourly basis is recommended, especially when intracranial pressure (ICP) is monitored in order to permit determination of CPP, calculated as mean arterial blood pressure (MABP) - ICP (intermediate data set).
SCI: Answer for the past week. Record the patient's blood pressure, height and weight on the scoring form.
FA: Record the systolic and diastolic blood pressure (systolic / diastolic) of the participant/ subject.
HEADACHE: Measure in mmHg. The preferred position for measuring blood pressure is sitting. Blood pressure is the ratio of systolic to diastolic. It is recommended that standard operating procedures be developed for measuring blood pressure in your study. The Atherosclerosis Risk in Communities (ARIC) and Multi-Ethnic Study of Atherosclerosis (MESA) studies offer examples on their Websites of the procedures they used for measuring blood pressure. Both of these studies measured blood pressure more than once (e.g., three times) at a given study visit. Please refer to the manuals posted on http: //www.cscc.unc.edu/aric and http: //www.mesa-nhbi.org/","CDISC variable: Vital Signs Test Code (VSTESTCD), Units for Vital Signs Results (VSRESU), Vital Signs Test Name (VSTEST), DIABP",Diastolic blood pressure,Vital_Signs,No references available,Adult and Pediatric,Assessments and Examinations.Vital Signs and Other Body Measures,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Blood pressure diastolic measurement,NA,NA,NIH/CIT/BRICS,Olga Vovk,olga.vovk@nih.gov,NA,NA,NIH/NINDS,NINDSCDE,NINDSCDE@emmes.com,NA,2018-04-18,Published,NA,NA
BldPressrMeasrPositionTyp,Vital Signs,Blood pressure measurement position type,Common Data Element,1.2,Indicator of the participant/subject's position during the blood pressure measurement.,Indicator of the participant/subject's position during the blood pressure measurement.,Alphanumeric,NA,Single Pre-Defined Value Selected,NA,NA,Sitting;Standing;Supine;Unknown,Sitting;Standing;Supine;Unknown,1;2;3;999,NA,NA,NA,"EPILEPSY/FA/GENERAL/STROKE: Record the position the participant/ subject was in when the blood pressure was measured.
SCI: Choose one. Cardiovascular parameters are affected by the position of the individual during the testing. For example blood pressure could decrease due to sitting or standing position. Therefore it is important to document the individual's position during testing.
ALS: Record the position the participant/ subject was in when blood pressure was taken.
DMD/MG/NMD/SMA: Record the position the participant/ subject was in when the blood pressure was measured. Standing blood pressure is an optional element and should only be recorded as needed
MS: Record the position the participant/ subject was in when the blood pressure was measured. Choose one. Cardiovascular parameters are affected by the position of the individual during the testing. For example blood pressure could decrease due to sitting or standing position. Therefore it is important to document the individual's position during testing.
HEADACHE: Record the position the participant/ subject was in when the blood pressure was measured. Sitting position preferred.",SCI Variable: TSTPOSIT,Position during testing,Vital_Signs,No references available,Adult and Pediatric,Assessments and Examinations.Vital Signs and Other Body Measures,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Blood pressure measurement position type,NA,NA,NIH/CIT/BRICS,Olga Vovk,olga.vovk@nih.gov,NA,NA,NIH/NINDS,NINDSCDE,NINDSCDE@emmes.com,NA,2018-04-18,Published,NA,NA
BldPressrSystMeasr,Vital Signs,Blood pressure systolic measurement,Common Data Element,1.4,Measurement of pressure of the participant's/subject's blood against the artery walls during systole (the contraction phase) in millimeters of mercury (mmHg),Measurement of pressure of the participant's/subject's blood against the artery walls during systole (the contraction phase) in millimeters of mercury (mmHg),Numeric Values,NA,Free-Form Entry,0,300,NA,NA,NA,NA,NA,Millimeters of Mercury,"GENERAL/ALS/MG/NMD/SMA/EPILEPSY/STROKE/DMD: 
Record the diastolic blood pressure of the participant/ subject. The standard unit for measuring blood pressure is mmHg, which is approximately equivalent to Torr.
TBI/TBIACUTE/TBIEPID/TBIMILD/TBIMOD/MS: Record blood pressure from the blood pressure monitor or measure manually by sphygmanometry. The suggested range is 0-300 mmHg. Add date stamp for when assessed.When hourly values are documented, we recommend to take readings at a fixed time point, for example the last minute of the hour. Exclude values which may be influenced by artifacts. Add date stamp for when assessed. The injured brain is often not able to pressure autoregulate normally, adequate perfusion may be more dependent on perfusion pressure; lower blood pressure and low perfusion pressure can aggravate ischemic damage to the injured brain whilst conversely a high blood pressure may lead to increased intracranial pressure and carries an increased risk of neurogenic lung edema. Hypotensive episodes before and after admission adversely affect outcome. In patients with severe traumatic brain injury, routine calculation of the cerebral perfusion pressure on an hourly basis is recommended. Pediatric-specific notes: As a minimum, vital signs should be recorded on admission and further, on a daily basis during the acute phase after injury. For the Core datasets, we recommend recording the average and lowest blood pressure over a given period. In the ICU environment, recording blood pressure on an hourly basis is recommended, especially when intracranial pressure (ICP) is monitored in order to permit determination of CPP, calculated as mean arterial blood pressure (MABP) - ICP (intermediate data set).
SCI: Answer for the past week. Record the patient's blood pressure, height and weight on the scoring form.
FA: Record the systolic and diastolic blood pressure (systolic / diastolic) of the participant/ subject.
HEADACHE: Measure in mmHg. The preferred position for measuring blood pressure is sitting. Blood pressure is the ratio of systolic to diastolic. It is recommended that standard operating procedures be developed for measuring blood pressure in your study. The Atherosclerosis Risk in Communities (ARIC) and Multi-Ethnic Study of Atherosclerosis (MESA) studies offer examples on their Websites of the procedures they used for measuring blood pressure. Both of these studies measured blood pressure more than once (e.g., three times) at a given study visit. Please refer to the manuals posted on http: //www.cscc.unc.edu/aric and http: //www.mesa-nhbi.org/","CDISC variable: Vital Signs Test Code (VSTESTCD), Units for Vital Signs Results (VSRESU), Vital Signs Test Name (VSTEST), SYSBP",Systolic blood pressure,Vital_Signs,No references available,Adult and Pediatric,Assessments and Examinations.Vital Signs and Other Body Measures,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Blood pressure systolic measurement,NA,NA,NIH/CIT/BRICS,Olga Vovk,olga.vovk@nih.gov,NA,NA,NIH/NINDS,NINDSCDE,NINDSCDE@emmes.com,NA,2018-04-18,Published,NA,NA
BloodCollCentrifDateTime,BloodCollection,Blood Collection Data Form - Date and time of centrifugation,Unique Data Element,1,Date and time when blood sample was centrifuged,Date and time when blood sample was centrifuged,Date or Date & Time,NA,Free-Form Entry,NA,NA,NA,NA,NA,NA,NA,NA,Specify the date and time the sample was centrifuged,NA,Date and time of centrifugation,sample;Sample,NA,Adult,NA,NA,Assessments and Examinations.Laboratory Tests and Biospecimens/Biomarkers,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NIH/CIT/BRICS,Linde Jenna,jenna.linde@nih.gov,NA,NA,NIH/CIT/BRICS,Olga Vovk,olga.vovk@nih.gov,2016-04-25,2016-04-25,Published,NA,NA
BloodCollectCentrifugationDur,BloodCollection,Blood Collection Data Form - Duration of centrifugation,Unique Data Element,1,Duration of the blood sample centrifugation in minutes,Duration of the blood sample centrifugation in minutes,Numeric Values,NA,Free-Form Entry,NA,NA,NA,NA,NA,NA,NA,NA,Specify the duration of the centrifugation.,NA,Duration of Centrifugation (minutes),sample;Sample,NA,Adult,NA,NA,Assessments and Examinations.Laboratory Tests and Biospecimens/Biomarkers,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NIH/CIT/BRICS,Linde Jenna,jenna.linde@nih.gov,NA,NA,NIH/CIT/BRICS,Olga Vovk,olga.vovk@nih.gov,2016-04-25,2016-04-25,Published,NA,NA
BloodCollectDateTime,BloodCollection,Blood Collection Data Form - Date and time blood data collected,Unique Data Element,1,Date and time blood was collected.,Date and time blood was collected.,Date or Date & Time,NA,Free-Form Entry,NA,NA,NA,NA,NA,NA,NA,NA,Specify the date blood was collected.,NA,Date and time blood sample was collcted?,sample;Sample,NA,Adult,NA,NA,Assessments and Examinations.Laboratory Tests and Biospecimens/Biomarkers,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NIH/CIT/BRICS,Linde Jenna,jenna.linde@nih.gov,NA,NA,NIH/CIT/BRICS,Olga Vovk,olga.vovk@nih.gov,2016-04-25,2016-04-25,Published,NA,NA
BloodCollectInd,BloodCollection,Blood Collection Data Form - Blood collected,Unique Data Element,1,Indicator that the blood sample was collected from the subject,Indicator that the blood sample was collected from the subject,Alphanumeric,NA,Single Pre-Defined Value Selected,NA,NA,No;Yes,No;Yes,0;1,NA,NA,NA,Indicate if the blood sample was collected.,NA,Was the sample collected?,sample;Sample,NA,Adult,NA,NA,Assessments and Examinations.Laboratory Tests and Biospecimens/Biomarkers,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NIH/CIT/BRICS,Linde Jenna,jenna.linde@nih.gov,NA,NA,NIH/CIT/BRICS,Olga Vovk,olga.vovk@nih.gov,2016-04-25,2016-04-25,Published,NA,NA
BloodCollectVol,BloodCollection,Blood Collection Data Form - Blood volume collected,Unique Data Element,1,The volume of the blood samples that was collected.,The volume of the blood samples that was collected.,Numeric Values,NA,Free-Form Entry,0,10,NA,NA,NA,NA,NA,NA,Specify the volume that was collected.,NA,Volume of blood collected (ml),sample;Sample,NA,Adult,NA,NA,Assessments and Examinations.Laboratory Tests and Biospecimens/Biomarkers,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NIH/CIT/BRICS,Linde Jenna,jenna.linde@nih.gov,NA,NA,NIH/CIT/BRICS,Olga Vovk,olga.vovk@nih.gov,2016-04-25,2016-04-25,Published,NA,NA
CSFCollectedInd,BloodCollection,Blood Collection Data Form - CSF sample collected,Unique Data Element,1,Indicator that the CSF sample was collected from the subject,Indicator that the CSF sample was collected from the subject,Alphanumeric,NA,Single Pre-Defined Value Selected,NA,NA,No;Yes,No;Yes,0;1,NA,NA,NA,Indicate if the CSF sample was collected.,NA,Was the CSF sample collected?,sample;Sample,NA,Adult,NA,NA,Assessments and Examinations.Laboratory Tests and Biospecimens/Biomarkers,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NIH/CIT/BRICS,Linde Jenna,jenna.linde@nih.gov,NA,NA,NIH/CIT/BRICS,Olga Vovk,olga.vovk@nih.gov,2016-04-25,2016-04-25,Published,NA,NA
CentrifgRate,BloodCollection,Centrifugation rate,Unique Data Element,1,Rate of centrifugation,Rate of centrifugation,Numeric Values,NA,Free-Form Entry,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,No references available,Adult and Pediatric,Assessments and Examinations.Laboratory Tests and Biospecimens/Biomarkers,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2014-04-01,2014-04-01,Published,NA,NA
CranlNervCentralScotomaLoc,NeurologicalExam,Cranial nerves II-XII central scotoma location(s),Unique Data Element,1,Cranial nerves II-XII area(s) of central scotoma,Cranial nerves II-XII area(s) of central scotoma,Alphanumeric,NA,Single Pre-Defined Value Selected,NA,NA,Bilateral;Left;Not Applicable;Not assessed;Right,Bilateral;Left;Normal;Not assessed;Right,6;4;777;222;5,NA,NA,NA,Select one.,PDBD Neurolocial Examination Form,5f-iii) Central scotoma,NA,NA,Adult and Pediatric,Assessments and Examinations.Physical/Neurological Examination,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2014-04-01,2014-04-01,Published,NA,NA
CranlNervDiscPallorFind,NeurologicalExam,Cranial nerves II-XII disc pallor findings,Unique Data Element,1,Cranial nerves II-XII disc pallor findings,Cranial nerves II-XII disc pallor findings,Alphanumeric,NA,Single Pre-Defined Value Selected,NA,NA,Bilateral;Left;Normal;Not assessed;Right,Bilateral;Left;Normal;Not assessed;Right,6;4;20;222;5,NA,NA,NA,Select one.,PDBD Neurolocial Examination Form,5c) Disc pallor,NA,NA,Adult and Pediatric,Assessments and Examinations.Physical/Neurological Examination,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2014-04-01,2014-04-01,Published,NA,NA
CranlNervExamFind,NeurologicalExam,Cranial nerves II-XII examination findings,Unique Data Element,1,Cranial nerves II-XII examination findings,Cranial nerves II-XII examination findings,Alphanumeric,NA,Single Pre-Defined Value Selected,NA,NA,Abnormal;Normal;Not assessed,Abnormal;Normal;Not assessed,10;20;222,NA,NA,NA,Select one.,PDBD Neurolocial Examination Form,5) Cranial nerves II-XII examination,NA,NA,Adult and Pediatric,Assessments and Examinations.Physical/Neurological Examination,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2014-04-01,2014-04-01,Published,NA,NA
CranlNervEyeMovmntDownFind,NeurologicalExam,Cranial nerves II-XII eye movements down findings,Unique Data Element,1,Cranial nerves II-XII eye movements down findings,Cranial nerves II-XII eye movements down findings,Alphanumeric,NA,Single Pre-Defined Value Selected,NA,NA,Bilateral;Left;Normal;Not assessed;Nystagmus;Right,Bilateral;Left;Normal;Not assessed;Nystagmus;Right,6;4;20;222;1;5,NA,NA,NA,Select one.,PDBD Neurolocial Examination Form,5g-iv) Down,NA,NA,Adult and Pediatric,Assessments and Examinations.Physical/Neurological Examination,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2014-04-01,2014-04-01,Published,NA,NA
CranlNervEyeMovmntFind,NeurologicalExam,Cranial nerves II-XII eye movements findings,Unique Data Element,1,Cranial nerves II-XII eye movements findings,Cranial nerves II-XII eye movements findings,Alphanumeric,NA,Single Pre-Defined Value Selected,NA,NA,Abnormal;Normal;Not assessed,Abnormal;Normal;Not assessed,10;20;222,NA,NA,NA,Select one.,PDBD Neurolocial Examination Form,5g) Eye movements,NA,NA,Adult and Pediatric,Assessments and Examinations.Physical/Neurological Examination,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2014-04-01,2014-04-01,Published,NA,NA
CranlNervEyeMovmntLatFind,NeurologicalExam,Cranial nerves II-XII eye movements lateral findings,Unique Data Element,1,Cranial nerves II-XII eye movements lateral findings,Cranial nerves II-XII eye movements lateral findings,Alphanumeric,NA,Single Pre-Defined Value Selected,NA,NA,Bilateral;Left;Normal;Not assessed;Nystagmus;Right,Bilateral;Left;Normal;Not assessed;Nystagmus;Right,6;4;20;222;1;5,NA,NA,NA,Select one.,PDBD Neurolocial Examination Form,5g-i) Lateral,NA,NA,Adult and Pediatric,Assessments and Examinations.Physical/Neurological Examination,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2014-04-01,2014-04-01,Published,NA,NA
CranlNervEyeMovmntMedialFind,NeurologicalExam,Cranial nerves II-XII eye movements medial findings,Unique Data Element,1,Cranial nerves II-XII eye movements medial findings,Cranial nerves II-XII eye movements medial findings,Alphanumeric,NA,Single Pre-Defined Value Selected,NA,NA,Bilateral;Left;Normal;Not assessed;Nystagmus;Right,Bilateral;Left;Normal;Not assessed;Nystagmus;Right,6;4;20;222;1;5,NA,NA,NA,Select one.,PDBD Neurolocial Examination Form,5g-ii) Medial,NA,NA,Adult and Pediatric,Assessments and Examinations.Physical/Neurological Examination,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2014-04-01,2014-04-01,Published,NA,NA
CranlNervEyeMovmntSaccadesFind,NeurologicalExam,Cranial nerves II-XII eye movements saccades findings,Unique Data Element,1,Cranial nerves II-XII eye movements saccades findings,Cranial nerves II-XII eye movements saccades findings,Alphanumeric,NA,Single Pre-Defined Value Selected,NA,NA,Bilateral;Left;Normal;Not assessed;Right,Bilateral;Left;Normal;Not assessed;Right,6;4;20;222;5,NA,NA,NA,Select one.,PDBD Neurolocial Examination Form,5g-v) Saccades,NA,NA,Adult and Pediatric,Assessments and Examinations.Physical/Neurological Examination,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2014-04-01,2014-04-01,Published,NA,NA
CranlNervEyeMovmntSmoothPur,NeurologicalExam,Cranial nerves II-XII eye movements smooth pursuit findings,Unique Data Element,1,Cranial nerves II-XII eye movements smooth pursuit findings,Cranial nerves II-XII eye movements smooth pursuit findings,Alphanumeric,NA,Single Pre-Defined Value Selected,NA,NA,Bilateral;Left;Normal;Not assessed;Right,Bilateral;Left;Normal;Not assessed;Right,6;4;20;222;5,NA,NA,NA,Select one.,PDBD Neurolocial Examination Form,5g-vi) Smooth pursuit,NA,NA,Adult and Pediatric,Assessments and Examinations.Physical/Neurological Examination,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2014-04-01,2014-04-01,Published,NA,NA
CranlNervEyeMovmntUpFind,NeurologicalExam,Cranial nerves II-XII eye movements up findings,Unique Data Element,1,Cranial nerves II-XII eye movements up findings,Cranial nerves II-XII eye movements up findings,Alphanumeric,NA,Single Pre-Defined Value Selected,NA,NA,Bilateral;Left;Normal;Not assessed;Nystagmus;Right,Bilateral;Left;Normal;Not assessed;Nystagmus;Right,6;4;20;222;1;5,NA,NA,NA,Select one.,PDBD Neurolocial Examination Form,5g-iii) Up,NA,NA,Adult and Pediatric,Assessments and Examinations.Physical/Neurological Examination,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2014-04-01,2014-04-01,Published,NA,NA
CranlNervFaclNumbnessFind,NeurologicalExam,Cranial nerves II-XII facial numbness findings,Unique Data Element,1,Cranial nerves II-XII facial numbness findings,Cranial nerves II-XII facial numbness findings,Alphanumeric,NA,Single Pre-Defined Value Selected,NA,NA,Abnormal;Normal;Not assessed,Abnormal;Normal;Not assessed,10;20;222,NA,NA,NA,Select one.,PDBD Neurolocial Examination Form,5h) Facial numbness,NA,NA,Adult and Pediatric,Assessments and Examinations.Physical/Neurological Examination,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2014-04-01,2014-04-01,Published,NA,NA
CranlNervFaclNumbnessLoc,NeurologicalExam,Cranial nerves II-XII facial numbness locations,Unique Data Element,1,Cranial nerves II-XII facial numbness locations,Cranial nerves II-XII facial numbness locations,Alphanumeric,4000,Free-Form Entry,NA,NA,V1 Bilateral;V1 Left;V1 Right;V2 Bilateral;V2 Left;V2 Right;V3 Bilateral;V3 Left;V3 Right,V1 Bilateral;V1 Left;V1 Right;V2 Bilateral;V2 Left;V2 Right;V3 Bilateral;V3 Left;V3 Right,;;;;;;;;,NA,NA,NA,Select all that apply.,PDBD Neurolocial Examination Form,5h-i) Note location(s) of facial numbness,NA,NA,Adult and Pediatric,Assessments and Examinations.Physical/Neurological Examination,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2014-04-01,2014-04-01,Published,NA,NA
CranlNervFaclStrngthFind,NeurologicalExam,Cranial nerves II-XII facial strength findings,Unique Data Element,1,Cranial nerves II-XII facial strength findings,Cranial nerves II-XII facial strength findings,Alphanumeric,NA,Single Pre-Defined Value Selected,NA,NA,Abnormal;Normal;Not assessed,Abnormal;Normal;Not assessed,10;20;222,NA,NA,NA,Select one.,PDBD Neurolocial Examination Form,5j) Facial strength,NA,NA,Adult and Pediatric,Assessments and Examinations.Physical/Neurological Examination,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2014-04-01,2014-04-01,Published,NA,NA
CranlNervFaclStrngthLft,NeurologicalExam,Cranial nerves II-XII peripheral facial strength left findings,Unique Data Element,1,Cranial nerves II-XII peripheral facial strength left findings,Cranial nerves II-XII peripheral facial strength left findings,Alphanumeric,NA,Single Pre-Defined Value Selected,NA,NA,Central weakness;Normal;Not assessed;Peripheral weakness,Central weakness;Normal;Not assessed;Peripheral weakness,;;;,NA,NA,NA,Select one.,PDBD Neurolocial Examination Form,5j-ii) Facial strength (L),NA,NA,Adult and Pediatric,Assessments and Examinations.Physical/Neurological Examination,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2014-04-01,2014-04-01,Published,NA,NA
CranlNervFaclStrngthRt,NeurologicalExam,Cranial nerves II-XII central facial strength right findings,Unique Data Element,1,Cranial nerves II-XII central facial strength right findings,Cranial nerves II-XII central facial strength right findings,Alphanumeric,NA,Single Pre-Defined Value Selected,NA,NA,Central weakness;Normal;Not assessed;Peripheral weakness,Central weakness;Normal;Not assessed;Peripheral weakness,;;;,NA,NA,NA,Select one.,PDBD Neurolocial Examination Form,5j-i) Facial strength (R),NA,NA,Adult and Pediatric,Assessments and Examinations.Physical/Neurological Examination,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2014-04-01,2014-04-01,Published,NA,NA
CranlNervGagRflxFind,NeurologicalExam,Cranial nerves II-XII gag reflex findings,Unique Data Element,1,Cranial nerves II-XII Gag reflex findings,Cranial nerves II-XII Gag reflex findings,Alphanumeric,NA,Single Pre-Defined Value Selected,NA,NA,Absent;Decreased;Normal;Not assessed,Absent;Decreased;Normal;Not assessed,2;10;20;555,NA,NA,NA,Select one.,PDBD Neurolocial Examination Form,5m) Gag reflex,NA,NA,Adult and Pediatric,Assessments and Examinations.Physical/Neurological Examination,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2014-04-01,2014-04-01,Published,NA,NA
CranlNervHearingAbnrmlyFind,NeurologicalExam,Cranial nerves II-XII hearing abnormality findings,Unique Data Element,1,Cranial nerves II-XII hearing abnormality findings,Cranial nerves II-XII hearing abnormality findings,Alphanumeric,NA,Single Pre-Defined Value Selected,NA,NA,Bilaterally decreased;Left decreased;Normal;Not assessed;Right decreased,Bilaterally decreased;Left decreased;Normal;Not assessed;Right decreased,6;4;20;222;5,NA,NA,NA,Select one.,PDBD Neurolocial Examination Form,9R,NA,NA,Adult and Pediatric,Assessments and Examinations.Physical/Neurological Examination,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2014-04-01,2014-04-01,Published,NA,NA
CranlNervHearingFind,NeurologicalExam,Cranial nerves II-XII hearing findings,Unique Data Element,1,Cranial nerves II-XII hearing findings,Cranial nerves II-XII hearing findings,Alphanumeric,NA,Single Pre-Defined Value Selected,NA,NA,Abnormal;Normal;Not assessed,Abnormal;Normal;Not assessed,10;20;222,NA,NA,NA,Select one.,PDBD Neurolocial Examination Form,5k) Hearing,NA,NA,Adult and Pediatric,Assessments and Examinations.Physical/Neurological Examination,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2014-04-01,2014-04-01,Published,NA,NA
CranlNervHemianopiaLoc,NeurologicalExam,Cranial nerves II-XII hemianopia location(s),Unique Data Element,1,Cranial nerves II-XII area(s) of hemianopia locations(s),Cranial nerves II-XII area(s) of hemianopia locations(s),Alphanumeric,4000,Free-Form Entry,NA,NA,Left Inferior;Left Lateral;Left Medial;Left Superior;Not applicable;Right Inferior;Right Lateral;Right Medial;Right Superior,Left Inferior;Left Lateral;Left Medial;Left Superior;Not applicable;Right Inferior;Right Lateral;Right Medial;Right Superior,;;;;;;;;,NA,NA,NA,Select all that apply.,PDBD Neurolocial Examination Form,5f-i) Note area(s) of hemianopia,NA,NA,Adult and Pediatric,Assessments and Examinations.Physical/Neurological Examination,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2014-04-01,2014-04-01,Published,NA,NA
CranlNervMassetWeakFind,NeurologicalExam,Cranial nerves II-XII masseter muscular weakness findings,Unique Data Element,1,Cranial nerves II-XII Masseter muscular weakness findings,Cranial nerves II-XII Masseter muscular weakness findings,Alphanumeric,NA,Single Pre-Defined Value Selected,NA,NA,Bilateral;Left;Normal;Not assessed;Right,Bilateral;Left;Normal;Not assessed;Right,6;4;20;222;5,NA,NA,NA,Select one.,PDBD Neurolocial Examination Form,5i) Masseter weakness,NA,NA,Adult and Pediatric,Assessments and Examinations.Physical/Neurological Examination,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2014-04-01,2014-04-01,Published,NA,NA
CranlNervPalatalElevatnFind,NeurologicalExam,Cranial nerves II-XII palatal elevation findings,Unique Data Element,1,Cranial nerves II-XII palatal elevation findings,Cranial nerves II-XII palatal elevation findings,Alphanumeric,NA,Single Pre-Defined Value Selected,NA,NA,Bilaterally decreased;Left decreased;Normal;Not assessed;Right decreased,Bilaterally decreased;Left decreased;Normal;Not assessed;Right decreased,6;4;20;222;5,NA,NA,NA,Select one.,PDBD Neurolocial Examination Form,5l) Palatal elevation,NA,NA,Adult and Pediatric,Assessments and Examinations.Physical/Neurological Examination,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2014-04-01,2014-04-01,Published,NA,NA
CranlNervPapilledemaFind,NeurologicalExam,Cranial nerves II-XII Papilledema  findings,Unique Data Element,1,Cranial nerves II-XII Papilledema findings,Cranial nerves II-XII Papilledema findings,Alphanumeric,NA,Single Pre-Defined Value Selected,NA,NA,Bilateral;Left;Normal;Not assessed;Right,Bilateral;Left;Normal;Not assessed;Right,6;4;20;222;5,NA,NA,NA,Select one.,PDBD Neurolocial Examination Form,5b) Papilledema,NA,NA,Adult and Pediatric,Assessments and Examinations.Physical/Neurological Examination,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2014-04-01,2014-04-01,Published,NA,NA
CranlNervPtosisLocFind,NeurologicalExam,Cranial nerves II-XII Ptosis findings,Unique Data Element,1,Cranial nerves II-XII Ptosis findings,Cranial nerves II-XII Ptosis findings,Alphanumeric,NA,Single Pre-Defined Value Selected,NA,NA,Bilateral;Left;Normal;Not assessed;Right,Bilateral;Left;Normal;Not assessed;Right,6;4;20;222;5,NA,NA,NA,Select one.,PDBD Neurolocial Examination Form,5e) Ptosis,NA,NA,Adult and Pediatric,Assessments and Examinations.Physical/Neurological Examination,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2014-04-01,2014-04-01,Published,NA,NA
CranlNervPupilsAbnrmlyFind,NeurologicalExam,Cranial nerves II-XII pupils abnormality findings,Unique Data Element,1,Cranial nerves II-XII pupils abnormality findings,Cranial nerves II-XII pupils abnormality findings,Alphanumeric,4000,Free-Form Entry,NA,NA,Left at rest;Left to accomodation;Left to light;Right at rest;Right to accomodation;Right to light,Left at rest;Left to accomodation;Left to light;Right at rest;Right to accomodation;Right to light,;;;;;,NA,NA,NA,Select all that apply.,PDBD Neurolocial Examination Form,"5d-i) If abnormal, check all abnormalities found",NA,NA,Adult and Pediatric,Assessments and Examinations.Physical/Neurological Examination,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2014-04-01,2014-04-01,Published,NA,NA
CranlNervPupilsFind,NeurologicalExam,Cranial nerves II-XII pupils findings,Unique Data Element,1,Cranial nerves II-XII pupils findings,Cranial nerves II-XII pupils findings,Alphanumeric,NA,Single Pre-Defined Value Selected,NA,NA,Abnormal;Normal;Not assessed,Abnormal;Normal;Not assessed,10;20;222,NA,NA,NA,Select one.,PDBD Neurolocial Examination Form,5d) Pupils,NA,NA,Adult and Pediatric,Assessments and Examinations.Physical/Neurological Examination,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2014-04-01,2014-04-01,Published,NA,NA
CranlNervQuadrantanopiaLoc,NeurologicalExam,Cranial nerves II-XII quadrantanopia location(s),Unique Data Element,1,Cranial nerves II-XII area(s) of quadrantanopia,Cranial nerves II-XII area(s) of quadrantanopia,Alphanumeric,4000,Free-Form Entry,NA,NA,Left Inferior;Left Lateral;Left Medial;Left Superior;Not applicable;Right Inferior;Right Lateral;Right Medial;Right Superior,Left Inferior;Left Lateral;Left Medial;Left Superior;Not applicable;Right Inferior;Right Lateral;Right Medial;Right Superior,;;;;;;;;,NA,NA,NA,Select all that apply.,PDBD Neurolocial Examination Form,5f-ii) Note area(s) of  quadrantanopia,NA,NA,Adult and Pediatric,Assessments and Examinations.Physical/Neurological Examination,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2014-04-01,2014-04-01,Published,NA,NA
CranlNervRinneTestRslt,NeurologicalExam,Cranial nerves II-XII Rinne test result,Unique Data Element,1,Cranial nerves II-XII Rinne test result,Cranial nerves II-XII Rinne test result,Alphanumeric,NA,Single Pre-Defined Value Selected,NA,NA,Air <  Bone;Air = Bone;Air > Bone,Air <  Bone;Air = Bone;Air > Bone,1;2;3,NA,NA,NA,Select one.,PDBD Neurolocial Examination Form,5k-iii) Rinne,NA,NA,Adult and Pediatric,Assessments and Examinations.Physical/Neurological Examination,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2014-04-01,2014-04-01,Published,NA,NA
CranlNervSCMWeakFind,NeurologicalExam,Cranial II-XII sternocleidomastoid weakness findings,Unique Data Element,1,Cranial II-XII sternocleidomastoid weakness findings,Cranial II-XII sternocleidomastoid weakness findings,Alphanumeric,NA,Single Pre-Defined Value Selected,NA,NA,Bilateral;Left;Normal;Not assessed;Right,Bilateral;Left;Normal;Not assessed;Right,6;4;20;222;5,NA,NA,NA,Select one.,PDBD Neurolocial Examination Form,5o) Sternocleidomastoid weakness,NA,NA,Adult and Pediatric,Assessments and Examinations.Physical/Neurological Examination,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2014-04-01,2014-04-01,Published,NA,NA
CranlNervShouldShrugWeakFind,NeurologicalExam,Cranial nerves II-XII shoulder shrug weakness findings,Unique Data Element,1,Cranial nerves II-XII shoulder shrug weakness findings,Cranial nerves II-XII shoulder shrug weakness findings,Alphanumeric,NA,Single Pre-Defined Value Selected,NA,NA,Bilateral;Left;Normal;Not assessed;Right,Bilateral;Left;Normal;Not assessed;Right,6;4;20;222;5,NA,NA,NA,Select one.,PDBD Neurolocial Examination Form,5n) Shoulder shrug weakness,NA,NA,Adult and Pediatric,Assessments and Examinations.Physical/Neurological Examination,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2014-04-01,2014-04-01,Published,NA,NA
CranlNervTongueOthrFind,NeurologicalExam,Cranial nerves II-XII other tongue findings,Unique Data Element,1,Cranial nerves II-XII other tongue findings,Cranial nerves II-XII other tongue findings,Alphanumeric,4000,Free-Form Entry,NA,NA,Atrophy;Fasciculations;None;Not assessed,Atrophy;Fasciculations;Normal;Not assessed,;;;,NA,NA,NA,Select one.,PDBD Neurolocial Examination Form,5q) Other tongue findings,NA,NA,Adult and Pediatric,Assessments and Examinations.Physical/Neurological Examination,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2014-04-01,2014-04-01,Published,NA,NA
CranlNervTongueWeakFind,NeurologicalExam,Cranial nerves II-XII tongue weakness findings,Unique Data Element,1,Cranial nerves II-XII tongue weakness findings,Cranial nerves II-XII tongue weakness findings,Alphanumeric,NA,Single Pre-Defined Value Selected,NA,NA,Left;Normal;Not Assessed;Right,Left;Normal;Not Assessed;Right,4;20;222;5,NA,NA,NA,Select one.,PDBD Neurolocial Examination Form,5p) Tongue weakness,NA,NA,Adult and Pediatric,Assessments and Examinations.Physical/Neurological Examination,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2014-04-01,2014-04-01,Published,NA,NA
CranlNervVisualAcuityAbnrmly,NeurologicalExam,Cranial nerves II-XII visual acuity abnormality findings,Unique Data Element,1,Cranial nerves II-XII visual acuity abnormality descriptor findings,Cranial nerves II-XII visual acuity abnormality descriptor,Alphanumeric,4000,Free-Form Entry,NA,NA,Able to read text;Detects light only;Detects movement only;Vision impaired on left;Vision impaired on right,Able to read text;Detects light only;Detects movement only;Vision impaired on left;Vision impaired on right,;;;;,NA,NA,NA,Select all that apply,PDBD Neurolocial Examination Form,"5a-i) If abnormal, check all that apply",NA,NA,Adult and Pediatric,Assessments and Examinations.Physical/Neurological Examination,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2014-04-01,2014-04-01,Published,NA,NA
CranlNervVisualAcuityFind,NeurologicalExam,Cranial nerves II-XII visual acuity (corrected) findings,Unique Data Element,1,Cranial nerves II-XII visual acuity (corrected) findings.,Cranial nerves II-XII visual acuity (corrected) findings.,Alphanumeric,NA,Single Pre-Defined Value Selected,NA,NA,Abnormal;Normal;Not assessed,Abnormal;Normal;Not assessed,10;20;222,NA,NA,NA,Select one.,PDBD Neurolocial Examination Form,5a) Visual acuity (corrected),NA,NA,Adult and Pediatric,Assessments and Examinations.Physical/Neurological Examination,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2014-04-01,2014-04-01,Published,NA,NA
CranlNervVisualFieldsFind,NeurologicalExam,Cranial nerves II-XII visual fields findings,Unique Data Element,1,Cranial nerve II-XII visual fields findings,Cranial nerve II-XII visual fields findings,Alphanumeric,NA,Single Pre-Defined Value Selected,NA,NA,Abnormal;Normal;Not assessed,Abnormal;Normal;Not assessed,10;20;222,NA,NA,NA,Select one.,PDBD Neurolocial Examination Form,5f) Visual fields,NA,NA,Adult and Pediatric,Assessments and Examinations.Physical/Neurological Examination,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2014-04-01,2014-04-01,Published,NA,NA
CranlNervWeberTestRsltFind,NeurologicalExam,Cranial nerves II-XII Weber test result findings,Unique Data Element,1,Cranial nerves II-XII Weber test result findings,Cranial nerves II-XII Weber test result findings,Alphanumeric,NA,Single Pre-Defined Value Selected,NA,NA,Lateralized Left;Lateralized Right;Normal;Not assessed,Lateralized Left;Lateralized Right;Normal;Not assessed,4;5;20;222,NA,NA,NA,Select one.,PDBD Neurolocial Examination Form,0,NA,NA,Adult and Pediatric,Assessments and Examinations.Physical/Neurological Examination,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2014-04-01,2014-04-01,Published,NA,NA
DrgSubIllctUseCatPDBP,BehavioralHistory,Drug or substance illicitly used category,Unique Data Element,1,"Category of illegal drugs, prescription, or over-the-counter drugs the participant/subject used for purposes other than those for which they are meant to be used, or in large amounts","Category of illegal drugs, prescription, or over-the-counter drugs the participant/subject used for purposes other than those for which they are meant to be used, or in large amounts",Alphanumeric,255,Free-Form Entry,NA,NA,"Cocaine or crack;Hallucinogens (e.g., Ecstasy, LSD, mescaline, psilocybin, PCP, angel dust, or peyote);Heroin;Inhalants or Solvents (e.g., amyl nitrate, nitrous oxide, glue, tolune, or gasoline;Marijuana, hash, THC, or grass;Other, specify (e.g., Methadone, Elavil, steroids, Thorazine, or Haldol);Painkillers (e.g., Codeine, Darvon, Percodan, Dilaudid, or Demerol);Sedatives (e.g., sleeping pills, barbiturates, Seconal, Quaaludes, or Chloral Hydrate);Stimulants (e.g., Preludin, Benzedrine, Methadrine, uppers, or speed);Tranquilizers or anti-anxiety drugs (e.g., Valium, Librium, muscle relaxants, or Zanax)","Cocaine or crack;Hallucinogens (e.g., Ecstasy, LSD, mescaline, psilocybin, PCP, angel dust, or peyote);Heroin;Inhalants or Solvents (e.g., amyl nitrate, nitrous oxide, glue, tolune, or gasoline;Marijuana, hash, THC, or grass;Other, specify (e.g., Methadone, Elavil, steroids, Thorazine, or Haldol);Painkillers (e.g., Codeine, Darvon, Percodan, Dilaudid, or Demerol);Sedatives (e.g., sleeping pills, barbiturates, Seconal, Quaaludes, or Chloral Hydrate);Stimulants (e.g., Preludin, Benzedrine, Methadrine, uppers, or speed);Tranquilizers or anti-anxiety drugs (e.g., Valium, Librium, muscle relaxants, or Zanax)",;;;;;;;;;,NA,NA,NA,"Choose all that apply. Response is obtained by report of the participant/subject or proxy as soon as possible after visit/admission.  Do not record medications that are prescribed for medical purposes.  Collect information on substances and medications taken for reasons other than prescription, or taken more frequently or at higher doses than prescribed. Assure participant/subject that information on such use will be treated as strictly confidential.",NA,"PD (F0755):
If YES, specify illicit drug type(s) used",NA,NA,Adult and Pediatric,NA,NA,Participant/Subject History and Family History.Epidemiology/Environmental History,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2014-04-09,2014-04-09,Published,NA,NA
DrgSubstCurrntIllicitUseCat,BehavioralHistory,Drug or substance current illicit use indicator,Common Data Element,1.6,"Indicator of participant's/subject's use of illegal drugs, prescription or over-the-counter drugs in the past year for purposes other than those for which they are meant to be used, or in large amounts","Indicator of participant's/subject's use of illegal drugs, prescription or over-the-counter drugs in the past year for purposes other than those for which they are meant to be used, or in large amounts",Alphanumeric,NA,Single Pre-Defined Value Selected,NA,NA,No;Unknown;Yes,No;Unknown;Yes,0;9;1,NA,NA,NA,"Choose one. Response is obtained by report of the participant/subject or proxy as soon as possible after visit/admission. Do not record medications that are prescribed for medical purposes. Collect information on substances and medications taken for reasons other than prescription, or taken more frequently or at higher doses than prescribed. Do not record medications that are prescribed for medical purposes (these should be entered in the element 'medical history'.) Collect information on substances and medications taken for reasons other than prescription, or taken more frequently or at higher doses than prescribed. Assure participant/subject that information on such use will be treated as strictly confidential. Recommend collection as soon as possible after visit/admission. Substance abuse directly before injury may have contributed to the incident causing injury. In general, substance abuse may indicate increased risk taking behavior.",NA,"Indicator of participant's/subject's use of illegal drugs, prescription or over-the-counter drugs in the past year for purposes other than those for which they are meant to be used, or in large amounts",Medical_History,"MS/TBI:
Corrigan JD, Bogner J, Holloman C. Lifetime history of traumatic brain injury among persons with substance use disorders. Brain Inj. 2012;26(2):139-50.",Adult and Pediatric,Participant/Subject History and Family History.General Health History,Participant/Subject History and Family History.General Health History,NA,Participant/Subject History and Family History.General Health History,Participant/Subject History and Family History.General Health History,NA,NA,Participant/Subject History and Family History.General Health History,NA,NA,NA,NA,NA,NA,NA,NA,Supplemental,Supplemental,Supplemental,Supplemental,Supplemental,NA,Core,Core,NA,NA,Supplemental,NA,NA,NA,NA,NA,NA,NA,NA,Drug or substance current illicit use indicator,NA,NA,NIH/NINDS,NINDSCDE,NINDSCDE@emmes.com,NA,NA,NIH/NINDS,NINDSCDE,NINDSCDE@emmes.com,2014-04-01,2017-09-07,Published,NA,NA
EarlyTerm_Expectns,EarlyTerminationQuest,Early Termination Questionnaire Expectations,Unique Data Element,1,The study did not live up to the expectations I had.,The study did not live up to the subject expectations indicator,Alphanumeric,NA,Single Pre-Defined Value Selected,NA,NA,Agree;Disagree;Neutral;Somewhat Agree;Somewhat Disagree;Strongly Agree;Strongly Disagree,Agree;Disagree;Neutral;Somewhat Agree;Somewhat Disagree;Strongly Agree;Strongly Disagree,;;;;;;,NA,NA,NA,Choose one,Early Termination  Questionnaire Expectations Q6,The study did not live up to the expectations I had.,NA,No references available,Adult and Pediatric,"Protocol Experience.Participant/Subject Identification, Eligibility, and Enrollment",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2014-04-01,2014-04-01,Published,NA,NA
EarlyTerm_ImportntFactor,EarlyTerminationQuest,Early Termination Questionnaire (ETQ) - important factor,Unique Data Element,1,"If you had to choose only one answer as the most important thing that led to you to participate, what would it be?",The most important reason that led to the subject to participate in the study,Alphanumeric,4000,Free-Form Entry,NA,NA,"Compensation for my time;My hope that my participation would help others;My hope that participation would help me medically;My hope that your participation would advance science;My opinion of the institution;Other, specify;The opinion of my doctor","Compensation for my time;My hope that my participation would help others;My hope that participation would help me medically;My hope that your participation would advance science;My opinion of the institution;Other, specify;The opinion of my doctor",;;;;;;,NA,NA,NA,Choose one,Early Termination Questionnaire Important Factor Q2,"If you had to choose only one answer as the most important thing that led to you to participate, what would it be?",NA,No references available,Adult and Pediatric,"Protocol Experience.Participant/Subject Identification, Eligibility, and Enrollment",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2014-04-01,2014-04-01,Published,NA,NA
EarlyTerm_PrtpWhy,EarlyTerminationQuest,Early Termination Questionnaire (ETQ) - participate why,Unique Data Element,1,I'd like you to try to remember why you initially chose to participate in the study. Please tell me if each of the following was part of why you originally chose to enroll?,The subject  initially chose to participate in the stud y reason,Alphanumeric,4000,Free-Form Entry,NA,NA,"Compensation for my time;My hope that my participation would help others;My hope that participation would help me medically;My hope that your participation would advance science;My opinion of the institution;Other, specify;The opinion of my doctor","Compensation for my time;My hope that my participation would help others;My hope that participation would help me medically;My hope that your participation would advance science;My opinion of the institution;Other, specify;The opinion of my doctor",;;;;;;,NA,NA,NA,Select all that apply,Early Termination Questionnaire Participate Why Q1,I'd like you to try to remember why you initially chose to participate in the study. Please tell me if each of the following was part of why you originally chose to enroll?,NA,No references available,Adult and Pediatric,"Protocol Experience.Participant/Subject Identification, Eligibility, and Enrollment",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2014-04-01,2014-04-01,Published,NA,NA
EarlyTerm_StdySatisfctn,EarlyTerminationQuest,Early Termination Questionnaire (ETQ) - study satisfaction,Unique Data Element,1,There was something specific I hoped to get out of participating and didn't.,Some specific  outcome the subject hoped to get out of study and did not,Alphanumeric,NA,Single Pre-Defined Value Selected,NA,NA,Agree;Disagree;Neutral;Somewhat Agree;Somewhat Disagree;Strongly Agree;Strongly Disagree,Agree;Disagree;Neutral;Somewhat Agree;Somewhat Disagree;Strongly Agree;Strongly Disagree,;;;;;;,NA,NA,NA,Choose one,Early Termination Questionnaire Study Satisfaction  Q5,There was something specific I hoped to get out of participating and didn't.,NA,No references available,Adult and Pediatric,"Protocol Experience.Participant/Subject Identification, Eligibility, and Enrollment",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2014-04-01,2014-04-01,Published,NA,NA
EarlyTerm_StopFactor,EarlyTerminationQuest,Early Termination Questionnaire (ETQ) - stop factor,Unique Data Element,1,Which of the following do you think best represents the reason you chose to stop participating? You can only choose one answer.,One reason the subject chose to stop participating in the study,Alphanumeric,255,Free-Form Entry,NA,NA,"Being in the study became too expensive;Being in the study became too logistically challenging because of the frequency of visits;Being in the study became too logistically challenging because of transportation;Being in the study interfered with my job;Being in the study wasn't worth the money;Being in the study was unpleasant, I didn't enjoy it;I didn't have time/Being in the study wasn't worth my time;I didn't think being in the study was benefiting me;I feared my health was in danger;I had other medical problems;It didn't seem that important;I thought I was assigned to placebo;Other, specify","Being in the study became too expensive;Being in the study became too logistically challenging because of the frequency of visits;Being in the study became too logistically challenging because of transportation;Being in the study interfered with my job;Being in the study wasn't worth the money;Being in the study was unpleasant, I didn't enjoy it;I didn't have time/Being in the study wasn't worth my time;I didn't think being in the study was benefiting me;I feared my health was in danger;I had other medical problems;It didn't seem that important;I thought I was assigned to placebo;Other, specify",;;;;;;;;;;;;,NA,NA,NA,Choose one,Early Termination Questionnaire Stop Factor Q4,Which of the following do you think best represents the reason you chose to stop participating? You can only choose one answer.,NA,No references available,Adult and Pediatric,"Protocol Experience.Participant/Subject Identification, Eligibility, and Enrollment",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2014-04-01,2014-04-01,Published,NA,NA
EarlyTerm_StopPrtpWhy,EarlyTerminationQuest,Early Termination Questionnaire (ETQ) - stop participating reason,Unique Data Element,1,Please tell me if each of the following was part of why you chose to stop participating,The list or reasons why the subject chose to stop participating in the study,Alphanumeric,4000,Free-Form Entry,NA,NA,"Being in the study became too expensive;Being in the study became too logistically challenging because of the frequency of visits;Being in the study became too logistically challenging because of transportation;Being in the study interfered with my job;Being in the study wasn't worth the money;Being in the study was unpleasant, I didn't enjoy it;I didn't have time/Being in the study wasn't worth my time;I didn't think being in the study was benefiting me;I feared my health was in danger;I had other medical problems;It didn't seem that important;I thought I was assigned to placebo;Other, specify","Being in the study became too expensive;Being in the study became too logistically challenging because of the frequency of visits;Being in the study became too logistically challenging because of transportation;Being in the study interfered with my job;Being in the study wasn't worth the money;Being in the study was unpleasant, I didn't enjoy it;I didn't have time/Being in the study wasn't worth my time;I didn't think being in the study was benefiting me;I feared my health was in danger;I had other medical problems;It didn't seem that important;I thought I was assigned to placebo;Other, specify",;;;;;;;;;;;;,NA,NA,NA,Select all that apply,Early Termination Questionnaire Stop Participating Why Q3,Please tell me if each of the following was part of why you chose to stop participating,NA,No references available,Adult and Pediatric,"Protocol Experience.Participant/Subject Identification, Eligibility, and Enrollment",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2014-04-01,2014-04-01,Published,NA,NA
EduLvlUSATypPDBP,Demographics,Education level USA type,Unique Data Element,1.3,Highest grade or level of school participant/subject has completed or the highest degree received,Highest grade or level of school participant/subject has completed or the highest degree received,Alphanumeric,NA,Single Pre-Defined Value Selected,NA,NA,"10th Grade;11th Grade;12th Grade, no diploma;1st Grade;2nd Grade;3rd Grade;4th Grade;5th Grade;6th Grade;7th Grade;8th Grade;9th Grade;Associate degree: academic program;Associate degree: occupational/technical/vocational program;Bachelor's degree (e.g., BA, AB, BS, BBA);Doctoral degree (e.g., PhD, EdD);GED or equivalent;High school graduate;Master's degree (e.g., MA, MS, MEng, MEd, MBA);Never attended/Kindergarten only;Professional school degree (e.g., MD, DDS, DVM, JD);Some college, no degree;Unknown","10th Grade;11th Grade;12th Grade, no diploma;1st Grade;2nd Grade;3rd Grade;4th Grade;5th Grade;6th Grade;7th Grade;8th Grade;9th Grade;Associate degree: academic program;Associate degree: occupational/technical/vocational program;Bachelor's degree (e.g., BA, AB, BS, BBA);Doctoral degree (e.g., PhD, EdD);GED or equivalent;High school graduate;Master's degree (e.g., MA, MS, MEng, MEd, MBA);Never attended/Kindergarten only;Professional school degree (e.g., MD, DDS, DVM, JD);Some college, no degree;Unknown",1;2;3;4;5;6;7;8;9;10;11;12;13;14;15;16;17;18;19;20;21;22;999,NA,NA,NA,"Select the highest level attained. Choose only one, the highest level of education the participant/subject has attained.","PDBP variable for Education level USA type. CDISC variables: DM=Demographics, SUPPDM= SUPPQUAL for Demographics, SC=Subject Characteristics,  when SCTESTCD=EDLEVEL, use SCTEST, SCORRES to provide education level detail. For more information, refer to https://wiki.cdisc.org/pages/viewpage.action?pageId=32815150","PD (F0745):
Education Level",CDISC,National Health and Nutrition Examination Survey (NHANES); National Health Interview Survey (NHIS); PhenX Toolkit Current Educational Attainment #011001 (https://www.phenxtoolkit.org),Adult and Pediatric,NA,NA,Participant/Subject Characteristics.Demographics,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,EduLvlMaternalUSATyp; EduLvlPaternalUSATyp; EduLvlUSATyp; EduPerfStatus; EduSrvcTyp; EduTyp; EduPrim,NIH/NINDS,NA,NA,NA,NA,NIH/NINDS,NA,NA,2014-04-09,2020-02-05,Published,NA,NA
EmplmtStatus,Demographics,Employment status,Unique Data Element,1.2,Status of participant/subject's current employment,Status of participant/subject's current employment,Alphanumeric,255,Free-Form Entry,NA,NA,"Disabled, permanently or temporarily;Keeping house;Looking for work, unemployed;Only temporarily laid off;Other, specify;Retired;Sick leave or maternity leave;Student;Unknown;Working Now","Disabled, permanently or temporarily;Keeping house;Looking for work, unemployed;Only temporarily laid off;Other, specify;Retired;Sick leave or maternity leave;Student;Unknown;Working Now",;;;;;;;;;,NA,NA,NA,"FA:
Choose one.
-----
NMD:
Choose one
-----
SMA:
Choose one
-----
EPILEPSY:
Choose one
-----
STROKE:
National Health and Nutrition Examination Survey (http://www.cdc.gov/nchs/nhanes.htm)
-----
MS:
Choose one.
-----
HEADACHE:
Choose all that apply.
-----
GENERAL:
For years completed, code the number of years attained (0-30 years), normed to someone moving full time at the usual pace, i.e. a year that was repeated counts as only 1 year and the usual single-year full-time load completed over several years counts as 1 year. Certificate and technical programs do NOT count no matter how specialized.    The number of years of typical completion of the relevant program is counted. If the subject obtained their education outside the United States, ask about their educational system to estimate the correct coding - Internship, Residency, and Fellowship years are experiential training and do not count.  Recommend collection at least on date of TBI.",NA,"EPILEPSY (F1101):
Employment status
-----
FA (F0920):
Employment status
-----
HEADACHE (F1351):
Employment status
-----
MS (F1274):
Employment Status
-----
NMD (F1032):
Employment status
-----
SMA (F1032):
Employment status
-----
STROKE (F1151):
Employment Status",NA,"EPILEPSY:
National Health and Nutrition Examination Survey (http://www.cdc.gov/nchs/nhanes.htm)
-----
FA:
National Health and Nutrition Examination Survey (http://www.cdc.gov/nchs/nhanes.htm)
-----
GENERAL:
No references available
-----
HEADACHE:
National Health and Nutrition Examination Survey (http://www.cdc.gov/nchs/nhanes.htm)
-----
MS:
No references available
-----
NMD:
National Health and Nutrition Examination Survey (http://www.cdc.gov/nchs/nhanes.htm)
-----
SMA:
National Health and Nutrition Examination Survey (http://www.cdc.gov/nchs/nhanes.htm)
-----
STROKE:
PhenX Toolkit (https://www.phenxtoolkit.org) Current Employment Status #011301 National Health and Nutrition Examination Survey (http://www.cdc.gov/nchs/nhanes.htm)",Adult and Pediatric,Participant/Subject Characteristics.Social Status,NA,NA,Participant/Subject Characteristics.Social Status,Participant/Subject Characteristics.Social Status,NA,NA,Participant/Subject Characteristics.Social Status,Participant/Subject Characteristics.Social Status,NA,Participant/Subject Characteristics.Social Status,NA,NA,NA,Participant/Subject Characteristics.Social Status,Participant/Subject Characteristics.Social Status,Supplemental,NA,NA,NA,NA,NA,Supplemental,Supplemental,NA,NA,Supplemental,Supplemental,NA,Supplemental,NA,NA,NA,Supplemental,Supplemental,Employment status,NA,EmplmtExpndStatus core CDE,N/A,NA,NA,NA,2020-01-28,NIH/CIT/BRICS,NA,NA,2014-04-01,2020-01-28,Retired,NA,NA
EnrldStdyDateTime,InformedConsent,Enrolled in study date and time,Common Data Element,1.1,"Date (and time, if applicable and known) the participant/subject is enrolled into the study","Date (and time, if applicable and known) the participant/subject is enrolled into the study",Date or Date & Time,NA,Free-Form Entry,NA,NA,NA,NA,NA,NA,NA,NA,"GENERAL: Record the date/time according to the ISO 8601, the International Standard for the representation of dates and times (http: //www.iso.org/iso/home.html). The date (and time) should be recorded to the level of granularity known (e.g., year, year and month, complete date plus hours and minutes, etc.) and in the format acceptable to the study database.","Data Sharing Instructions: When date/time data are prepared for aggregation or sharing they should be converted to the format specified by ISO 8601, YYYY-MM-DDThh:mm:ss.",Date Enrolled,NA,No references available,Adult and Pediatric,"Protocol Experience.Participant/Subject Identification, Eligibility, and Enrollment",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Core,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Enrolled in study date and time,NA,NA,NIH/CIT/BRICS,Olga Vovk,olga.vovk@nih.gov,NA,NA,NIH/NINDS,NINDSCDE,NINDSCDE@emmes.com,NA,2015-07-24,Published,NA,NA
EnrldStdyInd,InformedConsent,Enrolled in study indicator,Common Data Element,1.1,Indicator of whether the participant/subject was enrolled into the clinical research study.,Indicator of whether the participant/subject was enrolled into the clinical research study.,Alphanumeric,NA,Single Pre-Defined Value Selected,NA,NA,No;Unknown;Yes,No;Unknown;Yes,0;9;1,NA,NA,NA,"GENERAL: Choose one. If YES, record the date enrolled.",NA,Was the participant/subject enrolled into the study?,NA,No references available,Adult and Pediatric,"Protocol Experience.Participant/Subject Identification, Eligibility, and Enrollment",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Core,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Enrolled in study indicator,NA,NA,NIH/CIT/BRICS,Olga Vovk,olga.vovk@nih.gov,NA,NA,NIH/NINDS,NINDSCDE,NINDSCDE@emmes.com,NA,2015-07-24,Published,NA,NA
EthnUSACat,Demographics,Ethnicity USA category,Common Data Element,1.8,Category of ethnicity the participant/subject most closely identifies with,Category of ethnicity the participant/subject most closely identifies with,Alphanumeric,NA,Single Pre-Defined Value Selected,NA,NA,Hispanic or Latino;Not Hispanic or Latino;Not reported;Unknown,"A person of Cuban, Mexican, Puerto Rican, South or Central American, or other Spanish culture or origin, regardless of race. The term ""Spanish origin"" can also be used in addition to ""Hispanic or Latino"".;A person not meeting the definition for Hispanic or Latino.;Not provided or available;Could not be determined or unsure",1;2;0;999,NA,NA,NA,"Choose one.  Response is obtained by report of the participant/subject or caretaker.  If more detailed characterizations of ethnicity are collected to enhance data quality and consistency, it is recommended that they be ""collapsible"" up to the two categories for reportable ethnicity, as needed for reporting to FDA under its guidance. Other regulatory bodies may expect the reporting of ethnicity values which more appropriately reflect the population of their areas (e.g., Japanese ancestry for MHLW reporting to Japan). These may be collected as an extension to the suggested code list. The NIH Guidelines on Inclusion of Women and Minorities as Subjects in Clinical Research: The Office of Management and Budget Directive No. 15 defines the minimum standard of basic racial and ethnic categories. (http://grants.nih.gov/grants/funding/women_min/guidelines_update.htm)  Collection of Race and Ethnicity Data in Clinical Trials (FDA, September 2005 - http://www.fda.gov/RegulatoryInformation/Guidances/ucm126340.htm)","CDISC variables: DM=Demographics, SUPPDM= SUPPQUAL for Demographics, SC=Subject Characteristics,  ETHNIC. For more information, refer to https://wiki.cdisc.org/pages/viewpage.action?pageId=32815150. Core CDEs from ONC SET OF DATA CLASSES TO SUPPORT NATIONWIDE INTEROPERABILITY",What is the subject's ethnic background?,Demographics;ONC,"The NIH Guidelines on Inclusion of Women and Minorities as Subjects in Clinical Research: The Office of Management and Budget (OMB) Directive No. 15 defines the minimum standard of Core racial and ethnic categories. (http://grants.nih.gov/grants/funding/women_min/guidelines_update.htm)  Collection of Race and Ethnicity Data in Clinical Trials (FDA, September 2005 - http://www.fda.gov/RegulatoryInformation/Guidances/ucm126340.htm) Jorde LB and Wooding SP. Genetic variation, classification and ""race"". Nature Genetics. 2004;36(11):S28-S33. Bhopal R and Donaldson L. White, European, Western, Caucasian, or What? Inappropriate labeling in Research on Race, Ethnicity, and Health. Amer J of Publ Health. 1998;88:1303-1307.",Adult and Pediatric,Participant/Subject Characteristics.Demographics,Participant/Subject Characteristics.Demographics,Participant/Subject Characteristics.Demographics,Participant/Subject Characteristics.Demographics,Participant/Subject Characteristics.Demographics,Participant/Subject Characteristics.Demographics,Participant/Subject Characteristics.Demographics,Participant/Subject Characteristics.Demographics,Participant/Subject Characteristics.Demographics,Participant/Subject Characteristics.Demographics,Participant/Subject Characteristics.Demographics,NA,NA,NA,Participant/Subject Characteristics.Demographics,Participant/Subject Characteristics.Demographics,Core,Core,Core,Core,Core,Core,Core,Core,Core,Core,Core,Core,Core,Core,NA,NA,NA,Core,Core,Ethnicity USA category,NA,NA,NIH/NINDS,NINDSCDE,NINDSCDE@emmes.com,NA,NA,NIH/NINDS,NINDSCDE,NINDSCDE@emmes.com,2014-04-01,2019-08-15,Published,NA,NA
EverUsedAlcoholInd,BehavioralHistory,Alcohol usage ever indicator,Unique Data Element,1,Indicator of whether subject has ever used alcohol,Indicator of whether subject has ever used alcohol,Alphanumeric,NA,Single Pre-Defined Value Selected,NA,NA,No;Unknown;Yes,No;Unknown;Yes,0;9;1,NA,NA,NA,NA,NA,NA,NA,NA,Adult and Pediatric,Participant/Subject History and Family History.General Health History,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2014-04-01,2014-04-01,Published,NA,NA
EverUsedTobaccoInd,BehavioralHistory,Tobacco usage ever indicator,Unique Data Element,1,Indicator of whether subject has ever used tobacco,Indicator of whether subject has ever used tobacco,Alphanumeric,NA,Single Pre-Defined Value Selected,NA,NA,No;Unknown;Yes,No;Unknown;Yes,0;9;1,NA,NA,NA,NA,NA,NA,NA,NA,Adult and Pediatric,Participant/Subject History and Family History.General Health History,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2014-04-01,2014-04-01,Published,NA,NA
FamHistMedclCondInd,FamilyHistory,Family history medical condition indicator,Common Data Element,1.5,Indicator of whether a family member or first and second degree blood relatives of the participant/subject has had a history of the medical condition or health related event,Indicator of whether a family member or first and second degree blood relatives of the participant/subject has had a history of the medical condition or health related event,Alphanumeric,NA,Single Pre-Defined Value Selected,NA,NA,No;Unknown;Yes,No;Unknown;Yes,0;9;1,NA,NA,NA,"Choose one based on whether there is a history of the condition in a first degree family member.
","CDISC variables: AP=Associated Person, APMH=Associated Person Medical History, SQAPMH=Suppqual Associated Person Medical History, MHCAT=FAMILY HISTORY OF PD, MPRESP, MHOCCUR",Any family history of medical conditions?,CDISC,"No references available
",Adult and Pediatric,Participant/Subject History and Family History.General Health History,Participant/Subject History and Family History.General Health History,Participant/Subject History and Family History.General Health History,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Supplemental,Supplemental,Supplemental,Supplemental,Supplemental,Supplemental,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Family history medical condition indicator,NA,NA,NIH/NINDS,NINDSCDE,NINDSCDE@emmes.com,NA,NA,NIH/NINDS,NINDSCDE,NINDSCDE@emmes.com,2014-04-01,2020-02-05,Published,NA,NA
FamHistMedclCondReltvTyp,FamilyHistory,Family history medical condition relative type,Unique Data Element,1.3,Relationship of the family member or ancestor with the medical condition or health related event to the participant/subject,Relationship of the family member or ancestor with the medical condition or health related event to the participant/subject,Alphanumeric,255,Free-Form Entry,NA,NA,"Child;Father;Full sibling;Grandchild;Great-grandchild;Half sibling;Maternal aunt;Maternal cousin;Maternal grandfather;Maternal grandmother;Maternal niece/nephew;Maternal uncle;Mother;Other, specify;Paternal aunt;Paternal cousin;Paternal grandfather;Paternal grandmother;Paternal niece/nephew;Paternal uncle","Child;Father;Full sibling;Grandchild;Great-grandchild;Half sibling;Maternal aunt;Maternal cousin;Maternal grandfather;Maternal grandmother;Maternal niece/nephew;Maternal uncle;Mother;Other, specify;Paternal aunt;Paternal cousin;Paternal grandfather;Paternal grandmother;Paternal niece/nephew;Paternal uncle",;;;;;;;;;;;;;;;;;;;,NA,NA,NA,"GENERAL: Select the relationship from the options of the family members listed. Record/choose more than one family member, if applicable. PD: History can be obtained from participant/subject, family member, friend, or chart/medical record.","CDISC variables: AP=Associated Person, APMH=Associated Person Medical History, SQAPMH=Suppqual Associated Person Medical History, MHCAT=FAMILY HISTORY OF PD, MPRESP, MHOCCUR, MHRELSUB","ALS (F0957):
Relative
-----
DMD (F1513):
Relationship of Family Member to Participant/ Subject
-----
FA (F0922):
Relationship of Family Member to Participant/Subject
-----
GENERAL (F0011):
Relationship of Family Member to Participant/Subject
-----
HD (F1209):
Relative
-----
MG (F1084):
Relationship of Affected Family Member to Participant/Subject (Choose all that apply)
-----
MS (F1276):
Relationship
-----
MS (F1288):
Relative Type
-----
NMD (F1034):
Relationship of Family Member to Participant/ Subject
-----
PD (F0746):
Relative
-----
SCI (F0827):
Family history of cardiovascular disease
-----
SMA (F1072):
Realtionship of Family Member to Participant/Subject",CDISC,"ALS:
No references available
-----
DMD:
No references available
-----
FA:
No references available
-----
GENERAL:
No references available
-----
HD:
Krassioukov A, Alexander MS, Karlsson AK, Donovan W, Mathias CJ, Biering-Sï¿½rensen F. International spinal cord injury cardiovascular function basic data set. Spinal Cord. 2010 Aug;48(8):586-90.
-----
MG:
No references available
-----
MS:
Krassioukov A, Alexander MS, Karlsson AK, Donovan W, Mathias CJ, Biering-Sï¿½rensen F. International spinal cord injury cardiovascular function basic data set. Spinal Cord. 2010 Aug;48(8):586-90.
-----
NMD:
No references available
-----
PD:
No references available
-----
SCI:
Krassioukov A, Alexander MS, Karlsson AK, Donovan W, Mathias CJ, Biering-Sï¿½rensen F. International spinal cord injury cardiovascular function basic data set. Spinal Cord. 2010 Aug;48(8):586-90.
-----
SMA:
No references available",Adult and Pediatric,Participant/Subject History and Family History.General Health History,NA,Participant/Subject History and Family History.General Health History,Participant/Subject History and Family History.General Health History,NA,Participant/Subject History and Family History.General Health History,Participant/Subject History and Family History.General Health History,Participant/Subject History and Family History.General Health History;Assessments and Examinations.Laboratory Tests and Biospecimens/Biomarkers,Participant/Subject History and Family History.General Health History,Participant/Subject History and Family History.General Health History,Participant/Subject History and Family History.General Health History,Participant/Subject History and Family History.General Health History,NA,N/A.N/A,NA,NA,Supplemental,NA,NA,NA,NA,Supplemental,Supplemental,NA,Supplemental,Supplemental,Supplemental,Supplemental,Supplemental,Supplemental,Supplemental,NA,Supplemental,NA,NA,Family history medical condition relative type,NA,NA,NIH/NINDS,NA,NA,NA,NA,NIH/NINDS,NA,NA,2014-04-01,2020-02-05,Published,NA,NA
FamHistMedclCondTyp,FamilyHistory,Family history medical condition type,Unique Data Element,1.3,Type of medical condition or health related event for which the family history is taken,Type of medical condition or health related event for which the family history is taken,Alphanumeric,4000,Free-Form Entry,NA,NA,"Alcohol addiction;Allerg(ies);Alzheimer's disease;Amyotrophic lateral sclerosis (ALS);Anorexia;Anxiety;Arthritis;Asthma;Ataxia;Autism;Binge eating;Bi-polar disorder;Bleeding disorder;Brain aneurysm;Bulimia;CAG expansion but not diagnosed;Cancer;Cardiomyopathy;Cerebral aneurysm;Clotting disorder;Coronary artery disease;Cytosine-adenine-guanine (CAG) expansion but not diagnosed;Dementia;Depression;Developmental delays;Diabetes mellitus;Dystonia;Early childhood death;Eczema;Emotional/Verbal abuse;Endometriosis;Epilepsy;Extracranial aneurysm;Fibromyalgia;Friedreich's ataxia;Frontotemporal dementia (FTD);Gastroparesis;HD diagnosed;Headaches;Heart disease;Hemorrhagic stroke;Hereditary hemorrhagic telangiectasia (HHT);Hypercholesterolemia;Hypertension;Hypotension;Illicit drug addiction;Insomnia;Intracerebral hemorrhage;Intracranial vascular malformation;Irritable bowel syndrome (IBS);Ischemic Stroke;Learning disability;Memory loss;Migraines;Mitochondrial disease;Mitral valve prolapse;Multiple miscarriages;Multiple sclerosis;Muscle disease;Myasthenia gravis;Narcolepsy;Neuromuscular disease;Neuromuscular junction;Neuropathy;No neurological diagnosis;Obesity;Obsessive-compulsive disorder (OCD);Other neurological disorder, specify;Other, specify;Painful bladder;Parkinson's disease;Patent-Foramen Ovale (PFO)/Right-left shunt (RLS);Peripheral neuropathy;Periphereal vascular disease;Physical abuse;Post traumatic stress disorder (PTSD);Preeclampsia;Prescription drug addiction;Psychiatric illness;Restless leg syndrome (RLS);Reynaud's Syndrome;Rheumatoid arthritis;Schizophrenia;Seizures without diagnosis of epilepsy;Sexual abuse;Sinistrality;Sleep apnea;Spinal muscular atrophy (SMA);Stroke;Sudden deaths;Suicide or suicide attempt;Systemic lupus erythematosus (SLE);Thyroid condition;Tourette syndrome;Traumatic brain injury;Tremor;Unknown;Vertigo;Walking delays / Late acquisition of walking","Alcohol addiction;Allerg(ies);Alzheimer's disease;Amyotrophic lateral sclerosis (ALS);Anorexia;Anxiety;Arthritis;Asthma;Ataxia;Autism;Binge eating;Bi-polar disorder;Bleeding disorder;Brain aneurysm;Bulimia;CAG expansion but not diagnosed;Cancer;Cardiomyopathy;Cerebral aneurysm;Clotting disorder;Coronary artery disease;Cytosine-adenine-guanine (CAG) expansion but not diagnosed;Dementia;Depression;Developmental delays;Diabetes mellitus;Dystonia;Early childhood death;Eczema;Emotional/Verbal abuse;Endometriosis;Epilepsy;Extracranial aneurysm;Fibromyalgia;Friedreich's ataxia;Frontotemporal dementia (FTD);Gastroparesis;HD diagnosed;Headaches;Heart disease;Hemorrhagic stroke;Hereditary hemorrhagic telangiectasia (HHT);Hypercholesterolemia;Hypertension;Hypotension;Illicit drug addiction;Insomnia;Intracerebral hemorrhage;Intracranial vascular malformation;Irritable bowel syndrome (IBS);Ischemic Stroke;Learning disability;Memory loss;Migraines;Mitochondrial disease;Mitral valve prolapse;Multiple miscarriages;Multiple sclerosis;Muscle disease;Myasthenia gravis;Narcolepsy;Neuromuscular disease;Neuromuscular junction;Neuropathy;No neurological diagnosis;Obesity;Obsessive-compulsive disorder (OCD);Other neurological disorder, (specify);Other, specify;Painful bladder;Parkinson's disease;Patent-Foramen Ovale (PFO)/Right-left shunt (RLS);Peripheral neuropathy;Periphereal vascular disease;Physical abuse;Post traumatic stress disorder (PTSD);Preeclampsia;Prescription drug addiction;Psychiatric illness;Restless leg syndrome (RLS);Reynaud's Syndrome;Rheumatoid arthritis;Schizophrenia;Seizures without diagnosis of epilepsy;Sexual abuse;Sinistrality;Sleep apnea;Spinal muscular atrophy (SMA);Stroke;Sudden deaths;Suicide or suicide attempt;Systemic lupus erythematosus (SLE);Thyroid condition;Tourette syndrome;Traumatic brain injury;Tremor;Unknown;Vertigo;Walking delays / Late acquisition of walking",;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;,NA,NA,NA,"GENERAL: This CDE should be collected along with the ""Family history medical condition indicator"".
","CDISC variables: AP=Associated Person, APMH=Associated Person Medical History, SQAPMH=Suppqual Associated Person Medical History, MHCAT=FAMILY HISTORY OF PD, MPRESP, MHOCCUR","ALS (F0957):
Diagnosis
-----
DMD (F1513):
Condition
-----
FA (F0922):
Condition
-----
GENERAL (F0011):
Condition
-----
HD (F1209):
Diagnosis
-----
HEADACHE (F1352):
Condition
-----
MG (F1084):
Condition
-----
MS (F1276):
Condition
-----
NMD (F1034):
Condition
-----
SCI (F0827):
Family history of cardiovascular disease
-----
SMA (F1072):
Condition
-----
STROKE (F1153):
Condition",CDISC,"ALS:
No references available
-----
DMD:
No references available
-----
FA:
No references available
-----
GENERAL:
No references available
-----
HD:
No references available
-----
HEADACHE:
No references available
-----
MG:
No references available
-----
MS:
Krassioukov A, Alexander MS, Karlsson AK, Donovan W, Mathias CJ, Biering-Sï¿½rensen F. International spinal cord injury cardiovascular function basic data set. Spinal Cord. 2010 Aug;48(8):586-90.
-----
NMD:
No references available
-----
SCI:
Krassioukov A, Alexander MS, Karlsson AK, Donovan W, Mathias CJ, Biering-Sï¿½rensen F. International spinal cord injury cardiovascular function basic data set. Spinal Cord. 2010 Aug;48(8):586-90.
-----
SMA:
No references available
-----
STROKE:
No references available",Adult and Pediatric,Participant/Subject History and Family History.General Health History,NA,NA,Participant/Subject History and Family History.General Health History,Participant/Subject History and Family History.General Health History,Participant/Subject History and Family History.General Health History,Participant/Subject History and Family History.General Health History,Participant/Subject History and Family History.General Health History,Participant/Subject History and Family History.General Health History,Participant/Subject History and Family History.General Health History,Participant/Subject History and Family History.General Health History,Participant/Subject History and Family History.General Health History,NA,N/A.N/A,Participant/Subject History and Family History.General Health History,NA,Supplemental,NA,NA,NA,NA,NA,Supplemental,Supplemental,Supplemental,Supplemental,Supplemental,Supplemental,Supplemental,Supplemental,Supplemental,NA,Supplemental,Supplemental,NA,Family history medical condition type,NA,NA,NIH/NINDS,NA,NA,NA,NA,NIH/NINDS,NA,NA,2014-04-01,2020-02-05,Published,NA,NA
Gait,NeurologicalExam,Gait descriptor,Unique Data Element,1,Gait descriptor,Gait descriptor,Alphanumeric,4000,Free-Form Entry,NA,NA,"Ataxic;Normal;Not assessed;Other, specify;Romberg;Spastic;Steppage;Unable to Tandem;Wide-Based","Ataxic;Normal;Not assessed;Other, specify;Romberg;Spastic;Steppage;Unable to Tandem;Wide-Based",;;;;;;;;,NA,NA,NA,Select all that apply,PDBD Neurolocial Examination Form,9) Gait,NA,NA,Adult and Pediatric,Assessments and Examinations.Physical/Neurological Examination,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2014-04-01,2014-04-01,Published,NA,NA
GenderTypPDBP,Demographics,Gender Type,Common Data Element,1.3,Self-reported gender of the participant/subject. Gender is the socially constructed identity of sex. Gender is equated with phenotypic sex. Gender may differ from the sex of an individual determined genetically.,Self-reported gender of the participant/subject. Gender is the socially constructed identity of sex.,Alphanumeric,NA,Single Pre-Defined Value Selected,NA,NA,Female;Male;Not reported;Unknown;Unspecified,Female;Male;Not Reported;Unknown;Undifferentiated/Indeterminant/Intersex,1;2;222;999;555,NA,NA,NA,Choose one. Response is obtained by report of the participant/subject or caretaker.,"PDBP variable for Gender. CDISC variables: DM=Demographics, SUPPDM= SUPPQUAL for Demographics, SC=Subject Characteristics, SEX. For more information, refer to https://wiki.cdisc.org/pages/viewpage.action?pageId=32815150","PD (F0745):, PD (F0753): Gender
",CDISC,"The NIH Guidelines on Inclusion of Women and Minorities as Subjects in Clinical Research: The Office of Management and Budget (OMB) Directive No. 15 - http://grants.nih.gov/grants/funding/women_min/women_min.htm
-----
The NIH Guidelines on Inclusion of Women and Minorities as Subjects in Clinical Research: The Office of Management and Budget Directive No. 15 (http://grants.nih.gov/grants/funding/women_min/guidelines_update.htm)",Adult and Pediatric,NA,NA,Participant/Subject Characteristics.Demographics;Assessments and Examinations.Other Clinical Data,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Gender type,NA,GenderTyp; GenderTypExt; SWALQOLGenderTyp; STOPGendrTyp; FmlyHistGendTyp; SiblingGenderTyp,NIH/NINDS,NA,NA,NA,NA,NIH/NINDS,NA,NA,2014-04-09,2020-02-05,Published,NA,NA
HeartRate,Vital Signs,Heart rate,Common Data Element,1.3,The participant/subject's pulse or number of contractions (heart beats) per minute,The participant/subject's pulse or number of contractions (heart beats) per minute,Numeric Values,NA,Free-Form Entry,0,300,NA,NA,NA,NA,NA,Beats per minute,"GENERAL/FA/MG/NMD/SMA/EPILEPSY/STROKE/DMD:
Record the pulse of the participant/subject in beats per minute.
-----
TBI/TBIACUTE/TBIEPID/TBIMILD/TBIMOD:
Record heart rate from monitor or by counting pulse rate.  The suggested range is 0-300. Add date stamp for when assessed. Heart rate may be altered by trauma in a couple of ways. Tachycardia may indicate volume depletion, pain or stress, and higher heart rates have been found in patients that do not survive traumatic injuries. Bradycardia may be seen with elevated intracranial pressure. Pediatric-specific notes:  As a minimum, vital signs should be recorded on admission and further, on a daily basis during the acute phase after injury. For the basic datasets, we recommend recording the average and lowest blood pressure over a given period. In the ICU environment, recording blood pressure on an hourly basis is recommended, especially when intracranial pressure (ICP) is monitored in order to permit determination of CPP, calculated as mean arterial blood pressure (MABP) - ICP (intermediate data set).
-----
SCI:
Resting BP and HR should be obtained following empting of the bladder and 5 minutes of resting period. Both physical activities and full urinary bladder could affect these parameters.
-----
ALS:
This value should be taken from the Vital Signs CRF to prevent capturing duplicate data in different places.    Results should be recoreded in beats per minute (bpm).
-----
SMA:
Record the pulse of the participant/ subject in beats per minute.
-----
MS:
Record the pulse of the participant/ subject in beats per minute.  Record heart rate from monitor or by counting pulse rate.  The suggested range is 0-300. Add date stamp for when assessed. Heart rate may be altered by trauma in a couple of ways. Tachycardia may indicate volume depletion, pain or stress, and higher heart rates have been found in patients that do not survive traumatic injuries. Bradycardia may be seen with elevated intracranial pressure. Pediatric-specific notes:  As a minimum, vital signs should be recorded on admission and further, on a daily basis during the acute phase after injury. For the basic datasets, we recommend recording the average and lowest blood pressure over a given period. In the ICU environment, recording blood pressure on an hourly basis is recommended, especially when intracranial pressure (ICP) is monitored in order to permit determination of CPP, calculated as mean arterial blood pressure (MABP) ï¿½ ICP (intermediate data set).  Resting BP and HR should be obtained following empting of the bladder and 5 minutes of resting period. Both physical activities and full urinary bladder could affect these parameters.
-----
HEADACHE:
Measure in beats per minute (bpm).
","CDISC variable: Vital Signs Test Code (VSTESTCD), Units for Vital Signs Results (VSRESU), Vital Signs Test Name (VSTEST), HR",Heart rate/pulse,Vital_Signs,"ALS:
No references available
-----
DMD:
No references available
-----
EPILEPSY:
No references available
-----
FA:
No references available
-----
GENERAL:
No references available
-----
HEADACHE:
No references available
-----
MG:
No references available
-----
MS:
Shoemaker WC, Bayard DS, Botnen A, et al. Mathematical program for outcome prediction and therapeutic support for trauma beginning within 1 hr of admission: a preliminary report. Crit Care Med. Jul 2005;33(7):1499-1506. Agrawal A, Timothy J, Cincu R, et al. Bradycardia in neurosurgery. Clin Neurol Neurosurg. Apr 2008;110(4):321-7. Krassioukov A, Alexander MS, Karlsson AK, Donovan W, Mathias CJ, Biering-Sï¿½rensen F. International spinal cord injury cardiovascular function basic data set. Spinal Cord. 2010 Aug;48(8):586-90.  Lehmann,K.G., Shandling,A.H., Yusi,A.U. & Froelicher,V.F. Al
-----
NMD:
No references available
-----
SCI:
Krassioukov A, Alexander MS, Karlsson AK, Donovan W, Mathias CJ, Biering-Sï¿½rensen F. International spinal cord injury cardiovascular function basic data set. Spinal Cord. 2010 Aug;48(8):586-90.  Lehmann,K.G., Shandling,A.H., Yusi,A.U. & Froelicher,V.F. Al
-----
SMA:
No references available
-----
STROKE:
No references available
-----
TBI:
Shoemaker WC, Bayard DS, Botnen A, et al. Mathematical program for outcome prediction and therapeutic support for trauma beginning within 1 hr of admission: a preliminary report. Crit Care Med. Jul 2005;33(7):1499-1506. Agrawal A, Timothy J, Cincu R, et al. Bradycardia in neurosurgery. Clin Neurol Neurosurg. Apr 2008;110(4):321-7.",Adult and Pediatric,Assessments and Examinations.Vital Signs and Other Body Measures,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Heart rate,NA,NA,University of Washington,Malaika Schwartz,malaika@uw.edu,NA,NA,NIH/NINDS,NA,NA,NA,2018-04-18,Published,NA,NA
HgtMeasr,Vital Signs,Height measurement,Common Data Element,1.3,Measurement of participant's/subject's height.,Measurement of participant's/subject's height.,Numeric Values,NA,Free-Form Entry,0,400,NA,NA,NA,NA,NA,Centimeter,"GENERAL/TBI: Record the height (or length for the very young) of the participant/ subject. To be collected at the visit, not self-reported. Also, indicate whether height was measured in inches (in) or centimeters (cm). The suggested range is 0-400 cm or 0-150 inches. Height and weight can be measured or estimated upon admission, or alternatively information may be obtained from relatives. Add date stamp for when assessed if possible.  Documentation of height and weight is motivated by two reasons: 1. the risk of (systemic) complications is greater in the presence of obesity; 2. body weight is important for calculating required doses of (study) medications.
",SCI Variable: HEIGHT,Height measurement,Injury_History;TRACK_TBI,No references available,Adult and Pediatric,Assessments and Examinations.Vital Signs and Other Body Measures,Assessments and Examinations.Vital Signs and Other Body Measures,NA,Assessments and Examinations.Vital Signs and Other Body Measures,Assessments and Examinations.Vital Signs and Other Body Measures,Assessments and Examinations.Vital Signs and Other Body Measures,NA,Assessments and Examinations.Vital Signs and Other Body Measures,Assessments and Examinations.Vital Signs and Other Body Measures,Assessments and Examinations.Vital Signs and Other Body Measures,Assessments and Examinations.Vital Signs and Other Body Measures,Assessments and Examinations.Vital Signs and Other Body Measures,NA,N/A.N/A,Assessments and Examinations.Vital Signs and Other Body Measures,Assessments and Examinations.Vital Signs and Other Body Measures;Outcomes and End Points.Assessing Comorbidities,Supplemental,Supplemental,Supplemental,Supplemental,Supplemental,NA,Core,Core,Core,NA,Supplemental,Supplemental,Supplemental,Supplemental,Supplemental,NA,Supplemental,Core,Supplemental,Height measurement,NA,NA,NIH/NINDS,NINDSCDE,NINDSCDE@emmes.com,NA,NA,NIH/NINDS,NINDSCDE,NINDSCDE@emmes.com,2014-04-01,2017-07-18,Published,NA,NA
InclusnXclusnCntrlInd,NeurologicalExam,Inclusion Exclusion Criteria Control Indicator,Unique Data Element,1,Indicated if the participant is subject or control,Subject or Control Indicator,Alphanumeric,NA,Single Pre-Defined Value Selected,NA,NA,Case;Control,Case;Control,1;2,NA,NA,NA,NA,NA,Is the participant/subject a control?,NA,No references available,Adult and Pediatric,"Protocol Experience.Participant/Subject Identification, Eligibility, and Enrollment",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2014-04-01,2014-04-01,Published,NA,NA
InfConsntObtInd,InformedConsent,Informed consent obtained indicator,Common Data Element,1.1,Indicator of whether informed consent was obtained for the participant/subject to participate in the clinical research study.,Indicator of whether informed consent was obtained for the participant/subject to participate in the clinical research study,Alphanumeric,NA,Single Pre-Defined Value Selected,NA,NA,No;Unknown;Yes,No;Unknown;Yes,0;9;1,NA,NA,NA,"GENERAL: Choose one. If YES, record date informed consent was obtained.",NA,Was informed consent obtained?,NA,No references available,Adult and Pediatric,"Protocol Experience.Participant/Subject Identification, Eligibility, and Enrollment",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Core,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Informed consent obtained indicator,NA,NA,NIH/CIT/BRICS,Olga Vovk,olga.vovk@nih.gov,NA,NA,NIH/NINDS,NINDSCDE,NINDSCDE@emmes.com,NA,2015-07-24,Published,NA,NA
InformConsntObtnDateTime,InformedConsent,Informed consent obtained date and time,Common Data Element,1.1,"Date (and time, if applicable and known) on which the participant/subject (or the legal representative on behalf of the participant/subject) agrees to participate in a protocol, treatment, or other activity by signing an informed consent document.","Date (and time, if applicable and known) on which the participant/subject (or the legal representative on behalf of the participant/subject) agrees to participate in a protocol, treatment, or other activity by signing an informed consent document.",Date or Date & Time,NA,Free-Form Entry,NA,NA,NA,NA,NA,NA,NA,NA,"GENERAL: Record the date(and time) the informed consent form is signed. The date/time should be recorded to the level of granularity known(e.g., year, year and month, complete date plus hours and minutes, etc.) and in the format acceptable to the study database.
TBI: Record the date/time according to the ISO 8601, the International Standard for the representation of dates and times (http: //www.iso.org/iso/home.html). The date/time should be recorded to the level of granularity known (e.g., year, year and month, complete date plus hours and minutes, etc.).","Data Sharing Instructions: When date/time data are prepared for aggregation or sharing they should be converted to the format specified by ISO 8601, YYYY-MM-DDThh:mm:ss.",Date and time of informed consent,NA,"GENERAL: No references available
TBI: 21 CFR 50.20 General requirements for informed consent A Guide to Informed Consent - Information Sheet: Guidance for Institutional Review Boards and Clinical Investigators Contents (http: //www.fda.gov/RegulatoryInformation/Guidances/ucm126431.htm#general)",Adult and Pediatric,"Protocol Experience.Participant/Subject Identification, Eligibility, and Enrollment","Protocol Experience.Participant/Subject Identification, Eligibility, and Enrollment",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Core,Supplemental,Supplemental,Supplemental,Supplemental,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Informed consent obtained date and time,NA,NA,NIH/CIT/BRICS,Olga Vovk,olga.vovk@nih.gov,NA,NA,NIH/NINDS,NINDSCDE,NINDSCDE@emmes.com,NA,2015-10-13,Published,NA,NA
MDSUPDRSAnxsMoodScore,MDS-UPDRS,Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS UPDRS) - anxious mood score,Common Data Element,1.1,"Score for the participant's/subject's anxious mood over the past week determining if he or she felt nervous, tense, worried or anxious, as a part of Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS UPDRS)","Score for the participant's/subject's anxious mood over the past week determining if he or she felt nervous, tense, worried or anxious, as a part of Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS UPDRS)",Numeric Values,NA,Single Pre-Defined Value Selected,NA,NA,0;1;2;3;4;555,"Normal: No anxious feelings;Slight: Anxious feelings present but not sustained for more than one day at a time. No interference with patient's ability to carry out normal activities and social interactions;Mild: Anxious feelings are sustained over more than one day at a time, but without interference with patient's ability to carry out normal activities and social interactions;Moderate: Anxious feelings interfere with, but do not preclude, the patient's ability to carry out normal activities and social interactions;Severe: Anxious feelings preclude patient's ability to carry out normal activities and social interactions.;Unable To Rate",0;1;2;3;4;555,NA,NA,NA,"PD:
Instructions to examiner: Determine nervous, tense, worried or anxious feelings (including panic attacks) over the past week and rate their duration and interference with the patient's ability to carry out daily routines and engage in social interactions. Instructions to patients [and caregiver]: Over the past week have you felt nervous, worried or tense? If yes, was this feeling for longer than one day at a time? Did it make it difficult for you to follow your usual activities or to be with other people? [If yes, examiner asks patient or caregiver to elaborate and probes for information.]",MDS UPDRS Q1.4.  CDISC variables  QSORRES  for QSTESTCD=UPD2104,ANXIOUS MOOD,CDISC;MDSUPDRS,"PD:
URL: http://www.movementdisorders.org/UserFiles/New%20UPDRS%207%203%2008%20final.pdf",Adult,NA,NA,Outcomes and End Points.Motor Function,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Core,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,MDS UPDRS Q1.4,NA,NA,NIH/NINDS,NINDSCDE,NINDSCDE@emmes.com,NA,NA,NIH/NINDS,NINDSCDE,NINDSCDE@emmes.com,2014-04-01,2020-02-05,Published,NA,NA
MDSUPDRSApathyScore,MDS-UPDRS,Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS UPDRS) - apathy score,Common Data Element,1.1,"Score for the participant's/subject's apathy, considering the level of spontaneous activity, assertiveness, motivation and initiative and how it affects the performance of daily routines, as a part of Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS UPDRS)","Score for the participant's/subject's apathy, as a part of Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS UPDRS)",Numeric Values,NA,Single Pre-Defined Value Selected,NA,NA,0;1;2;3;4;555,"Normal: No apathy;Slight: Apathy appreciated by patient and/or caregiver, but no interference with daily activities and social interactions;Mild: Apathy interferes with isolated activities and social interactions;Moderate: Apathy interferes with most activities and social interactions;Severe: Passive and withdrawn, complete loss of initiative.;Unable To Rate",0;1;2;3;4;555,NA,NA,NA,"PD:
Instructions to examiner: Consider level of spontaneous activity, assertiveness, motivation and initiative and rate the impact of reduced levels on performance of daily routines and social interactions. Here the examiner should attempt to distinguish between apathy and similar symptoms that are best explained by depression. Instructions to patients (and caregiver): Over the past week, have you felt indifferent to doing activities or being with people? If yes, examiner asks patient or caregiver to elaborate and probes for information.]",MDS UPDRS Q1.5.  CDISC variables  QSORRES  for QSTESTCD=UPD2105,APATHY,CDISC;MDSUPDRS,"PD:
URL: http://www.movementdisorders.org/UserFiles/New%20UPDRS%207%203%2008%20final.pdf",Adult,NA,NA,Outcomes and End Points.Motor Function,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Core,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,MDS UPDRS Q1.5,NA,NA,NIH/NINDS,NINDSCDE,NINDSCDE@emmes.com,NA,NA,NIH/NINDS,NINDSCDE,NINDSCDE@emmes.com,2014-04-01,2020-02-05,Published,NA,NA
MDSUPDRSArisingFrmChrScore,MDS-UPDRS,Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS UPDRS) - arise from chair score,Common Data Element,1.1,"Score for the participant's/subject's ability to arise from a chair observing the posture, as a part of Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS UPDRS)","Score for the participant's/subject's ability to arise from a chair observing the posture, as a part of Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS UPDRS)",Numeric Values,NA,Single Pre-Defined Value Selected,NA,NA,0;1;2;3;4;555,"Normal: No problems. Able to arise quickly without hesitation;Slight: Arising is slower than normal, or may need more than one attempt, or may need to move forward in the chair to arise. No need to use the arms of the chair;Mild: Pushes self up from arms of chair without difficulty.;Moderate: Needs to push off, but tends to fall back or may have to try more than one time using arms of chair, but can get up without help.;Severe: Unable to arise without help.;Unable To Rate",0;1;2;3;4;555,NA,NA,NA,"PD:
Have the patient sit in a straight-backed chair with arms, with both feet on the floor and sitting back in the chair (if the patient is not too short). Allow only one attempt in this situation. If unsuccessful, allow the patient to push off using his/her hands on the arms of the chair. Allow a maximum of three trials of pushing off. If still not successful, assist the patient to arise. After the patient stands up, observe the posture for item 3.13",MDS UPDRS Q3.9.  CDISC variables  QSORRES  for QSTESTCD=UPD2309,ARISING FROM CHAIR,CDISC;MDSUPDRS,"PD:
URL: http://www.movementdisorders.org/UserFiles/New%20UPDRS%207%203%2008%20final.pdf",Adult,NA,NA,Outcomes and End Points.Motor Function,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Core,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,MDS UPDRS Q3.9,NA,NA,NIH/NINDS,NINDSCDE,NINDSCDE@emmes.com,NA,NA,NIH/NINDS,NINDSCDE,NINDSCDE@emmes.com,2014-04-01,2020-02-05,Published,NA,NA
MDSUPDRSChwngSwllwngScore,MDS-UPDRS,Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS UPDRS) - chew swallow score,Common Data Element,1.1,"Score for the participant's/subject's ability to chew and swallow food, as a part of Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS UPDRS)","Score for the participant's/subject's ability to chew and swallow food, as a part of Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS UPDRS)",Numeric Values,NA,Single Pre-Defined Value Selected,NA,NA,0;1;2;3;4,"Normal: No problems;Slight: I am aware of slowness in my chewing or increased effort at swallowing, but I do not choke or need to have my food specially prepared;Mild: I need to have my pills cut or my food specially prepared because of chewing or swallowing problems, but I have not choked over the past week;Moderate. I choked at least once in the past week;Severe: Because of chewing and swallowing problems, I need a feeding tube.",0;1;2;3;4,NA,NA,NA,"PD:
Refer to instrument for additional instructions",MDS UPDRS Q2.3.  CDISC variables  QSORRES  for QSTESTCD=UPD2203,CHEWING AND SWALLOWING,CDISC;MDSUPDRS,"PD:
URL: http://www.movementdisorders.org/UserFiles/New%20UPDRS%207%203%2008%20final.pdf",Adult,NA,NA,Outcomes and End Points.Motor Function,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Core,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,MDS UPDRS Q2.3,NA,NA,NIH/NINDS,NINDSCDE,NINDSCDE@emmes.com,NA,NA,NIH/NINDS,NINDSCDE,NINDSCDE@emmes.com,2014-04-01,2020-02-05,Published,NA,NA
MDSUPDRSComplxtyMtrFluctScore,MDS-UPDRS,Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS UPDRS) - complexity motor fluctuation score,Common Data Element,1.1,"Score for the participant's/subject's level of complex motor fluctuations, as a part of Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS UPDRS)","Score for the participant's/subject's level of complex motor fluctuations, as a part of Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS UPDRS)",Numeric Values,NA,Single Pre-Defined Value Selected,NA,NA,0;1;2;3;4;555,Normal: No motor fluctuations;Slight: OFF times are predictable all or almost all of the time (greater than 75 percent);Mild: OFF times are predictable most of the time (51-75 percent);Moderate: OFF times are predictable some of the time (26-50 percent);Severe: OFF episodes are rarely predictable (less than 25 percent);Unable To Rate,0;1;2;3;4;555,NA,NA,NA,"PD:
Determine the usual predictability of OFF function whether due to dose, time of day, food intake or other factors. Use the information provided by the patients and caregiver and supplement with your own observations. You will ask if the patient can count on them always coming at a special time, mostly coming at a special time (in which case you will probe further to separate slight from mild), only sometimes coming at a special time or are they totally unpredictable? Narrowing down the percentage will allow you to find the correct answer","MDS UPDRS 4.5.  CDISC variables  QSORRES  for QSTESTCD=UPD2405, QSEVLT=-P1W",COMPLEXITY OF MOTOR FLUCTUATIONS,CDISC;MDSUPDRS,"PD:
URL: http://www.movementdisorders.org/UserFiles/New%20UPDRS%207%203%2008%20final.pdf",Adult,NA,NA,Outcomes and End Points.Motor Function,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Core,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,MDS UPDRS 4.5,NA,NA,NIH/NINDS,NINDSCDE,NINDSCDE@emmes.com,NA,NA,NIH/NINDS,NINDSCDE,NINDSCDE@emmes.com,2014-04-01,2020-02-05,Published,NA,NA
MDSUPDRSConstipProbScore,MDS-UPDRS,Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS UPDRS) - constipation problem score,Common Data Element,1.1,"Score for the participant's/subject's level of constipation, as a part of Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS UPDRS)","Score for the participant's/subject's level of constipation, as a part of Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS UPDRS)",Numeric Values,NA,Single Pre-Defined Value Selected,NA,NA,0;1;2;3;4,"Normal: No constipation;Slight: I have been constipated. I use extra effort to move my bowels. However, this problem does not disturb my activities or my being comfortable;Mild: Constipation causes me to have some troubles doing things or being comfortable;Moderate: Constipation causes me to have a lot of trouble doing things or being comfortable. However, it does not stop me from doing anything;Severe: I usually need physical help from someone else to empty my bowels.",0;1;2;3;4,NA,NA,NA,"PD:
Refer to instrument for additional instructions",MDS UPDRS Q1.11.  CDISC variables  QSORRES  for QSTESTCD=UPD2111,CONSTIPATION PROBLEMS,CDISC;MDSUPDRS,"PD:
URL: http://www.movementdisorders.org/UserFiles/New%20UPDRS%207%203%2008%20final.pdf",Adult,NA,NA,Outcomes and End Points.Motor Function,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Core,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,MDS UPDRS Q1.11,NA,NA,NIH/NINDS,NINDSCDE,NINDSCDE@emmes.com,NA,NA,NIH/NINDS,NINDSCDE,NINDSCDE@emmes.com,2014-04-01,2020-02-05,Published,NA,NA
MDSUPDRSConstncyRestTremrScore,MDS-UPDRS,Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS UPDRS) - constancy of rest tremor score,Common Data Element,1.1,"Score for the participant's/subject's constancy of rest tremor when different body parts are at rest, as a part of Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS UPDRS)","Score for the participant's/subject's constancy of rest tremor when different body parts are at rest, as a part of Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS UPDRS)",Numeric Values,NA,Single Pre-Defined Value Selected,NA,NA,0;1;2;3;4;555,Normal: No tremor;Slight: Tremor at rest is present less than 25 percent of the entire examination period;Mild: Tremor at rest is present 26-50percent of the entire examination period;Moderate: Tremor at rest is present 51-75 percent of the entire examination period;Severe: Tremor at rest is present greater than 75 percent of the entire examination period;Unable To Rate,0;1;2;3;4;555,NA,NA,NA,"PD:
It is rated purposefully at the end of the examination so that several minutes of information can be coalesced into the rating.",MDS UPDRS Q3.18.  CDISC variables  QSORRES  for QSTESTCD=UPD2318,CONSTANCY OF REST TREMOR,CDISC;MDSUPDRS,"PD:
URL: http://www.movementdisorders.org/UserFiles/New%20UPDRS%207%203%2008%20final.pdf",Adult,NA,NA,Outcomes and End Points.Motor Function,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Core,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,MDS UPDRS Q3.18,NA,NA,NIH/NINDS,NINDSCDE,NINDSCDE@emmes.com,NA,NA,NIH/NINDS,NINDSCDE,NINDSCDE@emmes.com,2014-04-01,2020-02-05,Published,NA,NA
MDSUPDRSDaytmSleepScore,MDS-UPDRS,Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS UPDRS) - daytime sleepiness score,Common Data Element,1.1,"Score for the participant's/subject's daytime sleepiness level , as a part of Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS UPDRS)","Score for the participant's/subject's daytime sleepiness level , as a part of Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS UPDRS)",Numeric Values,NA,Single Pre-Defined Value Selected,NA,NA,0;1;2;3;4,"Normal: No daytime sleepiness.;Slight: Daytime sleepiness occurs but I can resist and I stay awake;Mild: Sometimes I fall asleep when alone and relaxing. For example, while reading or watching TV;Moderate: I sometimes fall asleep when I should not. For example, while eating or talking with other people;Severe: I often fall asleep when I should not. For example, while eating or talking with other people.",0;1;2;3;4,NA,NA,NA,"PD:
Refer to instrument for additional instructions",MDS UPDRS Q1.8.  CDISC variables  QSORRES  for QSTESTCD=UPD2108,DAYTIME SLEEPINESS,CDISC;MDSUPDRS,"PD:
URL: http://www.movementdisorders.org/UserFiles/New%20UPDRS%207%203%2008%20final.pdf",Adult,NA,NA,Outcomes and End Points.Motor Function,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Core,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,MDS UPDRS Q1.8,NA,NA,NIH/NINDS,NINDSCDE,NINDSCDE@emmes.com,NA,NA,NIH/NINDS,NINDSCDE,NINDSCDE@emmes.com,2014-04-01,2020-02-05,Published,NA,NA
MDSUPDRSDopmnDysregSyndScore,MDS-UPDRS,Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS UPDRS) - dopamine dysregulation syndrome score,Common Data Element,1.1,"Score for the participant's/subject's features of dopamine dysregulation syndrome considering involvement in a variety of activities including atypical or excessive gambling (e.g. casinos or lottery tickets), atypical or excessive sexual drive or interests (e.g., unusual interest in pornography, masturbation, sexual demands on partner), other repetitive activities (e.g. hobbies, dismantling objects, sorting or organizing), or taking extra non-prescribed medication for non-physical reasons (i.e., addictive behavior), as a part of Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS UPDRS).","Score for the participant's/subject's features of dopamine dysregulation syndrome considering involvement in a variety of activities, as a part of Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS UPDRS).",Numeric Values,NA,Single Pre-Defined Value Selected,NA,NA,0;1;2;3;4;555,Normal: No problems present;Slight: Problems are present but usually do not cause any difficulties for the patient or family/caregiver;Mild: Problems are present and usually cause a few difficulties in the patient's personal and family life;Moderate: Problems are present and usually cause a lot of difficulties in the patient's personal and family life;Severe: Problems are present and preclude the patient's ability to carry out normal activities or social interactions or to maintain previous standards in personal and family life.;Unable To Rate,0;1;2;3;4;555,NA,NA,NA,"PD:
Give patient examples such as gambling, cleaning, using the computer, taking extra medicine, obsessing about food or sex, all depending on the patients.",MDS UPDRS Q1.6.  CDISC variables  QSORRES  for QSTESTCD=UPD2106,FEATURES OF DOPAMINE DYSREGULATION SYNDROME,CDISC;MDSUPDRS,"PD:
URL: http://www.movementdisorders.org/UserFiles/New%20UPDRS%207%203%2008%20final.pdf",Adult,NA,NA,Outcomes and End Points.Motor Function,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Core,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,MDS UPDRS Q1.6,NA,NA,NIH/NINDS,NINDSCDE,NINDSCDE@emmes.com,NA,NA,NIH/NINDS,NINDSCDE,NINDSCDE@emmes.com,2014-04-01,2020-02-05,Published,NA,NA
MDSUPDRSDressingScore,MDS-UPDRS,Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS UPDRS) - dress score,Common Data Element,1.1,"Score for the participant's/subject's ability to dress himself or herself, as a part of Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS UPDRS)","Score for the participant's/subject's ability to dress himself or herself, as a part of Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS UPDRS)",Numeric Values,NA,Single Pre-Defined Value Selected,NA,NA,0;1;2;3;4,"Normal: Not at all (no problems);Slight: I am slow but I do not need help;Mild: I am slow and need help for a few dressing tasks (buttons, bracelets);Moderate: I need help for many dressing tasks;Severe: I need help for most or all dressing tasks",0;1;2;3;4,NA,NA,NA,"PD:
Refer to instrument for additional instructions",MDS UPDRS Q2.5.  CDISC variables  QSORRES  for QSTESTCD=UPD2205,DRESSING,CDISC;MDSUPDRS,"PD:
URL: http://www.movementdisorders.org/UserFiles/New%20UPDRS%207%203%2008%20final.pdf",Adult,NA,NA,Outcomes and End Points.Motor Function,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Core,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,MDS UPDRS Q2.5,NA,NA,NIH/NINDS,NINDSCDE,NINDSCDE@emmes.com,NA,NA,NIH/NINDS,NINDSCDE,NINDSCDE@emmes.com,2014-04-01,2020-02-05,Published,NA,NA
MDSUPDRSDrpssMoodScore,MDS-UPDRS,Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS UPDRS) - depress mood score,Common Data Element,1.1,"Score of the participant's/subject's depressed mood considering low mood, sadness, hopelessness, feelings of emptiness or loss of enjoyment, as a part of Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS UPDRS)","Score of the participant's/subject's depressed mood considering low mood, sadness, hopelessness, feelings of emptiness or loss of enjoyment, as a part of Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS UPDRS)",Numeric Values,NA,Single Pre-Defined Value Selected,NA,NA,0;1;2;3;4;555,"0= Normal: No depressed mood;Slight: Episodes of depressed mood that are not sustained for more than one day at a time. No interference with patient's ability to carry out normal activities;Mild: Depressed mood that is sustained over days, but without interference with normal activities and social interactions.;Moderate: Depressed mood that interferes with, but does not preclude, the patient's ability to carry out normal activities and social interactions.;Severe: Depressed mood precludes patient's ability to carry out normal activities and social interactions.;Unable To Rate",0;1;2;3;4;555,NA,NA,NA,"PD:
Instructions to examiner: Consider low mood, sadness, hopelessness, feelings of emptiness or loss of enjoyment. Determine their presence and duration over the past week and rate their interference with the patient's ability to carry out daily routines and engage in social interactions. Instruction to the patient (and caregiver): Over the past week have you felt low, sad, hopeless or unable to enjoy things? If yes, was this feeling for longer than one day at a time? Did it make it difficult for you carry out your usual activities or to be with people? If yes, examiner asks patient or caregiver to elaborate and probes for information]",MDS UPDRS Q1.3.  CDISC variables  QSORRES  for QSTESTCD=UPD2103,DEPRESSED MOOD,CDISC;MDSUPDRS,"PD:
URL: http://www.movementdisorders.org/UserFiles/New%20UPDRS%207%203%2008%20final.pdf",Adult,NA,NA,Outcomes and End Points.Motor Function,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Core,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,MDS UPDRS Q1.3,NA,NA,NIH/NINDS,NINDSCDE,NINDSCDE@emmes.com,NA,NA,NIH/NINDS,NINDSCDE,NINDSCDE@emmes.com,2014-04-01,2020-02-05,Published,NA,NA
MDSUPDRSDyskChreaDystnaPrsScr,MDS-UPDRS,Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS UPDRS) - dyskinesia chorea or dystonia presence score,Common Data Element,1.1,"Indicator for whether the participant's/subject's had any dyskinesia (chorea or dystonia) present during examination, as a part of Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS UPDRS)","Indicator for whether the participant's/subject's had any dyskinesia (chorea or dystonia) present during examination, as a part of Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS UPDRS)",Alphanumeric,NA,Single Pre-Defined Value Selected,NA,NA,No;Yes,No;Yes,0;1,NA,NA,NA,"PD:
Refer to instrument for additional instructions",MDS UPDRS Motor exam: Dyskinesia present indicator.  CDISC variables  QSORRES  for QSTESTCD=UPD2DA,Were dyskinesias (chorea or dystonia) present during examination?,CDISC;MDSUPDRS,"PD:
URL: http://www.movementdisorders.org/UserFiles/New%20UPDRS%207%203%2008%20final.pdf",Adult,NA,NA,Outcomes and End Points.Motor Function,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Core,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,MDS UPDRS Motor exam: Dyskinesia present indicator,NA,NA,NIH/NINDS,NINDSCDE,NINDSCDE@emmes.com,NA,NA,NIH/NINDS,NINDSCDE,NINDSCDE@emmes.com,2014-04-01,2020-02-05,Published,NA,NA
MDSUPDRSEatingTskScore,MDS-UPDRS,Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS UPDRS) - eat task score,Common Data Element,1.1,"Score for the participant's/subject's ability to eat and handle food and utensils, as a part of Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS UPDRS)","Score for the participant's/subject's ability to eat and handle food and utensils, as a part of Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS UPDRS)",Numeric Values,NA,Single Pre-Defined Value Selected,NA,NA,0;1;2;3;4,"Normal: Not at all (no problems);Slight: I am slow, but I do not need any help handling my food and have not had food spills while eating;Mild: I am slow with my eating and have occasional food spills. I may need help with a few tasks such as cutting meat;Moderate: I need help with many eating tasks but can manage some alone;Severe: I need help for most or all eating tasks.",0;1;2;3;4,NA,NA,NA,"PD:
Refer to instrument for additional instructions",MDS UPDRS Q2.4.  CDISC variables  QSORRES  for QSTESTCD=UPD2204,EATING TASKS,CDISC;MDSUPDRS,"PD:
URL: http://www.movementdisorders.org/UserFiles/New%20UPDRS%207%203%2008%20final.pdf",Adult,NA,NA,Outcomes and End Points.Motor Function,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Core,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,MDS UPDRS Q2.4,NA,NA,NIH/NINDS,NINDSCDE,NINDSCDE@emmes.com,NA,NA,NIH/NINDS,NINDSCDE,NINDSCDE@emmes.com,2014-04-01,2020-02-05,Published,NA,NA
MDSUPDRSFacialExprScore,MDS-UPDRS,Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS UPDRS) - facial expression score,Common Data Element,1.2,"Score for the participant's/subject's ability to make facial expressions observing the eye-blink frequency, masked faces or loss of facial expression, spontaneous smiling and parting of lips, as a part of Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS UPDRS)","Score for the participant's/subject's ability to make facial expressions, as a part of Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS UPDRS)",Numeric Values,NA,Single Pre-Defined Value Selected,NA,NA,0;1;2;3;4;555,"Normal: Normal facial expression;Slight: Minimal masked faces manifested only by decreased frequency of blinking;Mild: In addition to decreased eye-blink frequency, Masked faces present in the lower face as well, namely fewer movements around the mouth, such as less spontaneous smiling, but lips not parted;Moderate: Masked faces with lips parted some of the time when the mouth is at rest;Severe: Masked faces with lips parted most of the time when the mouth is at rest;Unable To Rate",0;1;2;3;4;555,NA,NA,NA,"PD:
Refer to instrument for additional instructions",MDS UPDRS Q3.2.  CDISC variables  QSORRES  for QSTESTCD=UPD2302,FACIAL EXPRESSION,CDISC;MDSUPDRS,"PD:
URL: http://www.movementdisorders.org/UserFiles/New%20UPDRS%207%203%2008%20final.pdf",Adult,NA,NA,Outcomes and End Points.Motor Function,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Core,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,MDS UPDRS Q3.2,NA,NA,NIH/NINDS,NINDSCDE,NINDSCDE@emmes.com,NA,NA,NIH/NINDS,NINDSCDE,NINDSCDE@emmes.com,2014-04-01,2020-02-05,Published,NA,NA
MDSUPDRSFatigueScore,MDS-UPDRS,Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS UPDRS) - fatigue score,Common Data Element,1.1,"Score for the participant's/subject's level of fatigue, as a part of Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS UPDRS)","Score for the participant's/subject's level of fatigue, as a part of Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS UPDRS)",Numeric Values,NA,Single Pre-Defined Value Selected,NA,NA,0;1;2;3;4,"Normal: No fatigue;Slight: Fatigue occurs. However it does not cause me troubles doing things or being with people;Mild: Fatigue causes me some troubles doing things or being with people;Moderate: Fatigue causes me a lot of troubles doing things or being with people. However, it does not stop me from doing anything;Severe: Fatigue stops me from doing things or being with people.",0;1;2;3;4,NA,NA,NA,"PD:
Refer to instrument for additional instructions",MDS UPDRS Q1.13.  CDISC variables  QSORRES  for QSTESTCD=UPD2113,FATIGUE,CDISC;MDSUPDRS,"PD:
URL: http://www.movementdisorders.org/UserFiles/New%20UPDRS%207%203%2008%20final.pdf",Adult,NA,NA,Outcomes and End Points.Motor Function,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Core,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,MDS UPDRS Q1.13,NA,NA,NIH/NINDS,NINDSCDE,NINDSCDE@emmes.com,NA,NA,NIH/NINDS,NINDSCDE,NINDSCDE@emmes.com,2014-04-01,2020-02-05,Published,NA,NA
MDSUPDRSFingerTppngLftHndScore,MDS-UPDRS,Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS UPDRS) - finger tap left hand score,Common Data Element,1.1,"Score for the participant's/subject's ability to tap the left hand fingers evaluating the speed, amplitude, hesitations, halts and decrementing amplitude, as a part of Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS UPDRS)","Score for the participant's/subject's ability to tap the left hand fingers evaluating the speed, amplitude, hesitations, halts and decrementing amplitude, as a part of Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS UPDRS)",Numeric Values,NA,Single Pre-Defined Value Selected,NA,NA,0;1;2;3;4;555,"Normal: No problems;Slight: Any of the following: a) the regular rhythm is broken with one or two interruptions or hesitations of the tapping movement| b) slight slowing| c) the amplitude decrements near the end of the 10 taps;Mild: Any of the following: a) 3 to 5 interruptions during tapping| b) mild slowing| c) the amplitude decrements midway in the 10-tap sequence;Moderate: Any of the following: a) more than 5 interruptions during tapping or at least one longer arrest (freeze) in ongoing movement| b) moderate slowing| c) the amplitude decrements starting after the 1st tap;Severe: Cannot or can only barely perform the task because of slowing, interruptions or decrements.;Unable To Rate",0;1;2;3;4;555,NA,NA,NA,"PD:
Each hand is tested separately. Demonstrate the task, but do not continue to perform the task while the patient is being tested. Rate each side separately, evaluating speed, amplitude, hesitations, halts and decrementing amplitude.",MDS UPDRS Q3.4b.  CDISC variables  QSORRES  for QSTESTCD=UPD2304B,FINGER TAPPING,CDISC;MDSUPDRS,"PD:
URL: http://www.movementdisorders.org/UserFiles/New%20UPDRS%207%203%2008%20final.pdf",Adult,NA,NA,Outcomes and End Points.Motor Function,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Core,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,MDS UPDRS Q3.4b,NA,NA,NIH/NINDS,NINDSCDE,NINDSCDE@emmes.com,NA,NA,NIH/NINDS,NINDSCDE,NINDSCDE@emmes.com,2014-04-01,2020-02-05,Published,NA,NA
MDSUPDRSFingerTppngRteHndScore,MDS-UPDRS,Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS UPDRS) - finger tap right hand score,Common Data Element,1.1,"Score for the participant's/subject's ability to tap the right hand fingers evaluating the speed, amplitude, hesitations, halts and decrementing amplitude, as a part of Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS UPDRS)","Score for the participant's/subject's ability to tap the right hand fingers evaluating the speed, amplitude, hesitations, halts and decrementing amplitude, as a part of Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS UPDRS)",Numeric Values,NA,Single Pre-Defined Value Selected,NA,NA,0;1;2;3;4;555,"Normal: No problems;Slight: Any of the following: a) the regular rhythm is broken with one or two interruptions or hesitations of the tapping movement| b) slight slowing| c) the amplitude decrements near the end of the 10 taps;Mild: Any of the following: a) 3 to 5 interruptions during tapping| b) mild slowing| c) the amplitude decrements midway in the 10-tap sequence;Moderate: Any of the following: a) more than 5 interruptions during tapping or at least one longer arrest (freeze) in ongoing movement| b) moderate slowing| c) the amplitude decrements starting after the 1st tap;Severe: Cannot or can only barely perform the task because of slowing, interruptions or decrements.;Unable To Rate",0;1;2;3;4;555,NA,NA,NA,"PD:
Each hand is tested separately. Demonstrate the task, but do not continue to perform the task while the patient is being tested. Rate each side separately, evaluating speed, amplitude, hesitations, halts and decrementing amplitude.",MDS UPDRS Q3.4a.  CDISC variables  QSORRES  for QSTESTCD=UPD2304A,FINGER TAPPING,CDISC;MDSUPDRS,"PD:
URL: http://www.movementdisorders.org/UserFiles/New%20UPDRS%207%203%2008%20final.pdf",Adult,NA,NA,Outcomes and End Points.Motor Function,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Core,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,MDS UPDRS Q3.4a,NA,NA,NIH/NINDS,NINDSCDE,NINDSCDE@emmes.com,NA,NA,NIH/NINDS,NINDSCDE,NINDSCDE@emmes.com,2014-04-01,2020-02-05,Published,NA,NA
MDSUPDRSFreeFlowSpeechScore,MDS-UPDRS,Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS UPDRS) - free flow speech score,Common Data Element,1.1,"Score for the participant's/subject's free flowing speech ability considering the volume, modulation, clarity, slurring, palilalia, and tachyphemia, as a part of Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS UPDRS)","Score for the participant's/subject's free flowing speech ability considering the volume, modulation, clarity, slurring, palilalia, and tachyphemia, as a part of Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS UPDRS)",Numeric Values,NA,Single Pre-Defined Value Selected,NA,NA,0;1;2;3;4;555,"Normal: No speech problems;Slight: Loss of modulation, diction or volume, but still all words easy to understand;Mild: Loss of modulation, diction, or volume, with a few words unclear, but the overall sentences easy to follow;Moderate: Speech is difficult to understand to the point that some, but not most, sentences are poorly understood;Severe: Most speech is difficult to understand or unintelligible;Unable To Rate",0;1;2;3;4;555,NA,NA,NA,"PD:
Refer to instrument for additional instructions",MDS UPDRS Q3.1.  CDISC variables  QSORRES  for QSTESTCD=UPD2301,SPEECH,CDISC;MDSUPDRS,"PD:
URL: http://www.movementdisorders.org/UserFiles/New%20UPDRS%207%203%2008%20final.pdf",Adult,NA,NA,Outcomes and End Points.Motor Function,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Core,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,MDS UPDRS Q3.1,NA,NA,NIH/NINDS,NINDSCDE,NINDSCDE@emmes.com,NA,NA,NIH/NINDS,NINDSCDE,NINDSCDE@emmes.com,2014-04-01,2020-02-05,Published,NA,NA
MDSUPDRSFreezingGaitScore,MDS-UPDRS,Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS UPDRS) - freeze gait score,Common Data Element,1.1,"Score for the participant's/subject's level of gait freezing episodes or hesitations especially when turning and reaching the end of the task, as a part of Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS UPDRS)","Score for the participant's/subject's level of gait freezing episodes or hesitations especially when turning and reaching the end of the task, as a part of Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS UPDRS)",Numeric Values,NA,Single Pre-Defined Value Selected,NA,NA,0;1;2;3;4;555,"Normal: No freezing;Slight: Freezes on starting, turning or walking through doorway with a single halt during any of these events, but then continues smoothly without freezing during straight walking;Mild: Freezes on starting, turning or walking through doorway with more than one halt during any of these activities, but continues smoothly without freezing during straight walking;Moderate: Freezes once during straight walking;Severe: Freezes multiple times during straight walking.;Unable To Rate",0;1;2;3;4;555,NA,NA,NA,"PD:
Observe for start hesitation and stuttering movements especially when turning and reaching the end of the task. To the extent that safety permits, patients may NOT use sensory tricks during the assessment.",MDS UPDRS Q3.11.  CDISC variables  QSORRES  for QSTESTCD=UPD2311,FREEZING OF GAIT,CDISC;MDSUPDRS,"PD:
URL: http://www.movementdisorders.org/UserFiles/New%20UPDRS%207%203%2008%20final.pdf",Adult,NA,NA,Outcomes and End Points.Motor Function,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Core,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,MDS UPDRS Q3.11,NA,NA,NIH/NINDS,NINDSCDE,NINDSCDE@emmes.com,NA,NA,NIH/NINDS,NINDSCDE,NINDSCDE@emmes.com,2014-04-01,2020-02-05,Published,NA,NA
MDSUPDRSFreezingScore,MDS-UPDRS,Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS UPDRS) - freeze score,Common Data Element,1.1,"Score for the participant's/subject's inability to move because he or she cannot suddenly move the feet, as a part of Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS UPDRS)","Score for the participant's/subject's inability to move because he or she cannot suddenly move the feet, as a part of Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS UPDRS)",Numeric Values,NA,Single Pre-Defined Value Selected,NA,NA,0;1;2;3;4,"Normal: Not at all (no problems);Slight: I briefly freeze but I can easily start walking again. I do not need help from someone else or a walking aid (cane or walker) because of freezing;Mild: I freeze and have trouble starting to walk again, but I do not need someone's help or a walking aid (cane or walker) because of freezing;Moderate: When I freeze I have a lot of trouble starting to walk again and, because of freezing, I sometimes need to use a walking aid or need someone else's help;Severe: Because of freezing, most or all of the time, I need to use a walking aid or someone's help",0;1;2;3;4,NA,NA,NA,"PD:
Refer to instrument for additional instructions",MDS UPDRS Q2.13.  CDISC variables  QSORRES  for QSTESTCD=UPD2213,Freezing when walking,CDISC;MDSUPDRS,"PD:
URL: http://www.movementdisorders.org/UserFiles/New%20UPDRS%207%203%2008%20final.pdf",Adult,NA,NA,Outcomes and End Points.Motor Function,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Core,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,MDS UPDRS Q2.13,NA,NA,NIH/NINDS,NINDSCDE,NINDSCDE@emmes.com,NA,NA,NIH/NINDS,NINDSCDE,NINDSCDE@emmes.com,2014-04-01,2020-02-05,Published,NA,NA
MDSUPDRSFuncImpactDyskScore,MDS-UPDRS,Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS UPDRS) - functional impact of dyskinesia score,Common Data Element,1.1,"Score for the participant's/subject's level of functional impact of dyskinesia, as a part of Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS UPDRS)","Score for the participant's/subject's level of functional impact of dyskinesia, as a part of Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS UPDRS)",Numeric Values,NA,Single Pre-Defined Value Selected,NA,NA,0;1;2;3;4;555,"Normal: No dyskinesias or no impact by dyskinesias on activities or social interactions;Slight: Dyskinesias impact on a few activities, but the patient usually performs all activities and participates in all social interactions during dyskinetic periods;Mild: Dyskinesias impact on many activities, but the patient usually performs all activities and participates in all social interactions during dyskinetic periods;Moderate: Dyskinesias impact on activities to the point that the patient usually does not perform some activities or does not usually participate in some social activities during dyskinetic episodes;Severe: Dyskinesias impact on function to the point that the patient usually does not perform most activities or participate in most social interactions during dyskinetic episodes.;Unable To Rate",0;1;2;3;4;555,NA,NA,NA,"PD:
Determine the degree to which dyskinesias impact on the patient's daily function in terms of activities and social interactions. Use the patient's and caregiver's response to your question and your own observations during the office visit to arrive at the best answer.","MDS UPDRS Q4.2.  CDISC variables  QSORRES  for QSTESTCD=UPD2402, QSEVLT=-P1W",FUNCTIONAL IMPACT OF DYSKINESIAS,CDISC;MDSUPDRS,"PD:
URL: http://www.movementdisorders.org/UserFiles/New%20UPDRS%207%203%2008%20final.pdf",Adult,NA,NA,Outcomes and End Points.Motor Function,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Core,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,MDS UPDRS Q4.2,NA,NA,NIH/NINDS,NINDSCDE,NINDSCDE@emmes.com,NA,NA,NIH/NINDS,NINDSCDE,NINDSCDE@emmes.com,2014-04-01,2020-02-05,Published,NA,NA
MDSUPDRSFuncImpactFluctScore,MDS-UPDRS,Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS UPDRS) - impact fluctuation score,Common Data Element,1.1,"Score for the participant's/subject's level of functional impact of fluctuations, as a part of Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS UPDRS)","Score for the participant's/subject's level of functional impact of fluctuations, as a part of Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS UPDRS)",Numeric Values,NA,Single Pre-Defined Value Selected,NA,NA,0;1;2;3;4;555,"Normal: No fluctuations or No impact by fluctuations on performance of activities or social interactions;Slight: Fluctuations impact on a few activities, but during OFF, the patient usually performs all activities and participates in all social interactions that typically occur during the ON state;Mild: Fluctuations impact many activities, but during OFF, the patient still usually performs all activities and participates in all social interactions that typically occur during the ON state;Moderate: Fluctuations impact on the performance of activities during OFF to the point that the patient usually does not perform some activities or participate in some social interactions that are performed during ON periods;Severe: Fluctuations impact on function to the point that, during OFF, the patient usually does not perform most activities or participate in most social interactions that are performed during ON periods;Unable To Rate",0;1;2;3;4;555,NA,NA,NA,"PD:
Determine the degree to which motor fluctuations impact on the patient's daily function in terms of activities and social interactions. This question concentrates on the difference between the ON state and the OFF state. If the patient has no OFF time, the rating must be 0, but if patients have very mild fluctuations, it is still possible to be rated 0 on this item if no impact on activities occurs.  Refer to instrument for additional instructions.","MDS UPDRS 4.4.  CDISC variables  QSORRES  for QSTESTCD=UPD2404, QSEVLT=-P1W",FUNCTIONAL IMPACT OF FLUCTUATIONS,CDISC;MDSUPDRS,"PD:
URL: http://www.movementdisorders.org/UserFiles/New%20UPDRS%207%203%2008%20final.pdf",Adult,NA,NA,Outcomes and End Points.Motor Function,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Core,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,MDS UPDRS 4.4,NA,NA,NIH/NINDS,NINDSCDE,NINDSCDE@emmes.com,NA,NA,NIH/NINDS,NINDSCDE,NINDSCDE@emmes.com,2014-04-01,2020-02-05,Published,NA,NA
MDSUPDRSGaitScore,MDS-UPDRS,Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS UPDRS) - gait score,Common Data Element,1.2,"Score for the participant's/subject's level of gait observing the stride amplitude, stride speed, height of foot lift, heel strike during walking, turning, and arm swing, as a part of Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS UPDRS)","Score for the participant's/subject's level of gait, as a part of Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS UPDRS).",Numeric Values,NA,Single Pre-Defined Value Selected,NA,NA,0;1;2;3;4;555,"Normal: No problems;Slight: Independent walking with minor gait impairment;Mild: Independent walking but with substantial gait impairment;Moderate: Requires an assistance device for safe walking (walking stick, walker) but not a person;Severe: Cannot walk at all or only with another person's assistance.;Unable To Rate",0;1;2;3;4;555,NA,NA,NA,"PD:
The patient should walk at least 10 meters (30 feet), then turn around and return to the examiner. This item measures multiple behaviors: stride amplitude, stride speed, height of foot lift, heel strike during walking, turning, and arm swing, but not freezing. Assess also for ""freezing of gait"" (next item 3.11) while patient is walking. observe posture for item 3.13",MDS UPDRS Q3.10.  CDISC variables  QSORRES  for QSTESTCD=UPD2310,GAIT,CDISC;MDSUPDRS,"PD:
URL: http://www.movementdisorders.org/UserFiles/New%20UPDRS%207%203%2008%20final.pdf",Adult,NA,NA,Outcomes and End Points.Motor Function,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Core,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,MDS UPDRS Q3.10,NA,NA,NIH/NINDS,NINDSCDE,NINDSCDE@emmes.com,NA,NA,NIH/NINDS,NINDSCDE,NINDSCDE@emmes.com,2014-04-01,2020-02-05,Published,NA,NA
MDSUPDRSGlblSpontntyMvmntScore,MDS-UPDRS,Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS UPDRS) - global spontaneity of movement score,Common Data Element,1.1,"Score for the participant's/subject's level of global spontaneity of movement observing the slowness, hesitancy, and small amplitude and poverty of movement in general","Score for the participant's/subject's level of global spontaneity of movement observing the slowness, hesitancy, and small amplitude and poverty of movement in general",Numeric Values,NA,Single Pre-Defined Value Selected,NA,NA,0;1;2;3;4;555,Normal: No problems;Slight: Slight global slowness and poverty of spontaneous movements;Mild: Mild global slowness and poverty of spontaneous movements;Moderate: Moderate global slowness and poverty of spontaneous movements;Severe: Severe global slowness and poverty of spontaneous movements.;Unable To Rate,0;1;2;3;4;555,NA,NA,NA,"PD:
This assessment is based on the examiner's global impression after observing for spontaneous gestures while sitting, and the nature of arising and walking.",MDS UPDRS Q3.14.  CDISC variables  QSORRES  for QSTESTCD=UPD2314,GLOBAL SPONTANEITY OF MOVEMENT (BODY BRADYKINESIA),CDISC;MDSUPDRS,"PD:
URL: http://www.movementdisorders.org/UserFiles/New%20UPDRS%207%203%2008%20final.pdf",Adult,NA,NA,Outcomes and End Points.Motor Function,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Core,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,MDS UPDRS Q3.14,NA,NA,NIH/NINDS,NINDSCDE,NINDSCDE@emmes.com,NA,NA,NIH/NINDS,NINDSCDE,NINDSCDE@emmes.com,2014-04-01,2020-02-05,Published,NA,NA
MDSUPDRSGttngOutBedScore,MDS-UPDRS,Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS UPDRS) - get out bed car deep chair score,Common Data Element,1.1,"Score for the participant's/subject's ability to get out of bed, a car, or a deep chair, as a part of Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS UPDRS)","Score for the participant's/subject's ability to get out of bed, a car, or a deep chair, as a part of Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS UPDRS)",Numeric Values,NA,Single Pre-Defined Value Selected,NA,NA,0;1;2;3;4,"Normal: Not at all (no problems);Slight: I am slow or awkward, but I usually can do it on my first try;Mild: I need more than one try to get up or need occasional help;Moderate: I sometimes need help to get up, but most times I can still do it on my own;Severe: I need help most or all of the time",0;1;2;3;4,NA,NA,NA,"PD:
Refer to instrument for additional instructions",MDS UPDRS Q2.11.  CDISC variables  QSORRES  for QSTESTCD=UPD2211,GETTING OUT OF BED A CAR OR A DEEP CHAIR,CDISC;MDSUPDRS,"PD:
URL: http://www.movementdisorders.org/UserFiles/New%20UPDRS%207%203%2008%20final.pdf",Adult,NA,NA,Outcomes and End Points.Motor Function,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Core,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,MDS UPDRS Q2.11,NA,NA,NIH/NINDS,NINDSCDE,NINDSCDE@emmes.com,NA,NA,NIH/NINDS,NINDSCDE,NINDSCDE@emmes.com,2014-04-01,2020-02-05,Published,NA,NA
MDSUPDRSHallucPsychosScore,MDS-UPDRS,Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS UPDRS) - hallucination psychosis score,Common Data Element,1.1,"Score of the participant's/subject's hallucination and psychosis considering both illusions and hallucinations, as a part of Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS UPDRS)","Score of the participant's/subject's hallucination and psychosis considering both illusions and hallucinations, as a part of Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS UPDRS)",Numeric Values,NA,Single Pre-Defined Value Selected,NA,NA,0;1;2;3;4;555,"Normal: No hallucinations or psychotic behavior;Slight: Illusions or non-formed hallucinations, but patient recognizes them without loss of insight;Mild: Formed hallucinations independent of environmental stimuli. No loss of insight;Moderate: Formed hallucinations with loss of insight;Severe: Patient has delusions or paranoia.;Unable To Rate",0;1;2;3;4;555,NA,NA,NA,"PD:
Instructions to examiner: Consider both illusions (misinterpretations of real stimuli) and hallucinations (spontaneous false sensations). Consider all major sensory domains (visual, auditory, tactile, olfactory and gustatory). Determine presence of unformed (for example sense of presence or fleeting false impressions) as well as formed (fully developed and detailed) sensations. Rate the patients insight into hallucinations and identify delusions and psychotic thinking. Instructions to patients [and caregiver]: Over the past week have you seen, heard, smelled or felt things that were not really there? [If yes, examiner asks patient or caregiver to elaborate and probes for information]",MDS UPDRS Q1.2.  CDISC variables  QSORRES  for QSTESTCD=UPD2102,HALLUCINATIONS AND PSYCHOSIS,CDISC;MDSUPDRS,"PD:
URL: http://www.movementdisorders.org/UserFiles/New%20UPDRS%207%203%2008%20final.pdf",Adult,NA,NA,Outcomes and End Points.Motor Function,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Core,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,MDS UPDRS Q1.2,NA,NA,NIH/NINDS,NINDSCDE,NINDSCDE@emmes.com,NA,NA,NIH/NINDS,NINDSCDE,NINDSCDE@emmes.com,2014-04-01,2020-02-05,Published,NA,NA
MDSUPDRSHandwritingScore,MDS-UPDRS,Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS UPDRS) - handwrite score,Common Data Element,1.1,"Score for the participant's/subject's handwriting abilities, as a part of Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS UPDRS)","Score for the participant's/subject's handwriting abilities, as a part of Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS UPDRS)",Numeric Values,NA,Single Pre-Defined Value Selected,NA,NA,0;1;2;3;4,"Normal: Not at all (no problems);Slight: My writing is slow, clumsy or uneven, but all words are clear;Mild: Some words are unclear and difficult to read;Moderate: Many words are unclear and difficult to read;Severe: Most or all words cannot be read.",0;1;2;3;4,NA,NA,NA,"PD:
Refer to instrument for additional instructions",MDS UPDRS Q2.7.  CDISC variables  QSORRES  for QSTESTCD=UPD2207,HANDWRITING,CDISC;MDSUPDRS,"PD:
URL: http://www.movementdisorders.org/UserFiles/New%20UPDRS%207%203%2008%20final.pdf",Adult,NA,NA,Outcomes and End Points.Motor Function,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Core,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,MDS UPDRS Q2.7,NA,NA,NIH/NINDS,NINDSCDE,NINDSCDE@emmes.com,NA,NA,NIH/NINDS,NINDSCDE,NINDSCDE@emmes.com,2014-04-01,2020-02-05,Published,NA,NA
MDSUPDRSHobbieOthrActScore,MDS-UPDRS,Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS UPDRS) - hobby other activity score,Common Data Element,1.1,"Score for the participant's/subject's ability to perform hobbies or other activities, as a part of Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS UPDRS)","Score for the participant's/subject's ability to perform hobbies or other activities, as a part of Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS UPDRS)",Numeric Values,NA,Single Pre-Defined Value Selected,NA,NA,0;1;2;3;4,"Normal: Not at all (no problems);Slight: I am a bit slow but do these activities easily;Mild: I have some difficulty doing these activities;Moderate: I have major problems doing these activities, but still do most;Severe: I am unable to do most or all of these activities",0;1;2;3;4,NA,NA,NA,"PD:
Refer to instrument for additional instructions",MDS UPDRS Q2.8.  CDISC variables  QSORRES  for QSTESTCD=UPD2208,DOING HOBBIES AND OTHER ACTIVITES,CDISC;MDSUPDRS,"PD:
URL: http://www.movementdisorders.org/UserFiles/New%20UPDRS%207%203%2008%20final.pdf",Adult,NA,NA,Outcomes and End Points.Motor Function,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Core,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,MDS UPDRS Q2.8,NA,NA,NIH/NINDS,NINDSCDE,NINDSCDE@emmes.com,NA,NA,NIH/NINDS,NINDSCDE,NINDSCDE@emmes.com,2014-04-01,2020-02-05,Published,NA,NA
MDSUPDRSHoehnYahrStageScore,MDS-UPDRS,Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS UPDRS) - Hoehn and Yahr stage score,Common Data Element,1.1,"Score for the participant's/subject's symptoms progression on the Hoehn and Yahr stage scale, as a part of Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS UPDRS)","Score for the participant's/subject's symptoms progression on the Hoehn and Yahr stage scale, as a part of Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS UPDRS)",Numeric Values,NA,Single Pre-Defined Value Selected,NA,NA,0;1;2;3;4;5,"Asymptomatic;Unilateral involvement only;Bilateral involvement without impairment of balance;Mild to moderate involvement, some postural instability but physically independent, needs assistance to recover from pull test;Severe disability, still able to walk or stand unassisted;Wheelchair bound or bedridden unless aided",0;1;2;3;4;5,NA,NA,NA,"PD:
Refer to instrument for additional instructions",MDS UPDRS Motor exam: Hoehn and Yahr stage.  CDISC variables  QSORRES  for QSTESTCD=UPDHY,HOEHN AND YAHR STAGE,CDISC;MDSUPDRS,"PD:
URL: http://www.movementdisorders.org/UserFiles/New%20UPDRS%207%203%2008%20final.pdf",Adult,NA,NA,Outcomes and End Points.Motor Function,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Core,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,MDS UPDRS Motor exam: Hoehn and Yahr stage,NA,NA,NIH/NINDS,NINDSCDE,NINDSCDE@emmes.com,NA,NA,NIH/NINDS,NINDSCDE,NINDSCDE@emmes.com,2014-04-01,2020-02-05,Published,NA,NA
MDSUPDRSHygieneScore,MDS-UPDRS,Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS UPDRS) - hygiene score,Common Data Element,1.1,"Score for the participant's/subject's level of hygiene, as a part of Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS UPDRS)","Score for the participant's/subject's level of hygiene, as a part of Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS UPDRS)",Numeric Values,NA,Single Pre-Defined Value Selected,NA,NA,0;1;2;3;4,Normal: Not at all (no problems);Slight: I am slow but I do not need any help;Mild: I need someone else to help me with some hygiene tasks;Moderate: I need help for many hygiene tasks;Severe: I need help for most or all of my hygiene tasks,0;1;2;3;4,NA,NA,NA,"PD:
Refer to instrument for additional instructions",MDS UPDRS Q2.6.  CDISC variables  QSORRES  for QSTESTCD=UPD2206,HYGIENE,CDISC;MDSUPDRS,"PD:
URL: http://www.movementdisorders.org/UserFiles/New%20UPDRS%207%203%2008%20final.pdf",Adult,NA,NA,Outcomes and End Points.Motor Function,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Core,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,MDS UPDRS Q2.6,NA,NA,NIH/NINDS,NINDSCDE,NINDSCDE@emmes.com,NA,NA,NIH/NINDS,NINDSCDE,NINDSCDE@emmes.com,2014-04-01,2020-02-05,Published,NA,NA
MDSUPDRSKineticTremrLftHndScr,MDS-UPDRS,Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS UPDRS) - kinetic tremor left hand score,Common Data Element,1.1,"Score for the participant's/subject's level of kinetic tremor of the left hand observing the highest amplitude seen, as a part of Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS UPDRS)","Score for the participant's/subject's level of kinetic tremor of the left hand observing the highest amplitude seen, as a part of Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS UPDRS)",Numeric Values,NA,Single Pre-Defined Value Selected,NA,NA,0;1;2;3;4;555,Normal: No tremor;Slight: Tremor is present but less than 1 cm in amplitude;Mild: Tremor is at least 1 but less than 3 cm in amplitude;Moderate: Tremor is at least 3 but less than 10 cm in amplitude;Severe: Tremor is at least 10 cm in amplitude.;Unable To Rate,0;1;2;3;4;555,NA,NA,NA,"PD:
The finger-to-nose maneuver should be performed slowly enough not to hide any tremor that could occur with very fast arm movements. Repeat with the other hand, rating each hand separately. The tremor can be present throughout the movement or as the tremor reaches either target (nose or finger). Rate the highest amplitude seen.",MDS UPDRS Q3.16b.  CDISC variables  QSORRES  for QSTESTCD=UPD2316B,KINETIC TREMOR OF THE HANDS,CDISC;MDSUPDRS,"PD:
URL: http://www.movementdisorders.org/UserFiles/New%20UPDRS%207%203%2008%20final.pdf",Adult,NA,NA,Outcomes and End Points.Motor Function,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Core,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,MDS UPDRS Q3.16b,NA,NA,NIH/NINDS,NINDSCDE,NINDSCDE@emmes.com,NA,NA,NIH/NINDS,NINDSCDE,NINDSCDE@emmes.com,2014-04-01,2020-02-05,Published,NA,NA
MDSUPDRSKineticTremrRtHndScore,MDS-UPDRS,Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS UPDRS) - kinetic tremor right hand score,Common Data Element,1.1,"Score for the participant's/subject's level of kinetic tremor of the right hand observing the highest amplitude seen, as a part of Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS UPDRS)","Score for the participant's/subject's level of kinetic tremor of the right hand observing the highest amplitude seen, as a part of Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS UPDRS)",Numeric Values,NA,Single Pre-Defined Value Selected,NA,NA,0;1;2;3;4;555,Normal: No tremor;Slight: Tremor is present but less than 1 cm in amplitude;Mild: Tremor is at least 1 but less than 3 cm in amplitude;Moderate: Tremor is at least 3 but less than 10 cm in amplitude;Severe: Tremor is at least 10 cm in amplitude.;Unable To Rate,0;1;2;3;4;555,NA,NA,NA,"PD:
The finger-to-nose maneuver should be performed slowly enough not to hide any tremor that could occur with very fast arm movements. Repeat with the other hand, rating each hand separately. The tremor can be present throughout the movement or as the tremor reaches either target (nose or finger). Rate the highest amplitude seen.",MDS UPDRS Q3.16a.  CDISC variables  QSORRES  for QSTESTCD=UPD2316A,KINETIC TREMOR OF THE HANDS,CDISC;MDSUPDRS,"PD:
URL: http://www.movementdisorders.org/UserFiles/New%20UPDRS%207%203%2008%20final.pdf",Adult,NA,NA,Outcomes and End Points.Motor Function,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Core,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,MDS UPDRS Q3.16a,NA,NA,NIH/NINDS,NINDSCDE,NINDSCDE@emmes.com,NA,NA,NIH/NINDS,NINDSCDE,NINDSCDE@emmes.com,2014-04-01,2020-02-05,Published,NA,NA
MDSUPDRSLLERigidScore,MDS-UPDRS,Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS UPDRS) - left lower extremity rigid score,Common Data Element,1.1,"Score for the participant's/subject's lower left extremities rigidity, as a part of Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS UPDRS)","Score for the participant's/subject's lower left extremities rigidity, as a part of Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS UPDRS)",Numeric Values,NA,Single Pre-Defined Value Selected,NA,NA,0;1;2;3;4;555,"Normal: No rigidity;Slight: Rigidity only detected with activation maneuver;Mild: Rigidity detected without the activation maneuver, but full range of motion is easily achieved;Moderate: Rigidity detected without the activation maneuver| full range of motion is achieved with effort;Severe: Rigidity detected without the activation maneuver and full range of motion not achieved.;Unable To Rate",0;1;2;3;4;555,NA,NA,NA,"PD:
First, test without an activation maneuver. Test and rate neck and each limb separately. For arms, test the wrist and elbow joints simultaneously. For legs, test the hip and knee joints simultaneously. If no rigidity is detected, use an activation maneuver such as tapping fingers, fist opening/closing, or heel tapping in a limb not being tested. Explain to the patient to go as limp as possible as you test for rigidity.",MDS UPDRS Q3.3e.  CDISC variables  QSORRES  for QSTESTCD=UPD2303E,RIGIDTY,CDISC;MDSUPDRS,"PD:
URL: http://www.movementdisorders.org/UserFiles/New%20UPDRS%207%203%2008%20final.pdf",Adult,NA,NA,Outcomes and End Points.Motor Function,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Core,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,MDS UPDRS Q3.3e,NA,NA,NIH/NINDS,NINDSCDE,NINDSCDE@emmes.com,NA,NA,NIH/NINDS,NINDSCDE,NINDSCDE@emmes.com,2014-04-01,2020-02-05,Published,NA,NA
MDSUPDRSLUERigidScore,MDS-UPDRS,Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS UPDRS) - left upper extremity rigid score,Common Data Element,1.1,"Score for the participant's/subject's left upper extremities rigidity, as a part of Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS UPDRS)","Score for the participant's/subject's left upper extremities rigidity, as a part of Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS UPDRS)",Numeric Values,NA,Single Pre-Defined Value Selected,NA,NA,0;1;2;3;4;555,"Normal: No rigidity;Slight: Rigidity only detected with activation maneuver;Mild: Rigidity detected without the activation maneuver, but full range of motion is easily achieved;Moderate: Rigidity detected without the activation maneuver| full range of motion is achieved with effort;Severe: Rigidity detected without the activation maneuver and full range of motion not achieved.;Unable To Rate",0;1;2;3;4;555,NA,NA,NA,"PD:
First, test without an activation maneuver. Test and rate neck and each limb separately. For arms, test the wrist and elbow joints simultaneously. For legs, test the hip and knee joints simultaneously. If no rigidity is detected, use an activation maneuver such as tapping fingers, fist opening/closing, or heel tapping in a limb not being tested. Explain to the patient to go as limp as possible as you test for rigidity.",MDS UPDRS Q3.3c.  CDISC variables  QSORRES  for QSTESTCD=UPD2303C,RIGIDTY,CDISC;MDSUPDRS,"PD:
URL: http://www.movementdisorders.org/UserFiles/New%20UPDRS%207%203%2008%20final.pdf",Adult,NA,NA,Outcomes and End Points.Motor Function,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Core,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,MDS UPDRS Q3.3c,NA,NA,NIH/NINDS,NINDSCDE,NINDSCDE@emmes.com,NA,NA,NIH/NINDS,NINDSCDE,NINDSCDE@emmes.com,2014-04-01,2020-02-05,Published,NA,NA
MDSUPDRSLegAgiltyLftLegScore,MDS-UPDRS,Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS UPDRS) - leg agility left leg score,Common Data Element,1.1,"Score for the participant's/subject's left leg agility evaluating speed, amplitude, hesitations, halts and decrementing amplitude","Score for the participant's/subject's left leg agility evaluating speed, amplitude, hesitations, halts and decrementing amplitude, as part of the Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS UPDRS).",Numeric Values,NA,Single Pre-Defined Value Selected,NA,NA,0;1;2;3;4;555,"Normal: No problems;Slight: Any of the following: a) the regular rhythm is broken with one or two interruptions or hesitations of the movement, b) slight slowing, c) amplitude decrements near the end of the task;Mild: Any of the following: a) 3 to 5 interruptions during the movements, b) mild slowness, c) amplitude decrements midway in the task;Moderate: Any of the following: a) more than 5 interruptions during the movement or at least one longer arrest (freeze) in ongoing movement, b) moderate slowing in speed, c) amplitude decrements after the first tap;Severe: Cannot or can only barely perform the task because of slowing, interruptions or decrements;Unable To Rate",0;1;2;3;4;555,NA,NA,NA,"PD:
Refer to instrument for additional instructions",MDS UPDRS Q3.8b.  CDISC variables  QSORRES  for QSTESTCD=UPD2308B,LEG AGILITY,CDISC;MDSUPDRS,"PD:
URL: http://www.movementdisorders.org/UserFiles/New%20UPDRS%207%203%2008%20final.pdf",Adult,NA,NA,Outcomes and End Points.Motor Function,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Core,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,MDS UPDRS Q3.8b,NA,NA,NIH/NINDS,NINDSCDE,NINDSCDE@emmes.com,NA,NA,NIH/NINDS,NINDSCDE,NINDSCDE@emmes.com,2014-04-01,2020-02-05,Published,NA,NA
MDSUPDRSLegAgiltyRteLegScore,MDS-UPDRS,Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS UPDRS) - leg agility right leg score,Common Data Element,1.1,"Score for the participant's/subject's right leg agility evaluating speed, amplitude, hesitations, halts and decrementing amplitude","Score for the participant's/subject's right leg agility evaluating speed, amplitude, hesitations, halts and decrementing amplitude, as part of the Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS UPDRS).",Numeric Values,NA,Single Pre-Defined Value Selected,NA,NA,0;1;2;3;4;555,"Normal: No problems;Slight: Any of the following: a) the regular rhythm is broken with one or two interruptions or hesitations of the movement, b) slight slowing, c) amplitude decrements near the end of the task;Mild: Any of the following: a) 3 to 5 interruptions during the movements, b) mild slowness, c) amplitude decrements midway in the task;Moderate: Any of the following: a) more than 5 interruptions during the movement or at least one longer arrest (freeze) in ongoing movement, b) moderate slowing in speed, c) amplitude decrements after the first tap;Severe: Cannot or can only barely perform the task because of slowing, interruptions or decrements;Unable To Rate",0;1;2;3;4;555,NA,NA,NA,"PD:
Have the patient sit in a straight-backed chair with arms. The patient should have both feet comfortably on the floor. Test each leg separately. Demonstrate the task, but do not continue to perform the task while the patient is being tested. Rate each side separately, evaluating speed, amplitude, hesitations, halts and decrementing amplitude.",MDS UPDRS Q3.8a.  CDISC variables  QSORRES  for QSTESTCD=UPD2308A,LEG AGILITY,CDISC;MDSUPDRS,"PD:
URL: http://www.movementdisorders.org/UserFiles/New%20UPDRS%207%203%2008%20final.pdf",Adult,NA,NA,Outcomes and End Points.Motor Function,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Core,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,MDS UPDRS Q3.8a,NA,NA,NIH/NINDS,NINDSCDE,NINDSCDE@emmes.com,NA,NA,NIH/NINDS,NINDSCDE,NINDSCDE@emmes.com,2014-04-01,2020-02-05,Published,NA,NA
MDSUPDRSLftFtToeTppngScore,MDS-UPDRS,Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS UPDRS) - left foot toe tap score,Common Data Element,1.1,"Score for the participant's/subject's ability to tap the left foot toes evaluating speed, amplitude, hesitations, halts and decrementing amplitude, as a part of Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS UPDRS)","Score for the participant's/subject's ability to tap the left foot toes evaluating speed, amplitude, hesitations, halts and decrementing amplitude, as a part of Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS UPDRS)",Numeric Values,NA,Single Pre-Defined Value Selected,NA,NA,0;1;2;3;4;555,"Normal: No problem;Slight: Any of the following: a) the regular rhythm is broken with one or two interruptions, or hesitations of the tapping movement, b) slight slowing| c) amplitude decrements near the end of the ten taps;Mild: Any of the following: a) 3 to 5 interruptions during the tapping movements, b) mild slowing, c) amplitude decrements midway in the task;Moderate: Any of the following: a) more than 5 interruptions during the tapping movements or at least one longer arrest (freeze) in ongoing movement, b) moderate slowing, c) amplitude decrements after the first tap;Severe: Cannot or can only barely perform the task because of slowing, interruptions or decrements;Unable To Rate",0;1;2;3;4;555,NA,NA,NA,"PD:
Have the patient sit in a straight-backed chair with arms, both feet on the floor. Test each foot separately. Demonstrate the task, but do not continue to perform the task while the patient is being tested. Rate each side separately, evaluating speed, amplitude, hesitations, halts and decrementing amplitude.",MDS UPDRS Q3.7b.  CDISC variables  QSORRES  for QSTESTCD=UPD2307B,TOE TAPPING,CDISC;MDSUPDRS,"PD:
URL: http://www.movementdisorders.org/UserFiles/New%20UPDRS%207%203%2008%20final.pdf",Adult,NA,NA,Outcomes and End Points.Motor Function,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Core,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,MDS UPDRS Q3.7b,NA,NA,NIH/NINDS,NINDSCDE,NINDSCDE@emmes.com,NA,NA,NIH/NINDS,NINDSCDE,NINDSCDE@emmes.com,2014-04-01,2020-02-05,Published,NA,NA
MDSUPDRSLftHndScore,MDS-UPDRS,Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS UPDRS) - left hand movement score,Common Data Element,1.1,"Score for the participant's/subject's ability to move the left hand evaluating speed, amplitude, hesitations, halts and decrementing amplitude, as a part of Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS UPDRS)","Score for the participant's/subject's ability to move the left hand evaluating speed, amplitude, hesitations, halts and decrementing amplitude, as a part of Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS UPDRS)",Numeric Values,NA,Single Pre-Defined Value Selected,NA,NA,0;1;2;3;4;555,"Normal: No problem;Slight: Any of the following: a) the regular rhythm is broken with one or two interruptions or hesitations of the movement| b) slight slowing| c) the amplitude decrements near the end of the task;Mild: Any of the following: a) 3 to 5 interruptions during the movements, b) mild slowing, c) the amplitude decrements midway in the task;Moderate: Any of the following: a) more than 5 interruptions during the movement or at least one longer arrest (freeze) in ongoing movement, b) moderate slowing, c) the amplitude decrements starting after the 1st open-and-close sequence;Severe: Cannot or can only barely perform the task because of slowing, interruptions or decrements;Unable To Rate",0;1;2;3;4;555,NA,NA,NA,"PD:
Test each hand separately. Demonstrate the task, but do not continue to perform the task while the patient is being tested. Instruct the patient to make a tight fist with the arm bent at the elbow so that the palm faces the examiner. Rate each side separately, evaluating speed, amplitude, hesitations, halts and decrementing amplitude.",MDS UPDRS Q3.5b.  CDISC variables  QSORRES  for QSTESTCD=UPD2305B,HAND MOVEMENTS,CDISC;MDSUPDRS,"PD:
URL: http://www.movementdisorders.org/UserFiles/New%20UPDRS%207%203%2008%20final.pdf",Adult,NA,NA,Outcomes and End Points.Motor Function,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Core,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,MDS UPDRS Q3.5b,NA,NA,NIH/NINDS,NINDSCDE,NINDSCDE@emmes.com,NA,NA,NIH/NINDS,NINDSCDE,NINDSCDE@emmes.com,2014-04-01,2020-02-05,Published,NA,NA
MDSUPDRSLiteHeadStndngScore,MDS-UPDRS,Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS UPDRS) - light headedness on stand score,Common Data Element,1.1,"Score for the participant's/subject's level of light headedness when standing, as a part of Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS UPDRS)","Score for the participant's/subject's level of light headedness when standing, as a part of Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS UPDRS)",Numeric Values,NA,Single Pre-Defined Value Selected,NA,NA,0;1;2;3;4,"Normal: No dizzy or foggy feelings;Slight: Dizzy or foggy feelings occur. However, they do not cause me troubles doing things;Mild: Dizzy or foggy feelings cause me to hold on to something, but I do not need to sit or lie back down;Moderate: Dizzy or foggy feelings cause me to sit or lie down to avoid fainting or falling;Severe: Dizzy or foggy feelings cause me to fall or faint.",0;1;2;3;4,NA,NA,NA,"PD:
Refer to instrument for additional instructions",MDS UPDRS Q1.12.  CDISC variables  QSORRES  for QSTESTCD=UPD2112,LIGHT HEADEDNESS ON STANDING,CDISC;MDSUPDRS,"PD:
URL: http://www.movementdisorders.org/UserFiles/New%20UPDRS%207%203%2008%20final.pdf",Adult,NA,NA,Outcomes and End Points.Motor Function,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Core,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,MDS UPDRS Q1.12,NA,NA,NIH/NINDS,NINDSCDE,NINDSCDE@emmes.com,NA,NA,NIH/NINDS,NINDSCDE,NINDSCDE@emmes.com,2014-04-01,2020-02-05,Published,NA,NA
MDSUPDRSLstLDOPADoseTm,MDS-UPDRS,Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS UPDRS) - last levodopa dose time,Common Data Element,1.1,"Duration of time, in minutes, since the participant/subject last took Levodopa, as a part of Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS UPDRS)","Duration of time, in minutes, since the participant/subject last took Levodopa, as a part of Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS UPDRS)",Numeric Values,NA,Free-Form Entry,NA,NA,NA,NA,NA,NA,NA,Minute,"PD:
Record the time in minutes",MDS UPDRS Q3C1.  CDISC variables  QSORRES  for QSTESTCD=UPD23C1,"If yes, minutes since last levodopa dose",CDISC;MDSUPDRS,"PD:
URL: http://www.movementdisorders.org/UserFiles/New%20UPDRS%207%203%2008%20final.pdf",Adult,NA,NA,Outcomes and End Points.Motor Function,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Core,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,MDS UPDRS Q3C1,NA,NA,NIH/NINDS,NINDSCDE,NINDSCDE@emmes.com,NA,NA,NIH/NINDS,NINDSCDE,NINDSCDE@emmes.com,2014-04-01,2020-02-05,Published,NA,NA
MDSUPDRSMvmntIntrfrnceScore,MDS-UPDRS,Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS UPDRS) - movement interference score,Common Data Element,1.1,"Indicator for whether the participant's/subject's movements interfered with the ratings because of the dyskinesia, as a part of Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS UPDRS)","Indicator for whether the participant's/subject's movements interfered with the ratings because of the dyskinesia, as a part of Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS UPDRS)",Alphanumeric,NA,Single Pre-Defined Value Selected,NA,NA,No;Yes,No;Yes,0;1,NA,NA,NA,"PD:
Refer to instrument for additional instructions",MDS UPDRS Motor exam: Dyskinesia present interference indicator.  CDISC variables  QSORRES  for QSTESTCD=UPD2DB,"If yes, did these movements interfere with your ratings?",CDISC;MDSUPDRS,"PD:
URL: http://www.movementdisorders.org/UserFiles/New%20UPDRS%207%203%2008%20final.pdf",Adult,NA,NA,Outcomes and End Points.Motor Function,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Core,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,MDS UPDRS Motor exam: Dyskinesia present interference indicator,NA,NA,NIH/NINDS,NINDSCDE,NINDSCDE@emmes.com,NA,NA,NIH/NINDS,NINDSCDE,NINDSCDE@emmes.com,2014-04-01,2020-02-05,Published,NA,NA
MDSUPDRSNeckRigidScore,MDS-UPDRS,Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS UPDRS) - neck rigidity score,Common Data Element,1.1,"Score for the participant's/subject's neck rigidity , as a part of Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS UPDRS)","Score for the participant's/subject's neck rigidity , as a part of Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS UPDRS)",Numeric Values,NA,Single Pre-Defined Value Selected,NA,NA,0;1;2;3;4;555,"Normal: No rigidity;Slight: Rigidity only detected with activation maneuver;Mild: Rigidity detected without the activation maneuver, but full range of motion is easily achieved;Moderate: Rigidity detected without the activation maneuver| full range of motion is achieved with effort;Severe: Rigidity detected without the activation maneuver and full range of motion not achieved.;Unable To Rate",0;1;2;3;4;555,NA,NA,NA,"PD:
First, test without an activation maneuver. Test and rate neck and each limb separately. For arms, test the wrist and elbow joints simultaneously. For legs, test the hip and knee joints simultaneously. If no rigidity is detected, use an activation maneuver such as tapping fingers, fist opening/closing, or heel tapping in a limb not being tested. Explain to the patient to go as limp as possible as you test for rigidity.",MDS UPDRS Q3.3a.  CDISC variables  QSORRES  for QSTESTCD=UPD2303A,RIGIDTY,CDISC;MDSUPDRS,"PD:
URL: http://www.movementdisorders.org/UserFiles/New%20UPDRS%207%203%2008%20final.pdf",Adult,NA,NA,Outcomes and End Points.Motor Function,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Core,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,MDS UPDRS Q3.3a,NA,NA,NIH/NINDS,NINDSCDE,NINDSCDE@emmes.com,NA,NA,NIH/NINDS,NINDSCDE,NINDSCDE@emmes.com,2014-04-01,2020-02-05,Published,NA,NA
MDSUPDRSPainOthrSensScore,MDS-UPDRS,Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS UPDRS) - pain other sensations score,Common Data Element,1.1,"Score for the participant's/subject's level of pain and other sensations, as a part of Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS UPDRS)","Score for the participant's/subject's level of pain and other sensations, as a part of Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS UPDRS)",Numeric Values,NA,Single Pre-Defined Value Selected,NA,NA,0;1;2;3;4,"Normal: No uncomfortable feelings.;Slight: I have these feelings. However, I can do things and be with other people without difficulty;Mild: These feelings cause some problems when I do things or am with other people;Moderate: These feelings cause a lot of problems, but they do not stop me from doing things or being with other people;Severe: These feelings stop me from doing things or being with other people.",0;1;2;3;4,NA,NA,NA,"PD:
Refer to instrument for additional instructions",MDS UPDRS Q1.9.  CDISC variables  QSORRES  for QSTESTCD=UPD2109,PAIN AND OTHER SENSATIONS,CDISC;MDSUPDRS,"PD:
URL: http://www.movementdisorders.org/UserFiles/New%20UPDRS%207%203%2008%20final.pdf",Adult,NA,NA,Outcomes and End Points.Motor Function,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Core,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,MDS UPDRS Q1.9,NA,NA,NIH/NINDS,NINDSCDE,NINDSCDE@emmes.com,NA,NA,NIH/NINDS,NINDSCDE,NINDSCDE@emmes.com,2014-04-01,2020-02-05,Published,NA,NA
MDSUPDRSPainflOffStatDystnaScr,MDS-UPDRS,Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS UPDRS) - painful off state dystonia score,Common Data Element,1.1,"Score for the participant's/subject's level of painful off-state dystonia, as a part of Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS UPDRS)","Score for the participant's/subject's level of painful off-state dystonia, as a part of Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS UPDRS)",Numeric Values,NA,Single Pre-Defined Value Selected,NA,NA,0;1;2;3;4;555,Normal: No dystonia OR NO OFF TIME;Slight: < 25% of time in OFF state;Mild: 26-50% of time in OFF state;Moderate: 51-75% of time in OFF state;Severe: > 75% of time in OFF state.;Unable To Rate,0;1;2;3;4;555,NA,NA,NA,"PD:
Refer to instrument for additional instructions","MDS UPDRS 4.6.  CDISC variables  QSORRES  for QSTESTCD=UPD2406, QSEVLT=-P1D",PAINFUL OFF STATE DYSTONIA,CDISC;MDSUPDRS,"PD:
URL: http://www.movementdisorders.org/UserFiles/New%20UPDRS%207%203%2008%20final.pdf",Adult,NA,NA,Outcomes and End Points.Motor Function,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Core,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,MDS UPDRS 4.6,NA,NA,NIH/NINDS,NINDSCDE,NINDSCDE@emmes.com,NA,NA,NIH/NINDS,NINDSCDE,NINDSCDE@emmes.com,2014-04-01,2020-02-05,Published,NA,NA
MDSUPDRSPostrlStabltyScore,MDS-UPDRS,Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS UPDRS) - postural stability score,Common Data Element,1.1,"Score for the participant's/subject's level of postural stability , as a part of Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS UPDRS)","Score for the participant's/subject's level of postural stability , as a part of Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS UPDRS)",Numeric Values,NA,Single Pre-Defined Value Selected,NA,NA,0;1;2;3;4;555,"Normal: No problems: Recovers with one or two steps;Slight: 3-5 steps, but subject recovers unaided;Mild: More than 5 steps, but subject recovers unaided;Moderate: Stands safely, but with absence of postural response| falls if not caught by examiner;Severe: Very unstable, tends to lose balance spontaneously or with just a gentle pull on the shoulders;Unable To Rate",0;1;2;3;4;555,NA,NA,NA,"PD:
Refer to instrument for additional instructions",MDS UPDRS Q3.12.  CDISC variables  QSORRES  for QSTESTCD=UPD2312,POSTURAL STABILITY,CDISC;MDSUPDRS,"PD:
URL: http://www.movementdisorders.org/UserFiles/New%20UPDRS%207%203%2008%20final.pdf",Adult,NA,NA,Outcomes and End Points.Motor Function,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Core,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,MDS UPDRS Q3.12,NA,NA,NIH/NINDS,NINDSCDE,NINDSCDE@emmes.com,NA,NA,NIH/NINDS,NINDSCDE,NINDSCDE@emmes.com,2014-04-01,2020-02-05,Published,NA,NA
MDSUPDRSPostrlTremorRtHndScore,MDS-UPDRS,Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS UPDRS) - postural tremor right hand score,Common Data Element,1.1,"Score for the participant's/subject's level of postural tremor of the right hand observing the highest amplitude seen, as a part of Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS UPDRS)","Score for the participant's/subject's level of postural tremor of the right hand observing the highest amplitude seen, as a part of Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS UPDRS)",Numeric Values,NA,Single Pre-Defined Value Selected,NA,NA,0;1;2;3;4;555,Normal: No tremor;Slight: Tremor is present but less than 1 cm in amplitude;Mild: Tremor is at least 1 but less than 3 cm in amplitude;Moderate: Tremor is at least 3 but less than 10 cm in amplitude;Severe: Tremor is at least 10 cm in amplitude;Unable To Rate,0;1;2;3;4;555,NA,NA,NA,"PD:
Rate each hand separately. Rate the highest amplitude seen. Instruct the patient to stretch the arms out in front of the body with palms down. The wrist should be straight and the fingers comfortably separated so that they do not touch each other. Observe this posture for 10 seconds.","MDS UPDRS Q3.15a.  CDISC variables  QSORRES  for QSTESTCD=UPD2315A, QSEVLINT=-P10S",POSTURAL TREMOR OF THE HANDS,CDISC;MDSUPDRS,"PD:
URL: http://www.movementdisorders.org/UserFiles/New%20UPDRS%207%203%2008%20final.pdf",Adult,NA,NA,Outcomes and End Points.Motor Function,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Core,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,MDS UPDRS Q3.15a,NA,NA,NIH/NINDS,NINDSCDE,NINDSCDE@emmes.com,NA,NA,NIH/NINDS,NINDSCDE,NINDSCDE@emmes.com,2014-04-01,2020-02-05,Published,NA,NA
MDSUPDRSPostrlTremrLftHndScore,MDS-UPDRS,Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS UPDRS) - postural tremor left hand score,Common Data Element,1.1,"Score for the participant's/subject's level of postural tremor of the left hand observing the highest amplitude seen, as a part of Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS UPDRS)","Score for the participant's/subject's level of postural tremor of the left hand observing the highest amplitude seen, as a part of Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS UPDRS)",Numeric Values,NA,Single Pre-Defined Value Selected,NA,NA,0;1;2;3;4;555,Normal: No tremor;Slight: Tremor is present but less than 1 cm in amplitude;Mild: Tremor is at least 1 but less than 3 cm in amplitude;Moderate: Tremor is at least 3 but less than 10 cm in amplitude;Severe: Tremor is at least 10 cm in amplitude;Unable To Rate,0;1;2;3;4;555,NA,NA,NA,"PD:
Rate each hand separately. Rate the highest amplitude seen. Instruct the patient to stretch the arms out in front of the body with palms down. The wrist should be straight and the fingers comfortably separated so that they do not touch each other. Observe this posture for 10 seconds.","MDS UPDRS Q3.15b.  CDISC variables  QSORRES  for QSTESTCD=UPD2315B, QSEVLINT=-P10S",POSTURAL TREMOR OF THE HANDS,CDISC;MDSUPDRS,"PD:
URL: http://www.movementdisorders.org/UserFiles/New%20UPDRS%207%203%2008%20final.pdf",Adult,NA,NA,Outcomes and End Points.Motor Function,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Core,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,MDS UPDRS Q3.15b,NA,NA,NIH/NINDS,NINDSCDE,NINDSCDE@emmes.com,NA,NA,NIH/NINDS,NINDSCDE,NINDSCDE@emmes.com,2014-04-01,2020-02-05,Published,NA,NA
MDSUPDRSPostureScore,MDS-UPDRS,Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS UPDRS) - posture score,Common Data Element,1.1,"Score for how well the participant's/subject's posture is by observing the flexion and side-to-side leaning, as a part of Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS UPDRS)","Score for how well the participant's/subject's posture is by observing the flexion and side-to-side leaning, as a part of Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS UPDRS)",Numeric Values,NA,Single Pre-Defined Value Selected,NA,NA,0;1;2;3;4;555,"Normal: No problems;Slight: Not quite erect, but posture could be normal for older person;Mild: Definite flexion, scoliosis or leaning to one side, but patient can correct posture to normal posture when asked to do so;Moderate: Stooped posture, scoliosis or leaning to one side that cannot be corrected volitionally to a normal posture by the patient;Severe: Flexion, scoliosis or leaning with extreme abnormality of posture;Unable To Rate",0;1;2;3;4;555,NA,NA,NA,"PD:
If you notice poor posture, tell the patient to stand up straight and see if the posture improves (see option 2 below). Rate the worst posture seen in these three observation points. Observe for flexion and side-to-side leaning.",MDS UPDRS Q3.13.  CDISC variables  QSORRES  for QSTESTCD=UPD2313,POSTURE,CDISC;MDSUPDRS,"PD:
URL: http://www.movementdisorders.org/UserFiles/New%20UPDRS%207%203%2008%20final.pdf",Adult,NA,NA,Outcomes and End Points.Motor Function,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Core,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,MDS UPDRS Q3.13,NA,NA,NIH/NINDS,NINDSCDE,NINDSCDE@emmes.com,NA,NA,NIH/NINDS,NINDSCDE,NINDSCDE@emmes.com,2014-04-01,2020-02-05,Published,NA,NA
MDSUPDRSPrcntDyskVal,MDS-UPDRS,Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS UPDRS) - percent dyskinesia value,Common Data Element,1.1,"Value of the percent of time the participant/subject has dyskinesia, as a part of Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS UPDRS)","Value of the percent of time the participant/subject has dyskinesia, as a part of Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS UPDRS)",Numeric Values,NA,Free-Form Entry,NA,NA,NA,NA,NA,NA,NA,NA,"PD:
Value should be recorded between 0-100%","MDS UPDRS Q4.1.3.  CDISC variables  QNAM=PCTDYSK, QLABEL=Percent Dyskinesia, QVAL=550%",Percent Dyskinesia equals two over one times one hundred,CDISC;MDSUPDRS,"PD:
URL: http://www.movementdisorders.org/UserFiles/New%20UPDRS%207%203%2008%20final.pdf",Adult,NA,NA,Outcomes and End Points.Motor Function,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Core,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,MDS UPDRS Q4.1.3,NA,NA,NIH/NINDS,NINDSCDE,NINDSCDE@emmes.com,NA,NA,NIH/NINDS,NINDSCDE,NINDSCDE@emmes.com,2014-04-01,2020-02-05,Published,NA,NA
MDSUPDRSPrcntOffDystniaVal,MDS-UPDRS,Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS UPDRS) - percent off dystonia value,Common Data Element,1.1,"Value of the percent of time the participant/subject is off with dystonia, as a part of Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS UPDRS)","Value of the percent of time the participant/subject is off with dystonia, as a part of Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS UPDRS)",Numeric Values,NA,Free-Form Entry,NA,NA,NA,NA,NA,NA,NA,NA,"PD:
Refer to instrument for additional instructions.  Value should be recorded between 0-100%","MDS UPDRS Percent OFF dystonia.  CDISC variables  QSORRES  for QSTESTCD=UPD2406, QSEVLT=-P1D, QNAM=PCTOFDYS, QLABEL=  Percent OFF  with Dystonia, QVAL=25%",Percent Off Dystonia equals two over one times one hundred,CDISC;MDSUPDRS,"PD:
URL: http://www.movementdisorders.org/UserFiles/New%20UPDRS%207%203%2008%20final.pdf",Adult,NA,NA,Outcomes and End Points.Motor Function,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Core,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,MDS UPDRS Percent OFF dystonia,NA,NA,NIH/NINDS,NINDSCDE,NINDSCDE@emmes.com,NA,NA,NIH/NINDS,NINDSCDE,NINDSCDE@emmes.com,2014-04-01,2020-02-05,Published,NA,NA
MDSUPDRSPrcntOffVal,MDS-UPDRS,Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS UPDRS) - percent off value,Common Data Element,1.1,"Value of the percent of time the participant/subject is OFF, as a part of Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS UPDRS)","Value of the percent of time the participant/subject is OFF, as a part of Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS UPDRS)",Numeric Values,NA,Free-Form Entry,NA,NA,NA,NA,NA,NA,NA,NA,"PD:
Refer to instrument for additional instructions","MDS UPDRS Percent OFF.  CDISC variables  QSORRES  for QSTESTCD=UPD2403, QSEVLT=-P1W. QNAM=PCTOFF, QLABEL= Percent of Hours OFF, qval=75%",Percent OFF equals two over one times one hundred,CDISC;MDSUPDRS,"PD:
URL: http://www.movementdisorders.org/UserFiles/New%20UPDRS%207%203%2008%20final.pdf",Adult,NA,NA,Outcomes and End Points.Motor Function,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Core,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,MDS UPDRS Percent OFF,NA,NA,NIH/NINDS,NINDSCDE,NINDSCDE@emmes.com,NA,NA,NIH/NINDS,NINDSCDE,NINDSCDE@emmes.com,2014-04-01,2020-02-05,Published,NA,NA
MDSUPDRSPrimrySrcInfoTyp,MDS-UPDRS,Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS UPDRS) - primary source information type,Common Data Element,1.2,"The type as related to the primary source of information for the participant's/subject's information, as a part of Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS UPDRS)","The type as related to the primary source of information for the participant's/subject's information, as a part of Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS UPDRS)",Alphanumeric,NA,Single Pre-Defined Value Selected,NA,NA,Caregiver;Patient;Patient and Caregiver in Equal Proportion,Caregiver;Patient;Patient and Caregiver in Equal Proportion,1;2;3,NA,NA,NA,"PD:
Refer to instrument for additional instructions","MDS UPDRS Q1a.  CDISC QNAM=PRIMSRC, QLABEL= Primary Source  of Information,  PART 1 QUESTIONS 1.1-1.7  set QVAL=PATIENT. PART 1 QUESTIONS 1.7-1.13 set QVAL=CAREGIVER. PART 2  set  QSEVAL=SUBJECT",Primary source of information,CDISC;MDSUPDRS,"PD:
URL: http://www.movementdisorders.org/",Adult,NA,NA,Outcomes and End Points.Motor Function,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Core,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,MDS UPDRS Q1a,NA,NA,NIH/NINDS,NINDSCDE,NINDSCDE@emmes.com,NA,NA,NIH/NINDS,NINDSCDE,NINDSCDE@emmes.com,2014-04-01,2020-02-05,Published,NA,NA
MDSUPDRSProntSupnRtHndMvmtScr,MDS-UPDRS,Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS UPDRS) - pronation supination right hand movement score,Common Data Element,1.1,"Score for the participant's/subject's ability to pronate and supinate the right hand evaluating speed, amplitude, hesitations, halts and decrementing amplitude, as a part of Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS UPDRS)","Score for the participant's/subject's ability to pronate and supinate the right hand evaluating speed, amplitude, hesitations, halts and decrementing amplitude, as a part of Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS UPDRS)",Numeric Values,NA,Single Pre-Defined Value Selected,NA,NA,0;1;2;3;4;555,"Normal: No problems;Slight: Any of the following: a) the regular rhythm is broken with one or two interruptions or hesitations of the movement| b) slight slowing| c) the amplitude decrements near the end of the sequence;Mild: Any of the following: a) 3 to 5 interruptions during the movements, b) mild slowing, c) the amplitude decrements midway in the sequence;Moderate: Any of the following: a) more than 5 interruptions during the movement or at least one longer arrest (freeze) in ongoing movement, b) moderate slowing c) the amplitude decrements starting after the 1st supination-pronation sequence;Severe: Cannot or can only barely perform the task because of slowing, interruptions or decrements;Unable To Rate",0;1;2;3;4;555,NA,NA,NA,"PD:
Test each hand separately. Demonstrate the task, but do not continue to perform the task while the patient is being tested. Rate each side separately, evaluating speed, amplitude, hesitations, halts and decrementing amplitude.",MDS UPDRS Q3.6a.  CDISC variables  QSORRES  for QSTESTCD=UPD2306A,PRONATION SUPINATION MOVEMENTS OF HANDS,CDISC;MDSUPDRS,"PD:
URL: http://www.movementdisorders.org/UserFiles/New%20UPDRS%207%203%2008%20final.pdf",Adult,NA,NA,Outcomes and End Points.Motor Function,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Core,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,MDS UPDRS Q3.6a,NA,NA,NIH/NINDS,NINDSCDE,NINDSCDE@emmes.com,NA,NA,NIH/NINDS,NINDSCDE,NINDSCDE@emmes.com,2014-04-01,2020-02-05,Published,NA,NA
MDSUPDRSPtClinStatePrknsnMdInd,MDS-UPDRS,Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS UPDRS) - patient clinical state while on Parkinson medication indicator,Common Data Element,1.2,"Indicator for whether the participant/subject is on the typical functional state or not , as a part of Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS UPDRS)","Indicator for whether the participant/subject is on the typical functional state or not , as a part of Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS UPDRS)",Alphanumeric,NA,Single Pre-Defined Value Selected,NA,NA,OFF;ON,Off is the typical functional state when patients have a poor response in spite of taking medications.;On is the typical functional state when patients are receiving medication and have a good response,0;1,NA,NA,NA,"PD:
Refer to instrument for additional instructions",MDS UPDRS Q3a.  CDISC variables  QSORRES  for QSTESTCD=UPD23A,If the patient is receiving medication for treating the symptoms of Parkinson's Disease mark the patient's clinical state using the following definitions,CDISC;MDSUPDRS,"PD:
URL: http://www.movementdisorders.org/",Adult,NA,NA,Outcomes and End Points.Motor Function,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Core,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,MDS UPDRS Q3a,NA,NA,NIH/NINDS,NINDSCDE,NINDSCDE@emmes.com,NA,NA,NIH/NINDS,NINDSCDE,NINDSCDE@emmes.com,2014-04-01,2020-02-05,Published,NA,NA
MDSUPDRSPtntPrknsnMedInd,MDS-UPDRS,Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS UPDRS) - patient on medication for Parkinson indicator,Common Data Element,1.1,"Indicator for whether the participant/subject is on medication for treating the symptoms of Parkinson's Disease, as a part of Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS UPDRS)","Indicator for whether the participant/subject is on medication for treating the symptoms of Parkinson's Disease, as a part of Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS UPDRS)",Alphanumeric,NA,Single Pre-Defined Value Selected,NA,NA,No;Yes,No;Yes,0;1,NA,NA,NA,"PD:
Refer to instrument for additional instructions",MDS UPDRS Q3a.  CDISC variables  QSORRES  for QSTESTCD=UPD23B,Is the patient on medication for treating the symptoms of Parkinson's Disease?,CDISC;MDSUPDRS,"PD:
URL: http://www.movementdisorders.org/UserFiles/New%20UPDRS%207%203%2008%20final.pdf",Adult,NA,NA,Outcomes and End Points.Motor Function,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Core,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,MDS UPDRS Q3a,NA,NA,NIH/NINDS,NINDSCDE,NINDSCDE@emmes.com,NA,NA,NIH/NINDS,NINDSCDE,NINDSCDE@emmes.com,2014-04-01,2020-02-05,Published,NA,NA
MDSUPDRSPtntUseLDOPAInd,MDS-UPDRS,Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS UPDRS) - patient use levodopa indicator,Common Data Element,1.1,"Indicator for whether the participant/subject is taking Levodopa, as a part of Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS UPDRS)","Indicator for whether the participant/subject is taking Levodopa, as a part of Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS UPDRS)",Alphanumeric,NA,Single Pre-Defined Value Selected,NA,NA,No;Yes,No;Yes,0;1,NA,NA,NA,"PD:
Refer to instrument for additional instructions",MDS UPDRS Q3c.  CDISC variables  QSORRES  for QSTESTCD=UPD23C,Is the patient on Levodopa,CDISC;MDSUPDRS,"PD:
URL: http://www.movementdisorders.org/UserFiles/New%20UPDRS%207%203%2008%20final.pdf",Adult,NA,NA,Outcomes and End Points.Motor Function,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Core,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,MDS UPDRS Q3c,NA,NA,NIH/NINDS,NINDSCDE,NINDSCDE@emmes.com,NA,NA,NIH/NINDS,NINDSCDE,NINDSCDE@emmes.com,2014-04-01,2020-02-05,Published,NA,NA
MDSUPDRSQstnnreInfoProvdrTyp,MDS-UPDRS,Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS UPDRS) - questionnaire information provider type,Common Data Element,1.2,"The type as related to the provider of the participant's/subject's information, as a part of Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS UPDRS)","The type as related to the provider of the participant's/subject's information, as a part of Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS UPDRS)",Alphanumeric,NA,Single Pre-Defined Value Selected,NA,NA,Caregiver;Patient;Patient and Caregiver in Equal Proportion,Caregiver;Patient;Patient and Caregiver in Equal Proportion,1;2;3,NA,NA,NA,"PD:
Refer to instrument for additional instructions","MDS UPDRS Source of patient questionnaire.  CDISC variables  PART 1a, Part 3,  Part 4 QSEVAL=INVESTIGATOR QSEVLINT=-P1W. Part 1, questions 1.7-1.13 and Part 2 QSEVAL=SUBJECT, QSEVLINT=-P1W",Who is filling out this questionnaire,CDISC;MDSUPDRS,"PD:
URL: http://www.movementdisorders.org/",Adult,NA,NA,Outcomes and End Points.Motor Function,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Core,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,MDS UPDRS Source of patient questionnaire,NA,NA,NIH/NINDS,NINDSCDE,NINDSCDE@emmes.com,NA,NA,NIH/NINDS,NINDSCDE,NINDSCDE@emmes.com,2014-04-01,2020-02-05,Published,NA,NA
MDSUPDRSRLERigidScore,MDS-UPDRS,Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS UPDRS) - right lower extremity rigid score,Common Data Element,1.1,"Score for the participant's/subject's right lower extremities rigidity, as a part of Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS UPDRS)","Score for the participant's/subject's right lower extremities rigidity, as a part of Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS UPDRS)",Numeric Values,NA,Single Pre-Defined Value Selected,NA,NA,0;1;2;3;4;555,"Normal: No rigidity;Slight: Rigidity only detected with activation maneuver;Mild: Rigidity detected without the activation maneuver, but full range of motion is easily achieved;Moderate: Rigidity detected without the activation maneuver| full range of motion is achieved with effort;Severe: Rigidity detected without the activation maneuver and full range of motion not achieved.;Unable To Rate",0;1;2;3;4;555,NA,NA,NA,"PD:
First, test without an activation maneuver. Test and rate neck and each limb separately. For arms, test the wrist and elbow joints simultaneously. For legs, test the hip and knee joints simultaneously. If no rigidity is detected, use an activation maneuver such as tapping fingers, fist opening/closing, or heel tapping in a limb not being tested. Explain to the patient to go as limp as possible as you test for rigidity.",MDS UPDRS Q3.3d.  CDISC variables  QSORRES  for QSTESTCD=UPD2303D,RIGIDTY,CDISC;MDSUPDRS,"PD:
URL: http://www.movementdisorders.org/UserFiles/New%20UPDRS%207%203%2008%20final.pdf",Adult,NA,NA,Outcomes and End Points.Motor Function,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Core,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,MDS UPDRS Q3.3d,NA,NA,NIH/NINDS,NINDSCDE,NINDSCDE@emmes.com,NA,NA,NIH/NINDS,NINDSCDE,NINDSCDE@emmes.com,2014-04-01,2020-02-05,Published,NA,NA
MDSUPDRSRUERigidScore,MDS-UPDRS,Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS UPDRS) - right upper extremity rigid score,Common Data Element,1.1,"Score for the participant's/subject's right upper extremities rigidity, as a part of Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS UPDRS)","Score for the participant's/subject's right upper extremities rigidity, as a part of Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS UPDRS)",Numeric Values,NA,Single Pre-Defined Value Selected,NA,NA,0;1;2;3;4;555,"Normal: No rigidity;Slight: Rigidity only detected with activation maneuver;Mild: Rigidity detected without the activation maneuver, but full range of motion is easily achieved;Moderate: Rigidity detected without the activation maneuver| full range of motion is achieved with effort;Severe: Rigidity detected without the activation maneuver and full range of motion not achieved.;Unable To Rate",0;1;2;3;4;555,NA,NA,NA,"PD:
First, test without an activation maneuver. Test and rate neck and each limb separately. For arms, test the wrist and elbow joints simultaneously. For legs, test the hip and knee joints simultaneously. If no rigidity is detected, use an activation maneuver such as tapping fingers, fist opening/closing, or heel tapping in a limb not being tested. Explain to the patient to go as limp as possible as you test for rigidity.",MDS UPDRS Q3.3b.  CDISC variables  QSORRES  for QSTESTCD=UPD2303B,RIGIDTY,CDISC;MDSUPDRS,"PD:
URL: http://www.movementdisorders.org/UserFiles/New%20UPDRS%207%203%2008%20final.pdf",Adult,NA,NA,Outcomes and End Points.Motor Function,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Core,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,MDS UPDRS Q3.3b,NA,NA,NIH/NINDS,NINDSCDE,NINDSCDE@emmes.com,NA,NA,NIH/NINDS,NINDSCDE,NINDSCDE@emmes.com,2014-04-01,2020-02-05,Published,NA,NA
MDSUPDRSRcntCogImprmntScore,MDS-UPDRS,Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS UPDRS) - recent cognitive impairment score,Common Data Element,1.1,"Score for the participant's/subject's cognitive impairment including the cognitive slowing, impaired reasoning, memory loss, deficits in attention and orientation and how it impacts the activities of daily living, as a part of Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS UPDRS)","Score for the participant's/subject's cognitive impairment including the cognitive slowing, impaired reasoning, memory loss, deficits in attention and orientation and how it impacts the activities of daily living, as a part of Movement Disorder Society -",Numeric Values,NA,Single Pre-Defined Value Selected,NA,NA,0;1;2;3;4;555,"Normal: No cognitive impairment;Slight: Impairment appreciated by patient or caregiver with no concrete interference with the patient's ability to carry out normal activities and social interactions;Mild: Clinically evident cognitive dysfunction, but only minimal interference with the patient's ability to carry out normal activities and social interactions;Moderate: Cognitive deficits interfere with but do not preclude the patient's ability to carry out normal activities and social interactions;Severe: Cognitive dysfunction precludes the patient's ability to carry out normal activities and social interactions.;Unable To Rate",0;1;2;3;4;555,NA,NA,NA,"PD:
Refer to instrument for additional instructions",MDS UPDRS Q1.1.  CDISC variables  QSORRES  for QSTESTCD=UPD2101,COGNITIVE IMPAIRMENT,CDISC;MDSUPDRS,"PD:
URL: http://www.movementdisorders.org/UserFiles/New%20UPDRS%207%203%2008%20final.pdf",Adult,NA,NA,Outcomes and End Points.Motor Function,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Core,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,MDS UPDRS Q1.1,NA,NA,NIH/NINDS,NINDSCDE,NINDSCDE@emmes.com,NA,NA,NIH/NINDS,NINDSCDE,NINDSCDE@emmes.com,2014-04-01,2020-02-05,Published,NA,NA
MDSUPDRSRestTremorAmpLLEScore,MDS-UPDRS,Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS UPDRS) - rest tremor amplitude left lower extremity score,Common Data Element,1.1,"Score for the participant's/subject's left lower extremities rest tremor amplitude, as a part of Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS UPDRS)","Score for the participant's/subject's left lower extremities rest tremor amplitude, as a part of Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS UPDRS)",Numeric Values,NA,Single Pre-Defined Value Selected,NA,NA,0;1;2;3;4;555,Normal: No tremor;Slight.: < 1 cm in maximal amplitude;Mild: > 1 cm but < 3 cm in maximal amplitude;Moderate: 3 - 10 cm in maximal amplitude;Severe: > 10 cm in maximal amplitude;Unable To Rate,0;1;2;3;4;555,NA,NA,NA,"PD:
Refer to instrument for additional instructions","MDS UPDRS Q3.17d.  CDISC variables  QSORRES  for QSTESTCD=UPD2317D, QSEVLINT=-P10S",REST TREMOR AMPLITUDE,CDISC;MDSUPDRS,"PD:
URL: http://www.movementdisorders.org/UserFiles/New%20UPDRS%207%203%2008%20final.pdf",Adult,NA,NA,Outcomes and End Points.Motor Function,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Core,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,MDS UPDRS Q3.17d,NA,NA,NIH/NINDS,NINDSCDE,NINDSCDE@emmes.com,NA,NA,NIH/NINDS,NINDSCDE,NINDSCDE@emmes.com,2014-04-01,2020-02-05,Published,NA,NA
MDSUPDRSRestTremorAmpLUEScore,MDS-UPDRS,Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS UPDRS) - rest tremor amplitude left upper extremity score,Common Data Element,1.1,"Score for the participant's/subject's left upper extremities rest tremor amplitude, as a part of Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS UPDRS)","Score for the participant's/subject's left upper extremities rest tremor amplitude, as a part of Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS UPDRS)",Numeric Values,NA,Single Pre-Defined Value Selected,NA,NA,0;1;2;3;4;555,Normal: No tremor;Slight.: < 1 cm in maximal amplitude;Mild: > 1 cm but < 3 cm in maximal amplitude;Moderate: 3 - 10 cm in maximal amplitude;Severe: > 10 cm in maximal amplitude;Unable To Rate,0;1;2;3;4;555,NA,NA,NA,"PD:
Refer to instrument for additional instructions","MDS UPDRS Q3.17b.  CDISC variables  QSORRES  for QSTESTCD=UPD2317B, QSEVLINT=-P10S",REST TREMOR AMPLITUDE,CDISC;MDSUPDRS,"PD:
URL: http://www.movementdisorders.org/UserFiles/New%20UPDRS%207%203%2008%20final.pdf",Adult,NA,NA,Outcomes and End Points.Motor Function,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Core,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,MDS UPDRS Q3.17b,NA,NA,NIH/NINDS,NINDSCDE,NINDSCDE@emmes.com,NA,NA,NIH/NINDS,NINDSCDE,NINDSCDE@emmes.com,2014-04-01,2020-02-05,Published,NA,NA
MDSUPDRSRestTremorAmpRLEScore,MDS-UPDRS,Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS UPDRS) - rest tremor amplitude right lower extremity score,Common Data Element,1.1,"Score for the participant's/subject's right lower extremities rest tremor amplitude, as a part of Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS UPDRS)","Score for the participant's/subject's right lower extremities rest tremor amplitude, as a part of Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS UPDRS)",Numeric Values,NA,Single Pre-Defined Value Selected,NA,NA,0;1;2;3;4;555,Normal: No tremor;Slight.: < 1 cm in maximal amplitude;Mild: > 1 cm but < 3 cm in maximal amplitude;Moderate: 3 - 10 cm in maximal amplitude;Severe: > 10 cm in maximal amplitude;Unable To Rate,0;1;2;3;4;555,NA,NA,NA,"PD:
Refer to instrument for additional instructions","MDS UPDRS Q3.17c.  CDISC variables  QSORRES  for QSTESTCD=UPD2317C, QSEVLINT=-P10S",REST TREMOR AMPLITUDE,CDISC;MDSUPDRS,"PD:
URL: http://www.movementdisorders.org/UserFiles/New%20UPDRS%207%203%2008%20final.pdf",Adult,NA,NA,Outcomes and End Points.Motor Function,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Core,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,MDS UPDRS Q3.17c,NA,NA,NIH/NINDS,NINDSCDE,NINDSCDE@emmes.com,NA,NA,NIH/NINDS,NINDSCDE,NINDSCDE@emmes.com,2014-04-01,2020-02-05,Published,NA,NA
MDSUPDRSRestTremorAmpRUEScore,MDS-UPDRS,Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS UPDRS) - rest tremor amplitude right upper extremity score,Common Data Element,1.1,"Score for the participant's/subject's right upper extremities rest tremor amplitude, as a part of Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS UPDRS)","Score for the participant's/subject's right upper extremities rest tremor amplitude, as a part of Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS UPDRS)",Numeric Values,NA,Single Pre-Defined Value Selected,NA,NA,0;1;2;3;4;555,Normal: No tremor;Slight.: < 1 cm in maximal amplitude;Mild: > 1 cm but < 3 cm in maximal amplitude;Moderate: 3 - 10 cm in maximal amplitude;Severe: > 10 cm in maximal amplitude;Unable To Rate,0;1;2;3;4;555,NA,NA,NA,"PD:
Refer to instrument for additional instructions","MDS UPDRS Q3.17a.  CDISC variables  QSORRES  for QSTESTCD=UPD2317A, QSEVLINT=-P10S",REST TREMOR AMPLITUDE,CDISC;MDSUPDRS,"PD:
URL: http://www.movementdisorders.org/UserFiles/New%20UPDRS%207%203%2008%20final.pdf",Adult,NA,NA,Outcomes and End Points.Motor Function,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Core,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,MDS UPDRS Q3.17a,NA,NA,NIH/NINDS,NINDSCDE,NINDSCDE@emmes.com,NA,NA,NIH/NINDS,NINDSCDE,NINDSCDE@emmes.com,2014-04-01,2020-02-05,Published,NA,NA
MDSUPDRSRestTremrAmpLipJawScr,MDS-UPDRS,Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS UPDRS) - rest tremor amplitude lip jaw score,Common Data Element,1.1,"Score for the participant's/subject's lip and jaw rest tremor amplitude, as a part of Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS UPDRS)","Score for the participant's/subject's lip and jaw rest tremor amplitude, as a part of Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS UPDRS)",Numeric Values,NA,Single Pre-Defined Value Selected,NA,NA,0;1;2;3;4;555,Normal: No tremor;Slight.: < 1 cm in maximal amplitude;Mild: > 1 cm but < 3 cm in maximal amplitude;Moderate: 3 - 10 cm in maximal amplitude;Severe: > 10 cm in maximal amplitude;Unable To Rate,0;1;2;3;4;555,NA,NA,NA,"PD:
Refer to instrument for additional instructions","MDS UPDRS Q3.17e.  CDISC variables  QSORRES  for QSTESTCD=UPD2317E, QSEVLINT=-P10S",REST TREMOR AMPLITUDE,CDISC;MDSUPDRS,"PD:
URL: http://www.movementdisorders.org/UserFiles/New%20UPDRS%207%203%2008%20final.pdf",Adult,NA,NA,Outcomes and End Points.Motor Function,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Core,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,MDS UPDRS Q3.17e,NA,NA,NIH/NINDS,NINDSCDE,NINDSCDE@emmes.com,NA,NA,NIH/NINDS,NINDSCDE,NINDSCDE@emmes.com,2014-04-01,2020-02-05,Published,NA,NA
MDSUPDRSRteHndScore,MDS-UPDRS,Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS UPDRS) - right hand movement score,Common Data Element,1.1,"Score for the participant's/subject's ability to move the right hand evaluating speed, amplitude, hesitations, halts and decrementing amplitude, as a part of Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS UPDRS)","Score for the participant's/subject's ability to move the right hand evaluating speed, amplitude, hesitations, halts and decrementing amplitude, as a part of Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS UPDRS)",Numeric Values,NA,Single Pre-Defined Value Selected,NA,NA,0;1;2;3;4;555,"Normal: No problem;Slight: Any of the following: a) the regular rhythm is broken with one or two interruptions or hesitations of the movement| b) slight slowing| c) the amplitude decrements near the end of the task;Mild: Any of the following: a) 3 to 5 interruptions during the movements, b) mild slowing, c) the amplitude decrements midway in the task;Moderate: Any of the following: a) more than 5 interruptions during the movement or at least one longer arrest (freeze) in ongoing movement, b) moderate slowing, c) the amplitude decrements starting after the 1st open-and-close sequence;Severe: Cannot or can only barely perform the task because of slowing, interruptions or decrements;Unable To Rate",0;1;2;3;4;555,NA,NA,NA,"PD:
Test each hand separately. Demonstrate the task, but do not continue to perform the task while the patient is being tested. Instruct the patient to make a tight fist with the arm bent at the elbow so that the palm faces the examiner. Rate each side separately, evaluating speed, amplitude, hesitations, halts and decrementing amplitude.",MDS UPDRS Q3.5a.  CDISC variables  QSORRES  for QSTESTCD=UPD2305A,HAND MOVEMENTS,CDISC;MDSUPDRS,"PD:
URL: http://www.movementdisorders.org/UserFiles/New%20UPDRS%207%203%2008%20final.pdf",Adult,NA,NA,Outcomes and End Points.Motor Function,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Core,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,MDS UPDRS Q3.5a,NA,NA,NIH/NINDS,NINDSCDE,NINDSCDE@emmes.com,NA,NA,NIH/NINDS,NINDSCDE,NINDSCDE@emmes.com,2014-04-01,2020-02-05,Published,NA,NA
MDSUPDRSSleepProbScore,MDS-UPDRS,Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS UPDRS) - sleep problem score,Common Data Element,1.1,"Score for the participant's/subject's ability to sleep considering how rested he or she felt waking up in the morning, as a part of Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS UPDRS)","Score for the participant's/subject's ability to sleep considering how rested he or she felt waking up in the morning, as a part of Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS UPDRS)",Numeric Values,NA,Single Pre-Defined Value Selected,NA,NA,0;1;2;3;4,"Normal: No problems;Slight: Sleep problems are present but usually do not cause trouble getting a full night of sleep;Mild: Sleep problems usually cause some difficulties getting a full night of sleep;Moderate: Sleep problems cause a lot of difficulties getting a full night of sleep, but I still usually sleep for more than half the night;Severe: I usually do not sleep for most of the night.",0;1;2;3;4,NA,NA,NA,"PD:
Consider how rested you felt after waking up in the morning.",MDS UPDRS Q1.7.  CDISC variables  QSORRES  for QSTESTCD=UPD2107,SLEEP PROBLEMS,CDISC;MDSUPDRS,"PD:
URL: http://www.movementdisorders.org/UserFiles/New%20UPDRS%207%203%2008%20final.pdf",Adult,NA,NA,Outcomes and End Points.Motor Function,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Core,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,MDS UPDRS Q1.7,NA,NA,NIH/NINDS,NINDSCDE,NINDSCDE@emmes.com,NA,NA,NIH/NINDS,NINDSCDE,NINDSCDE@emmes.com,2014-04-01,2020-02-05,Published,NA,NA
MDSUPDRSSlivaDroolScore,MDS-UPDRS,Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS UPDRS) - saliva and drool score,Common Data Element,1.1,"Score for the participant's/subject's ability to control saliva and drool, as a part of Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS UPDRS)","Score for the participant's/subject's ability to control saliva and drool, as a part of Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS UPDRS)",Numeric Values,NA,Single Pre-Defined Value Selected,NA,NA,0;1;2;3;4,"Normal: Not at all (no problems);Slight: I have too much saliva, but do not drool;Mild: I have some drooling during sleep, but none when I am awake;Moderate: I have some drooling when I am awake, but I usually do not need tissues or a handkerchief;Severe: I have so much drooling that I regularly need to use tissues or a handkerchief to protect my clothes.",0;1;2;3;4,NA,NA,NA,"PD:
Refer to instrument for additional instructions",MDS UPDRS Q2.2.  CDISC variables  QSORRES  for QSTESTCD=UPD2202,SALIVA AND DROOLING,CDISC;MDSUPDRS,"PD:
URL: http://www.movementdisorders.org/UserFiles/New%20UPDRS%207%203%2008%20final.pdf",Adult,NA,NA,Outcomes and End Points.Motor Function,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Core,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,MDS UPDRS Q2.2,NA,NA,NIH/NINDS,NINDSCDE,NINDSCDE@emmes.com,NA,NA,NIH/NINDS,NINDSCDE,NINDSCDE@emmes.com,2014-04-01,2020-02-05,Published,NA,NA
MDSUPDRSSpeechScore,MDS-UPDRS,Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS UPDRS) - speech score,Common Data Element,1.1,"Score for the participant's/subject's level of speech, as a part of Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS UPDRS)","Score for the participant's/subject's level of speech, as a part of Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS UPDRS)",Numeric Values,NA,Single Pre-Defined Value Selected,NA,NA,0;1;2;3;4,"Normal: Not at all (no problems);Slight: My speech is soft, slurred or uneven, but it does not cause others to ask me to repeat myself;Mild: My speech causes people to ask me to occasionally repeat myself, but not everyday;Moderate: My speech is unclear enough that others ask me to repeat myself every day even though most of my speech is understood;Severe: Most or all of my speech cannot be understood.",0;1;2;3;4,NA,NA,NA,"PD:
Refer to instrument for additional instructions",MDS UPDRS Q2.1.  CDISC variables  QSORRES  for QSTESTCD=UPD2201,SPEECH,CDISC;MDSUPDRS,"PD:
URL: http://www.movementdisorders.org/UserFiles/New%20UPDRS%207%203%2008%20final.pdf",Adult,NA,NA,Outcomes and End Points.Motor Function,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Core,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,MDS UPDRS Q2.1,NA,NA,NIH/NINDS,NINDSCDE,NINDSCDE@emmes.com,NA,NA,NIH/NINDS,NINDSCDE,NINDSCDE@emmes.com,2014-04-01,2020-02-05,Published,NA,NA
MDSUPDRSTmSpntDyskScore,MDS-UPDRS,Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS UPDRS) - time spent with dyskinesia score,Common Data Element,1.1,"Score for the participant's/subject's time spent with dyskinesia calculated from the total hours awake, total hours with dyskinesia, and percent dyskinesia, as a part of Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS UPDRS)","Score for the participant's/subject's time spent with dyskinesia calculated from the total hours awake, total hours with dyskinesia, and percent dyskinesia, as a part of Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS UPDRS)",Numeric Values,NA,Single Pre-Defined Value Selected,NA,NA,0;1;2;3;4;555,Normal: no dyskinesias;Slight:=25perecent of waking day;Mild: 26-50 percent of waking day;Moderate: 51-75 percent of waking day;Severe: > 75 percent of waking day;Unable To Rate,0;1;2;3;4;555,NA,NA,NA,"PD:
Refer to instrument for additional instructions","MDS UPDRS Q4.1.  CDISC variables  QSORRES  for QSTESTCD=UPD2402, QSEVLT=-P1W",TIME SPENT WITH DYSKINESIAS,CDISC;MDSUPDRS,"PD:
URL: http://www.movementdisorders.org/UserFiles/New%20UPDRS%207%203%2008%20final.pdf",Adult,NA,NA,Outcomes and End Points.Motor Function,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Core,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,MDS UPDRS Q4.1,NA,NA,NIH/NINDS,NINDSCDE,NINDSCDE@emmes.com,NA,NA,NIH/NINDS,NINDSCDE,NINDSCDE@emmes.com,2014-04-01,2020-02-05,Published,NA,NA
MDSUPDRSTmSpntOffStateScore,MDS-UPDRS,Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS UPDRS) - time spent in off state score,Common Data Element,1.1,"Score for the participant's/subject's level of complexity of motor fluctuations, as a part of Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS UPDRS)","Score for the participant's/subject's level of complexity of motor fluctuations, as a part of Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS UPDRS)",Numeric Values,NA,Single Pre-Defined Value Selected,NA,NA,0;1;2;3;4;555,Normal: No OFF time;Slight: less than or equal to 25 percent of waking day;Mild: 26 - 50 percent of waking day;Moderate: 51 - 75 percent of waking day;Severe: greater than 75 percent of waking day;Unable To Rate,0;1;2;3;4;555,NA,NA,NA,"PD:
If the patient has an OFF period in the office, you can point to this state as a reference. You may also use your knowledge of the patient to describe a typical OFF period. Additionally you may use your own acting skills to enact an OFF period you have seen in the patient before or show them OFF function typical of other patients.  Refer to instrument for additional instructions","MDS UPDRS Q4.3.  CDISC variables  QSORRES  for QSTESTCD=UPD2403, QSEVLT=-P1W",TIME SPENT IN THE OFF STATE,CDISC;MDSUPDRS,"PD:
URL: http://www.movementdisorders.org/UserFiles/New%20UPDRS%207%203%2008%20final.pdf",Adult,NA,NA,Outcomes and End Points.Motor Function,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Core,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,MDS UPDRS Q4.3,NA,NA,NIH/NINDS,NINDSCDE,NINDSCDE@emmes.com,NA,NA,NIH/NINDS,NINDSCDE,NINDSCDE@emmes.com,2014-04-01,2020-02-05,Published,NA,NA
MDSUPDRSTremorScore,MDS-UPDRS,Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS UPDRS) - tremor score,Common Data Element,1.1,"Score for the participant's/subject's level of shaking or tremor, as a part of Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS UPDRS)","Score for the participant's/subject's level of shaking or tremor, as a part of Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS UPDRS)",Numeric Values,NA,Single Pre-Defined Value Selected,NA,NA,0;1;2;3;4,Normal: Not at all. I have no shaking or tremor;Slight: Shaking or tremor occurs but does not cause problems with any activities;Mild: Shaking or tremor causes problems with only a few activities;Moderate: Shaking or tremor causes problems with many of my daily activities;Severe: Shaking or tremor causes problems with most or all activities,0;1;2;3;4,NA,NA,NA,"PD:
Refer to instrument for additional instructions",MDS UPDRS Q2.10.  CDISC variables  QSORRES  for QSTESTCD=UPD2210,TREMOR,CDISC;MDSUPDRS,"PD:
URL: http://www.movementdisorders.org/UserFiles/New%20UPDRS%207%203%2008%20final.pdf",Adult,NA,NA,Outcomes and End Points.Motor Function,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Core,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,MDS UPDRS Q2.10,NA,NA,NIH/NINDS,NINDSCDE,NINDSCDE@emmes.com,NA,NA,NIH/NINDS,NINDSCDE,NINDSCDE@emmes.com,2014-04-01,2020-02-05,Published,NA,NA
MDSUPDRSTtlHrAwkDyskNum,MDS-UPDRS,Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS UPDRS) - total hours awake number,Common Data Element,1.1,"Number of total number of hours the participant/subject stays awake, as a part of Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS UPDRS)","Number of total number of hours the participant/subject stays awake, as a part of Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS UPDRS)",Numeric Values,NA,Free-Form Entry,NA,NA,NA,NA,NA,NA,NA,NA,"PD:
Value should be recorded between 0-24 hours","MDS UPDRS Q4.1.1.  CDISC variables  QSORRES  for QSTESTCD=UPD2401, QSEVLINT=-P1W; QNAM=TOTAWK QLABEL= Total Hours  Awake, QVAL=16. 
",Total Hours Awake,CDISC;MDSUPDRS,"PD:
URL: http://www.movementdisorders.org/UserFiles/New%20UPDRS%207%203%2008%20final.pdf",Adult,NA,NA,Outcomes and End Points.Motor Function,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Core,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,MDS UPDRS Q4.1.1,NA,NA,NIH/NINDS,NINDSCDE,NINDSCDE@emmes.com,NA,NA,NIH/NINDS,NINDSCDE,NINDSCDE@emmes.com,2014-04-01,2020-02-05,Published,NA,NA
MDSUPDRSTtlHrAwkOffStateNum,MDS-UPDRS,Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS UPDRS) - total hour awake number,Common Data Element,1.1,"Number of total hours that the participant is awake, as a part of Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS UPDRS)","Number of total hours that the participant is awake, as a part of Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS UPDRS)",Numeric Values,NA,Free-Form Entry,NA,NA,NA,NA,NA,NA,NA,NA,"PD:
Value should be recorded between 0-24 hours  Refer to instrument for additional instructions","MDS UPDRS Total hours awake OFF state.  CDISC variables  QSORRES  for QSTESTCD=UPD2403, QSEVLINT=-P1W; QNAM=TOTAWK QLABEL= Total Hours  Awake, QVAL=16. 
",Total Hours Awake,CDISC;MDSUPDRS,"PD:
URL: http://www.movementdisorders.org/UserFiles/New%20UPDRS%207%203%2008%20final.pdf",Adult,NA,NA,Outcomes and End Points.Motor Function,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Core,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,MDS UPDRS Total hours awake OFF state,NA,NA,NIH/NINDS,NINDSCDE,NINDSCDE@emmes.com,NA,NA,NIH/NINDS,NINDSCDE,NINDSCDE@emmes.com,2014-04-01,2020-02-05,Published,NA,NA
MDSUPDRSTtlHrDyskNum,MDS-UPDRS,Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS UPDRS) - total hours with dyskinesia number,Common Data Element,1.1,"Number of total number of hours the participant/subject has dyskinesia, as a part of Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS UPDRS)","Number of total number of hours the participant/subject has dyskinesia, as a part of Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS UPDRS)",Numeric Values,NA,Free-Form Entry,NA,NA,NA,NA,NA,NA,NA,NA,"PD:
Value should be recorded between 0-24 hours","MDS UPDRS Q4.1.2.  CDISC variables  QSEVLINT=-P1W. QNAM=TOTDYSK, QLABEL= Total Hours with Dyskinesia, QVAL=8
",Total Hours with Dyskinesia,CDISC;MDSUPDRS,"PD:
URL: http://www.movementdisorders.org/UserFiles/New%20UPDRS%207%203%2008%20final.pdf",Adult,NA,NA,Outcomes and End Points.Motor Function,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Core,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,MDS UPDRS Q4.1.2,NA,NA,NIH/NINDS,NINDSCDE,NINDSCDE@emmes.com,NA,NA,NIH/NINDS,NINDSCDE,NINDSCDE@emmes.com,2014-04-01,2020-02-05,Published,NA,NA
MDSUPDRSTtlHrOffDemnDystniaNum,MDS-UPDRS,Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS UPDRS) - total hour off denominator dystonia number,Common Data Element,1.1,"Number of total hours in the off-state that the examiner records to use as the denominator to calculate proportion of Off hours affected by dystonia, as a part of Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS UPDRS)","Number of total hours that the participant/subject is Off, as a part of Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS UPDRS)",Numeric Values,NA,Free-Form Entry,NA,NA,NA,NA,NA,NA,NA,NA,"PD:
Value should be recorded between 0-24 hours","MDS UPDRS Total Hours OFF dystonia.  CDISC variables  QSORRES  for QSTESTCD=UPD2406, QSEVLT=-P1D, QNAM=TOTHROFF, QLABEL= Total Hours OFF, QVAL=4",Total Hours Off,CDISC;MDSUPDRS,"PD:
URL: http://www.movementdisorders.org/UserFiles/New%20UPDRS%207%203%2008%20final.pdf",Adult,NA,NA,Outcomes and End Points.Motor Function,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Core,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,MDS UPDRS Total Hours OFF dystonia,NA,NA,NIH/NINDS,NINDSCDE,NINDSCDE@emmes.com,NA,NA,NIH/NINDS,NINDSCDE,NINDSCDE@emmes.com,2014-04-01,2020-02-05,Published,NA,NA
MDSUPDRSTtlHrOffNum,MDS-UPDRS,Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS UPDRS) - total hour off number,Common Data Element,1.1,"Number of total hours that the participant/subject is Of, as a part of Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS UPDRS)","Number of total hours that the participant/subject is OFF, as a part of Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS UPDRS)",Numeric Values,NA,Free-Form Entry,NA,NA,NA,NA,NA,NA,NA,NA,"PD:
Value should be recorded between 0-24 hours  Refer to instrument for additional instructions","MDS UPDRS Total hours OFF.  CDISC variables  QSORRES  for QSTESTCD=UPD2403, QSEVLINT=-P1W; QNAM=TOTAWK QLABEL= Total Hours  Awake, QVAL=12. 
",Total Hours OFF,CDISC;MDSUPDRS,"PD:
URL: http://www.movementdisorders.org/UserFiles/New%20UPDRS%207%203%2008%20final.pdf",Adult,NA,NA,Outcomes and End Points.Motor Function,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Core,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,MDS UPDRS Total hours OFF,NA,NA,NIH/NINDS,NINDSCDE,NINDSCDE@emmes.com,NA,NA,NIH/NINDS,NINDSCDE,NINDSCDE@emmes.com,2014-04-01,2020-02-05,Published,NA,NA
MDSUPDRSTtlHrOffWDystniaNum,MDS-UPDRS,Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS UPDRS) - total hour off with dystonia number,Common Data Element,1.2,"Number of total hours that the participant/subject is Off with dystonia, as a part of Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS UPDRS)","Number of total hours that the participant/subject is Off with dystonia, as a part of Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS UPDRS)",Numeric Values,NA,Free-Form Entry,NA,NA,NA,NA,NA,NA,NA,NA,"PD:
You have already determined the number of hours of ""OFF"" time (4.3). Of these hours, determine how many are associated with dystonia. If there is no OFF time, mark 0.  Value should be recorded between 0-24 hours","MDS UPDRS Total OFF hours with dystonia.  CDISC variables  QSORRES  for QSTESTCD=UPD2406, QSEVLT=-P1D, QNAM=TOTOFDYS, QLABEL= Total Hours OFF with Dystonia, QVAL=1",Total Off Hours with Dystonia,CDISC;MDSUPDRS,"PD:
URL: http://www.movementdisorders.org/UserFiles/New%20UPDRS%207%203%2008%20final.pdf",Adult,NA,NA,Outcomes and End Points.Motor Function,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Core,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,MDS UPDRS Total OFF hours with dystonia,NA,NA,NIH/NINDS,NINDSCDE,NINDSCDE@emmes.com,NA,NA,NIH/NINDS,NINDSCDE,NINDSCDE@emmes.com,2014-04-01,2020-02-05,Published,NA,NA
MDSUPDRSTurngBedScore,MDS-UPDRS,Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS UPDRS) - turn bed score,Common Data Element,1.1,"Score for the participant's/subject's ability to turn in bed, as a part of Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS UPDRS)","Score for the participant's/subject's ability to turn in bed, as a part of Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS UPDRS)",Numeric Values,NA,Single Pre-Defined Value Selected,NA,NA,0;1;2;3;4,"Normal: Not at all (no problems);Slight: I have a bit of trouble turning, but I do not need any help;Mild I have a lot of trouble turning and need occasional help from someone else;Moderate: To turn over I often need help from someone else;Severe: I am unable to turn over without help from someone else",0;1;2;3;4,NA,NA,NA,"PD:
Refer to instrument for additional instructions",MDS UPDRS Q2.9.  CDISC variables  QSORRES  for QSTESTCD=UPD2209,Turning in bed and adjusting bed clothes,CDISC;MDSUPDRS,"PD:
URL: http://www.movementdisorders.org/UserFiles/New%20UPDRS%207%203%2008%20final.pdf",Adult,NA,NA,Outcomes and End Points.Motor Function,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Core,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,MDS UPDRS Q2.9,NA,NA,NIH/NINDS,NINDSCDE,NINDSCDE@emmes.com,NA,NA,NIH/NINDS,NINDSCDE,NINDSCDE@emmes.com,2014-04-01,2020-02-05,Published,NA,NA
MDSUPDRSUrnryProbScore,MDS-UPDRS,Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS UPDRS) - urinary problem score,Common Data Element,1.1,"Score for the participant's/subject's degree of urinary problems (e.g. urgent need to urinate, a need to urinate too often, or urine accidents), as a part of Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS UPDRS)","Score for the participant's/subject's degree of urinary problems (e.g. urgent need to urinate, a need to urinate too often, or urine accidents), as a part of Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS UPDRS)",Numeric Values,NA,Single Pre-Defined Value Selected,NA,NA,0;1;2;3;4,"Normal: No urine control problems;Slight: I need to urinate often or urgently. However, these problems do not cause difficulties with my daily activities;Mild: Urine problems cause some difficulties with my daily activities. However, I do not have urine accidents;Moderate: Urine problems cause a lot of difficulties with my daily activities, including urine accidents;Severe: I cannot control my urine and use a protective garment or have a bladder tube.",0;1;2;3;4,NA,NA,NA,"PD:
Refer to instrument for additional instructions",MDS UPDRS Q1.10.  CDISC variables  QSORRES  for QSTESTCD=UPD2110,URINARY PROBLEMS,CDISC;MDSUPDRS,"PD:
URL: http://www.movementdisorders.org/UserFiles/New%20UPDRS%207%203%2008%20final.pdf",Adult,NA,NA,Outcomes and End Points.Motor Function,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Core,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,MDS UPDRS Q1.10,NA,NA,NIH/NINDS,NINDSCDE,NINDSCDE@emmes.com,NA,NA,NIH/NINDS,NINDSCDE,NINDSCDE@emmes.com,2014-04-01,2020-02-05,Published,NA,NA
MDSUPDRSWlkngBalanceScore,MDS-UPDRS,Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS UPDRS) - walk balance score,Common Data Element,1.1,"Score for the participant's/subject's ability to walk and balance on his or her own, as a part of Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS UPDRS)","Score for the participant's/subject's ability to walk and balance on his or her own, as a part of Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS UPDRS)",Numeric Values,NA,Single Pre-Defined Value Selected,NA,NA,0;1;2;3;4,"Normal: Not at all (no problems);Slight: I am slightly slow or may drag a leg. I never use a walking aid;Mild: I occasionally use a walking aid, but I do not need any help from another person;Moderate: I usually use a walking aid (cane, walker) to walk safely without falling. However, I do not usually need the support of another person;Severe: I usually use the support of another persons to walk safely without falling",0;1;2;3;4,NA,NA,NA,"PD:
Refer to instrument for additional instructions",MDS UPDRS Q2.12.  CDISC variables  QSORRES  for QSTESTCD=UPD2212,WALKING AND BALANCE,CDISC;MDSUPDRS,"PD:
URL: http://www.movementdisorders.org/UserFiles/New%20UPDRS%207%203%2008%20final.pdf",Adult,NA,NA,Outcomes and End Points.Motor Function,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Core,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,MDS UPDRS Q2.12,NA,NA,NIH/NINDS,NINDSCDE,NINDSCDE@emmes.com,NA,NA,NIH/NINDS,NINDSCDE,NINDSCDE@emmes.com,2014-04-01,2020-02-05,Published,NA,NA
MDSUPDRS_PartIIIScore,MDS-UPDRS,Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS-UPDRS) - Part III score value,Unique Data Element,1.1,MDS-UPDRS part III score value,MDS-UPDRS part III score value,Numeric Values,NA,Free-Form Entry,0,137,NA,NA,NA,NA,NA,NA,NA,CDISC  variable is defined by ADaM,NA,CDISC;MDSUPDRS,NA,Adult,NA,NA,Assessments and Examinations.Other Clinical Data,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NIH/NINDS,NINDSCDE,NINDSCDE@emmes.com,NA,NA,NIH/NINDS,NINDSCDE,NINDSCDE@emmes.com,2014-04-01,2020-02-05,Published,NA,NA
MDSUPDRS_PartIIScore,MDS-UPDRS,Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS-UPDRS) - Part II score value,Unique Data Element,1.1,MDS-UPDRS part II score value,MDS-UPDRS part II score value,Numeric Values,NA,Free-Form Entry,0,52,NA,NA,NA,NA,NA,NA,NA,CDISC  variable is defined by ADaM,NA,CDISC;MDSUPDRS,NA,Adult,NA,NA,Assessments and Examinations.Other Clinical Data,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NIH/NINDS,NINDSCDE,NINDSCDE@emmes.com,NA,NA,NIH/NINDS,NINDSCDE,NINDSCDE@emmes.com,2014-04-01,2020-02-05,Published,NA,NA
MDSUPDRS_PartIScore,MDS-UPDRS,Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS-UPDRS) - Part I score value,Unique Data Element,1.1,MDS-UPDRS part I score value,MDS-UPDRS part I score value,Numeric Values,NA,Free-Form Entry,0,52,NA,NA,NA,NA,NA,NA,NA,CDISC  variable is defined by ADaM,NA,CDISC;MDSUPDRS,NA,Adult,NA,NA,Assessments and Examinations.Other Clinical Data,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NIH/NINDS,NINDSCDE,NINDSCDE@emmes.com,NA,NA,NIH/NINDS,NINDSCDE,NINDSCDE@emmes.com,2014-04-01,2020-02-05,Published,NA,NA
MDSUPDRS_PartIVScore,MDS-UPDRS,Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS-UPDRS) - Part IV score value,Unique Data Element,1.1,MDS-UPDRS part IV score value,MDS-UPDRS part IV score value,Numeric Values,NA,Free-Form Entry,0,24,NA,NA,NA,NA,NA,NA,NA,CDISC  variable is defined by ADaM,NA,CDISC;MDSUPDRS,NA,Adult,NA,NA,Assessments and Examinations.Other Clinical Data,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NIH/NINDS,NINDSCDE,NINDSCDE@emmes.com,NA,NA,NIH/NINDS,NINDSCDE,NINDSCDE@emmes.com,2014-04-01,2020-02-05,Published,NA,NA
MDSUPDRS_TotalScore,MDS-UPDRS,Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS-UPDRS) - Total score value,Unique Data Element,1.1,MDS-UPDRS total score value,MDS-UPDRS total score value,Numeric Values,NA,Free-Form Entry,0,265,NA,NA,NA,NA,NA,NA,NA,CDISC  variable is defined by ADaM,NA,CDISC;MDSUPDRS,NA,Adult,NA,NA,Assessments and Examinations.Other Clinical Data,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NIH/NINDS,NINDSCDE,NINDSCDE@emmes.com,NA,NA,NIH/NINDS,NINDSCDE,NINDSCDE@emmes.com,2014-04-01,2020-02-05,Published,NA,NA
MOCA_Abstraction,MoCA,Montreal Cognitive Assessment (MOCA) - serial  language abstraction score value,Common Data Element,1.2,Language test -  Serial  language abstraction points earned,Language test -  Serial  language abstraction,Numeric Values,NA,Single Pre-Defined Value Selected,NA,NA,0;1;2,0;1;2,0;1;2,NA,NA,NA,See instructions on the form,NA,MOCA Serial  Language Abstraction Points,NA,www.mocatest.org,Adult,Assessments and Examinations.Physical/Neurological Examination,NA,Assessments and Examinations.Other Clinical Data,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NIH/CIT/BRICS,David Grolling,NA,NA,NA,NIH/CIT/BRICS,Olga Vovk,olga.vovk@nih.gov,2014-04-01,2018-05-04,Published,NA,NA
MOCA_DelydRecalOptnlMultChoice,MoCA,Montreal Cognitive Assessment (MOCA) - delayed recall optional multiple choice cue score value,Common Data Element,1.2,Delayed recall test optional with multiple choice cue points earned,Delayed recall test optional - multiple choice cue,Numeric Values,NA,Single Pre-Defined Value Selected,NA,NA,0;1;2;3;4;5,0;1;2;3;4;5,0;1;2;3;4;5,NA,NA,NA,See instructions on the form,NA,NA,NA,NA,Adult,Assessments and Examinations.Physical/Neurological Examination,NA,Assessments and Examinations.Other Clinical Data,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NIH/CIT/BRICS,David Grolling,NA,NA,NA,NIH/CIT/BRICS,Olga Vovk,olga.vovk@nih.gov,2014-04-01,2018-05-04,Published,NA,NA
MOCA_DelydRecall,MoCA,Montreal Cognitive Assessment (MOCA) - delayed recall score value,Common Data Element,1.2,Delayed recall test - with no cue points earned,Delayed recall test - no cue,Numeric Values,NA,Single Pre-Defined Value Selected,NA,NA,0;1;2;3;4;5,0;1;2;3;4;5,0;1;2;3;4;5,NA,NA,NA,See instructions on the form,NA,MOCA Delayed Recall Points,NA,www.mocatest.org,Adult,Assessments and Examinations.Physical/Neurological Examination,NA,Assessments and Examinations.Other Clinical Data,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NIH/CIT/BRICS,David Grolling,NA,NA,NA,NIH/CIT/BRICS,Olga Vovk,olga.vovk@nih.gov,2014-04-01,2018-05-04,Published,NA,NA
MOCA_DelydRecallOptnlCatCue,MoCA,Montreal Cognitive Assessment (MOCA) - delayed recall optional category cue score value,Common Data Element,1.2,Delayed recall test optional with category cue points earned,Delayed recall test optional - category cue,Numeric Values,NA,Single Pre-Defined Value Selected,NA,NA,0;1;2;3;4;5,0;1;2;3;4;5,0;1;2;3;4;5,NA,NA,NA,See instructions on the form,NA,MOCA Delayed Recall Optional Points,NA,www.mocatest.org,Adult,Assessments and Examinations.Physical/Neurological Examination,NA,Assessments and Examinations.Other Clinical Data,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NIH/CIT/BRICS,David Grolling,NA,NA,NA,NIH/CIT/BRICS,Olga Vovk,olga.vovk@nih.gov,2014-04-01,2018-05-04,Published,NA,NA
MOCA_Digits,MoCA,Montreal Cognitive Assessment (MOCA) - attention read list of digits score value,Common Data Element,1.2,Attention test - read list of digits points earned (1 digit per second),Attention test - read list of digits,Numeric Values,NA,Single Pre-Defined Value Selected,NA,NA,0;1;2,0;1;2,0;1;2,NA,NA,NA,See instructions on the form,NA,MOCA Attention Read List of Digits,NA,www.mocatest.org,Adult,Assessments and Examinations.Physical/Neurological Examination,NA,Assessments and Examinations.Other Clinical Data,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NIH/CIT/BRICS,David Grolling,NA,NA,NA,NIH/CIT/BRICS,Olga Vovk,olga.vovk@nih.gov,2014-04-01,2018-05-04,Published,NA,NA
MOCA_EduInd,MoCA,Montreal Cognitive Assessment (MOCA) - education indicator,Common Data Element,1.4,Indicator of whether subject has completed 12 years of education.,Indicator of whether subject has completed 12 years of education.,Numeric Values,NA,Single Pre-Defined Value Selected,NA,NA,0;1,Subject has greater than 12 years of education;Subject has less than or equal to 12 years of education,0;1,NA,NA,NA,See instructions on the form,NA,NA,NA,www.mocatest.org,Adult,Assessments and Examinations.Physical/Neurological Examination,NA,Assessments and Examinations.Other Clinical Data,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,EduLvlMaternalUSATyp;EduLvlPaternalUSATyp;EduLvlUSATyp;EduTyp;EduYrCt,NIH/CIT/BRICS,David Grolling,NA,NA,NA,NIH/CIT/BRICS,Olga Vovk,olga.vovk@nih.gov,2014-04-01,2020-03-03,Published,NA,NA
MOCA_ImageResponse,MoCA,Montreal Cognitive Assessment (MoCA) - image response file,Common Data Element,1.4,"MoCA image response, usually uploaded as a scanned image.",MoCA image response file,File,NA,Free-Form Entry,NA,NA,NA,NA,NA,NA,NA,NA,Attach/upload a ZIP file.,NA,NA,NA,NA,Adult and Pediatric,Assessments and Examinations.Physical/Neurological Examination,NA,Assessments and Examinations.Other Clinical Data,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NIH/CIT/BRICS,David Grolling,NA,NA,NA,NIH/CIT/BRICS,Olga Vovk,olga.vovk@nih.gov,2014-04-01,2019-06-24,Published,NA,NA
MOCA_LangFluency,MoCA,Montreal Cognitive Assessment (MOCA) - serial  language fluency score value,Common Data Element,1.2,Language test - Serial  language fluency points earned,Language test - Serial  language fluency,Numeric Values,NA,Single Pre-Defined Value Selected,NA,NA,0;1,0;1,0;1,NA,NA,NA,See instructions on the form,NA,MOCA Serial  Language Fluency Points,NA,www.mocatest.org,Adult,Assessments and Examinations.Physical/Neurological Examination,NA,Assessments and Examinations.Other Clinical Data,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NIH/CIT/BRICS,David Grolling,NA,NA,NA,NIH/CIT/BRICS,Olga Vovk,olga.vovk@nih.gov,2014-04-01,2018-05-04,Published,NA,NA
MOCA_LangRepeat,MoCA,Montreal Cognitive Assessment (MOCA) - serial language repeat score value,Common Data Element,1.2,Attention test -  Serial  7 language repeat test points earned,Attention test -  Serial  7 language repeat test,Numeric Values,NA,Single Pre-Defined Value Selected,NA,NA,0;1;2,0;1;2,0;1;2,NA,NA,NA,See instructions on the form,NA,MOCA Serial  Language Repeat,NA,www.mocatest.org,Adult,Assessments and Examinations.Physical/Neurological Examination,NA,Assessments and Examinations.Other Clinical Data,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NIH/CIT/BRICS,David Grolling,NA,NA,NA,NIH/CIT/BRICS,Olga Vovk,olga.vovk@nih.gov,2014-04-01,2018-05-04,Published,NA,NA
MOCA_Letters,MoCA,Montreal Cognitive Assessment (MOCA) - read list of letters score value,Common Data Element,1.2,Attention test - Read list of letters test points earned,Attention test - Read list of letters test,Numeric Values,NA,Single Pre-Defined Value Selected,NA,NA,0;1,0;1,0;1,NA,NA,NA,See instructions on the form,NA,MOCA Read List of Letters,NA,www.mocatest.org,Adult,Assessments and Examinations.Physical/Neurological Examination,NA,Assessments and Examinations.Other Clinical Data,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NIH/CIT/BRICS,David Grolling,NA,NA,NA,NIH/CIT/BRICS,Olga Vovk,olga.vovk@nih.gov,2014-04-01,2018-05-04,Published,NA,NA
MOCA_Naming,MoCA,Montreal Cognitive Assessment (MOCA) - naming score value,Common Data Element,1.2,Naming test points earned,Naming test,Numeric Values,NA,Single Pre-Defined Value Selected,NA,NA,0;1;2;3,0;1;2;3,0;1;2;3,NA,NA,NA,See instructions on the form,NA,MOCA Naming Points,NA,www.mocatest.org,Adult,Assessments and Examinations.Physical/Neurological Examination,NA,Assessments and Examinations.Other Clinical Data,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NIH/CIT/BRICS,David Grolling,NA,NA,NA,NIH/CIT/BRICS,Olga Vovk,olga.vovk@nih.gov,2014-04-01,2018-05-04,Published,NA,NA
MOCA_Orient,MoCA,Montreal Cognitive Assessment (MOCA) - orientation score value,Common Data Element,1.2,Orientation test points earned,Orientation test,Numeric Values,NA,Single Pre-Defined Value Selected,NA,NA,0;1;2;3;4;5;6,0;1;2;3;4;5;6,0;1;2;3;4;5;6,NA,NA,NA,See instructions on the form,NA,MOCA Orientation Points,NA,www.mocatest.org,Adult,Assessments and Examinations.Physical/Neurological Examination,NA,Assessments and Examinations.Other Clinical Data,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NIH/CIT/BRICS,David Grolling,NA,NA,NA,NIH/CIT/BRICS,Olga Vovk,olga.vovk@nih.gov,2014-04-01,2018-05-04,Published,NA,NA
MOCA_Serial7,MoCA,Montreal Cognitive Assessment (MOCA) - serial 7 subtractions score value,Common Data Element,1.2,Attention test - Serial 7 subtractions test points earned,Attention test - Serial 7 subtractions test,Numeric Values,NA,Single Pre-Defined Value Selected,NA,NA,0;1;2;3,0;1;2;3,0;1;2;3,NA,NA,NA,See instructions on the form,NA,MOCA Serial 7 Subtractions,NA,www.mocatest.org,Adult,Assessments and Examinations.Physical/Neurological Examination,NA,Assessments and Examinations.Other Clinical Data,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NIH/CIT/BRICS,David Grolling,NA,NA,NA,NIH/CIT/BRICS,Olga Vovk,olga.vovk@nih.gov,2014-04-01,2018-05-04,Published,NA,NA
MOCA_Total,MoCA,Montreal Cognitive Assessment (MOCA) - total score value,Common Data Element,1.2,Total points earned Montreal Cognicitve Assessment (MOCA),Total score MOCA,Numeric Values,NA,Free-Form Entry,0,31,NA,NA,NA,NA,NA,NA,See instructions on the form,NA,MOCA Total,NA,www.mocatest.org,Adult,Assessments and Examinations.Physical/Neurological Examination,NA,Assessments and Examinations.Other Clinical Data,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NIH/CIT/BRICS,David Grolling,NA,NA,NA,NIH/CIT/BRICS,Olga Vovk,olga.vovk@nih.gov,2014-04-01,2018-05-04,Published,NA,NA
MOCA_VisuospatialExec,MoCA,Montreal Cognitive Assessment (MOCA) - visuospatial executive score value,Common Data Element,1.2,Visuospatial/Executive test points earned,Visuospatial/Executive test,Numeric Values,NA,Single Pre-Defined Value Selected,NA,NA,0;1;2;3;4;5,0;1;2;3;4;5,0;1;2;3;4;5,NA,NA,NA,See instructions on the form,NA,MOCA Visuospatial Executive points,NA,www.mocatest.org,Adult,Assessments and Examinations.Physical/Neurological Examination,NA,Assessments and Examinations.Other Clinical Data,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NIH/CIT/BRICS,David Grolling,NA,NA,NA,NIH/CIT/BRICS,Olga Vovk,olga.vovk@nih.gov,2014-04-01,2018-05-04,Published,NA,NA
MSQ_BedpartnerInjInd,MayoSleepQuestionnaire,Mayo Sleep Questionnaire (MSQ) - bedpartner injured indicator,Unique Data Element,1.1,A bedpartner been injured from the subject ''act out his/her dreams'' behavior indicator,A bedpartner been injured from the subject indicator,Alphanumeric,NA,Single Pre-Defined Value Selected,NA,NA,No;No bedpartner;Yes,No;No bedpartner;Yes,0;2;1,NA,NA,NA,Please mark YES if the described event has occurred at least 3 times.,REM Questionnaire_Bedpartner Injured Q1c,"Has a bedpartner ever been injured from these behaviors (bruises, blows, pulled hair)?",NA,Mayo Sleep Questionnaire-Informant.2009 Mayo Foundation for Medical Education and Research. All Rights Reserved. https://healthfinder.gov/FindServices/Organizations/Organization.aspx?code=HR3150,Adult,Assessments and Examinations.Physical/Neurological Examination,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NIH/CIT/BRICS,NA,NA,NA,NA,NIH/CIT/BRICS,Olga Vovk,olga.vovk@nih.gov,2014-04-01,2017-09-25,Published,NA,NA
MSQ_DreamsActInd,MayoSleepQuestionnaire,Mayo Sleep Questionnaire (MSQ) - act out dreams indicator,Unique Data Element,1.3,The subject appears to ''act out his/her dreams'' indication,The subject appears to ''act out his/her dreams'' indication,Alphanumeric,NA,Single Pre-Defined Value Selected,NA,NA,No;Yes,No;Yes,0;1,NA,NA,NA,"Please mark YES if the described event has occurred at least 3 times.  If yes, answer a-e, below.",REM Questionnaire Act Out Dreams Q1,"Have you ever seen the patient appear to ''act out his/her dreams'' while sleeping? (punched or flailed arms in the air, shouted or screamed)",NA,Mayo Sleep Questionnaire-Informant.2009 Mayo Foundation for Medical Education and Research. All Rights Reserved. https://healthfinder.gov/FindServices/Organizations/Organization.aspx?code=HR3151,Adult,Assessments and Examinations.Physical/Neurological Examination,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NIH/CIT/BRICS,NA,NA,NA,NA,NIH/CIT/BRICS,Olga Vovk,olga.vovk@nih.gov,2014-04-01,2017-09-25,Published,NA,NA
MSQ_DreamsActNumMo,MayoSleepQuestionnaire,Mayo Sleep Questionnaire (MSQ) - act out dreams number of months,Unique Data Element,1.2,Number of months the patient appear to ''act out his/her dreams'' while sleeping,Acting out dreams number of months,Numeric Values,NA,Free-Form Entry,NA,NA,NA,NA,NA,NA,NA,NA,NA,REM Questionnaire Act Out Months Q1a,How many months or years has this been going on?,NA,Mayo Sleep Questionnaire-Informant.2009 Mayo Foundation for Medical Education and Research. All Rights Reserved. https://healthfinder.gov/FindServices/Organizations/Organization.aspx?code=HR3152,Adult,Assessments and Examinations.Physical/Neurological Examination,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NIH/CIT/BRICS,NA,NA,NA,NA,NIH/CIT/BRICS,Olga Vovk,olga.vovk@nih.gov,2014-04-01,2017-09-25,Published,NA,NA
MSQ_DreamsActNumYr,MayoSleepQuestionnaire,Mayo Sleep Questionnaire (MSQ) - act out dreams number of years,Unique Data Element,1.3,Number of years the patient appear to ''act out his/her dreams'' while sleeping,Acting out dreams number of years,Numeric Values,NA,Free-Form Entry,NA,NA,NA,NA,NA,NA,NA,NA,NA,REM Questionnaire Act Out Years Q1a,Sleep Questionnaire.  1a. How many months or years has this been going on?,NA,Mayo Sleep Questionnaire-Informant.2009 Mayo Foundation for Medical Education and Research. All Rights Reserved. https://healthfinder.gov/FindServices/Organizations/Organization.aspx?code=HR3153,Adult,Assessments and Examinations.Physical/Neurological Examination,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NIH/CIT/BRICS,NA,NA,NA,NA,NIH/CIT/BRICS,Olga Vovk,olga.vovk@nih.gov,2014-04-01,2017-09-25,Published,NA,NA
MSQ_DreamsAttackedInd,MayoSleepQuestionnaire,Mayo Sleep Questionnaire (MSQ) - reported dreams of being attacked indicator,Unique Data Element,1.3,"The subject  reported about dreams of being chased, attacked, or had to defend himself/herself",The subject  reported about dreams of being chased or attacked,Alphanumeric,NA,Single Pre-Defined Value Selected,NA,NA,Never told you about dreams;No;Yes,Never told you about dreams;No;Yes,2;0;1,NA,NA,NA,Please mark YES if the described event has occurred at least 3 times.,REM Questionnaire Told Dreams Q1d,"Has the subject told you about dreams of being chased, attacked or that involve defending himself/herself?",NA,Mayo Sleep Questionnaire-Informant.2009 Mayo Foundation for Medical Education and Research. All Rights Reserved. https://healthfinder.gov/FindServices/Organizations/Organization.aspx?code=HR3154,Adult,Assessments and Examinations.Physical/Neurological Examination,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NIH/CIT/BRICS,NA,NA,NA,NA,NIH/CIT/BRICS,Olga Vovk,olga.vovk@nih.gov,2014-04-01,2017-09-25,Published,NA,NA
MSQ_DreamsMatchDetailsInd,MayoSleepQuestionnaire,Mayo Sleep Questionnaire (MSQ) - dream details match indicator,Unique Data Element,1.1,The details of the subject's dream match the subject movements made while sleeping,Details of the dream match the movements made while sleeping indicator,Alphanumeric,NA,Single Pre-Defined Value Selected,NA,NA,Never told you about dreams;No;Yes,Never told you about dreams;No;Yes,2;0;21,NA,NA,NA,Please mark YES if the described event has occurred at least 3 times.,REM Questionnaire_Dream Details Match Q1e,"If the subject woke up and told you about a dream, did the details of the dream match the movements made while sleeping?",NA,Mayo Sleep Questionnaire-Informant.2009 Mayo Foundation for Medical Education and Research. All Rights Reserved. https://healthfinder.gov/FindServices/Organizations/Organization.aspx?code=HR3155,Adult,Assessments and Examinations.Physical/Neurological Examination,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NIH/CIT/BRICS,NA,NA,NA,NA,NIH/CIT/BRICS,Olga Vovk,olga.vovk@nih.gov,2014-04-01,2017-09-25,Published,NA,NA
MSQ_LegCrampsInd,MayoSleepQuestionnaire,Mayo Sleep Questionnaire (MSQ) - leg cramps indicator,Unique Data Element,1.3,The subject experienced  leg cramps or intense pain in certain muscles in the leg at night indicator,The subject have leg cramps at night indicator,Alphanumeric,NA,Single Pre-Defined Value Selected,NA,NA,No;Yes,No;Yes,0;1,NA,NA,NA,Please mark YES if the described event has occurred at least 3 times.,REM Questionnaire Leg Cramps Q7,"Does the subject have leg cramps at night? (e.g., also called a ''charlie horse'' with intense pain in certain muscles in the leg)?",NA,Mayo Sleep Questionnaire-Informant.2009 Mayo Foundation for Medical Education and Research. All Rights Reserved. https://healthfinder.gov/FindServices/Organizations/Organization.aspx?code=HR3156,Adult,Assessments and Examinations.Physical/Neurological Examination,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NIH/CIT/BRICS,NA,NA,NA,NA,NIH/CIT/BRICS,Olga Vovk,olga.vovk@nih.gov,2014-04-01,2017-09-25,Published,NA,NA
MSQ_LegJerkInd,MayoSleepQuestionnaire,Mayo Sleep Questionnaire (MSQ) - legs jerk indicator,Unique Data Element,1.2,The subject's legs repeatedly jerk or twitch during sleep (not just when falling asleep) indicator,Legs repeatedly jerk or twitch during sleep indicator,Alphanumeric,NA,Single Pre-Defined Value Selected,NA,NA,No;Yes,No;Yes,0;1,NA,NA,NA,Please mark YES if the described event has occurred at least 3 times.,REM Questionnaire Legs Jerk Q2,Do the subject's legs repeatedly jerk or twitch during sleep (not just when falling asleep)?,NA,Mayo Sleep Questionnaire-Informant.2009 Mayo Foundation for Medical Education and Research. All Rights Reserved. https://healthfinder.gov/FindServices/Organizations/Organization.aspx?code=HR3157,Adult,Assessments and Examinations.Physical/Neurological Examination,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NIH/CIT/BRICS,NA,NA,NA,NA,NIH/CIT/BRICS,Olga Vovk,olga.vovk@nih.gov,2014-04-01,2017-09-25,Published,NA,NA
MSQ_LegSensationDecreaseInd,MayoSleepQuestionnaire,Mayo Sleep Questionnaire (MSQ) - leg sensations decrease indicator,Unique Data Element,1.1,Unpleasant leg sensations decrease when the subject moves or walks around indicator,Leg sensations decrease when the subject moves indicator,Alphanumeric,NA,Single Pre-Defined Value Selected,NA,NA,No;Yes,No;Yes,0;1,NA,NA,NA,Please mark YES if the described event has occurred at least 3 times.,REM Questionnaire Leg Sensations Decrease Q3a,Does the subject tell you that these leg sensations decrease when he/she moves them or walks around?,NA,Mayo Sleep Questionnaire-Informant.2009 Mayo Foundation for Medical Education and Research. All Rights Reserved. https://healthfinder.gov/FindServices/Organizations/Organization.aspx?code=HR3158,Adult,Assessments and Examinations.Physical/Neurological Examination,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NIH/CIT/BRICS,NA,NA,NA,NA,NIH/CIT/BRICS,Olga Vovk,olga.vovk@nih.gov,2014-04-01,2017-09-25,Published,NA,NA
MSQ_LegSensationWorst,MayoSleepQuestionnaire,Mayo Sleep Questionnaire (MSQ) - time leg sensations worst,Unique Data Element,1.3,Time when the unpleasant leg sensations are the worst,Time when the leg sensations are the worst,Alphanumeric,NA,Single Pre-Defined Value Selected,NA,NA,After 6pm;Before 6pm,After 6pm;Before 6pm,6;18,NA,NA,NA,Please mark YES if the described event has occurred at least 3 times.,REM Questionnaire Time Leg Sensations Worst Q3b,When do these sensations seem to be the worst?,NA,Mayo Sleep Questionnaire-Informant.2009 Mayo Foundation for Medical Education and Research. All Rights Reserved. https://healthfinder.gov/FindServices/Organizations/Organization.aspx?code=HR3159,Adult,Assessments and Examinations.Physical/Neurological Examination,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NIH/CIT/BRICS,NA,NA,NA,NA,NIH/CIT/BRICS,Olga Vovk,olga.vovk@nih.gov,2014-04-01,2017-09-25,Published,NA,NA
MSQ_LiveWithSubjInd,MayoSleepQuestionnaire,Mayo Sleep Questionnaire (MSQ) - live with subject indicator,Unique Data Element,1.2,Live with the subject indicator,Live with the subject indicator,Alphanumeric,NA,Single Pre-Defined Value Selected,NA,NA,No;Yes,No;Yes,0;1,NA,NA,NA,Choose one,REM Questionnaire Live With Subject,Information about the Informant. Do you Live with the subject?,NA,Mayo Sleep Questionnaire-Informant.2009 Mayo Foundation for Medical Education and Research. All Rights Reserved. https://healthfinder.gov/FindServices/Organizations/Organization.aspx?code=HR3160,Adult,Assessments and Examinations.Physical/Neurological Examination,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NIH/CIT/BRICS,NA,NA,NA,NA,NIH/CIT/BRICS,Olga Vovk,olga.vovk@nih.gov,2014-04-01,2017-09-25,Published,NA,NA
MSQ_PatientInjInd,MayoSleepQuestionnaire,Mayo Sleep Questionnaire (MSQ) - patient injured while sleeping indicator,Unique Data Element,1.3,"The subject  has been injured from ''act out his/her dreams'' while sleeping behaviors (bruises, cuts, broken bones) indicator",The subject  has been self-injured while sleeping  indicator,Alphanumeric,NA,Single Pre-Defined Value Selected,NA,NA,No;Yes,No;Yes,0;1,NA,NA,NA,Please mark YES if the described event has occurred at least 3 times.,REM Questionnaire_Patient injured Q1b,"Has the patient ever been injured from these behaviors (bruises, cuts, broken bones?",NA,Mayo Sleep Questionnaire-Informant.2009 Mayo Foundation for Medical Education and Research. All Rights Reserved. https://healthfinder.gov/FindServices/Organizations/Organization.aspx?code=HR3161,Adult,Assessments and Examinations.Physical/Neurological Examination,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NIH/CIT/BRICS,NA,NA,NA,NA,NIH/CIT/BRICS,Olga Vovk,olga.vovk@nih.gov,2014-04-01,2017-09-25,Published,NA,NA
MSQ_RateAlert,MayoSleepQuestionnaire,Mayo Sleep Questionnaire (MSQ) - rate of alertness,Unique Data Element,1.1,The rate of  the subject's general level of alertness for the past 3 weeks,The subject's general level of alertness for the past 3 weeks,Numeric Values,NA,Single Pre-Defined Value Selected,NA,NA,0;1;10;2;3;4;5;6;7;8;9,0;1;10;2;3;4;5;6;7;8;9,0;1;10;2;3;4;5;6;7;8;9,NA,NA,NA,"0 means Sleep all day, 10 means  Fully and Normally Awake",REM Questionnaire_Rate Of Alertness Q8,Rate the subject's general level of alertness for the past 3 weeks on a scale from 0 to 10.,NA,Mayo Sleep Questionnaire-Informant.2009 Mayo Foundation for Medical Education and Research. All Rights Reserved. https://healthfinder.gov/FindServices/Organizations/Organization.aspx?code=HR3162,Adult,Assessments and Examinations.Physical/Neurological Examination,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NIH/CIT/BRICS,NA,NA,NA,NA,NIH/CIT/BRICS,Olga Vovk,olga.vovk@nih.gov,2014-04-01,2017-09-25,Published,NA,NA
MSQ_RestlessLegInd,MayoSleepQuestionnaire,Mayo Sleep Questionnaire (MSQ) - restless legs indicator,Unique Data Element,1.1,"The subject complains of a restless, nervous, tingly, or creepy-crawly feeling in legs which affects his ability to fall or stay asleep indicator",Restless feeling in legs affect the subject ability to fall or stay asleep indicator,Alphanumeric,NA,Single Pre-Defined Value Selected,NA,NA,No;Yes,No;Yes,0;1,NA,NA,NA,"Please mark YES if the described event has occurred at least 3 times. If Yes, answer a-b below.",REM Questionnaire_Restless Legs Q3,"Does the subject complain of a restless, nervous, tingly, or creepy-crawly feeling in his/her legs that disrupts his/her ability to fall or stay asleep?",NA,Mayo Sleep Questionnaire-Informant.2009 Mayo Foundation for Medical Education and Research. All Rights Reserved. https://healthfinder.gov/FindServices/Organizations/Organization.aspx?code=HR3163,Adult,Assessments and Examinations.Physical/Neurological Examination,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NIH/CIT/BRICS,NA,NA,NA,NA,NIH/CIT/BRICS,Olga Vovk,olga.vovk@nih.gov,2014-04-01,2017-09-25,Published,NA,NA
MSQ_SleepBehavrInd,MayoSleepQuestionnaire,Mayo Sleep Questionnaire (MSQ) - distracting sleep behaviors indicator,Unique Data Element,1.3,"If no, is it because of his/her sleep behaviors (snores too loud, acts out dreams, etc.)",Distracting sleep behaviors indicator,Alphanumeric,NA,Single Pre-Defined Value Selected,NA,NA,No;Unknown;Yes,No;Unknown;Yes,0;9;1,NA,NA,NA,Choose one,REM Questionnaire_Distracting sleep behaviors indicator,"Information about the Informant. If no, is it because of his/her sleep behaviors (snores too loud, acts out dreams, etc.)",NA,Mayo Sleep Questionnaire-Informant.2009 Mayo Foundation for Medical Education and Research. All Rights Reserved. https://healthfinder.gov/FindServices/Organizations/Organization.aspx?code=HR3164,Adult and Pediatric,Assessments and Examinations.Physical/Neurological Examination,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NIH/CIT/BRICS,NA,NA,NA,NA,NIH/CIT/BRICS,Olga Vovk,olga.vovk@nih.gov,2014-04-01,2017-09-25,Published,NA,NA
MSQ_SleepSameRoomInd,MayoSleepQuestionnaire,Mayo Sleep Questionnaire (MSQ) - sleep in the same room indicator,Unique Data Element,1.3,Sleep in the same room with the subject indicator,Sleep in the same room with the subject indicator,Alphanumeric,NA,Single Pre-Defined Value Selected,NA,NA,No;Yes,No;Yes,0;1,NA,NA,NA,Choose one,REM Questionnaire_Sleep in the same room indicator,Information about the Informant. Do you sleep in the same room as the patient?,NA,Mayo Sleep Questionnaire-Informant.2009 Mayo Foundation for Medical Education and Research. All Rights Reserved. https://healthfinder.gov/FindServices/Organizations/Organization.aspx?code=HR3165,Adult,Assessments and Examinations.Physical/Neurological Examination,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NIH/CIT/BRICS,NA,NA,NA,NA,NIH/CIT/BRICS,Olga Vovk,olga.vovk@nih.gov,2014-04-01,2017-09-25,Published,NA,NA
MSQ_SleepWalk,MayoSleepQuestionnaire,Mayo Sleep Questionnaire (MSQ) - walked asleep indicator,Unique Data Element,1.2,The subject was seen  walking around the bedroom or house while asleep,The subject was seen  walking around  while asleep,Alphanumeric,NA,Single Pre-Defined Value Selected,NA,NA,No;Yes,No;Yes,0;1,NA,NA,NA,Please mark YES if the described event has occurred at least 3 times.,REM Questionnaire Walked Asleep Q4,Has the subject ever walked around the bedroom or house while asleep?,NA,Mayo Sleep Questionnaire-Informant.2009 Mayo Foundation for Medical Education and Research. All Rights Reserved. https://healthfinder.gov/FindServices/Organizations/Organization.aspx?code=HR3166,Adult,Assessments and Examinations.Physical/Neurological Examination,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NIH/CIT/BRICS,NA,NA,NA,NA,NIH/CIT/BRICS,Olga Vovk,olga.vovk@nih.gov,2014-04-01,2017-09-25,Published,NA,NA
MSQ_SnortAwakeInd,MayoSleepQuestionnaire,Mayo Sleep Questionnaire (MSQ) - snorted awake indicator,Unique Data Element,1.2,The subject snorted or choked him/herself awake indicator,The subject snorted him/herself awake indicator,Alphanumeric,NA,Single Pre-Defined Value Selected,NA,NA,No;Yes,No;Yes,0;1,NA,NA,NA,Please mark YES if the described event has occurred at least 3 times.,REM Questionnaire_Snorted Awake Q5,Has the subject ever snorted or choked him/herself awake?,NA,Mayo Sleep Questionnaire-Informant.2009 Mayo Foundation for Medical Education and Research. All Rights Reserved. https://healthfinder.gov/FindServices/Organizations/Organization.aspx?code=HR3167,Adult,Assessments and Examinations.Physical/Neurological Examination,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NIH/CIT/BRICS,NA,NA,NA,NA,NIH/CIT/BRICS,Olga Vovk,olga.vovk@nih.gov,2014-04-01,2017-09-25,Published,NA,NA
MSQ_StopBreathingInd,MayoSleepQuestionnaire,Mayo Sleep Questionnaire (MSQ) - stop breathing indicator,Unique Data Element,1.1,The subject stop breathing during sleep event indicator,The subject stop breathing  during sleep  indicator,Alphanumeric,NA,Single Pre-Defined Value Selected,NA,NA,No;Yes,No;Yes,0;1,NA,NA,NA,Please mark YES if the described event has occurred at least 3 times.,REM Questionnaire_Stop Breathing Q6,Does the subject ever seem to stop breathing during sleep?,NA,Mayo Sleep Questionnaire-Informant.2009 Mayo Foundation for Medical Education and Research. All Rights Reserved. https://healthfinder.gov/FindServices/Organizations/Organization.aspx?code=HR3168,Adult,Assessments and Examinations.Physical/Neurological Examination,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NIH/CIT/BRICS,NA,NA,NA,NA,NIH/CIT/BRICS,Olga Vovk,olga.vovk@nih.gov,2014-04-01,2017-09-25,Published,NA,NA
MSQ_TreatedStopBreathingInd,MayoSleepQuestionnaire,Mayo Sleep Questionnaire (MSQ) - treated for stop breathing indicator,Unique Data Element,1.3,The subject is currently being treated for stop breathing during the sleep (CPAP) indicator,The subject is currently being treated for stop breathing during the sleep,Alphanumeric,NA,Single Pre-Defined Value Selected,NA,NA,No;Yes,No;Yes,0;1,NA,NA,NA,Please mark YES if the described event has occurred at least 3 times.,REM Questionnaire Treated For Stop Breathing Q6a,"If Yes,  Is the subject currently being treated for this (e.g., CPAP)?",NA,Mayo Sleep Questionnaire-Informant.2009 Mayo Foundation for Medical Education and Research. All Rights Reserved. https://healthfinder.gov/FindServices/Organizations/Organization.aspx?code=HR3169,Adult,Assessments and Examinations.Physical/Neurological Examination,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NIH/CIT/BRICS,NA,NA,NA,NA,NIH/CIT/BRICS,Olga Vovk,olga.vovk@nih.gov,2014-04-01,2017-09-25,Published,NA,NA
MedctnPriorConcomDoseMsrTxt,PriorAndConcomitantMeds,Medication prior concomitant dose taken per administration text description,Unique Data Element,1.1,Dose of prior/concomitant medication taken per administration text description,Dose of prior/concomitant medication taken per administration text description,Alphanumeric,4000,Free-Form Entry,NA,NA,NA,NA,NA,NA,NA,NA,Alphanumeric medication dose field to capture dosages containing non-numeric characters,"CDISC variables: For PDBP use the following: CM=Concomitant Medications, CMINC=Parkinson's Disease, CMDOSU,",NA,CDISC,NA,Adult and Pediatric,Treatment/Intervention Data.Drugs,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NIH/NINDS,NA,NA,NA,NA,NIH/NINDS,NA,NA,2014-04-01,2020-02-05,Published,NA,NA
MedctnPriorConcomDoseUoM,PriorAndConcomitantMeds,Medication prior or concomitant dose unit of measure,Unique Data Element,1.5,Dosage unit of measure of the prior or concomitant medication administered.,Dosage unit of measure of the prior or concomitant medication administered.,Alphanumeric,255,Free-Form Entry,NA,NA,"g;mcg;mcL;mg;mL;NA;Other, specify;oz;Unknown","gram;microgram;microliter;milligram;milliliter;Not applicable;Other, specify;ounce;Unknown",1;2;3;4;5;777;444;6;999,NA,NA,NA,"Record the units of the medication the participant/subject is taking. See the data dictionary for additional information on coding the dosage unit of measure using Unified Code for Units of Measure (UCUM) (http://unitsofmeasure.org/trac).
","CDISC variables: For PDBP use the following: CM=Concomitant Medications, CMINC=Parkinson's Disease, CMDOSU","Dosage unit of measure 
",CDISC;Medical_History,"Unified Code for Units of Measure (UCUM) - http://unitsofmeasure.org/
",Adult and Pediatric,Treatment/Intervention Data.Drugs,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NIH/NINDS,NA,NA,NA,NA,NIH/NINDS,NA,NA,2014-04-01,2020-02-05,Published,NA,NA
MedctnPriorConcomFreqTxt,PriorAndConcomitantMeds,Medication prior concomitant frequency text,Unique Data Element,1.1,Medication prior or concomitant dose frequency text description,Medication prior or concomitant dose frequency text description,Alphanumeric,4000,Free-Form Entry,NA,NA,"BID;Other, specify;QD;QHS;QID;TID","Twice daily;Other, specify;Every day;Every night at bedtime;Four times per day;Three times per day",1;444;3;4;5;6,NA,NA,NA,Alphanumeric field describing medication dose frequency,"CDISC variables: For PDBP use the following: CM=Concomitant Medications, CMINC=Parkinson's Disease, CMDOSU, CMDOSFRQ",NA,CDISC,NA,Adult and Pediatric,Treatment/Intervention Data.Drugs,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NIH/NINDS,NA,NA,NA,NA,NIH/NINDS,NA,NA,2014-04-01,2020-02-05,Published,NA,NA
MedctnPriorConcomHrsLstDose,PriorAndConcomitantMeds,Medication prior concomitant hours since last dose,Unique Data Element,1.1,Medication prior or concomitant number of hours since the last dose,Medication prior or concomitant number of hours since the last dose,Numeric Values,NA,Free-Form Entry,NA,NA,NA,NA,NA,NA,NA,NA,Record the dose,"CDISC variables: For PDBP use the following: CM=Concomitant Medications, CMINC=Parkinson's Disease, CMDOSE",NA,CDISC,NA,Adult and Pediatric,Treatment/Intervention Data.Drugs,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NIH/NINDS,NA,NA,NA,NA,NIH/NINDS,NA,NA,2014-04-01,2020-02-05,Published,NA,NA
MedctnPriorConcomIndTxt,PriorAndConcomitantMeds,Medication prior or concomitant indication text,Common Data Element,1.5,"Text describing reason for administration of a prior/concomitant (no study) agent or measure. This is not the pharmacologic classification of an agent (antibiotic, analgesic, etc.), but the reason for its administration to the participant/subject.","Text describing reason for administration of a prior/concomitant (no study) agent or measure. This is not the pharmacologic classification of an agent (antibiotic, analgesic, etc.), but the reason for its administration to the participant/subject.",Alphanumeric,4000,Free-Form Entry,NA,NA,NA,NA,NA,NA,NA,NA,"GENERAL/HEADACHE/TBI/STROKE: 
Record the reason the participant/subject gives for taking the medication. If given for an AE, enter exact term from Adverse Event CRF.
","CDISC variables: For PDBP use the following: CM=Concomitant Medications, CMINDC=Parkinson's Disease, CMTRT=""immediate reason for administering the medication"", if CMINDC specifies the other reason for administering the medication, e.g. Neurosurgery, it should be on a separate line. CMSTRTPT=when the medication was administered, use with CMSTTPT=why it was administered",Reason for taking the medication,CDISC;Medical_History,No references available,Adult and Pediatric,Treatment/Intervention Data.Drugs,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Medication prior or concomitant indication text,NA,NA,NIH/NINDS,NINDSCDE,NINDSCDE@emmes.com,NA,NA,NIH/NINDS,NINDSCDE,NINDSCDE@emmes.com,2014-04-01,2020-02-05,Published,NA,NA
MedctnPriorConcomMinsLstDose,PriorAndConcomitantMeds,Medication prior concomitant minutes since last dose,Unique Data Element,1.1,Medication prior or concomitant number of minutes (additional to hours) since the last dose,Medication prior or concomitant number of minutes (additional to hours) since the last dose,Numeric Values,NA,Free-Form Entry,NA,NA,NA,NA,NA,NA,NA,NA,Only to be used in conjunction with Medication prior concomitant hours last dose CDE,"CDISC variables: For PDBP use the following: CM=Concomitant Medications, CMINC=Parkinson's Disease",NA,CDISC,NA,Adult and Pediatric,Treatment/Intervention Data.Drugs,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NIH/NINDS,NA,NA,NA,NA,NIH/NINDS,NA,NA,2014-04-01,2020-02-05,Published,NA,NA
MedctnPriorConcomName,PriorAndConcomitantMeds,Medication prior or concomitant name,Common Data Element,1.7,Name of the prior/concomitant agent or drug administered.,Name of the prior/concomitant agent or drug administered.,Alphanumeric,4000,Free-Form Entry,NA,NA,NA,NA,NA,NA,NA,NA,"Record the verbatim name (generic or trade name) of the medication the participant/subject reports taking. See the data dictionary for additional information on coding the medication name using RXNorm. Add date stamp for when assessed. Recommend collection at least on date of TBI.
","CDISC variables: For PDBP use the following: CM=Concomitant Medications, CMINC=Parkinson's Disease. CMCLAS=Medication Class, CMTRT=Medication Name",Medication name (trade of generic),SCAT;CDISC;Medical_History,"RXNorm (http://www.nlm.nih.gov/research/umls/rxnorm/)
",Adult and Pediatric,Assessments and Examinations.Physical/Neurological Examination,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Medication prior or concomitant name,NA,NA,NIH/CIT/BRICS,NINDSCDE,NINDSCDE@emmes.com,NA,NA,NIH/NINDS,NINDSCDE,NINDSCDE@emmes.com,2014-04-01,2020-02-05,Published,NA,NA
MedctnPriorConcomPD,PriorAndConcomitantMeds,Medication prior or concomitant for Parkinson's disease,Unique Data Element,1.1,Medication prior or concomitant for Parkinson's disease. List of FDA approved medications with an indication for PD as of November 2012,Medication Prior or Concomitant for Parkinson's disease,Alphanumeric,NA,Single Pre-Defined Value Selected,NA,NA,"Amantadine (Symmetrel);Apomorphine (Apokyn);Benztropine (Cogentin);Biperiden (Akineton);Bromocriptine (Parlodel);Carbidopa/levodopa (Atamet, Sinemet);Carbidopa/levodopa/entacapone (Stalevo);Carbidopa/levodopa orally disintegrating (Parcopa);Carbidopa/levodopa sustained release (Sinemet CR);Entacapone (Comtan);Pergolide (Permax);Pramipexole extended release (Mirapex ER);Pramipexole (Mirapex);Rasagiline (Azilect);Rivastigmine (Exelon);Ropinirole extended release (Requip XL);Ropinirole (Requip);Rotigotine transdermal patch (Neupro);Selegiline (Eldepryl);Selegiline orally disintegrating (Zelapar);Selegiline transdermal patch (Emsam);Tolcapone (Tasmar);Trihexyphenidyl (Artane, Tremin)","Amantadine (Symmetrel);Apomorphine (Apokyn);Benztropine (Cogentin);Biperiden (Akineton);Bromocriptine (Parlodel);Carbidopa/levodopa (Atamet, Sinemet);Carbidopa/levodopa/entacapone (Stalevo);Carbidopa/levodopa orally disintegrating (Parcopa);Carbidopa/levodopa sustained release (Sinemet CR);Entacapone (Comtan);Pergolide (Permax);Pramipexole extended release (Mirapex ER);Pramipexole (Mirapex);Rasagiline (Azilect);Rivastigmine (Exelon);Ropinirole extended release (Requip XL);Ropinirole (Requip);Rotigotine transdermal patch (Neupro);Selegiline (Eldepryl);Selegiline orally disintegrating (Zelapar);Selegiline transdermal patch (Emsam);Tolcapone (Tasmar);Trihexyphenidyl (Artane, Tremin)",1;2;3;4;5;6;7;8;9;10;11;12;13;14;15;16;17;18;19;20;21;22;23,NA,NA,NA,Select one,"CDISC variables: For PDBP use the following: CM=Concomitant Medications, CMINC=Parkinson's Disease, CMCLAS=Medication Class, CMTRT=Medication Name",NA,CDISC,No references available,Adult,Treatment/Intervention Data.Drugs,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NIH/NINDS,NA,NA,NA,NA,NIH/NINDS,NA,NA,2014-04-01,2020-02-05,Published,NA,NA
MedctnPriorConcomRteTyp,PriorAndConcomitantMeds,Medication prior or concomitant route type,Unique Data Element,1.3,Type of access route for the administration of the prior medication.,Type of access route for the administration of the prior medication.,Alphanumeric,255,Free-Form Entry,NA,NA,"Buccal;By ear;Inhaled;Intramuscular;Intravenous;Nasal;Oral;Other, specify;Rectal;Subcutaneous;Sublingual;Topical;Transdermal;Unknown","Buccal;By Ear;Inhaled;Intramuscular;Intravenous;Nasal;Oral;Other, specify;Rectal;Subcutaneous;Sublingual;Topical;Transdermal;Unknown",1;2;3;4;5;6;7;444;9;10;11;12;13;999,NA,NA,NA,Records theype of access route for the administration of the prior medication.,"CDISC variables: For PDBP use the following: CM=Concomitant Medications, CMINC=Parkinson's Disease, CMROUTE",Type of access route for the administration of the prior medication.,CDISC;Medical_History,"No references available
",Adult and Pediatric,Treatment/Intervention Data.Drugs,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NIH/NINDS,NA,NA,NA,NA,NIH/NINDS,NA,NA,2014-04-01,2020-02-05,Published,NA,NA
MentlStatExamCogAbnrmlyTxt,NeurologicalExam,Mental status examination cognitive abnormality text,Unique Data Element,1,Text description of cognitive abnormality,Text description of cognitive abnormality,Alphanumeric,4000,Free-Form Entry,NA,NA,NA,NA,NA,NA,NA,NA,"If no abnormalities, write ""None.""",PDBD Neurolocial Examination Form,"4a) Describe cognitive abnormality, e.g., dyspraxia, neglect, perseveration, etc. If none, write &quot;None.&quot;",NA,NA,Adult and Pediatric,Assessments and Examinations.Physical/Neurological Examination,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2014-04-01,2014-04-01,Published,NA,NA
MentlStatExamFind,NeurologicalExam,Mental status examination findings,Unique Data Element,1,Neurological examination mental status findings,Mental status examination,Alphanumeric,NA,Single Pre-Defined Value Selected,NA,NA,Abnormal;Normal;Not assessed,Abnormal;Normal;Not assessed,10;20;222,NA,NA,NA,Select one.,PDBD Neurolocial Examination Form,4) Mental status examination,NA,NA,Adult and Pediatric,Assessments and Examinations.Physical/Neurological Examination,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2014-04-01,2014-04-01,Published,NA,NA
MentlStatExamMoodAbnrmlyTxt,NeurologicalExam,Mental status examination mood or affect abnormality text,Unique Data Element,1,Text description of mood or affect abnormality,Text description of mood or affect abnormality,Alphanumeric,4000,Free-Form Entry,NA,NA,NA,NA,NA,NA,NA,NA,"If no abnormalities, write ""None.""",PDBD Neurolocial Examination Form,"4b) Describe other mood or affect abnormality, e.g., pseudobulbar affect, irritability, elation, etc. If none, write &quot;None.&quot;",NA,NA,Adult and Pediatric,Assessments and Examinations.Physical/Neurological Examination,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2014-04-01,2014-04-01,Published,NA,NA
MotorStrgthAtrophInd,NeurologicalExam,Motor strength atrophy indicator assessment,Unique Data Element,1,Motor strength atrophy indicator assessment,Motor strength atrophy findings,Alphanumeric,4000,Free-Form Entry,NA,NA,Biceps (L);Biceps (R);Deltoid (L);Deltoid (R);Gastrocnemius (L);Gastrocnemius (R);Hamstrings (L);Hamstrings (R);No atrophy present;Quadriceps (L);Quadriceps (R);Tibialis Anterior (L);Tibialis Anterior (R);Triceps (L);Triceps (R),Biceps (L);Biceps (R);Deltoid (L);Deltoid (R);Gastrocnemius (L);Gastrocnemius (R);Hamstrings (L);Hamstrings (R);No atrophy present;Quadriceps (L);Quadriceps (R);Tibialis Anterior (L);Tibialis Anterior (R);Triceps (L);Triceps (R),;;;;;;;;;;;;;;,NA,NA,NA,Select all that apply.,PDBD Neurolocial Examination Form,6w) Atrophy present in any muscle group(s)?,NA,NA,Adult and Pediatric,Assessments and Examinations.Physical/Neurological Examination,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2014-04-01,2014-04-01,Published,NA,NA
MotorStrgthBicepsLftAssmt,NeurologicalExam,Motor strength biceps left assessment,Unique Data Element,1,Motor strength Biceps left assessment,Motor strength Biceps left assessment,Numeric Values,NA,Single Pre-Defined Value Selected,NA,NA,0;1;2;3;4;5,"No muscle contraction;Visible muscle contraction, no movement;Active movement with gravity eliminated;Active movement against gravity;Less than normal strength aginst resistance;Normal strength against resistance",0;1;2;3;4;5,NA,NA,NA,Select one.,PDBD Neurolocial Examination Form,6d) Biceps (L),NA,NA,Adult and Pediatric,Assessments and Examinations.Physical/Neurological Examination,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2014-04-01,2014-04-01,Published,NA,NA
MotorStrgthBicepsRtAssmt,NeurologicalExam,Motor strength biceps right assessment,Unique Data Element,1,Motor strength Biceps right assessment,Motor strength Biceps right assessment,Numeric Values,NA,Single Pre-Defined Value Selected,NA,NA,0;1;2;3;4;5,"No muscle contraction;Visible muscle contraction, no movement;Active movement with gravity eliminated;Active movement against gravity;Less than normal strength aginst resistance;Normal strength against resistance",0;1;2;3;4;5,NA,NA,NA,Select one.,PDBD Neurolocial Examination Form,6c) Biceps R,NA,NA,Adult and Pediatric,Assessments and Examinations.Physical/Neurological Examination,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2014-04-01,2014-04-01,Published,NA,NA
MotorStrgthDeltoidLftAssmt,NeurologicalExam,Motor strength deltoid left assessment,Unique Data Element,1,Motor strength Deltoid left assessment,Motor strength Deltoid left assessment,Numeric Values,NA,Single Pre-Defined Value Selected,NA,NA,0;1;2;3;4;5,"No muscle contraction;Visible muscle contraction, no movement;Active movement with gravity eliminated;Active movement against gravity;Less than normal strength aginst resistance;Normal strength against resistance",0;1;2;3;4;5,NA,NA,NA,Select one.,PDBD Neurolocial Examination Form,6b) Deltoid (L),NA,NA,Adult and Pediatric,Assessments and Examinations.Physical/Neurological Examination,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2014-04-01,2014-04-01,Published,NA,NA
MotorStrgthDeltoidRtAssmt,NeurologicalExam,Motor strength deltoid right assessment,Unique Data Element,1,Motor strength Deltoid right assessment,Motor strength Deltoid right assessment,Numeric Values,NA,Single Pre-Defined Value Selected,NA,NA,0;1;2;3;4;5,"No muscle contraction;Visible muscle contraction, no movement;Active movement with gravity eliminated;Active movement against gravity;Less than normal strength aginst resistance;Normal strength against resistance",0;1;2;3;4;5,NA,NA,NA,Select one.,PDBD Neurolocial Examination Form,6a) Deltoid R,NA,NA,Adult and Pediatric,Assessments and Examinations.Physical/Neurological Examination,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2014-04-01,2014-04-01,Published,NA,NA
MotorStrgthExamFind,NeurologicalExam,Motor strength  examination findings,Unique Data Element,1,Motor strength  examination findings,Motor strength  examination findings,Alphanumeric,NA,Single Pre-Defined Value Selected,NA,NA,Abnormal;Normal;Not assessed,Abnormal;Normal;Not assessed,10;20;222,NA,NA,NA,Select one.,PDBD Neurolocial Examination Form,6) Motor strength,NA,NA,Adult and Pediatric,Assessments and Examinations.Physical/Neurological Examination,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2014-04-01,2014-04-01,Published,NA,NA
MotorStrgthExtCarpiRadLftAssmt,NeurologicalExam,Motor strength ext. carpi radialials left assessment,Unique Data Element,1,Motor strength ext. Carpi Radialials left assessment,Motor strength ext. Carpi Radialials left assessment,Numeric Values,NA,Single Pre-Defined Value Selected,NA,NA,0;1;2;3;4;5,"No muscle contraction;Visible muscle contraction, no movement;Active movement with gravity eliminated;Active movement against gravity;Less than normal strength aginst resistance;Normal strength against resistance",0;1;2;3;4;5,NA,NA,NA,Select one.,PDBD Neurolocial Examination Form,6h) Ext. Carpi Radialis (L),NA,NA,Adult and Pediatric,Assessments and Examinations.Physical/Neurological Examination,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2014-04-01,2014-04-01,Published,NA,NA
MotorStrgthExtCarpiRadRtAssmt,NeurologicalExam,Motor strength ext. carpi radialials right assessment,Unique Data Element,1,Motor strength ext. Carpi Radialials right assessment,Motor strength ext. Carpi Radialials right assessment,Numeric Values,NA,Single Pre-Defined Value Selected,NA,NA,0;1;2;3;4;5,"No muscle contraction;Visible muscle contraction, no movement;Active movement with gravity eliminated;Active movement against gravity;Less than normal strength aginst resistance;Normal strength against resistance",0;1;2;3;4;5,NA,NA,NA,Select one.,PDBD Neurolocial Examination Form,6g) Ext. Carpi Radialis (R),NA,NA,Adult and Pediatric,Assessments and Examinations.Physical/Neurological Examination,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2014-04-01,2014-04-01,Published,NA,NA
MotorStrgthFasciculationFind,NeurologicalExam,Motor strength fasciculations findings,Unique Data Element,1,Motor strength fasciculations findings,Motor strength fasciculations findings,Alphanumeric,4000,Free-Form Entry,NA,NA,Biceps (L);Biceps (R);Deltoid (L);Deltoid (R);Gastrocnemius (L);Gastrocnemius (R);Hamstrings (L);Hamstrings (R);No fasciculations present;Quadriceps (L);Quadriceps (R);Tibialis Anterior (L);Tibialis Anterior (R);Triceps (L);Triceps (R),Biceps (L);Biceps (R);Deltoid (L);Deltoid (R);Gastrocnemius (L);Gastrocnemius (R);Hamstrings (L);Hamstrings (R);No fasciculations present;Quadriceps (L);Quadriceps (R);Tibialis Anterior (L);Tibialis Anterior (R);Triceps (L);Triceps (R),;;;;;;;;;;;;;;,NA,NA,NA,Select all that apply.,PDBD Neurolocial Examination Form,6x) Fasciculations present in any muscle group(s)?,NA,NA,Adult and Pediatric,Assessments and Examinations.Physical/Neurological Examination,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2014-04-01,2014-04-01,Published,NA,NA
MotorStrgthFlexCarpiRadLtAssmt,NeurologicalExam,Motor strength flex carpi radialials left assessment,Unique Data Element,1,Motor strength flex Carpi Radialials left assessment,Motor strength flex Carpi Radialials left assessment,Numeric Values,NA,Single Pre-Defined Value Selected,NA,NA,0;1;2;3;4;5,"No muscle contraction;Visible muscle contraction, no movement;Active movement with gravity eliminated;Active movement against gravity;Less than normal strength aginst resistance;Normal strength against resistance",0;1;2;3;4;5,NA,NA,NA,Select one.,PDBD Neurolocial Examination Form,6j) Flex Carpi Radialis (L),NA,NA,Adult and Pediatric,Assessments and Examinations.Physical/Neurological Examination,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2014-04-01,2014-04-01,Published,NA,NA
MotorStrgthFlexCarpiRadRtAssmt,NeurologicalExam,Motor strength flex carpi radialials right assessment,Unique Data Element,1,Motor strength flex Carpi Radialials right assessment,Motor strength flex Carpi Radialials right assessment,Numeric Values,NA,Single Pre-Defined Value Selected,NA,NA,0;1;2;3;4;5,"No muscle contraction;Visible muscle contraction, no movement;Active movement with gravity eliminated;Active movement against gravity;Less than normal strength aginst resistance;Normal strength against resistance",0;1;2;3;4;5,NA,NA,NA,Select one.,PDBD Neurolocial Examination Form,6i) Flex Carpi Radialis (R),NA,NA,Adult and Pediatric,Assessments and Examinations.Physical/Neurological Examination,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2014-04-01,2014-04-01,Published,NA,NA
MotorStrgthGastrocnmusLftAssmt,NeurologicalExam,Motor strength gastrocnemius left assessment,Unique Data Element,1,Motor strength Gastrocnemius left assessment,Motor strength Gastrocnemius left assessment,Numeric Values,NA,Single Pre-Defined Value Selected,NA,NA,0;1;2;3;4;5,"No muscle contraction;Visible muscle contraction, no movement;Active movement with gravity eliminated;Active movement against gravity;Less than normal strength aginst resistance;Normal strength against resistance",0;1;2;3;4;5,NA,NA,NA,Select one.,PDBD Neurolocial Examination Form,6t) Gastrocnemius (L),NA,NA,Adult and Pediatric,Assessments and Examinations.Physical/Neurological Examination,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2014-04-01,2014-04-01,Published,NA,NA
MotorStrgthGastrocnmusRtAssmt,NeurologicalExam,Motor strength gastrocnemius right assessment,Unique Data Element,1,Motor strength Gastrocnemius right assessment,Motor strength Gastrocnemius right assessment,Numeric Values,NA,Single Pre-Defined Value Selected,NA,NA,0;1;2;3;4;5,"No muscle contraction;Visible muscle contraction, no movement;Active movement with gravity eliminated;Active movement against gravity;Less than normal strength aginst resistance;Normal strength against resistance",0;1;2;3;4;5,NA,NA,NA,Select one.,PDBD Neurolocial Examination Form,6s) Gastrocnemius (R),NA,NA,Adult and Pediatric,Assessments and Examinations.Physical/Neurological Examination,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2014-04-01,2014-04-01,Published,NA,NA
MotorStrgthHamstringLftAssmt,NeurologicalExam,Motor strength hamstrings left assessment,Unique Data Element,1,Motor strength Hamstrings left assessment,Motor strength Hamstrings left assessment,Numeric Values,NA,Single Pre-Defined Value Selected,NA,NA,0;1;2;3;4;5,"No muscle contraction;Visible muscle contraction, no movement;Active movement with gravity eliminated;Active movement against gravity;Less than normal strength aginst resistance;Normal strength against resistance",0;1;2;3;4;5,NA,NA,NA,Select one.,PDBD Neurolocial Examination Form,6r) Hamstrings (L),NA,NA,Adult and Pediatric,Assessments and Examinations.Physical/Neurological Examination,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2014-04-01,2014-04-01,Published,NA,NA
MotorStrgthHamstringRtAssmt,NeurologicalExam,Motor strength hamstrings right assessment,Unique Data Element,1,Motor strength Hamstrings right assessment,Motor strength Hamstrings right assessment,Numeric Values,NA,Single Pre-Defined Value Selected,NA,NA,0;1;2;3;4;5,"No muscle contraction;Visible muscle contraction, no movement;Active movement with gravity eliminated;Active movement against gravity;Less than normal strength aginst resistance;Normal strength against resistance",0;1;2;3;4;5,NA,NA,NA,Select one.,PDBD Neurolocial Examination Form,6q) Hamstrings (R),NA,NA,Adult and Pediatric,Assessments and Examinations.Physical/Neurological Examination,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2014-04-01,2014-04-01,Published,NA,NA
MotorStrgthInterosLftAssmt,NeurologicalExam,Motor strength interossei left assessment,Unique Data Element,1,Motor strength Interossei left assessment,Motor strength Interossei left assessment,Numeric Values,NA,Single Pre-Defined Value Selected,NA,NA,0;1;2;3;4;5,"No muscle contraction;Visible muscle contraction, no movement;Active movement with gravity eliminated;Active movement against gravity;Less than normal strength aginst resistance;Normal strength against resistance",0;1;2;3;4;5,NA,NA,NA,Select one.,PDBD Neurolocial Examination Form,6l) Interossei (L),NA,NA,Adult and Pediatric,Assessments and Examinations.Physical/Neurological Examination,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2014-04-01,2014-04-01,Published,NA,NA
MotorStrgthInterosRtAssmt,NeurologicalExam,Motor strength interossei right assessment,Unique Data Element,1,Motor strength Interossei right assessment,Motor strength Interossei right assessment,Numeric Values,NA,Single Pre-Defined Value Selected,NA,NA,0;1;2;3;4;5,"No muscle contraction;Visible muscle contraction, no movement;Active movement with gravity eliminated;Active movement against gravity;Less than normal strength aginst resistance;Normal strength against resistance",0;1;2;3;4;5,NA,NA,NA,Select one.,PDBD Neurolocial Examination Form,6k) Interossei (R),NA,NA,Adult and Pediatric,Assessments and Examinations.Physical/Neurological Examination,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2014-04-01,2014-04-01,Published,NA,NA
MotorStrgthQuadcpsLftAssmt,NeurologicalExam,Motor strength quadriceps left assessment,Unique Data Element,1,Motor strength Quadriceps left assessment,Motor strength Quadriceps left assessment,Numeric Values,NA,Single Pre-Defined Value Selected,NA,NA,0;1;2;3;4;5,"No muscle contraction;Visible muscle contraction, no movement;Active movement with gravity eliminated;Active movement against gravity;Less than normal strength aginst resistance;Normal strength against resistance",0;1;2;3;4;5,NA,NA,NA,Select one.,PDBD Neurolocial Examination Form,6p) Quadriceps (L),NA,NA,Adult and Pediatric,Assessments and Examinations.Physical/Neurological Examination,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2014-04-01,2014-04-01,Published,NA,NA
MotorStrgthQuadcpsRtAssmt,NeurologicalExam,Motor strength quadriceps right assessment,Unique Data Element,1,Motor strength Quadriceps right assessment,Motor strength Quadriceps right assessment,Numeric Values,NA,Single Pre-Defined Value Selected,NA,NA,0;1;2;3;4;5,"No muscle contraction;Visible muscle contraction, no movement;Active movement with gravity eliminated;Active movement against gravity;Less than normal strength aginst resistance;Normal strength against resistance",0;1;2;3;4;5,NA,NA,NA,Select one.,PDBD Neurolocial Examination Form,6o) Quadriceps (R),NA,NA,Adult and Pediatric,Assessments and Examinations.Physical/Neurological Examination,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2014-04-01,2014-04-01,Published,NA,NA
MotorStrgthTblAnterLftAssmt,NeurologicalExam,Motor strength tibialis anterior left assessment,Unique Data Element,1,Motor strength Tibialis Anterior left assessment,Motor strength Tibialis Anterior left assessment,Numeric Values,NA,Single Pre-Defined Value Selected,NA,NA,0;1;2;3;4;5,"No muscle contraction;Visible muscle contraction, no movement;Active movement with gravity eliminated;Active movement against gravity;Less than normal strength aginst resistance;Normal strength against resistance",0;1;2;3;4;5,NA,NA,NA,Select one.,PDBD Neurolocial Examination Form,6v) Tibialis Anterior (L),NA,NA,Adult and Pediatric,Assessments and Examinations.Physical/Neurological Examination,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2014-04-01,2014-04-01,Published,NA,NA
MotorStrgthTblAnterRtAssmt,NeurologicalExam,Motor strength tibialis anterior right assessment,Unique Data Element,1,Motor strength Tibialis Anterior right assessment,Motor strength Tibialis Anterior right assessment,Numeric Values,NA,Single Pre-Defined Value Selected,NA,NA,0;1;2;3;4;5,"No muscle contraction;Visible muscle contraction, no movement;Active movement with gravity eliminated;Active movement against gravity;Less than normal strength aginst resistance;Normal strength against resistance",0;1;2;3;4;5,NA,NA,NA,Select one.,PDBD Neurolocial Examination Form,6u) Tibialis Anterior (R),NA,NA,Adult and Pediatric,Assessments and Examinations.Physical/Neurological Examination,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2014-04-01,2014-04-01,Published,NA,NA
MotorStrgthTricepsLftAssmt,NeurologicalExam,Motor strength triceps left assessment,Unique Data Element,1,Motor strength Triceps left assessment,Motor strength Triceps left assessment,Numeric Values,NA,Single Pre-Defined Value Selected,NA,NA,0;1;2;3;4;5,"No muscle contraction;Visible muscle contraction, no movement;Active movement with gravity eliminated;Active movement against gravity;Less than normal strength aginst resistance;Normal strength against resistance",0;1;2;3;4;5,NA,NA,NA,Select one.,PDBD Neurolocial Examination Form,6f) Triceps (L),NA,NA,Adult and Pediatric,Assessments and Examinations.Physical/Neurological Examination,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2014-04-01,2014-04-01,Published,NA,NA
MotorStrgthTricepsRtAssmt,NeurologicalExam,Motor strength triceps right assessment,Unique Data Element,1,Motor strength Triceps right assessment,Motor strength Triceps right assessment,Numeric Values,NA,Single Pre-Defined Value Selected,NA,NA,0;1;2;3;4;5,"No muscle contraction;Visible muscle contraction, no movement;Active movement with gravity eliminated;Active movement against gravity;Less than normal strength aginst resistance;Normal strength against resistance",0;1;2;3;4;5,NA,NA,NA,Select one.,PDBD Neurolocial Examination Form,6e) Triceps (R),NA,NA,Adult and Pediatric,Assessments and Examinations.Physical/Neurological Examination,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2014-04-01,2014-04-01,Published,NA,NA
MotorStrgthlliopsoasLftAssmt,NeurologicalExam,Motor strength  iliopsoas left assessment,Unique Data Element,1,Motor strength  lliopsoas left assessment,Motor strength  lliopsoas left assessment,Numeric Values,NA,Single Pre-Defined Value Selected,NA,NA,0;1;2;3;4;5,"No muscle contraction;Visible muscle contraction, no movement;Active movement with gravity eliminated;Active movement against gravity;Less than normal strength aginst resistance;Normal strength against resistance",0;1;2;3;4;5,NA,NA,NA,Select one.,PDBD Neurolocial Examination Form,6n) lliopsoas (L),NA,NA,Adult and Pediatric,Assessments and Examinations.Physical/Neurological Examination,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2014-04-01,2014-04-01,Published,NA,NA
MotorStrgthlliopsoasRtAssmt,NeurologicalExam,Motor strength iliopsoas right assessment,Unique Data Element,1,Motor strength  lliopsoas right assessment,Motor strength  lliopsoas right assessment,Numeric Values,NA,Single Pre-Defined Value Selected,NA,NA,0;1;2;3;4;5,"No muscle contraction;Visible muscle contraction, no movement;Active movement with gravity eliminated;Active movement against gravity;Less than normal strength aginst resistance;Normal strength against resistance",0;1;2;3;4;5,NA,NA,NA,Select one.,PDBD Neurolocial Examination Form,6m) lliopsoas (R),NA,NA,Adult and Pediatric,Assessments and Examinations.Physical/Neurological Examination,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2014-04-01,2014-04-01,Published,NA,NA
NeuroExamAbnrmlFindDocumntd,NeurologicalExam,Abnormal neurological examination findings documented in another form indicator,Unique Data Element,1,"Whether abnormal Neurological examination findings were  documented in another form e.g., MDS-UPDRS, MoCA, Hamilton",Abnormal neurological examination findings documented in another form indicator,Alphanumeric,NA,Single Pre-Defined Value Selected,NA,NA,No;Yes,No;Yes,0;1,NA,NA,NA,Select one.,PDBD Neurolocial Examination Form,"3a) If abnormal, is abnormality documented in another form, e.g., MDS-UPDRS, MoCA, Hamilton?",NA,NA,Adult and Pediatric,Assessments and Examinations.Physical/Neurological Examination,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2014-04-01,2014-04-01,Published,NA,NA
NeuroExamFind,NeurologicalExam,Neurological examination findings,Unique Data Element,1,Neurological examination findings,Neurological examination findings,Alphanumeric,NA,Single Pre-Defined Value Selected,NA,NA,Abnormal;Normal;Not assessed,Abnormal;Normal;Not assessed,10;20;222,NA,NA,NA,Select one.,PDBD Neurolocial Examination Form,3) Neurological examination findings,NA,NA,Adult and Pediatric,Assessments and Examinations.Physical/Neurological Examination,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2014-04-01,2014-04-01,Published,NA,NA
NeuroExamPrimaryDiagnos,NeurologicalExam,Neurological examination primary diagnosis,Unique Data Element,1,Neurological exam primary diagnosis,Neurological exam primary diagnosis,Alphanumeric,55,Free-Form Entry,NA,NA,"Corticobasal Degeneration;Dementia with Lewy Bodies;Multisystem Atrophy;Other, specify;Parkinson's disease;Parkinson's Disease Dementia;Progressive Supranuclear Palsy","Corticobasal Degeneration;Dementia with Lewy Bodies;Multisystem Atrophy;Other, specify;Parkinson's disease;Parkinson's Disease Dementia;Progressive Supranuclear Palsy",;;;;;;,NA,NA,NA,Select one,PDBD Neurolocial Examination Form,2a) Primary diagnosis,NA,NA,Adult,Disease/Injury Related Events.History of Disease/Injury Event,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2014-04-01,2014-04-01,Published,NA,NA
OthrExamFindTxt,NeurologicalExam,Other exam findings text descriptor,Unique Data Element,1,Describe other exam findings not noted elsewhere.,Describe other exam findings not noted elsewhere.,Alphanumeric,4000,Free-Form Entry,NA,NA,NA,NA,NA,NA,NA,NA,Enter other exam finding not noted elsewhere.,PDBD Neurolocial Examination Form,11) Other exam finding not noted elsewhere,NA,NA,Adult and Pediatric,Assessments and Examinations.Physical/Neurological Examination,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2014-04-01,2014-04-01,Published,NA,NA
OthrMovmntAtaxiaLoc,NeurologicalExam,Ataxia location,Unique Data Element,1,Ataxia location,Ataxia location,Alphanumeric,4000,Free-Form Entry,NA,NA,LLE;LUE;Normal;RLE;RUE;Truncal,Left lower extremity;Left upper extremity;Normal;Right lower extremity;Right upper extremity;Truncal,;;;;;,NA,NA,NA,Select all that apply,PDBD Neurolocial Examination Form,10a) Ataxia,NA,NA,Adult and Pediatric,Assessments and Examinations.Physical/Neurological Examination,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2014-04-01,2014-04-01,Published,NA,NA
OthrMovmntAthetosisLoc,NeurologicalExam,Athetosis location,Unique Data Element,1,Athetosis,Athetosis,Alphanumeric,4000,Free-Form Entry,NA,NA,Generalized;LLE;LUE;Normal;RLE;RUE,Generalized;Left lower extremity;Left upper extremity;Normal;Right lower extremity;Right upper extremity,;;;;;,NA,NA,NA,Select all that apply,PDBD Neurolocial Examination Form,10e) Athetosis,NA,NA,Adult and Pediatric,Assessments and Examinations.Physical/Neurological Examination,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2014-04-01,2014-04-01,Published,NA,NA
OthrMovmntBallismusLoc,NeurologicalExam,Ballismus location,Unique Data Element,1,Ballismus location,Ballismus location,Alphanumeric,4000,Free-Form Entry,NA,NA,Generalized;LLE;LUE;Normal;RLE;RUE,Generalized;Left lower extremity;Left upper extremity;Normal;Right lower extremity;Right upper extremity,;;;;;,NA,NA,NA,Select all that apply,PDBD Neurolocial Examination Form,10c) Ballismus,NA,NA,Adult and Pediatric,Assessments and Examinations.Physical/Neurological Examination,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2014-04-01,2014-04-01,Published,NA,NA
OthrMovmntChoreaLoc,NeurologicalExam,Chorea location,Unique Data Element,1,Chorea location,Chorea location,Alphanumeric,4000,Free-Form Entry,NA,NA,Generalized;LLE;LUE;Normal;RLE;RUE,Generalized;Left lower extremity;Left upper extremity;Normal;Right lower extremity;Right upper extremity,;;;;;,NA,NA,NA,Select all that apply,PDBD Neurolocial Examination Form,10b) Chorea,NA,NA,Adult and Pediatric,Assessments and Examinations.Physical/Neurological Examination,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2014-04-01,2014-04-01,Published,NA,NA
OthrMovmntInd,NeurologicalExam,Other movements indicator,Unique Data Element,1,Other movements indicator,Other movements indicator,Alphanumeric,NA,Single Pre-Defined Value Selected,NA,NA,Abnormal;Normal;Not assessed,Abnormal;Normal;Not assessed,10;20;222,NA,NA,NA,Select one.,PDBD Neurolocial Examination Form,10)  Other movements,NA,NA,Adult and Pediatric,Assessments and Examinations.Physical/Neurological Examination,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2014-04-01,2014-04-01,Published,NA,NA
OthrMovmntMyoclonusLoc,NeurologicalExam,Myoclonus location,Unique Data Element,1,Myoclonus,Myoclonus,Alphanumeric,4000,Free-Form Entry,NA,NA,Generalized;LLE;LUE;Normal;RLE;RUE,Generalized;Left lower extremity;Left upper extremity;Normal;Right lower extremity;Right upper extremity,;;;;;,NA,NA,NA,Select all that apply,PDBD Neurolocial Examination Form,10f) Myoclonus,NA,NA,Adult and Pediatric,Assessments and Examinations.Physical/Neurological Examination,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2014-04-01,2014-04-01,Published,NA,NA
OthrMovmntTicsLoc,NeurologicalExam,Tics location,Unique Data Element,1,Tics,Tics,Alphanumeric,4000,Free-Form Entry,NA,NA,Generalized;LLE;LUE;Normal;RLE;RUE,Generalized;Left lower extremity;Left upper extremity;Normal;Right lower extremity;Right upper extremity,;;;;;,NA,NA,NA,Select all that apply,PDBD Neurolocial Examination Form,10d) Tics,NA,NA,Adult and Pediatric,Assessments and Examinations.Physical/Neurological Examination,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2014-04-01,2014-04-01,Published,NA,NA
PDBPInclusnXclusn_InclusnCase,InclExclCriteria,Parkinson's Disease Biomarkers Program (PDBP) inclusion/exclusion criteria inclusion criteria case,Unique Data Element,1,"Parkinson's Disease Biomarkers Program (PDBP) inclusion/exclusion criteria, inclusion criteria only that apply to the case",The list of PDBP inclusion criteria that apply to the case,Alphanumeric,4000,Free-Form Entry,NA,NA,Able to cooperate with consent procedures (or has appropriate surrogate as defined and approved per local IRB);Able to participate in study activities including all required clinical assessments and biological donations;Clinically diagnosed with Parkinson's Disease (or other Neurodegenerative disease appropriate for study protocol);Male or Female aged 21 years or older at screening;Participation would not lead to hardship or adverse health or mental health conditions,Able to cooperate with consent procedures (or has appropriate surrogate as defined and approved per local IRB);Able to participate in study activities including all required clinical assessments and biological donations;Clinically diagnosed with Parkinson's Disease (or other Neurodegenerative disease appropriate for study protocol);Male or Female aged 21 years or older at screening;Participation would not lead to hardship or adverse health or mental health conditions,;;;;,NA,NA,NA,Select all that apply,PDBP Inclusion Exclusion Criteria Inclusion Criteria (Case) _Q5,Please select which of the following inclusion criteria apply to the case.,NA,No references available,Adult,NA,NA,Participant/Subject Characteristics.Demographics,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2014-04-01,2014-04-01,Published,NA,NA
PDBPInclusnXclusn_InclusnCntrl,InclExclCriteria,Parkinson's Disease Biomarkers Program (PDBP) inclusion/exclusion criteria inclusion criteria control,Unique Data Element,1.1,Parkinson's Disease Biomarkers Program (PDBP) inclusion/exclusion criteria inclusion criteria applied to the control. Indication if the participant is a male or female aged 21 years or older at screening,PDBP inclusion/exclusion criteria inclusion criteria applied to the control. Indication if the participant is a male or female aged 21 years or older at screening,Alphanumeric,NA,Single Pre-Defined Value Selected,NA,NA,Male or Female aged 21 years or older at screening,Male or Female aged 21 years or older at screening,1,NA,NA,NA,NA,PDBP Inclusion Exclusion Criteria Inclusion Criteria (Control) _Q3,Please select which of the following inclusion criteria apply to the control:,NA,No references available,Adult,NA,NA,Participant/Subject Characteristics.Demographics,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NIH/CIT/BRICS,NA,NA,NA,NA,NIH/CIT/BRICS,NA,NA,2014-04-01,2020-02-13,Published,NA,NA
PDBPInclusnXclusn_XclusnCase,InclExclCriteria,Parkinson's Disease Biomarkers Program (PDBP) inclusion/exclusion criteria exclusion criteria case,Unique Data Element,1,"Parkinson's Disease Biomarkers Program (PDBP) inclusion/exclusion criteria,  exclusion criteria only that apply to the case",The list of PDBP exclusion criteria that apply to the case,Alphanumeric,4000,Free-Form Entry,NA,NA,"Clinical Diagnosis uncertain at time of enrollment;Condition that precludes the safe performance of routine lumbar puncture, such as prohibitive lumbar spinal disease, bleeding diathesis, or coagulopathy or thrombocytopenia;Current treatment with anti-coagulants (e.g., Coumadin, heparin) that might preclude safe completion of the lumbar puncture;Has a history of neuroleptic use or exposure;Has a history of schizophrenia;Otherwise excluded, reason not listed here;Otherwise unable to participate in biological specimen collection due to a medical condition or medication status (other than items listed above);Otherwise unable to participate in clinical assessments due to a medical condition or medication status (other than items listed above);Unable to participate in consent procedures (or does not have appropriate surrogate per IRB approved protocol for consent);Use of investigational drugs or devices within 60 days prior to baseline visit (dietary supplements such as Coenzyme Q10, for example, are not exclusionary)","Clinical Diagnosis uncertain at time of enrollment;Condition that precludes the safe performance of routine lumbar puncture, such as prohibitive lumbar spinal disease, bleeding diathesis, or coagulopathy or thrombocytopenia;Current treatment with anti-coagulants (e.g., Coumadin, heparin) that might preclude safe completion of the lumbar puncture;Has a history of neuroleptic use or exposure;Has a history of schizophrenia;Otherwise excluded, reason not listed here;Otherwise unable to participate in biological specimen collection due to a medical condition or medication status (other than items listed above);Otherwise unable to participate in clinical assessments due to a medical condition or medication status (other than items listed above);Unable to participate in consent procedures (or does not have appropriate surrogate per IRB approved protocol for consent);Use of investigational drugs or devices within 60 days prior to baseline visit (dietary supplements such as Coenzyme Q10, for example, are not exclusionary)",;;;;;;;;;,NA,NA,NA,Select all that apply,PDBP Inclusion Exclusion Criteria  Exclusion Criteria (Case)_Q6,Please select which of the following exclusion criteria apply to the case.,NA,No references available,Adult,NA,NA,Participant/Subject Characteristics.Demographics,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2014-04-01,2014-04-01,Published,NA,NA
PDBPInclusnXclusn_XclusnCntrl,InclExclCriteria,Parkinson's Disease Biomarkers Program (PDBP) inclusion/exclusion criteria exclusion criteria control,Unique Data Element,1,"Parkinson's Disease Biomarkers Program (PDBP) inclusion/exclusion criteria, exclusion criteria  only that apply to the control",The list of PDBP exclusion criteria that apply to the control,Alphanumeric,4000,Free-Form Entry,NA,NA,"Condition that preclude the safe performance of routine lumbar puncture, such as prohibitive lumbar spinal disease, bleeding diathesis, or coagulopathy or thrombocytopenia;Current treatment with anti-coagulants (e.g., Coumadin, heparin) that might preclude safe completion of the lumbar puncture;Family history of Neurodegenerative disease in a first degree relative or second degree blood relative;Has a current or clinically significant neurological disorder in the opinion of the investigator;Has a history of neuroleptic use or exposure;Has a history of schizophrenia;Otherwise excluded, reason not listed here;Otherwise unable to participate in biological specimen collection due to a medical condition or medication status (other than items listed above);Otherwise unable to participate in clinical assessments due to a medical condition or medication status (other than items listed above);Unable to participate in consent procedures;Use of investigational drugs or devices within 60 days prior to baseline visit (dietary supplements such as Coenzyme Q10, for example, are not exclusionary)","Condition that preclude the safe performance of routine lumbar puncture, such as prohibitive lumbar spinal disease, bleeding diathesis, or coagulopathy or thrombocytopenia;Current treatment with anti-coagulants (e.g., Coumadin, heparin) that might preclude safe completion of the lumbar puncture;Family history of Neurodegenerative disease in a first degree relative or second degree blood relative;Has a current or clinically significant neurological disorder in the opinion of the investigator;Has a history of neuroleptic use or exposure;Has a history of schizophrenia;Otherwise excluded, reason not listed here;Otherwise unable to participate in biological specimen collection due to a medical condition or medication status (other than items listed above);Otherwise unable to participate in clinical assessments due to a medical condition or medication status (other than items listed above);Unable to participate in consent procedures;Use of investigational drugs or devices within 60 days prior to baseline visit (dietary supplements such as Coenzyme Q10, for example, are not exclusionary)",;;;;;;;;;;,NA,NA,NA,Select all that apply,PDBP Inclusion Exclusion Criteria Exclusion Criteria (Control)_Q4,Please select which of the following exclusion criteria apply to the control.,NA,No references available,Adult,NA,NA,Participant/Subject Characteristics.Demographics,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2014-04-01,2014-04-01,Published,NA,NA
PDBPLBDInclusnCritCaseSubjTyp,LBD InclusnXclusn,PDBP and LBD case inclusion criteria type,Unique Data Element,1,Type of Inclusion criteria for case subjects - Parkinson's Disease Biomarkers Program (PDBP) and Lewy Body Dementia (LBD),Type of Inclusion criteria for case subjects in Parkinson's Disease Biomarkers Program (PDBP) and Lewy Body Dementia (LBD),Alphanumeric,NA,Multiple Pre-Defined Values Selected,NA,NA,"able to cooperate with consent procedures (or has all appropriate surrogate as defined and approved per local IRB);Able to participate in study activities including all required clinical assessments and biological donations;Clinially diagnosed with Parkinson's Disease Dementia, per MDS Criteria;Clinically diagnosed with Alzheimer's Disease per NIAA-AA criteria;Clinically diagnosed with DBL-MCI (provisional criteria);Clinically diagnosed with Lewy Body Dementia, per McKeith criteria;Clinically diagnosed with Mild Cognitive Impairment per NIAA-AA criteria;Clinically diagnosed with Parkinson's Disease, per MDS or UK Brain Bank Criteria;Male or Female aged 21 years or older at screening;No contraindication to lumbar puncture;No major psychiatric disorder (e.g., schizophrenia) currently or by history;Not using investigational drugs or devices within 60 days prior to baseline visit","able to cooperate with consent procedures (or has all appropriate surrogate as defined and approved per local IRB);Able to participate in study activities including all required clinical assessments and biological donations;Clinially diagnosed with Parkinson's Disease Dementia, per MDS Criteria;Clinically diagnosed with Alzheimer's Disease per NIAA-AA criteria;Clinically diagnosed with DBL-MCI (provisional criteria);Clinically diagnosed with Lewy Body Dementia, per McKeith criteria;Clinically diagnosed with Mild Cognitive Impairment per NIAA-AA criteria;Clinically diagnosed with Parkinson's Disease, per MDS or UK Brain Bank Criteria;Male or Female aged 21 years or older at screening;No contraindication to lumbar puncture;No major psychiatric disorder (e.g., schizophrenia) currently or by history;Not using investigational drugs or devices within 60 days prior to baseline visit",10;11;3;5;7;4;6;2;1;9;8;12,NA,NA,NA,Select all that apply,NA,Please select which of the following apply to the case,PDBP;LBD;Inclusion;Control,"Postuma RB, Berg D, Stern M, Poewe W, Olanow CW, Oertel W, Obeso J, Marek K, Litvan I, Lang AE, Halliday G, Goetz CG, Gasser T, Dubois B, Chan P, Bloem BR, Adler CH, Deuschl G.  MDS clinical diagnostic criteria for Parkinson's disease.Mov Disord. 2015 Oct;30(12):1591-601.
http://onlinelibrary.wiley.com/doi/10.1002/mds.26424/epdf
Hughes AJ, Daniel SE, Kilford L, Lees AJ.  Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases.  J Neurol Neurosurg Psychiatry. 1992 Mar;55(3):181-4.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1014720/pdf/jnnpsyc00488-0011.pdf 
Dubois B1, Burn D, Goetz C, Aarsland D, Brown RG, Broe GA, Dickson D, Duyckaerts C, Cummings J, Gauthier S, Korczyn A, Lees A, Levy R, Litvan I, Mizuno Y, McKeith IG, Olanow CW, Poewe W, Sampaio C, Tolosa E, Emre M. Diagnostic procedures for Parkinson's disease dementia: recommendations from the movement disorder society task force. Mov Disord. 2007 Dec;22(16):2314-24.
http://onlinelibrary.wiley.com/doi/10.1002/mds.21844/epdf
McKeith IG1, Dickson DW, Lowe J, Emre M, O'Brien JT, Feldman H, Cummings J, Duda JE, Lippa C, Perry EK, Aarsland D, Arai H, Ballard CG, Boeve B, Burn DJ, Costa D, Del Ser T, Dubois B, Galasko D, Gauthier S, Goetz CG, Gomez-Tortosa E, Halliday G, Hansen LA, Hardy J, Iwatsubo T, Kalaria RN, Kaufer D, Kenny RA, Korczyn A, Kosaka K, Lee VM, Lees A, Litvan I, Londos E, Lopez OL, Minoshima S, Mizuno Y, Molina JA, Mukaetova-Ladinska EB, Pasquier F, Perry RH, Schulz JB, Trojanowski JQ, Yamada M; Consortium on DLB. Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium.  Neurology. 2005 Dec 27;65(12):1863-72. 
http://www.neurology.org/content/65/12/1863.long
McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR Jr, Kawas CH, Klunk WE, Koroshetz WJ, Manly JJ, Mayeux R, Mohs RC, Morris JC, Rossor MN, Scheltens P, Carrillo MC, Thies B, Weintraub S, Phelps CH.  The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011 May;7(3):263-9.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3312024/pdf/nihms363310.pdf
Albert MS, DeKosky ST, Dickson D, et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimer's & dementia : the journal of the Alzheimer's Association. 2011;7(3):270?279. 
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3312027/
",Adult,"Protocol Experience.Participant/Subject Identification, Eligibility, and Enrollment",NA,Participant/Subject Characteristics.Demographics,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,CIT/NIH/BRICS,Kendra Arce,karce@sapient.com,NA,NA,CIT/NIH/BRICS,Olga Vovk,olga.vovk@nih.gov,2017-02-08,2017-02-08,Published,NA,NA
PDBPLBDInclusnCritCntrlSubjTyp,LBD InclusnXclusn,PDBP and LBD control inclusion criteria type,Unique Data Element,1,Type of inclusion criteria for control subjects in Parkinson's Disease Biomarkers Program (PDBP) and Lewy Body Dementia (LBD),Type of inclusion criteria for control subjects in Parkinson's Disease Biomarkers Program (PDBP) and Lewy Body Dementia (LBD),Alphanumeric,NA,Multiple Pre-Defined Values Selected,NA,NA,"Male or female aged 21 years or older at screening;No contraindication to lumbar puncture;No major psychiatric disorder (e.g., schizophrenia) currently or by history;No neurological disorder in subject or 1st degree blood relative;Not using investigational drugs or devices within 60 days prior to baseline visit","Male or female aged 21 years or older at screening;No contraindication to lumbar puncture;No major psychiatric disorder (e.g., schizophrenia) currently or by history;No neurological disorder in subject or 1st degree blood relative;Not using investigational drugs or devices within 60 days prior to baseline visit",1;4;3;2;5,NA,NA,NA,Select all that apply,NA,Please select which of the following apply to the control,PDBP;LBD;Inclusion;CASE,NA,Adult,"Protocol Experience.Participant/Subject Identification, Eligibility, and Enrollment",NA,Participant/Subject Characteristics.Demographics,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,CIT/NIH/BRICS,Kendra Arce,karce@sapient.com,NA,NA,CIT/NIH/BRICS,Olga Vovk,olga.vovk@nih.gov,2017-02-08,2017-02-08,Published,NA,NA
PDQ_39_AchesPains,PDQ-39,Parkinson's Disease Questionnaire (PDQ-39) - aches and pains in joints or body scale,Unique Data Element,1,Parkinson's Disease Questionnaire (PDQ-39) - aches and pains in joints or body scale. Indicates if the subject reported aches and pains in his/her joints or body,PDQ-39 - aches and pains in joints or body scale,Alphanumeric,NA,Single Pre-Defined Value Selected,NA,NA,Always or cannot do at all;Never;Occasionally;Often;Sometimes,Always or cannot do at all;Never;Occasionally;Often;Sometimes,;;;;,NA,NA,NA,Select the answer which best describes your personal situation.,PDQ-39-Q38,Had aches and pains in your joints or body?,NA,"PDQ-39 Copyright Isis Innovation Limited, 1993. All rights reserved. 
Adapted from English (UK) to English (USA) in 1996 by Health Research Associates, Inc.
Mikie Welsh and the Parkinson Study Group (Trademark) are the copyright holders for the PDQUALIF Copyright.  The instrument may not be reproduced or translated in whole or in part without the express written permission of the lead author, Mickie Welsh.  See http://pdqualif.com for full terms and use and licensing information.

Development and Testing of the Parkinson's Disease Quality of Life Scale (PDQUALIF)Welsh et al. 2003 Mov Dis 18(6) 637-645.

A Controlled Trial of Rasagiline in Early PD The TEMPO Study. Parkinson Study Group. 2002 Arch Neurol 59: 1937-1943

Pramipexole vs. Levodopa as Initial Treatment for Parkinson's Disease. The Parkinson Study Group. Arch Neurol. 2004;(61): 1044-1053.

A Randomized Placebo-Controlled Trial of Rasagiline in Levodopa-Treated patients with Parkinson Disease and Motor Fluctuations The Presto Study, The Parkinson Study Group 2005 Arch Neurol 62 241-248.

Does Levodopa slow or hasten the rate of progression of Parkinson's disease? JNeurol 2005;(22):731-40.

SF-36 includes less Parkinson Disease targeted content but is more responsive to change than two PD-targeted Healths-related quality of life measures. Brown et al 1009 Qual Life Res 18-1219-1237",Adult,NA,NA,Outcomes and End Points.Quality of Life,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2014-04-01,2014-04-01,Published,NA,NA
PDQ_39_Angry,PDQ-39,Parkinson's Disease Questionnaire (PDQ-39) - feeling angry or bitter scale,Unique Data Element,1,Parkinson's Disease Questionnaire (PDQ-39) - feeling angry or bitter scale. Indicates if the subject reported feeling angry and/or bitter,PDQ-39 - feeling angry or bitter scale,Alphanumeric,NA,Single Pre-Defined Value Selected,NA,NA,Always or cannot do at all;Never;Occasionally;Often;Sometimes,Always or cannot do at all;Never;Occasionally;Often;Sometimes,;;;;,NA,NA,NA,Select the answer which best describes your personal situation.,PDQ-39-Q20,Felt angry or bitter?,NA,"PDQ-39 Copyright Isis Innovation Limited, 1993. All rights reserved. 
Adapted from English (UK) to English (USA) in 1996 by Health Research Associates, Inc.
Mikie Welsh and the Parkinson Study Group (Trademark) are the copyright holders for the PDQUALIF Copyright.  The instrument may not be reproduced or translated in whole or in part without the express written permission of the lead author, Mickie Welsh.  See http://pdqualif.com for full terms and use and licensing information.

Development and Testing of the Parkinson's Disease Quality of Life Scale (PDQUALIF)Welsh et al. 2003 Mov Dis 18(6) 637-645.

A Controlled Trial of Rasagiline in Early PD The TEMPO Study. Parkinson Study Group. 2002 Arch Neurol 59: 1937-1943

Pramipexole vs. Levodopa as Initial Treatment for Parkinson's Disease. The Parkinson Study Group. Arch Neurol. 2004;(61): 1044-1053.

A Randomized Placebo-Controlled Trial of Rasagiline in Levodopa-Treated patients with Parkinson Disease and Motor Fluctuations The Presto Study, The Parkinson Study Group 2005 Arch Neurol 62 241-248.

Does Levodopa slow or hasten the rate of progression of Parkinson's disease? JNeurol 2005;(22):731-40.

SF-36 includes less Parkinson Disease targeted content but is more responsive to change than two PD-targeted Healths-related quality of life measures. Brown et al 1009 Qual Life Res 18-1219-1237",Adult,NA,NA,Outcomes and End Points.Quality of Life,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2014-04-01,2014-04-01,Published,NA,NA
PDQ_39_Anxious,PDQ-39,Parkinson's Disease Questionnaire (PDQ-39) feeling anxious scale,Unique Data Element,1,Parkinson's Disease Questionnaire (PDQ-39) feeling anxious scale. Indicates if the subject reported feeling anxious,PDQ-39 feeling anxious scale,Alphanumeric,NA,Single Pre-Defined Value Selected,NA,NA,Always or cannot do at all;Never;Occasionally;Often;Sometimes,Always or cannot do at all;Never;Occasionally;Often;Sometimes,;;;;,NA,NA,NA,Select the answer which best describes your personal situation.,PDQ-39-Q21,Felt anxious?,NA,"PDQ-39 Copyright Isis Innovation Limited, 1993. All rights reserved. 
Adapted from English (UK) to English (USA) in 1996 by Health Research Associates, Inc.
Mikie Welsh and the Parkinson Study Group (Trademark) are the copyright holders for the PDQUALIF Copyright.  The instrument may not be reproduced or translated in whole or in part without the express written permission of the lead author, Mickie Welsh.  See http://pdqualif.com for full terms and use and licensing information.

Development and Testing of the Parkinson's Disease Quality of Life Scale (PDQUALIF)Welsh et al. 2003 Mov Dis 18(6) 637-645.

A Controlled Trial of Rasagiline in Early PD The TEMPO Study. Parkinson Study Group. 2002 Arch Neurol 59: 1937-1943

Pramipexole vs. Levodopa as Initial Treatment for Parkinson's Disease. The Parkinson Study Group. Arch Neurol. 2004;(61): 1044-1053.

A Randomized Placebo-Controlled Trial of Rasagiline in Levodopa-Treated patients with Parkinson Disease and Motor Fluctuations The Presto Study, The Parkinson Study Group 2005 Arch Neurol 62 241-248.

Does Levodopa slow or hasten the rate of progression of Parkinson's disease? JNeurol 2005;(22):731-40.

SF-36 includes less Parkinson Disease targeted content but is more responsive to change than two PD-targeted Healths-related quality of life measures. Brown et al 1009 Qual Life Res 18-1219-1237",Adult,NA,NA,Outcomes and End Points.Quality of Life,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2014-04-01,2014-04-01,Published,NA,NA
PDQ_39_Buttons,PDQ-39,Parkinson's Disease Questionnaire (PDQ-39) - difficulty with buttons and shoelaces scale,Unique Data Element,1,Parkinson's Disease Questionnaire (PDQ-39) - difficulty with buttons and shoelaces scale. Indicates if the subject reported difficulty with buttons or shoelaces,PDQ-39 - difficulty with buttons and shoelaces scale,Alphanumeric,NA,Single Pre-Defined Value Selected,NA,NA,Always or cannot do at all;Never;Occasionally;Often;Sometimes,Always or cannot do at all;Never;Occasionally;Often;Sometimes,;;;;,NA,NA,NA,Select the answer which best describes your personal situation.,PDQ-39-Q13,Had difficulty with buttons or shoelaces?,NA,"PDQ-39 Copyright Isis Innovation Limited, 1993. All rights reserved. 
Adapted from English (UK) to English (USA) in 1996 by Health Research Associates, Inc.
Mikie Welsh and the Parkinson Study Group (Trademark) are the copyright holders for the PDQUALIF Copyright.  The instrument may not be reproduced or translated in whole or in part without the express written permission of the lead author, Mickie Welsh.  See http://pdqualif.com for full terms and use and licensing information.

Development and Testing of the Parkinson's Disease Quality of Life Scale (PDQUALIF)Welsh et al. 2003 Mov Dis 18(6) 637-645.

A Controlled Trial of Rasagiline in Early PD The TEMPO Study. Parkinson Study Group. 2002 Arch Neurol 59: 1937-1943

Pramipexole vs. Levodopa as Initial Treatment for Parkinson's Disease. The Parkinson Study Group. Arch Neurol. 2004;(61): 1044-1053.

A Randomized Placebo-Controlled Trial of Rasagiline in Levodopa-Treated patients with Parkinson Disease and Motor Fluctuations The Presto Study, The Parkinson Study Group 2005 Arch Neurol 62 241-248.

Does Levodopa slow or hasten the rate of progression of Parkinson's disease? JNeurol 2005;(22):731-40.

SF-36 includes less Parkinson Disease targeted content but is more responsive to change than two PD-targeted Healths-related quality of life measures. Brown et al 1009 Qual Life Res 18-1219-1237",Adult,NA,NA,Outcomes and End Points.Quality of Life,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2014-04-01,2014-04-01,Published,NA,NA
PDQ_39_Communicate,PDQ-39,Parkinson's Disease Questionnaire (PDQ-39) - unable to communicate effectively scale,Unique Data Element,1,Parkinson's Disease Questionnaire (PDQ-39) - unable to communicate effectively scale. Indicates if the subject reported feeling that he/she is unable to communicate effectively,PDQ-39 - unable to communicate effectively scale,Alphanumeric,NA,Single Pre-Defined Value Selected,NA,NA,Always or cannot do at all;Never;Occasionally;Often;Sometimes,Always or cannot do at all;Never;Occasionally;Often;Sometimes,;;;;,NA,NA,NA,Select the answer which best describes your personal situation.,PDQ-39-Q35,Felt unable to communicate effectively?,NA,"PDQ-39 Copyright Isis Innovation Limited, 1993. All rights reserved. 
Adapted from English (UK) to English (USA) in 1996 by Health Research Associates, Inc.
Mikie Welsh and the Parkinson Study Group (Trademark) are the copyright holders for the PDQUALIF Copyright.  The instrument may not be reproduced or translated in whole or in part without the express written permission of the lead author, Mickie Welsh.  See http://pdqualif.com for full terms and use and licensing information.

Development and Testing of the Parkinson's Disease Quality of Life Scale (PDQUALIF)Welsh et al. 2003 Mov Dis 18(6) 637-645.

A Controlled Trial of Rasagiline in Early PD The TEMPO Study. Parkinson Study Group. 2002 Arch Neurol 59: 1937-1943

Pramipexole vs. Levodopa as Initial Treatment for Parkinson's Disease. The Parkinson Study Group. Arch Neurol. 2004;(61): 1044-1053.

A Randomized Placebo-Controlled Trial of Rasagiline in Levodopa-Treated patients with Parkinson Disease and Motor Fluctuations The Presto Study, The Parkinson Study Group 2005 Arch Neurol 62 241-248.

Does Levodopa slow or hasten the rate of progression of Parkinson's disease? JNeurol 2005;(22):731-40.

SF-36 includes less Parkinson Disease targeted content but is more responsive to change than two PD-targeted Healths-related quality of life measures. Brown et al 1009 Qual Life Res 18-1219-1237",Adult,NA,NA,Outcomes and End Points.Quality of Life,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2014-04-01,2014-04-01,Published,NA,NA
PDQ_39_Concentration,PDQ-39,Parkinson's Disease Questionnaire (PDQ-39) - problems with concentration scale,Unique Data Element,1,"Parkinson's Disease Questionnaire (PDQ-39) - problems with concentration scale. Indicates if the subject reported problems with his/her concentration when reading, watching TV, etc.",PDQ-39 - problems with concentration scale,Alphanumeric,NA,Single Pre-Defined Value Selected,NA,NA,Always or cannot do at all;Never;Occasionally;Often;Sometimes,Always or cannot do at all;Never;Occasionally;Often;Sometimes,;;;;,NA,NA,NA,Select the answer which best describes your personal situation.,PDQ-39-Q31,"Had problems with your concentration, for example when reading or watching TV?",NA,"PDQ-39 Copyright Isis Innovation Limited, 1993. All rights reserved. 
Adapted from English (UK) to English (USA) in 1996 by Health Research Associates, Inc.
Mikie Welsh and the Parkinson Study Group (Trademark) are the copyright holders for the PDQUALIF Copyright.  The instrument may not be reproduced or translated in whole or in part without the express written permission of the lead author, Mickie Welsh.  See http://pdqualif.com for full terms and use and licensing information.

Development and Testing of the Parkinson's Disease Quality of Life Scale (PDQUALIF)Welsh et al. 2003 Mov Dis 18(6) 637-645.

A Controlled Trial of Rasagiline in Early PD The TEMPO Study. Parkinson Study Group. 2002 Arch Neurol 59: 1937-1943

Pramipexole vs. Levodopa as Initial Treatment for Parkinson's Disease. The Parkinson Study Group. Arch Neurol. 2004;(61): 1044-1053.

A Randomized Placebo-Controlled Trial of Rasagiline in Levodopa-Treated patients with Parkinson Disease and Motor Fluctuations The Presto Study, The Parkinson Study Group 2005 Arch Neurol 62 241-248.

Does Levodopa slow or hasten the rate of progression of Parkinson's disease? JNeurol 2005;(22):731-40.

SF-36 includes less Parkinson Disease targeted content but is more responsive to change than two PD-targeted Healths-related quality of life measures. Brown et al 1009 Qual Life Res 18-1219-1237",Adult,NA,NA,Outcomes and End Points.Quality of Life,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2014-04-01,2014-04-01,Published,NA,NA
PDQ_39_Confined,PDQ-39,Parkinson's Disease Questionnaire (PDQ-39) - confined to house scale,Unique Data Element,1,Parkinson's Disease Questionnaire (PDQ-39) - confined to house scale. Indicates if the subject had been confined to the house more than he/she liked,PDQ-39- confined to house scale,Alphanumeric,NA,Single Pre-Defined Value Selected,NA,NA,Always or cannot do at all;Never;Occasionally;Often;Sometimes,Always or cannot do at all;Never;Occasionally;Often;Sometimes,;;;;,NA,NA,NA,Select the answer which best describes your personal situation.,PDQ-39-Q10,Been confined to the house more than you would like?,NA,"PDQ-39 Copyright Isis Innovation Limited, 1993. All rights reserved. 
Adapted from English (UK) to English (USA) in 1996 by Health Research Associates, Inc.
Mikie Welsh and the Parkinson Study Group (Trademark) are the copyright holders for the PDQUALIF Copyright.  The instrument may not be reproduced or translated in whole or in part without the express written permission of the lead author, Mickie Welsh.  See http://pdqualif.com for full terms and use and licensing information.

Development and Testing of the Parkinson's Disease Quality of Life Scale (PDQUALIF)Welsh et al. 2003 Mov Dis 18(6) 637-645.

A Controlled Trial of Rasagiline in Early PD The TEMPO Study. Parkinson Study Group. 2002 Arch Neurol 59: 1937-1943

Pramipexole vs. Levodopa as Initial Treatment for Parkinson's Disease. The Parkinson Study Group. Arch Neurol. 2004;(61): 1044-1053.

A Randomized Placebo-Controlled Trial of Rasagiline in Levodopa-Treated patients with Parkinson Disease and Motor Fluctuations The Presto Study, The Parkinson Study Group 2005 Arch Neurol 62 241-248.

Does Levodopa slow or hasten the rate of progression of Parkinson's disease? JNeurol 2005;(22):731-40.

SF-36 includes less Parkinson Disease targeted content but is more responsive to change than two PD-targeted Healths-related quality of life measures. Brown et al 1009 Qual Life Res 18-1219-1237",Adult,NA,NA,Outcomes and End Points.Quality of Life,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2014-04-01,2014-04-01,Published,NA,NA
PDQ_39_CrampsSpasms,PDQ-39,Parkinson's Disease Questionnaire (PDQ-39) - painful muscle cramps or spasms scale,Unique Data Element,1,Parkinson's Disease Questionnaire (PDQ-39) - painful muscle cramps or spasms scale. Indicates if the subject reported having painful muscle cramps or spasms,PDQ-39 - painful muscle cramps or spasms scale,Alphanumeric,NA,Single Pre-Defined Value Selected,NA,NA,Always or cannot do at all;Never;Occasionally;Often;Sometimes,Always or cannot do at all;Never;Occasionally;Often;Sometimes,;;;;,NA,NA,NA,Select the answer which best describes your personal situation.,PDQ-39-Q37,Had painful muscle cramps or spasms?,NA,"PDQ-39 Copyright Isis Innovation Limited, 1993. All rights reserved. 
Adapted from English (UK) to English (USA) in 1996 by Health Research Associates, Inc.
Mikie Welsh and the Parkinson Study Group (Trademark) are the copyright holders for the PDQUALIF Copyright.  The instrument may not be reproduced or translated in whole or in part without the express written permission of the lead author, Mickie Welsh.  See http://pdqualif.com for full terms and use and licensing information.

Development and Testing of the Parkinson's Disease Quality of Life Scale (PDQUALIF)Welsh et al. 2003 Mov Dis 18(6) 637-645.

A Controlled Trial of Rasagiline in Early PD The TEMPO Study. Parkinson Study Group. 2002 Arch Neurol 59: 1937-1943

Pramipexole vs. Levodopa as Initial Treatment for Parkinson's Disease. The Parkinson Study Group. Arch Neurol. 2004;(61): 1044-1053.

A Randomized Placebo-Controlled Trial of Rasagiline in Levodopa-Treated patients with Parkinson Disease and Motor Fluctuations The Presto Study, The Parkinson Study Group 2005 Arch Neurol 62 241-248.

Does Levodopa slow or hasten the rate of progression of Parkinson's disease? JNeurol 2005;(22):731-40.

SF-36 includes less Parkinson Disease targeted content but is more responsive to change than two PD-targeted Healths-related quality of life measures. Brown et al 1009 Qual Life Res 18-1219-1237",Adult,NA,NA,Outcomes and End Points.Quality of Life,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2014-04-01,2014-04-01,Published,NA,NA
PDQ_39_CuttingFood,PDQ-39,Parkinson's Disease Questionnaire (PDQ-39) - difficulty cutting food scale,Unique Data Element,1,Parkinson's Disease Questionnaire (PDQ-39) - difficulty cutting food scale. Indicates if the subject reported difficulty cutting up  food,PDQ-39 - difficulty cutting food scale,Alphanumeric,NA,Single Pre-Defined Value Selected,NA,NA,Always or cannot do at all;Never;Occasionally;Often;Sometimes,Always or cannot do at all;Never;Occasionally;Often;Sometimes,;;;;,NA,NA,NA,Select the answer which best describes your personal situation.,PDQ-39-Q15,Had difficulty cutting up your food?,NA,"PDQ-39 Copyright Isis Innovation Limited, 1993. All rights reserved. 
Adapted from English (UK) to English (USA) in 1996 by Health Research Associates, Inc.
Mikie Welsh and the Parkinson Study Group (Trademark) are the copyright holders for the PDQUALIF Copyright.  The instrument may not be reproduced or translated in whole or in part without the express written permission of the lead author, Mickie Welsh.  See http://pdqualif.com for full terms and use and licensing information.

Development and Testing of the Parkinson's Disease Quality of Life Scale (PDQUALIF)Welsh et al. 2003 Mov Dis 18(6) 637-645.

A Controlled Trial of Rasagiline in Early PD The TEMPO Study. Parkinson Study Group. 2002 Arch Neurol 59: 1937-1943

Pramipexole vs. Levodopa as Initial Treatment for Parkinson's Disease. The Parkinson Study Group. Arch Neurol. 2004;(61): 1044-1053.

A Randomized Placebo-Controlled Trial of Rasagiline in Levodopa-Treated patients with Parkinson Disease and Motor Fluctuations The Presto Study, The Parkinson Study Group 2005 Arch Neurol 62 241-248.

Does Levodopa slow or hasten the rate of progression of Parkinson's disease? JNeurol 2005;(22):731-40.

SF-36 includes less Parkinson Disease targeted content but is more responsive to change than two PD-targeted Healths-related quality of life measures. Brown et al 1009 Qual Life Res 18-1219-1237",Adult,NA,NA,Outcomes and End Points.Quality of Life,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2014-04-01,2014-04-01,Published,NA,NA
PDQ_39_Depressed,PDQ-39,Parkinson's Disease Questionnaire (PDQ-39) - feeling depressed scale,Unique Data Element,1,Parkinson's Disease Questionnaire (PDQ-39) - feeling depressed scale. Indicates if the subject reported feeling depressed,PDQ-39 - feeling depressed scale,Alphanumeric,NA,Single Pre-Defined Value Selected,NA,NA,Always or cannot do at all;Never;Occasionally;Often;Sometimes,Always or cannot do at all;Never;Occasionally;Often;Sometimes,;;;;,NA,NA,NA,Select the answer which best describes your personal situation.,PDQ-39-Q17,Felt depressed?,NA,"PDQ-39 Copyright Isis Innovation Limited, 1993. All rights reserved. 
Adapted from English (UK) to English (USA) in 1996 by Health Research Associates, Inc.
Mikie Welsh and the Parkinson Study Group (Trademark) are the copyright holders for the PDQUALIF Copyright.  The instrument may not be reproduced or translated in whole or in part without the express written permission of the lead author, Mickie Welsh.  See http://pdqualif.com for full terms and use and licensing information.

Development and Testing of the Parkinson's Disease Quality of Life Scale (PDQUALIF)Welsh et al. 2003 Mov Dis 18(6) 637-645.

A Controlled Trial of Rasagiline in Early PD The TEMPO Study. Parkinson Study Group. 2002 Arch Neurol 59: 1937-1943

Pramipexole vs. Levodopa as Initial Treatment for Parkinson's Disease. The Parkinson Study Group. Arch Neurol. 2004;(61): 1044-1053.

A Randomized Placebo-Controlled Trial of Rasagiline in Levodopa-Treated patients with Parkinson Disease and Motor Fluctuations The Presto Study, The Parkinson Study Group 2005 Arch Neurol 62 241-248.

Does Levodopa slow or hasten the rate of progression of Parkinson's disease? JNeurol 2005;(22):731-40.

SF-36 includes less Parkinson Disease targeted content but is more responsive to change than two PD-targeted Healths-related quality of life measures. Brown et al 1009 Qual Life Res 18-1219-1237",Adult,NA,NA,Outcomes and End Points.Quality of Life,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2014-04-01,2014-04-01,Published,NA,NA
PDQ_39_Dreams,PDQ-39,Parkinson's Disease Questionnaire (PDQ-39) - distressing dreams or hallucinations scale,Unique Data Element,1,Parkinson's Disease Questionnaire (PDQ-39) - distressing dreams or hallucinations scale. Indicates if the subject reported having  distressing dreams  and/or hallucinations,PDQ-39 - distressing dreams or hallucinations scale,Alphanumeric,NA,Single Pre-Defined Value Selected,NA,NA,Always or cannot do at all;Never;Occasionally;Often;Sometimes,Always or cannot do at all;Never;Occasionally;Often;Sometimes,;;;;,NA,NA,NA,Select the answer which best describes your personal situation.,PDQ-39-Q33,Had distressing dreams or hallucinations?,NA,"PDQ-39 Copyright Isis Innovation Limited, 1993. All rights reserved. 
Adapted from English (UK) to English (USA) in 1996 by Health Research Associates, Inc.
Mikie Welsh and the Parkinson Study Group (Trademark) are the copyright holders for the PDQUALIF Copyright.  The instrument may not be reproduced or translated in whole or in part without the express written permission of the lead author, Mickie Welsh.  See http://pdqualif.com for full terms and use and licensing information.

Development and Testing of the Parkinson's Disease Quality of Life Scale (PDQUALIF)Welsh et al. 2003 Mov Dis 18(6) 637-645.

A Controlled Trial of Rasagiline in Early PD The TEMPO Study. Parkinson Study Group. 2002 Arch Neurol 59: 1937-1943

Pramipexole vs. Levodopa as Initial Treatment for Parkinson's Disease. The Parkinson Study Group. Arch Neurol. 2004;(61): 1044-1053.

A Randomized Placebo-Controlled Trial of Rasagiline in Levodopa-Treated patients with Parkinson Disease and Motor Fluctuations The Presto Study, The Parkinson Study Group 2005 Arch Neurol 62 241-248.

Does Levodopa slow or hasten the rate of progression of Parkinson's disease? JNeurol 2005;(22):731-40.

SF-36 includes less Parkinson Disease targeted content but is more responsive to change than two PD-targeted Healths-related quality of life measures. Brown et al 1009 Qual Life Res 18-1219-1237",Adult,NA,NA,Outcomes and End Points.Quality of Life,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2014-04-01,2014-04-01,Published,NA,NA
PDQ_39_Dressing,PDQ-39,Parkinson's Disease Questionnaire (PDQ-39) - difficulty dressing scale,Unique Data Element,1,Parkinson's Disease Questionnaire (PDQ-39) - difficulty dressing scale. Indicates if the subject reported difficulty dressing,PDQ-39 - difficulty dressing scale,Alphanumeric,NA,Single Pre-Defined Value Selected,NA,NA,Always or cannot do at all;Never;Occasionally;Often;Sometimes,Always or cannot do at all;Never;Occasionally;Often;Sometimes,;;;;,NA,NA,NA,Select the answer which best describes your personal situation.,PDQ-39-Q12,Had difficulty dressing?,NA,"PDQ-39 Copyright Isis Innovation Limited, 1993. All rights reserved. 
Adapted from English (UK) to English (USA) in 1996 by Health Research Associates, Inc.
Mikie Welsh and the Parkinson Study Group (Trademark) are the copyright holders for the PDQUALIF Copyright.  The instrument may not be reproduced or translated in whole or in part without the express written permission of the lead author, Mickie Welsh.  See http://pdqualif.com for full terms and use and licensing information.

Development and Testing of the Parkinson's Disease Quality of Life Scale (PDQUALIF)Welsh et al. 2003 Mov Dis 18(6) 637-645.

A Controlled Trial of Rasagiline in Early PD The TEMPO Study. Parkinson Study Group. 2002 Arch Neurol 59: 1937-1943

Pramipexole vs. Levodopa as Initial Treatment for Parkinson's Disease. The Parkinson Study Group. Arch Neurol. 2004;(61): 1044-1053.

A Randomized Placebo-Controlled Trial of Rasagiline in Levodopa-Treated patients with Parkinson Disease and Motor Fluctuations The Presto Study, The Parkinson Study Group 2005 Arch Neurol 62 241-248.

Does Levodopa slow or hasten the rate of progression of Parkinson's disease? JNeurol 2005;(22):731-40.

SF-36 includes less Parkinson Disease targeted content but is more responsive to change than two PD-targeted Healths-related quality of life measures. Brown et al 1009 Qual Life Res 18-1219-1237",Adult,NA,NA,Outcomes and End Points.Quality of Life,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2014-04-01,2014-04-01,Published,NA,NA
PDQ_39_EatingPublic,PDQ-39,Parkinson's Disease Questionnaire (PDQ-39) - avoiding eating or drinking in public scale,Unique Data Element,1,Parkinson's Disease Questionnaire (PDQ-39) - avoiding eating or drinking in public scale. Indicates if the subject reported that he/she avoided situations which involve eating or drinking in public,PDQ-39 - avoiding eating or drinking in public scale,Alphanumeric,NA,Single Pre-Defined Value Selected,NA,NA,Always or cannot do at all;Never;Occasionally;Often;Sometimes,Always or cannot do at all;Never;Occasionally;Often;Sometimes,;;;;,NA,NA,NA,Select the answer which best describes your personal situation.,PDQ-39-Q24,Avoided situations which involve eating or drinking in public?,NA,"PDQ-39 Copyright Isis Innovation Limited, 1993. All rights reserved. 
Adapted from English (UK) to English (USA) in 1996 by Health Research Associates, Inc.
Mikie Welsh and the Parkinson Study Group (Trademark) are the copyright holders for the PDQUALIF Copyright.  The instrument may not be reproduced or translated in whole or in part without the express written permission of the lead author, Mickie Welsh.  See http://pdqualif.com for full terms and use and licensing information.

Development and Testing of the Parkinson's Disease Quality of Life Scale (PDQUALIF)Welsh et al. 2003 Mov Dis 18(6) 637-645.

A Controlled Trial of Rasagiline in Early PD The TEMPO Study. Parkinson Study Group. 2002 Arch Neurol 59: 1937-1943

Pramipexole vs. Levodopa as Initial Treatment for Parkinson's Disease. The Parkinson Study Group. Arch Neurol. 2004;(61): 1044-1053.

A Randomized Placebo-Controlled Trial of Rasagiline in Levodopa-Treated patients with Parkinson Disease and Motor Fluctuations The Presto Study, The Parkinson Study Group 2005 Arch Neurol 62 241-248.

Does Levodopa slow or hasten the rate of progression of Parkinson's disease? JNeurol 2005;(22):731-40.

SF-36 includes less Parkinson Disease targeted content but is more responsive to change than two PD-targeted Healths-related quality of life measures. Brown et al 1009 Qual Life Res 18-1219-1237",Adult,NA,NA,Outcomes and End Points.Quality of Life,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2014-04-01,2014-04-01,Published,NA,NA
PDQ_39_EmbarrassedPublic,PDQ-39,Parkinson's Disease Questionnaire (PDQ-39) - feeling embarrassed in public scale,Unique Data Element,1,Parkinson's Disease Questionnaire (PDQ-39) - feeling embarrassed in public scale. Indicates if the subject reported feeling embarrassed in public,PDQ-39 - feeling embarrassed in public scale,Alphanumeric,NA,Single Pre-Defined Value Selected,NA,NA,Always or cannot do at all;Never;Occasionally;Often;Sometimes,Always or cannot do at all;Never;Occasionally;Often;Sometimes,;;;;,NA,NA,NA,Select the answer which best describes your personal situation.,PDQ-39-Q25,Felt embarrassed in public?,NA,"PDQ-39 Copyright Isis Innovation Limited, 1993. All rights reserved. 
Adapted from English (UK) to English (USA) in 1996 by Health Research Associates, Inc.
Mikie Welsh and the Parkinson Study Group (Trademark) are the copyright holders for the PDQUALIF Copyright.  The instrument may not be reproduced or translated in whole or in part without the express written permission of the lead author, Mickie Welsh.  See http://pdqualif.com for full terms and use and licensing information.

Development and Testing of the Parkinson's Disease Quality of Life Scale (PDQUALIF)Welsh et al. 2003 Mov Dis 18(6) 637-645.

A Controlled Trial of Rasagiline in Early PD The TEMPO Study. Parkinson Study Group. 2002 Arch Neurol 59: 1937-1943

Pramipexole vs. Levodopa as Initial Treatment for Parkinson's Disease. The Parkinson Study Group. Arch Neurol. 2004;(61): 1044-1053.

A Randomized Placebo-Controlled Trial of Rasagiline in Levodopa-Treated patients with Parkinson Disease and Motor Fluctuations The Presto Study, The Parkinson Study Group 2005 Arch Neurol 62 241-248.

Does Levodopa slow or hasten the rate of progression of Parkinson's disease? JNeurol 2005;(22):731-40.

SF-36 includes less Parkinson Disease targeted content but is more responsive to change than two PD-targeted Healths-related quality of life measures. Brown et al 1009 Qual Life Res 18-1219-1237",Adult,NA,NA,Outcomes and End Points.Quality of Life,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2014-04-01,2014-04-01,Published,NA,NA
PDQ_39_Falling,PDQ-39,Parkinson's Disease Questionnaire (PDQ-39) - worried about falling in public places scale,Unique Data Element,1,Parkinson's Disease Questionnaire (PDQ-39) - worried about falling in public places scale. Indicates if the subject worried about falling in public places,PDQ-39 - worry about falling in public places scale,Alphanumeric,NA,Single Pre-Defined Value Selected,NA,NA,Always or cannot do at all;Never;Occasionally;Often;Sometimes,Always or cannot do at all;Never;Occasionally;Often;Sometimes,;;;;,NA,NA,NA,Select the answer which best describes your personal situation.,PDQ-39-Q9,Felt frightened or worried about falling in public?,NA,"PDQ-39 Copyright Isis Innovation Limited, 1993. All rights reserved. 
Adapted from English (UK) to English (USA) in 1996 by Health Research Associates, Inc.
Mikie Welsh and the Parkinson Study Group (Trademark) are the copyright holders for the PDQUALIF Copyright.  The instrument may not be reproduced or translated in whole or in part without the express written permission of the lead author, Mickie Welsh.  See http://pdqualif.com for full terms and use and licensing information.

Development and Testing of the Parkinson's Disease Quality of Life Scale (PDQUALIF)Welsh et al. 2003 Mov Dis 18(6) 637-645.

A Controlled Trial of Rasagiline in Early PD The TEMPO Study. Parkinson Study Group. 2002 Arch Neurol 59: 1937-1943

Pramipexole vs. Levodopa as Initial Treatment for Parkinson's Disease. The Parkinson Study Group. Arch Neurol. 2004;(61): 1044-1053.

A Randomized Placebo-Controlled Trial of Rasagiline in Levodopa-Treated patients with Parkinson Disease and Motor Fluctuations The Presto Study, The Parkinson Study Group 2005 Arch Neurol 62 241-248.

Does Levodopa slow or hasten the rate of progression of Parkinson's disease? JNeurol 2005;(22):731-40.

SF-36 includes less Parkinson Disease targeted content but is more responsive to change than two PD-targeted Healths-related quality of life measures. Brown et al 1009 Qual Life Res 18-1219-1237",Adult,NA,NA,Outcomes and End Points.Quality of Life,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2014-04-01,2014-04-01,Published,NA,NA
PDQ_39_GroceryBags,PDQ-39,Parkinson's Disease Questionnaire (PDQ-39) - difficulty carrying grocery bags scale,Unique Data Element,1,Parkinson's Disease Questionnaire (PDQ-39) - difficulty carrying grocery bags scale. Indicates if the subject had difficulty carrying grocery bags,PDQ-39 - difficulty carrying grocery bags scale,Alphanumeric,NA,Single Pre-Defined Value Selected,NA,NA,Always or cannot do at all;Never;Occasionally;Often;Sometimes,Always or cannot do at all;Never;Occasionally;Often;Sometimes,;;;;,NA,NA,NA,Select the answer which best describes your personal situation.,PDQ-39-Q3,Had difficulty carrying grocery bags?,NA,"PDQ-39 Copyright Isis Innovation Limited, 1993. All rights reserved. 
Adapted from English (UK) to English (USA) in 1996 by Health Research Associates, Inc.
Mikie Welsh and the Parkinson Study Group (Trademark) are the copyright holders for the PDQUALIF Copyright.  The instrument may not be reproduced or translated in whole or in part without the express written permission of the lead author, Mickie Welsh.  See http://pdqualif.com for full terms and use and licensing information.

Development and Testing of the Parkinson's Disease Quality of Life Scale (PDQUALIF)Welsh et al. 2003 Mov Dis 18(6) 637-645.

A Controlled Trial of Rasagiline in Early PD The TEMPO Study. Parkinson Study Group. 2002 Arch Neurol 59: 1937-1943

Pramipexole vs. Levodopa as Initial Treatment for Parkinson's Disease. The Parkinson Study Group. Arch Neurol. 2004;(61): 1044-1053.

A Randomized Placebo-Controlled Trial of Rasagiline in Levodopa-Treated patients with Parkinson Disease and Motor Fluctuations The Presto Study, The Parkinson Study Group 2005 Arch Neurol 62 241-248.

Does Levodopa slow or hasten the rate of progression of Parkinson's disease? JNeurol 2005;(22):731-40.

SF-36 includes less Parkinson Disease targeted content but is more responsive to change than two PD-targeted Healths-related quality of life measures. Brown et al 1009 Qual Life Res 18-1219-1237",Adult,NA,NA,Outcomes and End Points.Quality of Life,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2014-04-01,2014-04-01,Published,NA,NA
PDQ_39_HidePD,PDQ-39,Parkinson's Disease Questionnaire (PDQ-39) - feels need to hide Parkinson's Disease from people scale,Unique Data Element,1,Parkinson's Disease Questionnaire (PDQ-39) - feels need to hide Parkinson's Disease from people scale. Indicates if the subject reported that he/she felt that he/she needs to  hide her/his Parkinson's from people,PDQ-39 - need to hide Parkinson's disease from people scale,Alphanumeric,NA,Single Pre-Defined Value Selected,NA,NA,Always or cannot do at all;Never;Occasionally;Often;Sometimes,Always or cannot do at all;Never;Occasionally;Often;Sometimes,;;;;,NA,NA,NA,Select the answer which best describes your personal situation.,PDQ-39-Q23,Felt you had to hide your Parkinson's from people?,NA,"PDQ-39 Copyright Isis Innovation Limited, 1993. All rights reserved. 
Adapted from English (UK) to English (USA) in 1996 by Health Research Associates, Inc.
Mikie Welsh and the Parkinson Study Group (Trademark) are the copyright holders for the PDQUALIF Copyright.  The instrument may not be reproduced or translated in whole or in part without the express written permission of the lead author, Mickie Welsh.  See http://pdqualif.com for full terms and use and licensing information.

Development and Testing of the Parkinson's Disease Quality of Life Scale (PDQUALIF)Welsh et al. 2003 Mov Dis 18(6) 637-645.

A Controlled Trial of Rasagiline in Early PD The TEMPO Study. Parkinson Study Group. 2002 Arch Neurol 59: 1937-1943

Pramipexole vs. Levodopa as Initial Treatment for Parkinson's Disease. The Parkinson Study Group. Arch Neurol. 2004;(61): 1044-1053.

A Randomized Placebo-Controlled Trial of Rasagiline in Levodopa-Treated patients with Parkinson Disease and Motor Fluctuations The Presto Study, The Parkinson Study Group 2005 Arch Neurol 62 241-248.

Does Levodopa slow or hasten the rate of progression of Parkinson's disease? JNeurol 2005;(22):731-40.

SF-36 includes less Parkinson Disease targeted content but is more responsive to change than two PD-targeted Healths-related quality of life measures. Brown et al 1009 Qual Life Res 18-1219-1237",Adult,NA,NA,Outcomes and End Points.Quality of Life,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2014-04-01,2014-04-01,Published,NA,NA
PDQ_39_HoldingDrink,PDQ-39,Parkinson's Disease Questionnaire (PDQ-39) - difficulty holding drink without spilling scale,Unique Data Element,1,Parkinson's Disease Questionnaire (PDQ-39) - difficulty holding drink without spilling scale. Indicates if the subject reported difficulty holding a drink without spilling,PDQ-39 - difficulty holding drink without spilling scale,Alphanumeric,NA,Single Pre-Defined Value Selected,NA,NA,Always or cannot do at all;Never;Occasionally;Often;Sometimes,Always or cannot do at all;Never;Occasionally;Often;Sometimes,;;;;,NA,NA,NA,Select the answer which best describes your personal situation.,PDQ-39-Q16,Had difficulty holding a drink without spilling it?,NA,"PDQ-39 Copyright Isis Innovation Limited, 1993. All rights reserved. 
Adapted from English (UK) to English (USA) in 1996 by Health Research Associates, Inc.
Mikie Welsh and the Parkinson Study Group (Trademark) are the copyright holders for the PDQUALIF Copyright.  The instrument may not be reproduced or translated in whole or in part without the express written permission of the lead author, Mickie Welsh.  See http://pdqualif.com for full terms and use and licensing information.

Development and Testing of the Parkinson's Disease Quality of Life Scale (PDQUALIF)Welsh et al. 2003 Mov Dis 18(6) 637-645.

A Controlled Trial of Rasagiline in Early PD The TEMPO Study. Parkinson Study Group. 2002 Arch Neurol 59: 1937-1943

Pramipexole vs. Levodopa as Initial Treatment for Parkinson's Disease. The Parkinson Study Group. Arch Neurol. 2004;(61): 1044-1053.

A Randomized Placebo-Controlled Trial of Rasagiline in Levodopa-Treated patients with Parkinson Disease and Motor Fluctuations The Presto Study, The Parkinson Study Group 2005 Arch Neurol 62 241-248.

Does Levodopa slow or hasten the rate of progression of Parkinson's disease? JNeurol 2005;(22):731-40.

SF-36 includes less Parkinson Disease targeted content but is more responsive to change than two PD-targeted Healths-related quality of life measures. Brown et al 1009 Qual Life Res 18-1219-1237",Adult,NA,NA,Outcomes and End Points.Quality of Life,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2014-04-01,2014-04-01,Published,NA,NA
PDQ_39_HotCold,PDQ-39,Parkinson's Disease Questionnaire (PDQ-39) - feeling uncomfortably hot or cold scale,Unique Data Element,1,Parkinson's Disease Questionnaire (PDQ-39) - feeling uncomfortably hot or cold scale. Indicates if the subject reported feeling  uncomfortably hot and/or cold,PDQ-39 - feeling uncomfortably hot or cold scale,Alphanumeric,NA,Single Pre-Defined Value Selected,NA,NA,Always or cannot do at all;Never;Occasionally;Often;Sometimes,Always or cannot do at all;Never;Occasionally;Often;Sometimes,;;;;,NA,NA,NA,Select the answer which best describes your personal situation.,PDQ-39-Q39,Felt uncomfortably hot or cold?,NA,"PDQ-39 Copyright Isis Innovation Limited, 1993. All rights reserved. 
Adapted from English (UK) to English (USA) in 1996 by Health Research Associates, Inc.
Mikie Welsh and the Parkinson Study Group (Trademark) are the copyright holders for the PDQUALIF Copyright.  The instrument may not be reproduced or translated in whole or in part without the express written permission of the lead author, Mickie Welsh.  See http://pdqualif.com for full terms and use and licensing information.

Development and Testing of the Parkinson's Disease Quality of Life Scale (PDQUALIF)Welsh et al. 2003 Mov Dis 18(6) 637-645.

A Controlled Trial of Rasagiline in Early PD The TEMPO Study. Parkinson Study Group. 2002 Arch Neurol 59: 1937-1943

Pramipexole vs. Levodopa as Initial Treatment for Parkinson's Disease. The Parkinson Study Group. Arch Neurol. 2004;(61): 1044-1053.

A Randomized Placebo-Controlled Trial of Rasagiline in Levodopa-Treated patients with Parkinson Disease and Motor Fluctuations The Presto Study, The Parkinson Study Group 2005 Arch Neurol 62 241-248.

Does Levodopa slow or hasten the rate of progression of Parkinson's disease? JNeurol 2005;(22):731-40.

SF-36 includes less Parkinson Disease targeted content but is more responsive to change than two PD-targeted Healths-related quality of life measures. Brown et al 1009 Qual Life Res 18-1219-1237",Adult,NA,NA,Outcomes and End Points.Quality of Life,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2014-04-01,2014-04-01,Published,NA,NA
PDQ_39_House,PDQ-39,Parkinson's Disease Questionnaire (PDQ-39) problems getting around the house scale,Unique Data Element,1,Parkinson's Disease Questionnaire (PDQ-39) problems getting around the house scale. Indicates if the subject had problems getting around the house easily,PDQ-39 problems getting around the house scale,Alphanumeric,NA,Single Pre-Defined Value Selected,NA,NA,Always or cannot do at all;Never;Occasionally;Often;Sometimes,Always or cannot do at all;Never;Occasionally;Often;Sometimes,;;;;,NA,NA,NA,Select the answer which best describes your personal situation.,PDQ-39-Q6,Had problems getting around the house as easily as you would like?,NA,"PDQ-39 Copyright Isis Innovation Limited, 1993. All rights reserved. 
Adapted from English (UK) to English (USA) in 1996 by Health Research Associates, Inc.
Mikie Welsh and the Parkinson Study Group (Trademark) are the copyright holders for the PDQUALIF Copyright.  The instrument may not be reproduced or translated in whole or in part without the express written permission of the lead author, Mickie Welsh.  See http://pdqualif.com for full terms and use and licensing information.

Development and Testing of the Parkinson's Disease Quality of Life Scale (PDQUALIF)Welsh et al. 2003 Mov Dis 18(6) 637-645.

A Controlled Trial of Rasagiline in Early PD The TEMPO Study. Parkinson Study Group. 2002 Arch Neurol 59: 1937-1943

Pramipexole vs. Levodopa as Initial Treatment for Parkinson's Disease. The Parkinson Study Group. Arch Neurol. 2004;(61): 1044-1053.

A Randomized Placebo-Controlled Trial of Rasagiline in Levodopa-Treated patients with Parkinson Disease and Motor Fluctuations The Presto Study, The Parkinson Study Group 2005 Arch Neurol 62 241-248.

Does Levodopa slow or hasten the rate of progression of Parkinson's disease? JNeurol 2005;(22):731-40.

SF-36 includes less Parkinson Disease targeted content but is more responsive to change than two PD-targeted Healths-related quality of life measures. Brown et al 1009 Qual Life Res 18-1219-1237",Adult,NA,NA,Outcomes and End Points.Quality of Life,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2014-04-01,2014-04-01,Published,NA,NA
PDQ_39_Housework,PDQ-39,Parkinson's Disease Questionnaire (PDQ-39) -difficulty looking after home scale,Unique Data Element,1,"Parkinson's Disease Questionnaire (PDQ-39) -difficulty looking after the subject's  home scale. Indicates if the subject reports having  difficulty looking after his/her home, for example, housework, cooking or yardwork",PDQ-39 -difficulty looking after the subject's  home scale,Alphanumeric,NA,Single Pre-Defined Value Selected,NA,NA,Always or cannot do at all;Never;Occasionally;Often;Sometimes,Always or cannot do at all;Never;Occasionally;Often;Sometimes,;;;;,NA,NA,NA,Select the answer which best describes your personal situation.,PDQ-39-Q2,"Had difficulty looking after your home, for example, housework, cooking or yardwork?",NA,"PDQ-39 Copyright Isis Innovation Limited, 1993. All rights reserved. 
Adapted from English (UK) to English (USA) in 1996 by Health Research Associates, Inc.
Mikie Welsh and the Parkinson Study Group (Trademark) are the copyright holders for the PDQUALIF Copyright.  The instrument may not be reproduced or translated in whole or in part without the express written permission of the lead author, Mickie Welsh.  See http://pdqualif.com for full terms and use and licensing information.

Development and Testing of the Parkinson's Disease Quality of Life Scale (PDQUALIF)Welsh et al. 2003 Mov Dis 18(6) 637-645.

A Controlled Trial of Rasagiline in Early PD The TEMPO Study. Parkinson Study Group. 2002 Arch Neurol 59: 1937-1943

Pramipexole vs. Levodopa as Initial Treatment for Parkinson's Disease. The Parkinson Study Group. Arch Neurol. 2004;(61): 1044-1053.

A Randomized Placebo-Controlled Trial of Rasagiline in Levodopa-Treated patients with Parkinson Disease and Motor Fluctuations The Presto Study, The Parkinson Study Group 2005 Arch Neurol 62 241-248.

Does Levodopa slow or hasten the rate of progression of Parkinson's disease? JNeurol 2005;(22):731-40.

SF-36 includes less Parkinson Disease targeted content but is more responsive to change than two PD-targeted Healths-related quality of life measures. Brown et al 1009 Qual Life Res 18-1219-1237",Adult,NA,NA,Outcomes and End Points.Quality of Life,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2014-04-01,2014-04-01,Published,NA,NA
PDQ_39_Ignored,PDQ-39,Parkinson's Disease Questionnaire (PDQ-39) - feeling ignored by people scale,Unique Data Element,1,Parkinson's Disease Questionnaire (PDQ-39) - feeling ignored by people scale. Indicates if the subject reported feeling ignored by people,PDQ-39 - feeling ignored by people scale,Alphanumeric,NA,Single Pre-Defined Value Selected,NA,NA,Always or cannot do at all;Never;Occasionally;Often;Sometimes,Always or cannot do at all;Never;Occasionally;Often;Sometimes,;;;;,NA,NA,NA,Select the answer which best describes your personal situation.,PDQ-39-Q36,Felt ignored by people?,NA,"PDQ-39 Copyright Isis Innovation Limited, 1993. All rights reserved. 
Adapted from English (UK) to English (USA) in 1996 by Health Research Associates, Inc.
Mikie Welsh and the Parkinson Study Group (Trademark) are the copyright holders for the PDQUALIF Copyright.  The instrument may not be reproduced or translated in whole or in part without the express written permission of the lead author, Mickie Welsh.  See http://pdqualif.com for full terms and use and licensing information.

Development and Testing of the Parkinson's Disease Quality of Life Scale (PDQUALIF)Welsh et al. 2003 Mov Dis 18(6) 637-645.

A Controlled Trial of Rasagiline in Early PD The TEMPO Study. Parkinson Study Group. 2002 Arch Neurol 59: 1937-1943

Pramipexole vs. Levodopa as Initial Treatment for Parkinson's Disease. The Parkinson Study Group. Arch Neurol. 2004;(61): 1044-1053.

A Randomized Placebo-Controlled Trial of Rasagiline in Levodopa-Treated patients with Parkinson Disease and Motor Fluctuations The Presto Study, The Parkinson Study Group 2005 Arch Neurol 62 241-248.

Does Levodopa slow or hasten the rate of progression of Parkinson's disease? JNeurol 2005;(22):731-40.

SF-36 includes less Parkinson Disease targeted content but is more responsive to change than two PD-targeted Healths-related quality of life measures. Brown et al 1009 Qual Life Res 18-1219-1237",Adult,NA,NA,Outcomes and End Points.Quality of Life,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2014-04-01,2014-04-01,Published,NA,NA
PDQ_39_LackOfSuprtFmly,PDQ-39,Parkinson's Disease Questionnaire (PDQ-39) - lack of support from family or friends scale,Unique Data Element,1,Parkinson's Disease Questionnaire (PDQ-39) - lack of support from family or friends scale. Indicates if the subject reported lack of support he/she needed from  family and/or close friends,PDQ-39 - lack of support from family or friends scale,Alphanumeric,NA,Single Pre-Defined Value Selected,NA,NA,Always or cannot do at all;Never;Occasionally;Often;Sometimes,Always or cannot do at all;Never;Occasionally;Often;Sometimes,;;;;,NA,NA,NA,Select the answer which best describes your personal situation.,PDQ-39-Q29,Lacked the support you needed from your family or close friends?,NA,"PDQ-39 Copyright Isis Innovation Limited, 1993. All rights reserved. 
Adapted from English (UK) to English (USA) in 1996 by Health Research Associates, Inc.
Mikie Welsh and the Parkinson Study Group (Trademark) are the copyright holders for the PDQUALIF Copyright.  The instrument may not be reproduced or translated in whole or in part without the express written permission of the lead author, Mickie Welsh.  See http://pdqualif.com for full terms and use and licensing information.

Development and Testing of the Parkinson's Disease Quality of Life Scale (PDQUALIF)Welsh et al. 2003 Mov Dis 18(6) 637-645.

A Controlled Trial of Rasagiline in Early PD The TEMPO Study. Parkinson Study Group. 2002 Arch Neurol 59: 1937-1943

Pramipexole vs. Levodopa as Initial Treatment for Parkinson's Disease. The Parkinson Study Group. Arch Neurol. 2004;(61): 1044-1053.

A Randomized Placebo-Controlled Trial of Rasagiline in Levodopa-Treated patients with Parkinson Disease and Motor Fluctuations The Presto Study, The Parkinson Study Group 2005 Arch Neurol 62 241-248.

Does Levodopa slow or hasten the rate of progression of Parkinson's disease? JNeurol 2005;(22):731-40.

SF-36 includes less Parkinson Disease targeted content but is more responsive to change than two PD-targeted Healths-related quality of life measures. Brown et al 1009 Qual Life Res 18-1219-1237",Adult,NA,NA,Outcomes and End Points.Quality of Life,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2014-04-01,2014-04-01,Published,NA,NA
PDQ_39_LackOfSuprtPrtnr,PDQ-39,Parkinson's Disease Questionnaire (PDQ-39) - lack of support from spouse or partner scale,Unique Data Element,1,Parkinson's Disease Questionnaire (PDQ-39) - lack of support from spouse or partner scale. Indicates if the subject reported lack of support he/she needed from a spouse or a partner,PDQ-39 - lack of support from spouse or partner scale,Alphanumeric,NA,Single Pre-Defined Value Selected,NA,NA,Always or cannot do at all;Never;No spouse or partner;Occasionally;Often;Sometimes,Always or cannot do at all;Never;No spouse or partner;Occasionally;Often;Sometimes,4;0;777;1;2;3,NA,NA,NA,Select the answer which best describes your personal situation.,PDQ-39-Q28,Lacked the support you needed from your spouse or partner?,NA,"PDQ-39 Copyright Isis Innovation Limited, 1993. All rights reserved. 
Adapted from English (UK) to English (USA) in 1996 by Health Research Associates, Inc.
Mikie Welsh and the Parkinson Study Group (Trademark) are the copyright holders for the PDQUALIF Copyright.  The instrument may not be reproduced or translated in whole or in part without the express written permission of the lead author, Mickie Welsh.  See http://pdqualif.com for full terms and use and licensing information.

Development and Testing of the Parkinson's Disease Quality of Life Scale (PDQUALIF)Welsh et al. 2003 Mov Dis 18(6) 637-645.

A Controlled Trial of Rasagiline in Early PD The TEMPO Study. Parkinson Study Group. 2002 Arch Neurol 59: 1937-1943

Pramipexole vs. Levodopa as Initial Treatment for Parkinson's Disease. The Parkinson Study Group. Arch Neurol. 2004;(61): 1044-1053.

A Randomized Placebo-Controlled Trial of Rasagiline in Levodopa-Treated patients with Parkinson Disease and Motor Fluctuations The Presto Study, The Parkinson Study Group 2005 Arch Neurol 62 241-248.

Does Levodopa slow or hasten the rate of progression of Parkinson's disease? JNeurol 2005;(22):731-40.

SF-36 includes less Parkinson Disease targeted content but is more responsive to change than two PD-targeted Healths-related quality of life measures. Brown et al 1009 Qual Life Res 18-1219-1237",Adult,NA,NA,Outcomes and End Points.Quality of Life,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2014-04-01,2014-04-01,Published,NA,NA
PDQ_39_Leisure,PDQ-39,Parkinson's Disease Questionnaire (PDQ-39) - difficulty with leisure activities scale,Unique Data Element,1,Parkinson's Disease Questionnaire (PDQ-39) - difficulty with leisure activities scale. Indicates if the subject had difficulty doing the leisure activities he/she likes to do,PDQ-39 - difficulty with leisure activities scale,Alphanumeric,NA,Single Pre-Defined Value Selected,NA,NA,Always or cannot do at all;Never;Occasionally;Often;Sometimes,Always or cannot do at all;Never;Occasionally;Often;Sometimes,;;;;,NA,NA,NA,Select the answer which best describes your personal situation.,PDQ-39-Q1,Had difficulty doing the leisure activities you would like to do?,NA,"PDQ-39 Copyright Isis Innovation Limited, 1993. All rights reserved. 
Adapted from English (UK) to English (USA) in 1996 by Health Research Associates, Inc.
Mikie Welsh and the Parkinson Study Group (Trademark) are the copyright holders for the PDQUALIF Copyright.  The instrument may not be reproduced or translated in whole or in part without the express written permission of the lead author, Mickie Welsh.  See http://pdqualif.com for full terms and use and licensing information.

Development and Testing of the Parkinson's Disease Quality of Life Scale (PDQUALIF)Welsh et al. 2003 Mov Dis 18(6) 637-645.

A Controlled Trial of Rasagiline in Early PD The TEMPO Study. Parkinson Study Group. 2002 Arch Neurol 59: 1937-1943

Pramipexole vs. Levodopa as Initial Treatment for Parkinson's Disease. The Parkinson Study Group. Arch Neurol. 2004;(61): 1044-1053.

A Randomized Placebo-Controlled Trial of Rasagiline in Levodopa-Treated patients with Parkinson Disease and Motor Fluctuations The Presto Study, The Parkinson Study Group 2005 Arch Neurol 62 241-248.

Does Levodopa slow or hasten the rate of progression of Parkinson's disease? JNeurol 2005;(22):731-40.

SF-36 includes less Parkinson Disease targeted content but is more responsive to change than two PD-targeted Healths-related quality of life measures. Brown et al 1009 Qual Life Res 18-1219-1237",Adult,NA,NA,Outcomes and End Points.Quality of Life,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2014-04-01,2014-04-01,Published,NA,NA
PDQ_39_Lonely,PDQ-39,Parkinson's Disease Questionnaire (PDQ-39) - feeling lonely and isolated scale,Unique Data Element,1,Parkinson's Disease Questionnaire (PDQ-39) - feeling lonely and isolated scale. Indicates if the subject reported feeling  lonely and isolated,PDQ-39 - feeling lonely and isolated scale,Alphanumeric,NA,Single Pre-Defined Value Selected,NA,NA,Always or cannot do at all;Never;Occasionally;Often;Sometimes,Always or cannot do at all;Never;Occasionally;Often;Sometimes,;;;;,NA,NA,NA,Select the answer which best describes your personal situation.,PDQ-39-Q18,Felt isolated and lonely?,NA,"PDQ-39 Copyright Isis Innovation Limited, 1993. All rights reserved. 
Adapted from English (UK) to English (USA) in 1996 by Health Research Associates, Inc.
Mikie Welsh and the Parkinson Study Group (Trademark) are the copyright holders for the PDQUALIF Copyright.  The instrument may not be reproduced or translated in whole or in part without the express written permission of the lead author, Mickie Welsh.  See http://pdqualif.com for full terms and use and licensing information.

Development and Testing of the Parkinson's Disease Quality of Life Scale (PDQUALIF)Welsh et al. 2003 Mov Dis 18(6) 637-645.

A Controlled Trial of Rasagiline in Early PD The TEMPO Study. Parkinson Study Group. 2002 Arch Neurol 59: 1937-1943

Pramipexole vs. Levodopa as Initial Treatment for Parkinson's Disease. The Parkinson Study Group. Arch Neurol. 2004;(61): 1044-1053.

A Randomized Placebo-Controlled Trial of Rasagiline in Levodopa-Treated patients with Parkinson Disease and Motor Fluctuations The Presto Study, The Parkinson Study Group 2005 Arch Neurol 62 241-248.

Does Levodopa slow or hasten the rate of progression of Parkinson's disease? JNeurol 2005;(22):731-40.

SF-36 includes less Parkinson Disease targeted content but is more responsive to change than two PD-targeted Healths-related quality of life measures. Brown et al 1009 Qual Life Res 18-1219-1237",Adult,NA,NA,Outcomes and End Points.Quality of Life,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2014-04-01,2014-04-01,Published,NA,NA
PDQ_39_Memory,PDQ-39,Parkinson's Disease Questionnaire (PDQ-39) - memory failing scale,Unique Data Element,1,Parkinson's Disease Questionnaire (PDQ-39) - memory failing scale. Indicates if the subject reported his/her  memory  was failing,PDQ-39 - memory failing scale,Alphanumeric,NA,Single Pre-Defined Value Selected,NA,NA,Always or cannot do at all;Never;Occasionally;Often;Sometimes,Always or cannot do at all;Never;Occasionally;Often;Sometimes,;;;;,NA,NA,NA,Select the answer which best describes your personal situation.,PDQ-39-Q32,Felt your memory was failing?,NA,"PDQ-39 Copyright Isis Innovation Limited, 1993. All rights reserved. 
Adapted from English (UK) to English (USA) in 1996 by Health Research Associates, Inc.
Mikie Welsh and the Parkinson Study Group (Trademark) are the copyright holders for the PDQUALIF Copyright.  The instrument may not be reproduced or translated in whole or in part without the express written permission of the lead author, Mickie Welsh.  See http://pdqualif.com for full terms and use and licensing information.

Development and Testing of the Parkinson's Disease Quality of Life Scale (PDQUALIF)Welsh et al. 2003 Mov Dis 18(6) 637-645.

A Controlled Trial of Rasagiline in Early PD The TEMPO Study. Parkinson Study Group. 2002 Arch Neurol 59: 1937-1943

Pramipexole vs. Levodopa as Initial Treatment for Parkinson's Disease. The Parkinson Study Group. Arch Neurol. 2004;(61): 1044-1053.

A Randomized Placebo-Controlled Trial of Rasagiline in Levodopa-Treated patients with Parkinson Disease and Motor Fluctuations The Presto Study, The Parkinson Study Group 2005 Arch Neurol 62 241-248.

Does Levodopa slow or hasten the rate of progression of Parkinson's disease? JNeurol 2005;(22):731-40.

SF-36 includes less Parkinson Disease targeted content but is more responsive to change than two PD-targeted Healths-related quality of life measures. Brown et al 1009 Qual Life Res 18-1219-1237",Adult,NA,NA,Outcomes and End Points.Quality of Life,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2014-04-01,2014-04-01,Published,NA,NA
PDQ_39_Outside,PDQ-39,Parkinson's Disease Questionnaire (PDQ-39) - needs someone to accompany outside scale,Unique Data Element,1,Parkinson's Disease Questionnaire (PDQ-39) - needs someone to accompany outside scale. Indicates if the subject needed someone else  to accompany him/her when goes outside,PDQ-39 - needs someone's help to accompany outside scale,Alphanumeric,NA,Single Pre-Defined Value Selected,NA,NA,Always or cannot do at all;Never;Occasionally;Often;Sometimes,Always or cannot do at all;Never;Occasionally;Often;Sometimes,;;;;,NA,NA,NA,Select the answer which best describes your personal situation.,PDQ-39-Q8,Needed someone else to accompany you when you went out?,NA,"PDQ-39 Copyright Isis Innovation Limited, 1993. All rights reserved. 
Adapted from English (UK) to English (USA) in 1996 by Health Research Associates, Inc.
Mikie Welsh and the Parkinson Study Group (Trademark) are the copyright holders for the PDQUALIF Copyright.  The instrument may not be reproduced or translated in whole or in part without the express written permission of the lead author, Mickie Welsh.  See http://pdqualif.com for full terms and use and licensing information.

Development and Testing of the Parkinson's Disease Quality of Life Scale (PDQUALIF)Welsh et al. 2003 Mov Dis 18(6) 637-645.

A Controlled Trial of Rasagiline in Early PD The TEMPO Study. Parkinson Study Group. 2002 Arch Neurol 59: 1937-1943

Pramipexole vs. Levodopa as Initial Treatment for Parkinson's Disease. The Parkinson Study Group. Arch Neurol. 2004;(61): 1044-1053.

A Randomized Placebo-Controlled Trial of Rasagiline in Levodopa-Treated patients with Parkinson Disease and Motor Fluctuations The Presto Study, The Parkinson Study Group 2005 Arch Neurol 62 241-248.

Does Levodopa slow or hasten the rate of progression of Parkinson's disease? JNeurol 2005;(22):731-40.

SF-36 includes less Parkinson Disease targeted content but is more responsive to change than two PD-targeted Healths-related quality of life measures. Brown et al 1009 Qual Life Res 18-1219-1237",Adult,NA,NA,Outcomes and End Points.Quality of Life,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2014-04-01,2014-04-01,Published,NA,NA
PDQ_39_PublicPlaces,PDQ-39,Parkinson's Disease Questionnaire (PDQ-39) - difficulty moving around in public places scale,Unique Data Element,1,Parkinson's Disease Questionnaire (PDQ-39) - difficulty moving around in public places scale. Indicates if the subject had difficulty moving around in public places,PDQ-39 - difficulty moving around in public places scale,Alphanumeric,NA,Single Pre-Defined Value Selected,NA,NA,Always or cannot do at all;Never;Occasionally;Often;Sometimes,Always or cannot do at all;Never;Occasionally;Often;Sometimes,;;;;,NA,NA,NA,Select the answer which best describes your personal situation.,PDQ-39-Q7,Had difficulty getting around in public places?,NA,"PDQ-39 Copyright Isis Innovation Limited, 1993. All rights reserved. 
Adapted from English (UK) to English (USA) in 1996 by Health Research Associates, Inc.
Mikie Welsh and the Parkinson Study Group (Trademark) are the copyright holders for the PDQUALIF Copyright.  The instrument may not be reproduced or translated in whole or in part without the express written permission of the lead author, Mickie Welsh.  See http://pdqualif.com for full terms and use and licensing information.

Development and Testing of the Parkinson's Disease Quality of Life Scale (PDQUALIF)Welsh et al. 2003 Mov Dis 18(6) 637-645.

A Controlled Trial of Rasagiline in Early PD The TEMPO Study. Parkinson Study Group. 2002 Arch Neurol 59: 1937-1943

Pramipexole vs. Levodopa as Initial Treatment for Parkinson's Disease. The Parkinson Study Group. Arch Neurol. 2004;(61): 1044-1053.

A Randomized Placebo-Controlled Trial of Rasagiline in Levodopa-Treated patients with Parkinson Disease and Motor Fluctuations The Presto Study, The Parkinson Study Group 2005 Arch Neurol 62 241-248.

Does Levodopa slow or hasten the rate of progression of Parkinson's disease? JNeurol 2005;(22):731-40.

SF-36 includes less Parkinson Disease targeted content but is more responsive to change than two PD-targeted Healths-related quality of life measures. Brown et al 1009 Qual Life Res 18-1219-1237",Adult,NA,NA,Outcomes and End Points.Quality of Life,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2014-04-01,2014-04-01,Published,NA,NA
PDQ_39_Relationships,PDQ-39,Parkinson's Disease Questionnaire (PDQ-39) - problems with personal relationships scale,Unique Data Element,1,Parkinson's Disease Questionnaire (PDQ-39) - problems with personal relationships scale. Indicates if the subject reported having problems with his/her close personal relationships,PDQ-39 - problems with personal relationships scale,Alphanumeric,NA,Single Pre-Defined Value Selected,NA,NA,Always or cannot do at all;Never;Occasionally;Often;Sometimes,Always or cannot do at all;Never;Occasionally;Often;Sometimes,;;;;,NA,NA,NA,Select the answer which best describes your personal situation.,PDQ-39-Q27,Had problems with your close personal relationships?,NA,"PDQ-39 Copyright Isis Innovation Limited, 1993. All rights reserved. 
Adapted from English (UK) to English (USA) in 1996 by Health Research Associates, Inc.
Mikie Welsh and the Parkinson Study Group (Trademark) are the copyright holders for the PDQUALIF Copyright.  The instrument may not be reproduced or translated in whole or in part without the express written permission of the lead author, Mickie Welsh.  See http://pdqualif.com for full terms and use and licensing information.

Development and Testing of the Parkinson's Disease Quality of Life Scale (PDQUALIF)Welsh et al. 2003 Mov Dis 18(6) 637-645.

A Controlled Trial of Rasagiline in Early PD The TEMPO Study. Parkinson Study Group. 2002 Arch Neurol 59: 1937-1943

Pramipexole vs. Levodopa as Initial Treatment for Parkinson's Disease. The Parkinson Study Group. Arch Neurol. 2004;(61): 1044-1053.

A Randomized Placebo-Controlled Trial of Rasagiline in Levodopa-Treated patients with Parkinson Disease and Motor Fluctuations The Presto Study, The Parkinson Study Group 2005 Arch Neurol 62 241-248.

Does Levodopa slow or hasten the rate of progression of Parkinson's disease? JNeurol 2005;(22):731-40.

SF-36 includes less Parkinson Disease targeted content but is more responsive to change than two PD-targeted Healths-related quality of life measures. Brown et al 1009 Qual Life Res 18-1219-1237",Adult,NA,NA,Outcomes and End Points.Quality of Life,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2014-04-01,2014-04-01,Published,NA,NA
PDQ_39_Showering,PDQ-39,Parkinson's Disease Questionnaire (PDQ-39) - difficulty showering and bathing scale,Unique Data Element,1,Parkinson's Disease Questionnaire (PDQ-39) - difficulty showering and bathing scale. Indicates if the subject reported  difficulty showering and bathing,PDQ-39 - difficulty showering and bathing scale,Alphanumeric,NA,Single Pre-Defined Value Selected,NA,NA,Always or cannot do at all;Never;Occasionally;Often;Sometimes,Always or cannot do at all;Never;Occasionally;Often;Sometimes,;;;;,NA,NA,NA,Select the answer which best describes your personal situation.,PDQ-39-Q11,Had difficulty showering and bathing?,NA,"PDQ-39 Copyright Isis Innovation Limited, 1993. All rights reserved. 
Adapted from English (UK) to English (USA) in 1996 by Health Research Associates, Inc.
Mikie Welsh and the Parkinson Study Group (Trademark) are the copyright holders for the PDQUALIF Copyright.  The instrument may not be reproduced or translated in whole or in part without the express written permission of the lead author, Mickie Welsh.  See http://pdqualif.com for full terms and use and licensing information.

Development and Testing of the Parkinson's Disease Quality of Life Scale (PDQUALIF)Welsh et al. 2003 Mov Dis 18(6) 637-645.

A Controlled Trial of Rasagiline in Early PD The TEMPO Study. Parkinson Study Group. 2002 Arch Neurol 59: 1937-1943

Pramipexole vs. Levodopa as Initial Treatment for Parkinson's Disease. The Parkinson Study Group. Arch Neurol. 2004;(61): 1044-1053.

A Randomized Placebo-Controlled Trial of Rasagiline in Levodopa-Treated patients with Parkinson Disease and Motor Fluctuations The Presto Study, The Parkinson Study Group 2005 Arch Neurol 62 241-248.

Does Levodopa slow or hasten the rate of progression of Parkinson's disease? JNeurol 2005;(22):731-40.

SF-36 includes less Parkinson Disease targeted content but is more responsive to change than two PD-targeted Healths-related quality of life measures. Brown et al 1009 Qual Life Res 18-1219-1237",Adult,NA,NA,Outcomes and End Points.Quality of Life,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2014-04-01,2014-04-01,Published,NA,NA
PDQ_39_Speaking,PDQ-39,Parkinson's Disease Questionnaire (PDQ-39) - difficulty speaking scale,Unique Data Element,1,Parkinson's Disease Questionnaire (PDQ-39) - difficulty speaking scale. Indicates if the subject reported difficulties speaking,PDQ-39 - difficulty speaking scale,Alphanumeric,NA,Single Pre-Defined Value Selected,NA,NA,Always or cannot do at all;Never;Occasionally;Often;Sometimes,Always or cannot do at all;Never;Occasionally;Often;Sometimes,;;;;,NA,NA,NA,Select the answer which best describes your personal situation.,PDQ-39-Q34,Had difficulty speaking?,NA,"PDQ-39 Copyright Isis Innovation Limited, 1993. All rights reserved. 
Adapted from English (UK) to English (USA) in 1996 by Health Research Associates, Inc.
Mikie Welsh and the Parkinson Study Group (Trademark) are the copyright holders for the PDQUALIF Copyright.  The instrument may not be reproduced or translated in whole or in part without the express written permission of the lead author, Mickie Welsh.  See http://pdqualif.com for full terms and use and licensing information.

Development and Testing of the Parkinson's Disease Quality of Life Scale (PDQUALIF)Welsh et al. 2003 Mov Dis 18(6) 637-645.

A Controlled Trial of Rasagiline in Early PD The TEMPO Study. Parkinson Study Group. 2002 Arch Neurol 59: 1937-1943

Pramipexole vs. Levodopa as Initial Treatment for Parkinson's Disease. The Parkinson Study Group. Arch Neurol. 2004;(61): 1044-1053.

A Randomized Placebo-Controlled Trial of Rasagiline in Levodopa-Treated patients with Parkinson Disease and Motor Fluctuations The Presto Study, The Parkinson Study Group 2005 Arch Neurol 62 241-248.

Does Levodopa slow or hasten the rate of progression of Parkinson's disease? JNeurol 2005;(22):731-40.

SF-36 includes less Parkinson Disease targeted content but is more responsive to change than two PD-targeted Healths-related quality of life measures. Brown et al 1009 Qual Life Res 18-1219-1237",Adult,NA,NA,Outcomes and End Points.Quality of Life,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2014-04-01,2014-04-01,Published,NA,NA
PDQ_39_Tearful,PDQ-39,Parkinson's Disease Questionnaire (PDQ-39) - feeling tearful or weepy scale,Unique Data Element,1,Parkinson's Disease Questionnaire (PDQ-39) - feeling tearful or weepy scale. Indicates if the subject reported feeling  tearful or weepy,PDQ-39 - feeling tearful or weepy scale,Alphanumeric,NA,Single Pre-Defined Value Selected,NA,NA,Always or cannot do at all;Never;Occasionally;Often;Sometimes,Always or cannot do at all;Never;Occasionally;Often;Sometimes,;;;;,NA,NA,NA,Select the answer which best describes your personal situation.,PDQ-39-Q19,Felt weepy or tearful?,NA,"PDQ-39 Copyright Isis Innovation Limited, 1993. All rights reserved. 
Adapted from English (UK) to English (USA) in 1996 by Health Research Associates, Inc.
Mikie Welsh and the Parkinson Study Group (Trademark) are the copyright holders for the PDQUALIF Copyright.  The instrument may not be reproduced or translated in whole or in part without the express written permission of the lead author, Mickie Welsh.  See http://pdqualif.com for full terms and use and licensing information.

Development and Testing of the Parkinson's Disease Quality of Life Scale (PDQUALIF)Welsh et al. 2003 Mov Dis 18(6) 637-645.

A Controlled Trial of Rasagiline in Early PD The TEMPO Study. Parkinson Study Group. 2002 Arch Neurol 59: 1937-1943

Pramipexole vs. Levodopa as Initial Treatment for Parkinson's Disease. The Parkinson Study Group. Arch Neurol. 2004;(61): 1044-1053.

A Randomized Placebo-Controlled Trial of Rasagiline in Levodopa-Treated patients with Parkinson Disease and Motor Fluctuations The Presto Study, The Parkinson Study Group 2005 Arch Neurol 62 241-248.

Does Levodopa slow or hasten the rate of progression of Parkinson's disease? JNeurol 2005;(22):731-40.

SF-36 includes less Parkinson Disease targeted content but is more responsive to change than two PD-targeted Healths-related quality of life measures. Brown et al 1009 Qual Life Res 18-1219-1237",Adult,NA,NA,Outcomes and End Points.Quality of Life,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2014-04-01,2014-04-01,Published,NA,NA
PDQ_39_TotalScore_ADL,PDQ-39,Parkinson's Disease Questionnaire (PDQ-39) - activities of daily living (ADL) total score,Unique Data Element,1,The total Score for Activities of daily living (ADL) for the Parkinson's Disease Questionnaire (PDQ-39),The total  ADL score for the PDQ-39,Numeric Values,NA,Free-Form Entry,0,100,NA,NA,NA,NA,NA,NA,Enter the total score for the subject ADL,PDQ-39-TotalScore-Activities of daily Living (ADL),Enter the total score for the subject ADL,NA,"PDQ-39 Copyright Isis Innovation Limited, 1993. All rights reserved. 
Adapted from English (UK) to English (USA) in 1996 by Health Research Associates, Inc.
Mikie Welsh and the Parkinson Study Group (Trademark) are the copyright holders for the PDQUALIF Copyright.  The instrument may not be reproduced or translated in whole or in part without the express written permission of the lead author, Mickie Welsh.  See http://pdqualif.com for full terms and use and licensing information.

Development and Testing of the Parkinson's Disease Quality of Life Scale (PDQUALIF)Welsh et al. 2003 Mov Dis 18(6) 637-645.

A Controlled Trial of Rasagiline in Early PD The TEMPO Study. Parkinson Study Group. 2002 Arch Neurol 59: 1937-1943

Pramipexole vs. Levodopa as Initial Treatment for Parkinson's Disease. The Parkinson Study Group. Arch Neurol. 2004;(61): 1044-1053.

A Randomized Placebo-Controlled Trial of Rasagiline in Levodopa-Treated patients with Parkinson Disease and Motor Fluctuations The Presto Study, The Parkinson Study Group 2005 Arch Neurol 62 241-248.

Does Levodopa slow or hasten the rate of progression of Parkinson's disease? JNeurol 2005;(22):731-40.

SF-36 includes less Parkinson Disease targeted content but is more responsive to change than two PD-targeted Healths-related quality of life measures. Brown et al 1009 Qual Life Res 18-1219-1237",Adult,NA,NA,Outcomes and End Points.Quality of Life,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2014-04-01,2014-04-01,Published,NA,NA
PDQ_39_TotalScore_BodDiscomfrt,PDQ-39,Parkinson's Disease Questionnaire (PDQ-39) - bodily discomfort total score,Unique Data Element,1,Parkinson's Disease Questionnaire (PDQ-39) - bodily discomfort total score,PDQ-39 - the total score for bodily discomfort,Numeric Values,NA,Free-Form Entry,0,100,NA,NA,NA,NA,NA,NA,Enter the total score for the subject bodily discomfort,PDQ-39-TotalScore-Bodily discomfort,Enter the total score for the subject bodily discomfort,NA,"PDQ-39 Copyright Isis Innovation Limited, 1993. All rights reserved. 
Adapted from English (UK) to English (USA) in 1996 by Health Research Associates, Inc.
Mikie Welsh and the Parkinson Study Group (Trademark) are the copyright holders for the PDQUALIF Copyright.  The instrument may not be reproduced or translated in whole or in part without the express written permission of the lead author, Mickie Welsh.  See http://pdqualif.com for full terms and use and licensing information.

Development and Testing of the Parkinson's Disease Quality of Life Scale (PDQUALIF)Welsh et al. 2003 Mov Dis 18(6) 637-645.

A Controlled Trial of Rasagiline in Early PD The TEMPO Study. Parkinson Study Group. 2002 Arch Neurol 59: 1937-1943

Pramipexole vs. Levodopa as Initial Treatment for Parkinson's Disease. The Parkinson Study Group. Arch Neurol. 2004;(61): 1044-1053.

A Randomized Placebo-Controlled Trial of Rasagiline in Levodopa-Treated patients with Parkinson Disease and Motor Fluctuations The Presto Study, The Parkinson Study Group 2005 Arch Neurol 62 241-248.

Does Levodopa slow or hasten the rate of progression of Parkinson's disease? JNeurol 2005;(22):731-40.

SF-36 includes less Parkinson Disease targeted content but is more responsive to change than two PD-targeted Healths-related quality of life measures. Brown et al 1009 Qual Life Res 18-1219-1237",Adult,NA,NA,Outcomes and End Points.Quality of Life,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2014-04-01,2014-04-01,Published,NA,NA
PDQ_39_TotalScore_CogImpairmnt,PDQ-39,Parkinson's Disease Questionnaire (PDQ-39) - cognitive impairment (cognitions) total score,Unique Data Element,1,Parkinson's Disease Questionnaire (PDQ-39) - cognitive impairment (cognitions) total score,PDQ-39 - the total score for cognitive impairment (Cognitions),Numeric Values,NA,Free-Form Entry,0,100,NA,NA,NA,NA,NA,NA,Enter the total score for the subject cognitive impairment,PDQ-39-TotalScore-Cognitive impairment (Cognitions),Enter the total score for the subject cognitive impairment,NA,"PDQ-39 Copyright Isis Innovation Limited, 1993. All rights reserved. 
Adapted from English (UK) to English (USA) in 1996 by Health Research Associates, Inc.
Mikie Welsh and the Parkinson Study Group (Trademark) are the copyright holders for the PDQUALIF Copyright.  The instrument may not be reproduced or translated in whole or in part without the express written permission of the lead author, Mickie Welsh.  See http://pdqualif.com for full terms and use and licensing information.

Development and Testing of the Parkinson's Disease Quality of Life Scale (PDQUALIF)Welsh et al. 2003 Mov Dis 18(6) 637-645.

A Controlled Trial of Rasagiline in Early PD The TEMPO Study. Parkinson Study Group. 2002 Arch Neurol 59: 1937-1943

Pramipexole vs. Levodopa as Initial Treatment for Parkinson's Disease. The Parkinson Study Group. Arch Neurol. 2004;(61): 1044-1053.

A Randomized Placebo-Controlled Trial of Rasagiline in Levodopa-Treated patients with Parkinson Disease and Motor Fluctuations The Presto Study, The Parkinson Study Group 2005 Arch Neurol 62 241-248.

Does Levodopa slow or hasten the rate of progression of Parkinson's disease? JNeurol 2005;(22):731-40.

SF-36 includes less Parkinson Disease targeted content but is more responsive to change than two PD-targeted Healths-related quality of life measures. Brown et al 1009 Qual Life Res 18-1219-1237",Adult,NA,NA,Outcomes and End Points.Quality of Life,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2014-04-01,2014-04-01,Published,NA,NA
PDQ_39_TotalScore_Communcation,PDQ-39,Parkinson's Disease Questionnaire (PDQ-39) - communication total score,Unique Data Element,1,Parkinson's Disease Questionnaire (PDQ-39) - communication total score,PDQ-39 - the total Score for communication,Numeric Values,NA,Free-Form Entry,0,100,NA,NA,NA,NA,NA,NA,Enter the total score for the subject communication,PDQ-39-TotalScore-Communication,Enter the total score for the subject communication,NA,"PDQ-39 Copyright Isis Innovation Limited, 1993. All rights reserved. 
Adapted from English (UK) to English (USA) in 1996 by Health Research Associates, Inc.
Mikie Welsh and the Parkinson Study Group (Trademark) are the copyright holders for the PDQUALIF Copyright.  The instrument may not be reproduced or translated in whole or in part without the express written permission of the lead author, Mickie Welsh.  See http://pdqualif.com for full terms and use and licensing information.

Development and Testing of the Parkinson's Disease Quality of Life Scale (PDQUALIF)Welsh et al. 2003 Mov Dis 18(6) 637-645.

A Controlled Trial of Rasagiline in Early PD The TEMPO Study. Parkinson Study Group. 2002 Arch Neurol 59: 1937-1943

Pramipexole vs. Levodopa as Initial Treatment for Parkinson's Disease. The Parkinson Study Group. Arch Neurol. 2004;(61): 1044-1053.

A Randomized Placebo-Controlled Trial of Rasagiline in Levodopa-Treated patients with Parkinson Disease and Motor Fluctuations The Presto Study, The Parkinson Study Group 2005 Arch Neurol 62 241-248.

Does Levodopa slow or hasten the rate of progression of Parkinson's disease? JNeurol 2005;(22):731-40.

SF-36 includes less Parkinson Disease targeted content but is more responsive to change than two PD-targeted Healths-related quality of life measures. Brown et al 1009 Qual Life Res 18-1219-1237",Adult,NA,NA,Outcomes and End Points.Quality of Life,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2014-04-01,2014-04-01,Published,NA,NA
PDQ_39_TotalScore_Emotional,PDQ-39,Parkinson's Disease Questionnaire (PDQ-39) -emotional well being total score,Unique Data Element,1,Parkinson's Disease Questionnaire (PDQ-39) -emotional well being total score,PDQ-39 - the total score for emotional well being,Numeric Values,NA,Free-Form Entry,0,100,NA,NA,NA,NA,NA,NA,Enter the total score for the subject emotional well being,PDQ-39-TotalScore-Emotional well being,Enter the total score for the subject emotional well being,NA,"PDQ-39 Copyright Isis Innovation Limited, 1993. All rights reserved. 
Adapted from English (UK) to English (USA) in 1996 by Health Research Associates, Inc.
Mikie Welsh and the Parkinson Study Group (Trademark) are the copyright holders for the PDQUALIF Copyright.  The instrument may not be reproduced or translated in whole or in part without the express written permission of the lead author, Mickie Welsh.  See http://pdqualif.com for full terms and use and licensing information.

Development and Testing of the Parkinson's Disease Quality of Life Scale (PDQUALIF)Welsh et al. 2003 Mov Dis 18(6) 637-645.

A Controlled Trial of Rasagiline in Early PD The TEMPO Study. Parkinson Study Group. 2002 Arch Neurol 59: 1937-1943

Pramipexole vs. Levodopa as Initial Treatment for Parkinson's Disease. The Parkinson Study Group. Arch Neurol. 2004;(61): 1044-1053.

A Randomized Placebo-Controlled Trial of Rasagiline in Levodopa-Treated patients with Parkinson Disease and Motor Fluctuations The Presto Study, The Parkinson Study Group 2005 Arch Neurol 62 241-248.

Does Levodopa slow or hasten the rate of progression of Parkinson's disease? JNeurol 2005;(22):731-40.

SF-36 includes less Parkinson Disease targeted content but is more responsive to change than two PD-targeted Healths-related quality of life measures. Brown et al 1009 Qual Life Res 18-1219-1237",Adult,NA,NA,Outcomes and End Points.Quality of Life,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2014-04-01,2014-04-01,Published,NA,NA
PDQ_39_TotalScore_Mobility,PDQ-39,Parkinson's Disease Questionnaire (PDQ-39) - mobility total score,Unique Data Element,1,Parkinson's Disease Questionnaire (PDQ-39) - mobility total score,PDQ-39 - the total score for mobility,Numeric Values,NA,Free-Form Entry,0,100,NA,NA,NA,NA,NA,NA,Enter the total score for the subject mobility,PDQ-39-TotalScore-Mobility,Enter the total score for the subject mobility,NA,"PDQ-39 Copyright Isis Innovation Limited, 1993. All rights reserved. 
Adapted from English (UK) to English (USA) in 1996 by Health Research Associates, Inc.
Mikie Welsh and the Parkinson Study Group (Trademark) are the copyright holders for the PDQUALIF Copyright.  The instrument may not be reproduced or translated in whole or in part without the express written permission of the lead author, Mickie Welsh.  See http://pdqualif.com for full terms and use and licensing information.

Development and Testing of the Parkinson's Disease Quality of Life Scale (PDQUALIF)Welsh et al. 2003 Mov Dis 18(6) 637-645.

A Controlled Trial of Rasagiline in Early PD The TEMPO Study. Parkinson Study Group. 2002 Arch Neurol 59: 1937-1943

Pramipexole vs. Levodopa as Initial Treatment for Parkinson's Disease. The Parkinson Study Group. Arch Neurol. 2004;(61): 1044-1053.

A Randomized Placebo-Controlled Trial of Rasagiline in Levodopa-Treated patients with Parkinson Disease and Motor Fluctuations The Presto Study, The Parkinson Study Group 2005 Arch Neurol 62 241-248.

Does Levodopa slow or hasten the rate of progression of Parkinson's disease? JNeurol 2005;(22):731-40.

SF-36 includes less Parkinson Disease targeted content but is more responsive to change than two PD-targeted Healths-related quality of life measures. Brown et al 1009 Qual Life Res 18-1219-1237",Adult,NA,NA,Outcomes and End Points.Quality of Life,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2014-04-01,2014-04-01,Published,NA,NA
PDQ_39_TotalScore_SocialSuprt,PDQ-39,Parkinson's Disease Questionnaire (PDQ-39) - social support total score,Unique Data Element,1,Parkinson's Disease Questionnaire (PDQ-39) - social support total score,PDQ-39 - the total score for social support,Numeric Values,NA,Free-Form Entry,0,100,NA,NA,NA,NA,NA,NA,Enter the total score for the subject social support,PDQ-39-TotalScore-Social support,Enter the total score for the subject social support,NA,"PDQ-39 Copyright Isis Innovation Limited, 1993. All rights reserved. 
Adapted from English (UK) to English (USA) in 1996 by Health Research Associates, Inc.
Mikie Welsh and the Parkinson Study Group (Trademark) are the copyright holders for the PDQUALIF Copyright.  The instrument may not be reproduced or translated in whole or in part without the express written permission of the lead author, Mickie Welsh.  See http://pdqualif.com for full terms and use and licensing information.

Development and Testing of the Parkinson's Disease Quality of Life Scale (PDQUALIF)Welsh et al. 2003 Mov Dis 18(6) 637-645.

A Controlled Trial of Rasagiline in Early PD The TEMPO Study. Parkinson Study Group. 2002 Arch Neurol 59: 1937-1943

Pramipexole vs. Levodopa as Initial Treatment for Parkinson's Disease. The Parkinson Study Group. Arch Neurol. 2004;(61): 1044-1053.

A Randomized Placebo-Controlled Trial of Rasagiline in Levodopa-Treated patients with Parkinson Disease and Motor Fluctuations The Presto Study, The Parkinson Study Group 2005 Arch Neurol 62 241-248.

Does Levodopa slow or hasten the rate of progression of Parkinson's disease? JNeurol 2005;(22):731-40.

SF-36 includes less Parkinson Disease targeted content but is more responsive to change than two PD-targeted Healths-related quality of life measures. Brown et al 1009 Qual Life Res 18-1219-1237",Adult,NA,NA,Outcomes and End Points.Quality of Life,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2014-04-01,2014-04-01,Published,NA,NA
PDQ_39_TotalScore_Stigma,PDQ-39,Parkinson's Disease Questionnaire (PDQ-39) - stigma total score,Unique Data Element,1,Parkinson's Disease Questionnaire (PDQ-39) - stigma total score,PDQ-39 - the total Score for stigma,Numeric Values,NA,Free-Form Entry,0,100,NA,NA,NA,NA,NA,NA,Enter the total score for the subject stigma,PDQ-39-TotalScore-Stigma,Enter the total score for the subject stigma,NA,"PDQ-39 Copyright Isis Innovation Limited, 1993. All rights reserved. 
Adapted from English (UK) to English (USA) in 1996 by Health Research Associates, Inc.
Mikie Welsh and the Parkinson Study Group (Trademark) are the copyright holders for the PDQUALIF Copyright.  The instrument may not be reproduced or translated in whole or in part without the express written permission of the lead author, Mickie Welsh.  See http://pdqualif.com for full terms and use and licensing information.

Development and Testing of the Parkinson's Disease Quality of Life Scale (PDQUALIF)Welsh et al. 2003 Mov Dis 18(6) 637-645.

A Controlled Trial of Rasagiline in Early PD The TEMPO Study. Parkinson Study Group. 2002 Arch Neurol 59: 1937-1943

Pramipexole vs. Levodopa as Initial Treatment for Parkinson's Disease. The Parkinson Study Group. Arch Neurol. 2004;(61): 1044-1053.

A Randomized Placebo-Controlled Trial of Rasagiline in Levodopa-Treated patients with Parkinson Disease and Motor Fluctuations The Presto Study, The Parkinson Study Group 2005 Arch Neurol 62 241-248.

Does Levodopa slow or hasten the rate of progression of Parkinson's disease? JNeurol 2005;(22):731-40.

SF-36 includes less Parkinson Disease targeted content but is more responsive to change than two PD-targeted Healths-related quality of life measures. Brown et al 1009 Qual Life Res 18-1219-1237",Adult,NA,NA,Outcomes and End Points.Quality of Life,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2014-04-01,2014-04-01,Published,NA,NA
PDQ_39_UnexpctdSleep,PDQ-39,Parkinson's Disease Questionnaire (PDQ-39) - unexpectedly falling asleep during the day scale,Unique Data Element,1,Parkinson's Disease Questionnaire (PDQ-39) - unexpectedly falling asleep during the day scale. Indicates if the subject reported unexpectedly fallen asleep during the day,PDQ-39 - unexpectedly falling asleep during the day scale,Alphanumeric,NA,Single Pre-Defined Value Selected,NA,NA,Always or cannot do at all;Never;Occasionally;Often;Sometimes,Always or cannot do at all;Never;Occasionally;Often;Sometimes,;;;;,NA,NA,NA,Select the answer which best describes your personal situation.,PDQ-39-Q30,Unexpectedly fallen asleep during the day?,NA,"PDQ-39 Copyright Isis Innovation Limited, 1993. All rights reserved. 
Adapted from English (UK) to English (USA) in 1996 by Health Research Associates, Inc.
Mikie Welsh and the Parkinson Study Group (Trademark) are the copyright holders for the PDQUALIF Copyright.  The instrument may not be reproduced or translated in whole or in part without the express written permission of the lead author, Mickie Welsh.  See http://pdqualif.com for full terms and use and licensing information.

Development and Testing of the Parkinson's Disease Quality of Life Scale (PDQUALIF)Welsh et al. 2003 Mov Dis 18(6) 637-645.

A Controlled Trial of Rasagiline in Early PD The TEMPO Study. Parkinson Study Group. 2002 Arch Neurol 59: 1937-1943

Pramipexole vs. Levodopa as Initial Treatment for Parkinson's Disease. The Parkinson Study Group. Arch Neurol. 2004;(61): 1044-1053.

A Randomized Placebo-Controlled Trial of Rasagiline in Levodopa-Treated patients with Parkinson Disease and Motor Fluctuations The Presto Study, The Parkinson Study Group 2005 Arch Neurol 62 241-248.

Does Levodopa slow or hasten the rate of progression of Parkinson's disease? JNeurol 2005;(22):731-40.

SF-36 includes less Parkinson Disease targeted content but is more responsive to change than two PD-targeted Healths-related quality of life measures. Brown et al 1009 Qual Life Res 18-1219-1237",Adult,NA,NA,Outcomes and End Points.Quality of Life,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2014-04-01,2014-04-01,Published,NA,NA
PDQ_39_WalkingBlock,PDQ-39,Parkinson's Disease Questionnaire (PDQ-39) - problems walking for one block scale,Unique Data Element,1,Parkinson's Disease Questionnaire (PDQ-39) - problems walking for one block scale. Indicates if the subject had problems walking approximately 1 block,PDQ-39 - problems walking for 1 block scale,Alphanumeric,NA,Single Pre-Defined Value Selected,NA,NA,Always or cannot do at all;Never;Occasionally;Often;Sometimes,Always or cannot do at all;Never;Occasionally;Often;Sometimes,;;;;,NA,NA,NA,Select the answer which best describes your personal situation.,PDQ-39-Q5,Had problems walking 100 yards (approximately 1 block)?,NA,"PDQ-39 Copyright Isis Innovation Limited, 1993. All rights reserved. 
Adapted from English (UK) to English (USA) in 1996 by Health Research Associates, Inc.
Mikie Welsh and the Parkinson Study Group (Trademark) are the copyright holders for the PDQUALIF Copyright.  The instrument may not be reproduced or translated in whole or in part without the express written permission of the lead author, Mickie Welsh.  See http://pdqualif.com for full terms and use and licensing information.

Development and Testing of the Parkinson's Disease Quality of Life Scale (PDQUALIF)Welsh et al. 2003 Mov Dis 18(6) 637-645.

A Controlled Trial of Rasagiline in Early PD The TEMPO Study. Parkinson Study Group. 2002 Arch Neurol 59: 1937-1943

Pramipexole vs. Levodopa as Initial Treatment for Parkinson's Disease. The Parkinson Study Group. Arch Neurol. 2004;(61): 1044-1053.

A Randomized Placebo-Controlled Trial of Rasagiline in Levodopa-Treated patients with Parkinson Disease and Motor Fluctuations The Presto Study, The Parkinson Study Group 2005 Arch Neurol 62 241-248.

Does Levodopa slow or hasten the rate of progression of Parkinson's disease? JNeurol 2005;(22):731-40.

SF-36 includes less Parkinson Disease targeted content but is more responsive to change than two PD-targeted Healths-related quality of life measures. Brown et al 1009 Qual Life Res 18-1219-1237",Adult,NA,NA,Outcomes and End Points.Quality of Life,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2014-04-01,2014-04-01,Published,NA,NA
PDQ_39_WalkingHalfMile,PDQ-39,Parkinson's Disease Questionnaire (PDQ-39) - problems walking for a half mile scale,Unique Data Element,1,Parkinson's Disease Questionnaire (PDQ-39) - problems walking for a half mile scale. Indicates if the subject had problems walking for half a mile,PDQ-39 - problems walking for 0.5  mile scale,Alphanumeric,NA,Single Pre-Defined Value Selected,NA,NA,Always or cannot do at all;Never;Occasionally;Often;Sometimes,Always or cannot do at all;Never;Occasionally;Often;Sometimes,;;;;,NA,NA,NA,Select the answer which best describes your personal situation.,PDQ-39-Q4,Had problems walking half a mile?,NA,"PDQ-39 Copyright Isis Innovation Limited, 1993. All rights reserved. 
Adapted from English (UK) to English (USA) in 1996 by Health Research Associates, Inc.
Mikie Welsh and the Parkinson Study Group (Trademark) are the copyright holders for the PDQUALIF Copyright.  The instrument may not be reproduced or translated in whole or in part without the express written permission of the lead author, Mickie Welsh.  See http://pdqualif.com for full terms and use and licensing information.

Development and Testing of the Parkinson's Disease Quality of Life Scale (PDQUALIF)Welsh et al. 2003 Mov Dis 18(6) 637-645.

A Controlled Trial of Rasagiline in Early PD The TEMPO Study. Parkinson Study Group. 2002 Arch Neurol 59: 1937-1943

Pramipexole vs. Levodopa as Initial Treatment for Parkinson's Disease. The Parkinson Study Group. Arch Neurol. 2004;(61): 1044-1053.

A Randomized Placebo-Controlled Trial of Rasagiline in Levodopa-Treated patients with Parkinson Disease and Motor Fluctuations The Presto Study, The Parkinson Study Group 2005 Arch Neurol 62 241-248.

Does Levodopa slow or hasten the rate of progression of Parkinson's disease? JNeurol 2005;(22):731-40.

SF-36 includes less Parkinson Disease targeted content but is more responsive to change than two PD-targeted Healths-related quality of life measures. Brown et al 1009 Qual Life Res 18-1219-1237",Adult,NA,NA,Outcomes and End Points.Quality of Life,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2014-04-01,2014-04-01,Published,NA,NA
PDQ_39_Worried,PDQ-39,Parkinson's Disease Questionnaire (PDQ-39) - feeling worried scale,Unique Data Element,1,Parkinson's Disease Questionnaire (PDQ-39) - feeling worried scale. Indicates if the subject reported feeling worried about his/her  future,PDQ-39 - feeling worried scale,Alphanumeric,NA,Single Pre-Defined Value Selected,NA,NA,Always or cannot do at all;Never;Occasionally;Often;Sometimes,Always or cannot do at all;Never;Occasionally;Often;Sometimes,;;;;,NA,NA,NA,Select the answer which best describes your personal situation.,PDQ-39-Q22,Felt worried about your future?,NA,"PDQ-39 Copyright Isis Innovation Limited, 1993. All rights reserved. 
Adapted from English (UK) to English (USA) in 1996 by Health Research Associates, Inc.
Mikie Welsh and the Parkinson Study Group (Trademark) are the copyright holders for the PDQUALIF Copyright.  The instrument may not be reproduced or translated in whole or in part without the express written permission of the lead author, Mickie Welsh.  See http://pdqualif.com for full terms and use and licensing information.

Development and Testing of the Parkinson's Disease Quality of Life Scale (PDQUALIF)Welsh et al. 2003 Mov Dis 18(6) 637-645.

A Controlled Trial of Rasagiline in Early PD The TEMPO Study. Parkinson Study Group. 2002 Arch Neurol 59: 1937-1943

Pramipexole vs. Levodopa as Initial Treatment for Parkinson's Disease. The Parkinson Study Group. Arch Neurol. 2004;(61): 1044-1053.

A Randomized Placebo-Controlled Trial of Rasagiline in Levodopa-Treated patients with Parkinson Disease and Motor Fluctuations The Presto Study, The Parkinson Study Group 2005 Arch Neurol 62 241-248.

Does Levodopa slow or hasten the rate of progression of Parkinson's disease? JNeurol 2005;(22):731-40.

SF-36 includes less Parkinson Disease targeted content but is more responsive to change than two PD-targeted Healths-related quality of life measures. Brown et al 1009 Qual Life Res 18-1219-1237",Adult,NA,NA,Outcomes and End Points.Quality of Life,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2014-04-01,2014-04-01,Published,NA,NA
PDQ_39_WorriedReaction,PDQ-39,Parkinson's Disease Questionnaire (PDQ-39) - feeling worried about other's reaction scale,Unique Data Element,1,Parkinson's Disease Questionnaire (PDQ-39) - feeling worried about other's reaction scale. Indicates if the subject reported feeling worried about other people's reaction to him/her,PDQ-39 - feeling worried about other's reaction scale,Alphanumeric,NA,Single Pre-Defined Value Selected,NA,NA,Always or cannot do at all;Never;Occasionally;Often;Sometimes,Always or cannot do at all;Never;Occasionally;Often;Sometimes,;;;;,NA,NA,NA,Select the answer which best describes your personal situation.,PDQ-39-Q26,Felt worried about other people's reaction to you?,NA,"PDQ-39 Copyright Isis Innovation Limited, 1993. All rights reserved. 
Adapted from English (UK) to English (USA) in 1996 by Health Research Associates, Inc.
Mikie Welsh and the Parkinson Study Group (Trademark) are the copyright holders for the PDQUALIF Copyright.  The instrument may not be reproduced or translated in whole or in part without the express written permission of the lead author, Mickie Welsh.  See http://pdqualif.com for full terms and use and licensing information.

Development and Testing of the Parkinson's Disease Quality of Life Scale (PDQUALIF)Welsh et al. 2003 Mov Dis 18(6) 637-645.

A Controlled Trial of Rasagiline in Early PD The TEMPO Study. Parkinson Study Group. 2002 Arch Neurol 59: 1937-1943

Pramipexole vs. Levodopa as Initial Treatment for Parkinson's Disease. The Parkinson Study Group. Arch Neurol. 2004;(61): 1044-1053.

A Randomized Placebo-Controlled Trial of Rasagiline in Levodopa-Treated patients with Parkinson Disease and Motor Fluctuations The Presto Study, The Parkinson Study Group 2005 Arch Neurol 62 241-248.

Does Levodopa slow or hasten the rate of progression of Parkinson's disease? JNeurol 2005;(22):731-40.

SF-36 includes less Parkinson Disease targeted content but is more responsive to change than two PD-targeted Healths-related quality of life measures. Brown et al 1009 Qual Life Res 18-1219-1237",Adult,NA,NA,Outcomes and End Points.Quality of Life,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2014-04-01,2014-04-01,Published,NA,NA
PDQ_39_Writing,PDQ-39,Parkinson's Disease Questionnaire (PDQ-39) - difficulty writing clearly scale,Unique Data Element,1,Parkinson's Disease Questionnaire (PDQ-39) - difficulty writing clearly scale. Indicates if the subject reported problems writing clearly,PDQ-39 - difficulty writing clearly scale,Alphanumeric,NA,Single Pre-Defined Value Selected,NA,NA,Always or cannot do at all;Never;Occasionally;Often;Sometimes,Always or cannot do at all;Never;Occasionally;Often;Sometimes,;;;;,NA,NA,NA,Select the answer which best describes your personal situation.,PDQ-39-Q14,Had problems writing clearly?,NA,"PDQ-39 Copyright Isis Innovation Limited, 1993. All rights reserved. 
Adapted from English (UK) to English (USA) in 1996 by Health Research Associates, Inc.
Mikie Welsh and the Parkinson Study Group (Trademark) are the copyright holders for the PDQUALIF Copyright.  The instrument may not be reproduced or translated in whole or in part without the express written permission of the lead author, Mickie Welsh.  See http://pdqualif.com for full terms and use and licensing information.

Development and Testing of the Parkinson's Disease Quality of Life Scale (PDQUALIF)Welsh et al. 2003 Mov Dis 18(6) 637-645.

A Controlled Trial of Rasagiline in Early PD The TEMPO Study. Parkinson Study Group. 2002 Arch Neurol 59: 1937-1943

Pramipexole vs. Levodopa as Initial Treatment for Parkinson's Disease. The Parkinson Study Group. Arch Neurol. 2004;(61): 1044-1053.

A Randomized Placebo-Controlled Trial of Rasagiline in Levodopa-Treated patients with Parkinson Disease and Motor Fluctuations The Presto Study, The Parkinson Study Group 2005 Arch Neurol 62 241-248.

Does Levodopa slow or hasten the rate of progression of Parkinson's disease? JNeurol 2005;(22):731-40.

SF-36 includes less Parkinson Disease targeted content but is more responsive to change than two PD-targeted Healths-related quality of life measures. Brown et al 1009 Qual Life Res 18-1219-1237",Adult,NA,NA,Outcomes and End Points.Quality of Life,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2014-04-01,2014-04-01,Published,NA,NA
PronatSupinLftHndMvmntScore,MDS-UPDRS,Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS UPDRS) - pronation supination left hand movement score,Common Data Element,1.1,"Score for the participant's/subject's ability to pronate and supinate the left hand evaluating speed, amplitude, hesitations, halts and decrementing amplitude, as a part of Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS UPDRS)","Score for the participant's/subject's ability to pronate and supinate the left hand evaluating speed, amplitude, hesitations, halts and decrementing amplitude, as a part of Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS UPDRS)",Numeric Values,NA,Single Pre-Defined Value Selected,NA,NA,0;1;2;3;4;555,"Normal: No problems;Slight: Any of the following: a) the regular rhythm is broken with one or two interruptions or hesitations of the movement| b) slight slowing| c) the amplitude decrements near the end of the sequence;Mild: Any of the following: a) 3 to 5 interruptions during the movements, b) mild slowing, c) the amplitude decrements midway in the sequence;Moderate: Any of the following: a) more than 5 interruptions during the movement or at least one longer arrest (freeze) in ongoing movement, b) moderate slowing c) the amplitude decrements starting after the 1st supination-pronation sequence;Severe: Cannot or can only barely perform the task because of slowing, interruptions or decrements;Unable To Rate",0;1;2;3;4;555,NA,NA,NA,"PD:
Test each hand separately. Demonstrate the task, but do not continue to perform the task while the patient is being tested. Rate each side separately, evaluating speed, amplitude, hesitations, halts and decrementing amplitude.",MDS UPDRS Q3.6b.  CDISC variables  QSORRES  for QSTESTCD=UPD2306B,PRONATION SUPINATION MOVEMENTS OF HANDS,CDISC;MDSUPDRS,"PD:
URL: http://www.movementdisorders.org/UserFiles/New%20UPDRS%207%203%2008%20final.pdf",Adult,NA,NA,Outcomes and End Points.Motor Function,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Core,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,MDS UPDRS Q3.6b,NA,NA,NIH/NINDS,NINDSCDE,NINDSCDE@emmes.com,NA,NA,NIH/NINDS,NINDSCDE,NINDSCDE@emmes.com,2014-04-01,2020-02-05,Published,NA,NA
RaceExpndCatPDBP,Demographics,Race expanded category,Unique Data Element,1.1,Category of race(s) or region(s) the participant/subject most closely identifies with,Category of race(s) or region(s) the participant/subject most closely identifies with,Alphanumeric,1000,Free-Form Entry,NA,NA,"African - Black (i.e., south of the Sahara);African - North (i.e., Sahara or north of the Sahara: e.g., Algeria, Egypt, Morocco, Tunisia, etc.);American - Black (i.e., people of African descent whose area of origin is within the Americas: e.g., Canada, Caribbean, Brazil, US, etc.);American Indian/Alaska Native;Asian - East (i.e., China, Japan, Korea, etc.);Asian - West (i.e., Bangladesh, India, Iran, Iraq, Pakistan, etc.);Caucasian (e.g., British Isles, Germany, Peninsular Spain, Latin America, France, Italy, Ireland, Sweden, etc.);Native Hawaiian or other Pacific Islander;Other, specify;Unknown or not reported","African - Black (i.e., south of the Sahara);African - North (i.e., Sahara or north of the Sahara: e.g., Algeria, Egypt, Morocco, Tunisia, etc.);American - Black (i.e., people of African descent whose area of origin is within the Americas: e.g., Canada, Caribbean, Brazil, US, etc.);American Indian/Alaska Native;Asian - East (i.e., China, Japan, Korea, etc.);Asian - West (i.e., Bangladesh, India, Iran, Iraq, Pakistan, etc.);Caucasian (e.g., British Isles, Germany, Peninsular Spain, Latin America, France, Italy, Ireland, Sweden, etc.);Native Hawaiian or other Pacific Islander;Other, specify;Unknown or not reported",1;2;3;4;5;6;7;8;9;999,NA,NA,NA,X those with which you identify. Choose all those with which the participant/subject identifies.,"PDBP variable for race category. CDISC variables: DM=Demographics, SUPPDM= SUPPQUAL for Demographics, SC=Subject Characteristics,  RACE, RACE, when more than one selected, RACE=MULTIPLE and individual responses are RACE1, RACE2, RACEn, QNAM=RACEOR in SUPPDM, QNAM=RACEOTH in SUPPDM. in SUPPDM. For more information, refer to https://wiki.cdisc.org/pages/viewpage.action?pageId=32815150",NA,CDISC,NA,Adult and Pediatric,NA,NA,Participant/Subject Characteristics.Demographics,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NIH/NINDS,NA,NA,NA,NA,NIH/NINDS,NA,NA,2014-04-09,2020-02-05,Published,NA,NA
RandomizedDateTime,InformedConsent,Randomized date and time,Common Data Element,1,"Date (and time, if applicable and known) the participant/subject is randomly assigned (i.e., by chance not choice) to an intervention/treatment group or control group.","Date (and time, if applicable and known) the participant/subject is randomly assigned (i.e., by chance not choice) to an intervention/treatment group or control group.",Date or Date & Time,NA,Free-Form Entry,NA,NA,NA,NA,NA,NA,NA,NA,"GENERAL:
Record the date(and time) the participant/subject is randomized to a treatment or control group. The date/time should be recorded to the level of granularity known (e.g., year, year and month, complete date plus hours and minutes, etc.) and in the format acceptable to the study database. This CDE should only be included on the CRF if the study is a randomized clinical trial. Otherwise, it can be removed.","Data Sharing Instructions: When date/time data are prepared for aggregation or sharing they should be converted to the format specified by ISO 8601, YYYY-MM-DDThh:mm:ss.",Date Randomized,NA,"GENERAL:
No references available",Adult and Pediatric,"Protocol Experience.Participant/Subject Identification, Eligibility, and Enrollment",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Randomized date and time,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2014-04-01,2014-04-01,Published,NA,NA
RandomizedInd,InformedConsent,Randomized indicator,Common Data Element,1,"Indicator of whether the participant/subject was randomly assigned (i.e., by chance not choice) to an intervention/treatment group or control group.","Indicator of whether the participant/subject was randomly assigned (i.e., by chance not choice) to an intervention/treatment group or control group",Alphanumeric,NA,Single Pre-Defined Value Selected,NA,NA,No;Not applicable;Yes,No;Not applicable;Yes,0;777;1,NA,NA,NA,"GENERAL:
Choose one.  If YES, record the date randomized. This CDE should only be on the CRF if the study is a randomized clinical trial. Otherwise, it can be removed.",NA,Was the participant/subject randomized?,NA,"GENERAL:
No references available",Adult and Pediatric,"Protocol Experience.Participant/Subject Identification, Eligibility, and Enrollment",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Randomized indicator,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2014-04-01,2014-04-01,Published,NA,NA
ReflexAchillesLftAssmt,NeurologicalExam,Reflexes Achilles left assessment,Unique Data Element,1,Reflexes Achilles left assessment,Reflexes Achilles left assessment,Alphanumeric,NA,Single Pre-Defined Value Selected,NA,NA,0;1+;2+;3+;4+,No response;Low normal;Normal;Brisk;Very brisk with clonus,0;1;20;2;3,NA,NA,NA,Select one.,PDBD Neurolocial Examination Form,8j) Achilles (L),NA,NA,Adult and Pediatric,Assessments and Examinations.Physical/Neurological Examination,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2014-04-01,2014-04-01,Published,NA,NA
ReflexAchillesRtAssmt,NeurologicalExam,Reflexes Achilles right assessment,Unique Data Element,1,Reflexes Achilles right assessment,Reflexes Achilles right assessment,Alphanumeric,NA,Single Pre-Defined Value Selected,NA,NA,0;1+;2+;3+;4+,No response;Low normal;Normal;Brisk;Very brisk with clonus,0;1;20;2;3,NA,NA,NA,Select one.,PDBD Neurolocial Examination Form,8i) Achilles (R),NA,NA,Adult and Pediatric,Assessments and Examinations.Physical/Neurological Examination,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2014-04-01,2014-04-01,Published,NA,NA
ReflexBabinskyInd,NeurologicalExam,Reflexes Babinsky indicator,Unique Data Element,1,Reflexes Babinsky indicator,Reflexes Babinsky indicator,Alphanumeric,NA,Single Pre-Defined Value Selected,NA,NA,Not present;Present;Unknown,Not present;Present;Unknown,0;1;999,NA,NA,NA,Select one.,PDBD Neurolocial Examination Form,8k) Babinsky present,NA,NA,Adult and Pediatric,Assessments and Examinations.Physical/Neurological Examination,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2014-04-01,2014-04-01,Published,NA,NA
ReflexBabinskyLoc,NeurologicalExam,Reflexes Babinsky location,Unique Data Element,1,Reflexes Babinsky location,Reflexes Babinsky location,Alphanumeric,4000,Free-Form Entry,NA,NA,Left;Right,Left;Right,;,NA,NA,NA,Select all that apply,PDBD Neurolocial Examination Form,8k-i) Babinsky,NA,NA,Adult and Pediatric,Assessments and Examinations.Physical/Neurological Examination,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2014-04-01,2014-04-01,Published,NA,NA
ReflexBicepsLftAssmt,NeurologicalExam,Reflexes biceps left assessment,Unique Data Element,1,Reflexes Biceps left assessment,Reflexes Biceps left assessment,Alphanumeric,NA,Single Pre-Defined Value Selected,NA,NA,0;1+;2+;3+;4+,No response;Low normal;Normal;Brisk;Very brisk with clonus,0;1;20;2;3,NA,NA,NA,Select one.,PDBD Neurolocial Examination Form,8b) Biceps (L),NA,NA,Adult and Pediatric,Assessments and Examinations.Physical/Neurological Examination,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2014-04-01,2014-04-01,Published,NA,NA
ReflexBicepsRtAssmt,NeurologicalExam,Reflexes biceps right assessment,Unique Data Element,1,Reflexes Biceps right assessment,Reflexes Biceps right assessment,Alphanumeric,NA,Single Pre-Defined Value Selected,NA,NA,0;1+;2+;3+;4+,No response;Low normal;Normal;Brisk;Very brisk with clonus,0;1;20;2;3,NA,NA,NA,Select one.,PDBD Neurolocial Examination Form,8a) Biceps (R),NA,NA,Adult and Pediatric,Assessments and Examinations.Physical/Neurological Examination,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2014-04-01,2014-04-01,Published,NA,NA
ReflexBrachioradLtAssmt,NeurologicalExam,Reflexes brachioradialis left assessment,Unique Data Element,1,Reflexes Brachioradialis left assessment,Reflexes Brachioradialis left assessment,Alphanumeric,NA,Single Pre-Defined Value Selected,NA,NA,0;1+;2+;3+;4+,No response;Low normal;Normal;Brisk;Very brisk with clonus,0;1;20;2;3,NA,NA,NA,Select one.,PDBD Neurolocial Examination Form,8f) Brachioradialis (L),NA,NA,Adult and Pediatric,Assessments and Examinations.Physical/Neurological Examination,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2014-04-01,2014-04-01,Published,NA,NA
ReflexBrachioradRtAssmt,NeurologicalExam,Reflexes brachioradialis right assessment,Unique Data Element,1,Reflexes Brachioradialis right assessment,Reflexes Brachioradialis right assessment,Alphanumeric,NA,Single Pre-Defined Value Selected,NA,NA,0;1+;2+;3+;4+,No response;Low normal;Normal;Brisk;Very brisk with clonus,0;1;20;2;3,NA,NA,NA,Select one.,PDBD Neurolocial Examination Form,8e) Brachioradialis (R),NA,NA,Adult and Pediatric,Assessments and Examinations.Physical/Neurological Examination,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2014-04-01,2014-04-01,Published,NA,NA
ReflexInd,NeurologicalExam,Reflexes indicator,Unique Data Element,1,Reflexes indicator,Reflexes indicator,Alphanumeric,NA,Single Pre-Defined Value Selected,NA,NA,Abnormal;Normal;Not assessed,Abnormal;Normal;Not assessed,10;20;222,NA,NA,NA,Select one.,PDBD Neurolocial Examination Form,8) Reflexes,NA,NA,Adult and Pediatric,Assessments and Examinations.Physical/Neurological Examination,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2014-04-01,2014-04-01,Published,NA,NA
ReflexOthrTxt,NeurologicalExam,Reflexes other text,Unique Data Element,1,Text descriptor of other reflexes tested and the result.,Text descriptor of other reflexes tested and the result.,Alphanumeric,4000,Free-Form Entry,NA,NA,NA,NA,NA,NA,NA,NA,Describe other reflexes tested and the result.,PDBD Neurolocial Examination Form,"8i) Other, e.g., grasp, snout, suck, palmomental, etc.",NA,NA,Adult and Pediatric,Assessments and Examinations.Physical/Neurological Examination,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2014-04-01,2014-04-01,Published,NA,NA
ReflexPatellarLftAssmt,NeurologicalExam,Reflexes patellar left assessment,Unique Data Element,1,Reflexes Patellar left assessment,Reflexes Patellar left assessment,Alphanumeric,NA,Single Pre-Defined Value Selected,NA,NA,0;1+;2+;3+;4+,No response;Low normal;Normal;Brisk;Very brisk with clonus,0;1;20;2;3,NA,NA,NA,Select one.,PDBD Neurolocial Examination Form,8h) Patellar (L),NA,NA,Adult and Pediatric,Assessments and Examinations.Physical/Neurological Examination,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2014-04-01,2014-04-01,Published,NA,NA
ReflexPatellarRtAssmt,NeurologicalExam,Reflexes patellar right assessment,Unique Data Element,1,Reflexes Patellar right assessment,Reflexes Patellar right assessment,Alphanumeric,NA,Single Pre-Defined Value Selected,NA,NA,0;1+;2+;3+;4+,No response;Low normal;Normal;Brisk;Very brisk with clonus,0;1;20;2;3,NA,NA,NA,Select one.,PDBD Neurolocial Examination Form,6g) Patellar (R),NA,NA,Adult and Pediatric,Assessments and Examinations.Physical/Neurological Examination,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2014-04-01,2014-04-01,Published,NA,NA
ReflexTricepsLftAssmt,NeurologicalExam,Reflexes triceps left assessment,Unique Data Element,1,Reflexes Triceps left assessment,Reflexes Triceps left assessment,Alphanumeric,NA,Single Pre-Defined Value Selected,NA,NA,0;1+;2+;3+;4+,No response;Low normal;Normal;Brisk;Very brisk with clonus,0;1;20;2;3,NA,NA,NA,Select one.,PDBD Neurolocial Examination Form,8d) Triceps (L),NA,NA,Adult and Pediatric,Assessments and Examinations.Physical/Neurological Examination,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2014-04-01,2014-04-01,Published,NA,NA
ReflexTricepsRtAssmt,NeurologicalExam,Reflexes triceps right assessment,Unique Data Element,1,Reflexes Triceps right assessment,Reflexes Triceps right assessment,Alphanumeric,NA,Single Pre-Defined Value Selected,NA,NA,0;1+;2+;3+;4+,No response;Low normal;Normal;Brisk;Very brisk with clonus,0;1;20;2;3,NA,NA,NA,Select one.,PDBD Neurolocial Examination Form,8c) Triceps (R),NA,NA,Adult and Pediatric,Assessments and Examinations.Physical/Neurological Examination,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2014-04-01,2014-04-01,Published,NA,NA
ReporterTyp,MayoSleepQuestionnaire,Reporter type,Unique Data Element,1,Who was interviewed for this questionnaire,Who was interviewed for this questionnaire,Alphanumeric,NA,Single Pre-Defined Value Selected,NA,NA,Informant;Subject served as informant,Informant;Subject served as informant,3;1,NA,NA,NA,NA,NA,NA,NA,No references available,Adult and Pediatric,"Protocol Experience.Participant/Subject Identification, Eligibility, and Enrollment",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2014-04-01,2014-04-01,Published,NA,NA
RespRate,Vital Signs,Respiratory rate,Common Data Element,1.1,Rate of the participant/subject's breathing (inhalation and exhalation).,Rate of the participant/subject's breathing (inhalation and exhalation).,Numeric Values,NA,Free-Form Entry,0,150,NA,NA,NA,NA,NA,Breaths per minute,"ALS/DMD/EPILEPSY/FA/GENERAL/HEADACHE/MG/MS/NMD/SMA/STROKE: Record the respiratory rate of the participant/subject in breaths per minute.
NMD/SMA:Respiratory Support/Assisted Ventilation Devices
MS/TBI: Add date stamp for when assessed. Hypoxia, hypercapnia, and hypocapnia have all been associated with poor outcome.",NA,Respiratory rate,TRACK_TBI,"ALS/DMD/EPILEPSY/FA/GENERAL/HEADACHE/MG/NMD/SMA/STROKE/: No references available
MS/TBI: Davis, DP. Early ventilation in traumatic brain injury. Resuscitation. Mar 2008;76(3):333-340. Guidelines for the management of severe traumatic brain injury. XIV. Hyperventilation. J Neurotrauma. 2008;25:276-8.  Murray GD, Butcher I, McHugh GS, et al. Multivariable prognostic analysis in traumatic brain injury: results from the IMPACT study. J Neurotrauma. Feb 2007;24(2):329-337.",Adult and Pediatric,Assessments and Examinations.Vital Signs and Other Body Measures,Assessments and Examinations.Vital Signs and Other Body Measures,NA,Assessments and Examinations.Vital Signs and Other Body Measures,Assessments and Examinations.Vital Signs and Other Body Measures,Assessments and Examinations.Vital Signs and Other Body Measures,NA,Assessments and Examinations.Vital Signs and Other Body Measures,Assessments and Examinations.Vital Signs and Other Body Measures;Treatment/Intervention Data.Therapies,Assessments and Examinations.Vital Signs and Other Body Measures;Treatment/Intervention Data.Therapies,Treatment/Intervention Data.Therapies;Assessments and Examinations.Vital Signs and Other Body Measures,Assessments and Examinations.Vital Signs and Other Body Measures,NA,NA,Assessments and Examinations.Vital Signs and Other Body Measures,Assessments and Examinations.Vital Signs and Other Body Measures,Supplemental,Supplemental,Supplemental,Supplemental,Supplemental,NA,Core,Core,Core,NA,Supplemental,Supplemental,Supplemental,Supplemental,Supplemental,NA,NA,Supplemental,Supplemental,Respiratory rate,NA,NA,NIH/CIT/BRICS,Olga Vovk,olga.vovk@nih.gov,NA,NA,NIH/NINDS,NINDSCDE,NINDSCDE@emmes.com,2014-04-01,2015-10-14,Published,NA,NA
RteFtToeTppngScore,MDS-UPDRS,Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS UPDRS) - right foot toe tap score,Common Data Element,1.1,"Score for the participant's/subject's ability to tap the right foot toes evaluating speed, amplitude, hesitations, halts and decrementing amplitude, as a part of Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS UPDRS)","Score for the participant's/subject's ability to tap the right foot toes evaluating speed, amplitude, hesitations, halts and decrementing amplitude, as a part of Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS UPDRS)",Numeric Values,NA,Single Pre-Defined Value Selected,NA,NA,0;1;2;3;4;555,"Normal: No problem;Slight: Any of the following: a) the regular rhythm is broken with one or two interruptions, or hesitations of the tapping movement, b) slight slowing| c) amplitude decrements near the end of the ten taps;Mild: Any of the following: a) 3 to 5 interruptions during the tapping movements, b) mild slowing, c) amplitude decrements midway in the task;Moderate: Any of the following: a) more than 5 interruptions during the tapping movements or at least one longer arrest (freeze) in ongoing movement, b) moderate slowing, c) amplitude decrements after the first tap;Severe: Cannot or can only barely perform the task because of slowing, interruptions or decrements;Unable To Rate",0;1;2;3;4;555,NA,NA,NA,"PD:
Have the patient sit in a straight-backed chair with arms, both feet on the floor. Test each foot separately. Demonstrate the task, but do not continue to perform the task while the patient is being tested. Rate each side separately, evaluating speed, amplitude, hesitations, halts and decrementing amplitude.",MDS UPDRS Q3.7a.  CDISC variables  QSORRES  for QSTESTCD=UPD2307A,TOE TAPPING,CDISC;MDSUPDRS,"PD:
URL: http://www.movementdisorders.org/UserFiles/New%20UPDRS%207%203%2008%20final.pdf",Adult,NA,NA,Outcomes and End Points.Motor Function,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Core,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,MDS UPDRS Q3.7a,NA,NA,NIH/NINDS,NINDSCDE,NINDSCDE@emmes.com,NA,NA,NIH/NINDS,NINDSCDE,NINDSCDE@emmes.com,2014-04-01,2020-02-05,Published,NA,NA
SampPlacedFreezerDateTime,BloodCollection,Sample collection  placed in freezer block date and time,Unique Data Element,1,Samples placed in freezer block date and time,Samples placed in freezer block date and time,Date or Date & Time,NA,Free-Form Entry,NA,NA,NA,NA,NA,NA,NA,NA,"Record the date/time according to the ISO 8601, the International Standard for the representation of dates and times (http://www.iso.org/iso/home.html).  The date/time should be recorded to the level of granularity known (e.g., year, year and month, complete date plus hours and minutes, etc.).","Data Sharing Instructions: When date/time data are prepared for aggregation or sharing they should be converted to the format specified by ISO 8601, YYYY-MM-DDThh:mm:ss.",Time samples were placed in freezer block: (24 hour clock),NA,No references available,Adult and Pediatric,Assessments and Examinations.Laboratory Tests and Biospecimens/Biomarkers,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2014-04-01,2014-04-01,Published,NA,NA
SampleCentrifTempVal,BloodCollection,Blood Collection Data Form - Temperature of sample during centrifugation,Unique Data Element,1,"Temperature of the sample (blood, urine, CSF, etc.) during centrifugation (Celsius)","Temperature of the sample (blood, urine, CSF, etc.) during centrifugation (Celsius)",Numeric Values,NA,Free-Form Entry,NA,NA,NA,NA,NA,NA,NA,NA,Specify the temperature of sample during centrifugation.,NA,What was the temperature of the sample during centrifugation?,sample;Sample,NA,Adult,NA,NA,Assessments and Examinations.Laboratory Tests and Biospecimens/Biomarkers,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NIH/CIT/BRICS,Linde Jenna,jenna.linde@nih.gov,NA,NA,NIH/CIT/BRICS,Olga Vovk,olga.vovk@nih.gov,2016-04-25,2016-04-25,Published,NA,NA
SampleShippedDateTime,BloodCollection,Blood Collection Data Form - Date and time sample shipped,Unique Data Element,1,The date and time the sample (including blood sample) was shipped.,The date and time the sample (including blood sample) was shipped.,Date or Date & Time,NA,Free-Form Entry,NA,NA,NA,NA,NA,NA,NA,NA,Specify the date the blood sample was shipped.,NA,Date and time sample was shipped.,sample;Sample,NA,Adult,NA,NA,Assessments and Examinations.Laboratory Tests and Biospecimens/Biomarkers,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NIH/CIT/BRICS,Linde Jenna,jenna.linde@nih.gov,NA,NA,NIH/CIT/BRICS,Olga Vovk,olga.vovk@nih.gov,2016-04-25,2016-04-25,Published,NA,NA
SensationAssmtExamFind,NeurologicalExam,Sensation assessment examination findings,Unique Data Element,1,Sensation assessment,Sensation assessment,Alphanumeric,NA,Single Pre-Defined Value Selected,NA,NA,Abnormal;Normal;Not assessed,Abnormal;Normal;Not assessed,10;20;222,NA,NA,NA,Select one.,PDBD Neurolocial Examination Form,7) Sensation,NA,NA,Adult and Pediatric,Assessments and Examinations.Physical/Neurological Examination,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2014-04-01,2014-04-01,Published,NA,NA
SensationDistlArmLftFind,NeurologicalExam,Sensation distal arm left findings,Unique Data Element,1,Sensation Distal Arm left findings,Sensation Distal Arm left findings,Alphanumeric,4000,Free-Form Entry,NA,NA,Light Touch;Pain;Position;Temperature;Vibration,Light Touch;Pain;Position;Temperature;Vibration,;;;;,NA,NA,NA,Select all that apply.,PDBD Neurolocial Examination Form,7d) Distal Arm (L),NA,NA,Adult and Pediatric,Assessments and Examinations.Physical/Neurological Examination,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2014-04-01,2014-04-01,Published,NA,NA
SensationDistlArmRtFind,NeurologicalExam,Sensation distal arm right findings,Unique Data Element,1,Sensation Distal Arm right findings,Sensation Distal Arm right findings,Alphanumeric,4000,Free-Form Entry,NA,NA,Light Touch;Pain;Position;Temperature;Vibration,Light Touch;Pain;Position;Temperature;Vibration,;;;;,NA,NA,NA,Select all that apply.,PDBD Neurolocial Examination Form,7c) Distal Arm (R),NA,NA,Adult and Pediatric,Assessments and Examinations.Physical/Neurological Examination,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2014-04-01,2014-04-01,Published,NA,NA
SensationDistlLegLftFind,NeurologicalExam,Sensation distal leg left findings,Unique Data Element,1,Sensation Distal Leg left findings,Sensation Distal Leg left findings,Alphanumeric,4000,Free-Form Entry,NA,NA,Light Touch;Pain;Position;Temperature;Vibration,Light Touch;Pain;Position;Temperature;Vibration,;;;;,NA,NA,NA,Select all that apply.,PDBD Neurolocial Examination Form,7h) Distal Leg (L),NA,NA,Adult and Pediatric,Assessments and Examinations.Physical/Neurological Examination,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2014-04-01,2014-04-01,Published,NA,NA
SensationDistlLegRtFind,NeurologicalExam,Sensation distal leg right findings,Unique Data Element,1,Sensation Distal Leg right findings,Sensation Distal Leg right findings,Alphanumeric,4000,Free-Form Entry,NA,NA,Light Touch;Pain;Position;Temperature;Vibration,Light Touch;Pain;Position;Temperature;Vibration,;;;;,NA,NA,NA,Select all that apply.,PDBD Neurolocial Examination Form,7g) Distal Leg (R),NA,NA,Adult and Pediatric,Assessments and Examinations.Physical/Neurological Examination,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2014-04-01,2014-04-01,Published,NA,NA
SensationProxmlArmLftFind,NeurologicalExam,Sensation proximal arm left findings,Unique Data Element,1,Sensation Proximal Arm left findings,Sensation Proximal Arm left findings,Alphanumeric,4000,Free-Form Entry,NA,NA,Light Touch;Pain;Position;Temperature;Vibration,Light Touch;Pain;Position;Temperature;Vibration,;;;;,NA,NA,NA,Select all that apply.,PDBD Neurolocial Examination Form,7b) Proximal Arm (L),NA,NA,Adult and Pediatric,Assessments and Examinations.Physical/Neurological Examination,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2014-04-01,2014-04-01,Published,NA,NA
SensationProxmlArmRtFind,NeurologicalExam,Sensation proximal arm right findings,Unique Data Element,1,Sensation Proximal Arm right findings,Sensation Proximal Arm right findings,Alphanumeric,4000,Free-Form Entry,NA,NA,Light Touch;Pain;Position;Temperature;Vibration,Light Touch;Pain;Position;Temperature;Vibration,;;;;,NA,NA,NA,Select all that apply.,PDBD Neurolocial Examination Form,7a) Proximal Arm (R),NA,NA,Adult and Pediatric,Assessments and Examinations.Physical/Neurological Examination,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2014-04-01,2014-04-01,Published,NA,NA
SensationProxmlLegLftFind,NeurologicalExam,Sensation proximal leg left findings,Unique Data Element,1,Sensation Proximal Leg left findings,Sensation Proximal Leg left findings,Alphanumeric,4000,Free-Form Entry,NA,NA,Light Touch;Pain;Position;Temperature;Vibration,Light Touch;Pain;Position;Temperature;Vibration,;;;;,NA,NA,NA,Select all that apply.,PDBD Neurolocial Examination Form,7f) Proximal Leg (L),NA,NA,Adult and Pediatric,Assessments and Examinations.Physical/Neurological Examination,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2014-04-01,2014-04-01,Published,NA,NA
SensationProxmlLegRtFind,NeurologicalExam,Sensation proximal leg right findings,Unique Data Element,1,Sensation Proximal Leg right findings,Sensation Proximal Leg right findings,Alphanumeric,4000,Free-Form Entry,NA,NA,Light Touch;Pain;Position;Temperature;Vibration,Light Touch;Pain;Position;Temperature;Vibration,;;;;,NA,NA,NA,Select all that apply.,PDBD Neurolocial Examination Form,7e) Proximal Leg (R),NA,NA,Adult and Pediatric,Assessments and Examinations.Physical/Neurological Examination,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2014-04-01,2014-04-01,Published,NA,NA
SensationStockingGloveFind,NeurologicalExam,Sensation stocking/glove findings,Unique Data Element,1,Sensation  Stocking/Glove findings,Sensation  Stocking/Glove findings,Alphanumeric,4000,Free-Form Entry,NA,NA,Light Touch;Pain;Position;Temperature;Vibration,Light Touch;Pain;Position;Temperature;Vibration,;;;;,NA,NA,NA,Select all that apply.,PDBD Neurolocial Examination Form,7i) Stocking/Glove,NA,NA,Adult and Pediatric,Assessments and Examinations.Physical/Neurological Examination,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2014-04-01,2014-04-01,Published,NA,NA
SeriousAdvrsEvntInd,AdverseEvents,Serious adverse event indicator,Common Data Element,1.5,The indicator of whether the adverse event is serious.,The indicator of whether the adverse event is serious.,Alphanumeric,NA,Single Pre-Defined Value Selected,NA,NA,No;Unknown;Yes,No;Unknown;Yes,0;9;1,NA,NA,NA,"GENERAL:
Choose either Yes or No.  This question should only be answered YES if the outcome of the AE results in at least one of the following: death; a life-threatening adverse drug experience; results in inpatient hospitalization or prolongation of existing hospitalization; a persistent or significant disability/incapacity; or a congenital anomaly/birth defect. If an AE is serious, this provides a trigger that additional information must be provided by the site investigator. The site investigator then completes a Serious Adverse Event (SAE) form. Additionally, the site institution and/or IRB may also have an SAE form and procedures for reporting SAEs. If an AE is serious, this provides a trigger that additional information must be provided by the site investigator. The site investigator then completes a Serious Adverse Event (SAE) form. Additionally, the site institution and/or IRB may also have an SAE form and procedures for reporting SAEs.",CDISC CDASH: AESER. There is no relevant  SDTM CDISC variable,Serious Adverse Event?,AE_Mapped;Adverse_Event,No references available,Adult and Pediatric,Safety Data.Adverse Events,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Safety Data.Adverse Events,Supplemental,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Supplemental,Serious adverse event indicator,NA,AdvrsEvntDuringStudyInd;AdvrsEvntSeverScale;AdvrsEvntStartDateTime;AdverseEvntEndDateTime;AdvrsEvntVerbatimTermText;AdvEvntMedDRALowerLvlTermCode;AdvrsEvntCTCAELowLvlTermName;InjElapsedTime,NIH/NINDS,NINDSCDE,NINDSCDE@emmes.com,NA,NA,NIH/NINDS,NINDSCDE,NINDSCDE@emmes.com,2014-04-01,2020-03-04,Published,NA,NA
StdyEligibilityInd,InclExclCriteria,Study eligibility indicator,Common Data Element,1.1,Indicator of whether the participant/subject is eligible for participation in the clinical research protocol according to its inclusion and exclusion criteria,Indicator of whether the participant/subject is eligible for participation in the clinical research protocol according to its inclusion and exclusion criteria,Alphanumeric,NA,Single Pre-Defined Value Selected,NA,NA,No;Unknown;Yes,No;Unknown;Yes,0;9;1,NA,NA,NA,GENERAL: The participants/subject is eligible for study enrollment if all the inclusion criteria are answered YES and all the exclusion criteria are answered NO or N/A.,NA,Is the participant subject eligible for study enrollment based on the above criteria?,NA,No references available,Adult and Pediatric,"Protocol Experience.Participant/Subject Identification, Eligibility, and Enrollment",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Core,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Study eligibility indicator,NA,NA,NIH/CIT/BRICS,Olga Vovk,olga.vovk@nih.gov,NA,NA,NIH/NINDS,NINDSCDE,NINDSCDE@emmes.com,NA,2015-07-24,Published,NA,NA
TempMeasr,Vital Signs,Temperature measurement,Common Data Element,1.4,Measurement of the participant's/subject's body temperature.,Measurement of the participant's/subject's body temperature.,Numeric Values,NA,Free-Form Entry,0,50,NA,NA,NA,NA,NA,Degree Celsius,"Record the temperature of the participant/ subject. All temperature measurements should be converted to degrees Celsius (C) prior to aggregation or sharing.
TBI: Response is measured in Celsius. Add date stamp for when assessed. Pediatric-specific notes: As a minimum, vital signs should be recorded on admission and further, on a daily basis during the acute phase after injury. For the basic datasets, we recommend recording the average and lowest blood pressure over a given period. In the ICU environment, recording blood pressure on an hourly basis is recommended, especially when intracranial pressure (ICP) is monitored in order to permit determination of CPP, calculated as mean arterial blood pressure (MABP) - ICP (intermediate data set).
",All temperature measurements should be converted to degrees Celsius (C) prior to aggregation or sharing.,Temperature,Vital_Signs,"Karlsson AK, Krassioukov A, Alexander MS, Donovan W, Biering-Saarensen F. International Spinal Cord Injury Skin and Thermoregulation Function Basic Data Set. Spinal Cord. 2012; 50(7):512-6. Sund-Levander M, Forsberg C, Wahren LK : Normal oral, rectal, tympanic and axillary body temperature in adult men and women: a systematic literature review. Scand J Caring Sci. 2002 Jun;16: 122-8.",Adult and Pediatric,Assessments and Examinations.Vital Signs and Other Body Measures,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Temperature measurement,NA,SCI Var: TEMPMEAS,NIH/NINDS,NINDSCDE,NINDSCDE@EMMES.COM,NA,NA,NIH/NINDS,NINDSCDE,NINDSCDE@EMMES.COM,NA,2018-04-18,Published,NA,NA
TempMeasrAntmicSite,Vital Signs,Temperature measurement anatomic site,Common Data Element,1.3,Anatomic site on or within the body where the temperature was measured.,Anatomic site on or within the body where the temperature was measured.,Alphanumeric,NA,Single Pre-Defined Value Selected,NA,NA,"Axillary;Bladder;Brain;Esophageal;Forehead Cutaneous Infrared;Oral;Other, specify;Rectal;Tympanic;Unknown","Axillary;Bladder;Brain;Esophageal;Forehead Cutaneous Infrared;Oral;Other, specify;Rectal;Tympanic;Unknown",1;2;3;4;5;6;7;8;10;999,NA,NA,NA,Choose one.,SCI Var: TEMPMETH,Temperature method,Vital_Signs,No references available,Adult and Pediatric,Assessments and Examinations.Vital Signs and Other Body Measures,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Temperature measurement anatomic site,NA,NA,NIH/NINDS,NINDSCDE,NINDSCDE@EMMES.COM,NA,NA,NIH/NINDS,NINDSCDE,NINDSCDE@EMMES.COM,2014-04-01,2018-04-18,Published,NA,NA
TempMeasrFreezerPDBP,BloodCollection,Temperature measurement freezer,Unique Data Element,1,Measurement of the freezer temperature,Measurement of the freezer temperature,Numeric Values,NA,Free-Form Entry,-85,8,NA,NA,NA,NA,NA,NA,Response is measured in Celsius. Add date stamp for when assessed.,NA,NA,NA,NA,Adult and Pediatric,NA,NA,Assessments and Examinations.Laboratory Tests and Biospecimens/Biomarkers,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2014-04-09,2014-04-09,Published,NA,NA
TobcoCigaretSmokedDlyAvgNum,BehavioralHistory,Tobacco cigarettes smoked daily average number,Common Data Element,1,"Average number of cigarettes the participant/subject smokes daily (On the days you smoked cigarettes during the past 30 days, how many cigarettes did you smoke per day, on average?)","Average number of cigarettes the participant/subject smokes daily (On the days you smoked cigarettes during the past 30 days, how many cigarettes did you smoke per day, on average?)",Alphanumeric,NA,Single Pre-Defined Value Selected,NA,NA,16 to 25 cigarettes per day (about 1 pack);1 cigarette per day;26 to 35 cigarettes per day (about 1 1/2 packs);2 to 5 cigarettes per day;6 to 15 cigarettes per day (about 1/2 pack);Less than one cigarette per day;More than 35 cigarettes per day (about 2 packs or more);Unknown,16 to 25 cigarettes per day (about 1 pack);1 cigarette per day;26 to 35 cigarettes per day (about 1 1/2 packs);2 to 5 cigarettes per day;6 to 15 cigarettes per day (about 1/2 pack);Less than one cigarette per day;More than 35 cigarettes per day (about 2 packs or more);Unknown,6;2;5;3;4;1;7;999,NA,NA,NA,"GENERAL:
Choose one. Response is obtained from participant/ subject, family member, friend, or chart/ medical record.
-----
SCI:
Only answer if former or current smoker.  If average number of cigarettes is unknown then code 999 (999 = Unknown).
-----
FA:
Skip if cigarettes is NOT an answer to ""Tobacco Product Used Type.""   Choose one. Response is obtained from participant/ subject, family member, friend, or chart/ medical record.
-----
STROKE:
History can be obtained from participant/ subject, family member, friend, or chart/ medical record.
-----
MS:
Record average number of cigarettes currently smoked a day. Only answer if former or current smoker.   Choose one. Response is obtained from participant/ subject, family member, friend, or chart/ medical record.",SCI Variable: NOCIGRTS,Average number of cigarettes smoked per day,NA,"FA:
PhenX Toolkit: https://www.phenxtoolkit.org/index.php -  Protocol 1: Tobacco - 30-Day Quantity and Frequency (Adolescent Protocol) #030801
-----
GENERAL:
PhenX Toolkit: https://www.phenxtoolkit.org/index.php -  Protocol 1: Tobacco - 30-Day Quantity and Frequency (Adolescent Protocol) #030801
-----
MS:
PhenX Toolkit: https://www.phenxtoolkit.org/index.php -  Protocol 1: Tobacco - 30-Day Quantity and Frequency (Adolescent Protocol) #030801 For SCI: Biering-Sï¿½rensen F, Krassioukov A, Alexander MS, Donovan W, Karlsson AK, Mueller G, Perkash I, William Sheel A, Wecht J, Schilero GJ.International Spinal Cord Injury Pulmonary Function Basic Data Set. Spinal Cord. 2012 Jun; 50(6):418-21.
-----
SCI:
Biering-Sï¿½rensen F, Krassioukov A, Alexander MS, Donovan W, Karlsson AK, Mueller G, Perkash I, William Sheel A, Wecht J, Schilero GJ.International Spinal Cord Injury Pulmonary Function Basic Data Set. Spinal Cord. 2012 Jun; 50(6):418-21.
-----
STROKE:
PhenX Toolkit: https://www.phenxtoolkit.org/index.php - Protocol 1: Tobacco - 30-Day Quantity and Frequency (Adolescent Protocol) #030801",Adult and Pediatric,Participant/Subject History and Family History.General Health History,NA,NA,Participant/Subject History and Family History.General Health History,Participant/Subject History and Family History.General Health History,NA,NA,Participant/Subject History and Family History.General Health History,NA,NA,NA,NA,NA,N/A.N/A,NA,NA,Supplemental,NA,NA,NA,NA,NA,Supplemental,Supplemental,NA,NA,Supplemental,NA,NA,NA,NA,NA,Supplemental,NA,NA,Tobacco cigarettes smoked daily average count,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2014-04-01,2014-04-01,Published,NA,NA
TobcoPriorUseInd,BehavioralHistory,Tobacco prior use indicator,Common Data Element,1.4,"Indicator of the participant's/subject's past regular tobacco (e.g. cigarettes, cigars, chewing tobacco or pipe) use prior to the past 12 months","Indicator of the participant's/subject's past regular tobacco (e.g. cigarettes, cigars, chewing tobacco or pipe) use prior to the past 12 months",Alphanumeric,NA,Single Pre-Defined Value Selected,NA,NA,No;Unknown;Yes,No;Unknown;Yes,0;9;1,NA,NA,NA,"FA/GENERAL: Choose one. Response is obtained from participant/ subject, family member, friend, or chart/ medical record.
STROKE: History can be obtained from participant/ subject, family member, friend, or chart/ medical record.
MS/TBI: Choose one. Response is obtained by report of the participant/subject or proxy as soon as possible after visit/admission. Document when the behavioral history was collected so as to determine whether this information was obtained prior to study enrollment or later. Substance abuse directly before injury may have contributed to the incident causing injury. In general, substance abuse may indicate increased risk taking behavior.",NA,Is the family member of the participant/subject used tobacco in the past?,Medical_History,"MS/TBI: For TBI: Corrigan JD, Bogner J, Holloman C. Lifetime history of traumatic brain injury among persons with substance use disorders. Brain Inj. 2012;26(2):139-50.",Adult and Pediatric,Participant/Subject History and Family History.General Health History,Participant/Subject History and Family History.General Health History,NA,Participant/Subject History and Family History.General Health History,Participant/Subject History and Family History.General Health History,NA,NA,Participant/Subject History and Family History.General Health History,NA,NA,NA,NA,NA,NA,NA,NA,Supplemental,Supplemental,Supplemental,Supplemental,Supplemental,NA,Supplemental,Core,NA,NA,Supplemental,NA,NA,NA,NA,NA,NA,NA,NA,Tobacco prior use indicator,NA,NA,NIH/NINDS,NINDSCDE,NINDSCDE@emmes.com,NA,NA,NIH/NINDS,NINDSCDE,NINDSCDE@emmes.com,2014-04-01,2016-06-15,Published,NA,NA
TobcoProdctUsedTypPDBP,BehavioralHistory,Tobacco product used type,Unique Data Element,1,"Type of tobacco product (e.g. cigarettes, cigars, chewing tobacco or pipe) used by the participant/subject","Type of tobacco product (e.g. cigarettes, cigars, chewing tobacco or pipe) used by the participant/subject",Alphanumeric,255,Free-Form Entry,NA,NA,"Chewing tobacco;Cigars;Filtered cigarettes;Low tar cigarettes;Non-filtered cigarettes;Other, specify;Pipes","Chewing tobacco;Cigars;Filtered cigarettes;Low tar cigarettes;Non-filtered cigarettes;Other, specify;Pipes",;;;;;;,NA,NA,NA,"Choose all that apply. Response is obtained from participant/ subject, family member, friend, or chart/ medical record.
",NA,NA,NA,NA,Adult and Pediatric,NA,NA,Participant/Subject History and Family History.Epidemiology/Environmental History,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2014-04-09,2014-04-09,Published,NA,NA
TobcoRcntUseIndPDBP,BehavioralHistory,Tobacco recent use indicator,Unique Data Element,1,"Indicator of the participant's/subject's current regular tobacco (e.g. cigarettes, cigars, chewing tobacco or pipe) use within the past 12 months",Participant tobacco use (current)  indicator,Alphanumeric,NA,Single Pre-Defined Value Selected,NA,NA,No;Unknown;Yes,No current use of  tobacco;Current use of tobacco reported as unknown;Current regular use of tobacco,0;9;1,NA,NA,NA,NA,NA,NA,NA,NA,Adult and Pediatric,NA,NA,Participant/Subject History and Family History.Epidemiology/Environmental History,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2014-04-09,2014-04-09,Published,NA,NA
TobcoUseCurntInd,BehavioralHistory,Tobacco current use indicator,Common Data Element,1.4,"Indicator for whether the participant/subject regularly uses tobacco products (e.g. cigarettes, cigars, chewing tobacco or pipe) at the present time.","Indicator for whether the participant/subject regularly uses tobacco products (e.g. cigarettes, cigars, chewing tobacco or pipe) at the present time.",Alphanumeric,NA,Single Pre-Defined Value Selected,NA,NA,No;Unknown;Yes,No;Unknown;Yes,0;9;1,NA,NA,NA,"FA/GENERAL/MS/TBI: Choose one. Response is obtained from participant/ subject, family member, friend, or chart/ medical record. Add date stamp for when assessed. Recommend collection at least on date of TBI.
STROKE: History can be obtained from participant/ subject, family member, friend, or chart/ medical record.

",NA,Is the family member of the participant/subject currently using  tobacco?,Medical_History,"MS/TBI: Corrigan JD, Bogner J, Holloman C. Lifetime history of traumatic brain injury among persons with substance use disorders. Brain Inj. 2012;26(2):139-50.",Adult and Pediatric,Participant/Subject History and Family History.General Health History,Participant/Subject History and Family History.General Health History,NA,Participant/Subject History and Family History.General Health History,Participant/Subject History and Family History.General Health History,NA,NA,Participant/Subject History and Family History.General Health History,NA,NA,NA,NA,NA,NA,NA,NA,Supplemental,Supplemental,Supplemental,Supplemental,Supplemental,NA,Core,Core,NA,NA,Supplemental,NA,NA,NA,NA,NA,NA,NA,NA,Tobacco current use indicator,NA,NA,NIH/NINDS,NINDSCDE,NINDSCDE@emmes.com,NA,NA,NIH/NINDS,NINDSCDE,NINDSCDE@emmes.com,2014-04-01,2016-06-15,Published,NA,NA
TobcoUseStopAgeVal,BehavioralHistory,Tobacco use stopped age value,Common Data Element,1,"Age in years when participant/subject  stopped using tobacco products (e.g. cigarettes, cigars, chewing tobacco or pipe)","Age in years when participant/subject  stopped using tobacco products (e.g. cigarettes, cigars, chewing tobacco or pipe)",Numeric Values,NA,Free-Form Entry,0,120,NA,NA,NA,NA,NA,Year,"GENERAL:
History can be obtained from participant/ subject, family member, friend, or chart/ medical record.
-----
FA:
Skip if ""Tobacco use current indicator"" and ""Tobacco use past indicator"" are both ""NO""  History can be obtained from participant/ subject, family member, friend, or chart/ medical record.
-----
STROKE:
History can be obtained from participant/ subject, family member, friend, or chart/ medical record.  The age in years should be collected or N/A (Not applicable if subject never smoked) should be selected.
-----
MS:
History can be obtained from participant/ subject, family member, friend, or chart/ medical record.  The age in years should be collected or N/A (Not applicable if subject never smoked) should be selected.",NA,Age stopped tobacco use,NA,"FA:
No references available
-----
GENERAL:
No references available
-----
MS:
No references available
-----
STROKE:
No references available",Adult and Pediatric,Participant/Subject History and Family History.General Health History,NA,NA,Participant/Subject History and Family History.General Health History,Participant/Subject History and Family History.General Health History,NA,NA,Participant/Subject History and Family History.General Health History,NA,NA,NA,NA,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,NA,Supplemental,Supplemental,NA,NA,Supplemental,NA,NA,NA,NA,NA,NA,NA,NA,Tobacco use stopped age value,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2014-04-01,2014-04-01,Published,NA,NA
TobcoUseStrtAgeVal,BehavioralHistory,Tobacco use started age value,Common Data Element,1,"Age in years when participant/subject started using tobacco products (e.g. cigarettes, cigars, chewing tobacco or pipe)","Age in years when participant/subject started using tobacco products (e.g. cigarettes, cigars, chewing tobacco or pipe)",Numeric Values,NA,Free-Form Entry,0,120,NA,NA,NA,NA,NA,Year,"GENERAL:
History can be obtained from participant/ subject, family member, friend, or chart/ medical record.
-----
FA:
Skip if ""Tobacco use current indicator"" and ""Tobacco use past indicator"" are both ""NO""  History can be obtained from participant/ subject, family member, friend, or chart/ medical record.
-----
STROKE:
History can be obtained from participant/ subject, family member, friend, or chart/ medical record.  The age in years should be collected or N/A (Not applicable if subject never smoked) should be selected.
-----
MS:
History can be obtained from participant/ subject, family member, friend, or chart/ medical record.",NA,Age started tobacco use,NA,"FA:
No references available
-----
GENERAL:
No references available
-----
MS:
No references available
-----
STROKE:
No references available",Adult and Pediatric,Participant/Subject History and Family History.General Health History,NA,NA,Participant/Subject History and Family History.General Health History,Participant/Subject History and Family History.General Health History,NA,NA,Participant/Subject History and Family History.General Health History,NA,NA,NA,NA,NA,NA,NA,NA,Supplemental,NA,NA,NA,NA,NA,Supplemental,Supplemental,NA,NA,Supplemental,NA,NA,NA,NA,NA,NA,NA,NA,Tobacco use started age value,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2014-04-01,2014-04-01,Published,NA,NA
UPDRStScaleSchEngDalLivScl,ModSchwabAndEnglandScale,Unified Parkinson's Disease Rating Scale (UPDRS) - Schwab England daily living scale,Common Data Element,1.2,Schwab and England Activities of Daily Living scale,Schwab and England activities of daily living scale as part of Unified Parkinson's Disease Rating Scale (UPDRS).,Numeric Values,NA,Single Pre-Defined Value Selected,NA,NA,0;0.1;0.2;0.3;0.4;0.5;0.6;0.7;0.8;0.9;1,"0% - Vegetative functions such as swallowing, bladder and bowel functions are not functioning. Bedridden;10% - Totally dependent, helpless. Complete invalid;20% - Nothing alone. Can be a slight help with some chores. Severe invalid;30% - With effort, now and then does a few chores alone or begins alone. Much help needed;40% - Very dependent. Can assist with all chores, but few alone;50% - More dependent. Help with half, slower, etc. Difficulty with everything;60% - Some dependency. Can do most chores, but exceedingly slowly and with much effort;70% - Not completely independent. More difficulty with some chores. Three to four times as long in some. Must spend a large part of the day with chores;80% - Completely independent in most chores. Takes twice as long. Conscious of difficulty and slowness;90% - Completely independent. Able to do all chores with some degree of slowness, difficulty and impairment. Might take twice as long. Beginning to be aware of difficulty;100% - Completely independent. Able to do all chores without slowness, difficulty or impairment. Essentially normal. Unaware of any difficulty",0;1;2;3;4;5;6;7;8;9;10,NA,NA,NA,No instructions available,UPDRS QVI. CDISC variables: QSORRES for QSTESTCD =UPD144,Schwab and England activities of daily living,UPDRS;CDISC,"PD:
Fahn S, Elton RL, Members of the UPDRS Development Committee. The Unified Parkinson's Disease Rating Scale.  In Fahn S, Marsden CD, Calne DB, Goldstein M, eds: Recent Developments in Parkinson's Disease, Vol. 2. Florham Park, NJ: Macmillan Healthcare Information, 1987. pp. 153 163, 293 304.",Adult,NA,NA,Outcomes and End Points.Motor Function,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Core,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,UPDRS QVI,NA,NA,NIH/NINDS,NINDSCDE,NINDSCDE@emmes.com,NA,NA,NIH/NINDS,NINDSCDE,NINDSCDE@emmes.com,2014-04-01,2020-02-05,Published,NA,NA
VitalSgnDateTime,Vital Signs,Vital signs date and time,Common Data Element,1,"Date (and time, if applicable and known) the vital signs and other body measurements were taken by indicating the month, day, and year for the date and am, pm, or 24 hour clock for time","Date (and time, if applicable and known) the vital signs and other body measurements were taken by indicating the month, day, and year for the date and am, pm, or 24 hour clock for time",Date or Date & Time,NA,Free-Form Entry,NA,NA,NA,NA,NA,NA,NA,NA,"GENERAL/HEADACHE:
Record the date vital signs are taken. The date/time should be recorded to the level of granularity known (e.g., year, year and month, complete date plus hours and minutes, etc.) and in the format acceptable to the study database.  Not every study will need to collect time and this field should be removed if not applicable
-----
SCI/MG/NMD/SMA/MS:
Record the date/time according to the ISO 8601, the International Standard for the representation of dates and times (http://www.iso.org/iso/home.html).  The date/time should be recorded to the level of granularity known (e.g., year, year and month, complete date plus hours and minutes, etc.).
-----
FA:
Record the date vital signs are taken. If the exact month/day is not known, some ""unknown"" convention should be used. Record the time vital signs are taken. If the exact time is not known, some ""unknown"" convention should be used. From study inception, specify the manner in which time will be collected. If a twelve hour clock is used, then AM or PM must be designated. If it is your institution's custom to use military time (24-hour clock), that designation will not be necessary.    Record the date/time according to the ISO 8601, the International Standard for the representation of dates and times (http://www.iso.org/iso/home.html).  The date/time should be recorded to the level of granularity known (e.g., year, year and month, complete date plus hours and minutes, etc.).
-----
ALS:
Record the date/time according to the ISO 8601, the International Standard for the representation of dates and times (http://www.iso.org/iso/home.html). The date/time should be recorded to the level of granularity known (e.g., year, year and month, complete date plus hours and minutes, etc.).   Record the date vital signs are taken. If the exact month/day is not known, some ""unknown"" convention should be used. Record the time vital signs are taken. If the exact time is not known, some ""unknown"" convention should be used. From study inception, specify the manner in which time will be collected. If a twelve hour clock is used, then AM or PM must be designated. If it is your institution's custom to use military time (24-hour clock), that designation will not be necessary.
-----
EPILEPSY:
Record the date vital signs are taken. Record the date/time according to the ISO 8601, the International Standard for the representation of dates and times (http://www.iso.org/iso/home.html).  The date/time should be recorded to the level of granularity known (e.g., year, year and month, complete date plus hours and minutes, etc.).
-----
STROKE:
Record the date/time according to the ISO 8601, the International Standard for the representation of dates and times (http://www.iso.org/iso/home.html).  The date/time should be recorded to the level of granularity known (e.g., year, year and month, complete date plus hours and minutes, etc.).  Record the date vital signs are taken.
-----
DMD:
Record the date vital signs are taken. If the exact month/day is not known, some ""unknown"" convention should be used. Record the time vital signs are taken. If the exact time is not known, some ""unknown"" convention should be used. From study inception, specify the manner in which time will be collected. If a twelve hour clock is used, then AM or PM must be designated. If it is your institution's custom to use military time (24-hour clock), that designation will not be necessary.","Data Sharing Instructions: When date/time data are prepared for aggregation or sharing they should be converted to the format specified by ISO 8601, YYYY-MM-DDThh:mm:ss.",Vital signs taken date and time,NA,"ALS:
No references available
-----
DMD:
No references available
-----
EPILEPSY:
No references available
-----
FA:
No references available
-----
GENERAL:
No references available
-----
HEADACHE:
No references available
-----
MG:
No references available
-----
MS:
Karlsson AK, Krassioukov A, Alexander MS, Donovan W, Biering-Sï¿½rensen F. International Spinal Cord Injury Skin and Thermoregulation Function Basic Data Set. Spinal Cord. 2012; 50(7):512-6.
-----
NMD:
No references available
-----
SCI:
Karlsson AK, Krassioukov A, Alexander MS, Donovan W, Biering-Sï¿½rensen F. International Spinal Cord Injury Skin and Thermoregulation Function Basic Data Set. Spinal Cord. 2012 Jan 31. [Epub ahead of print]
-----
SMA:
No references available
-----
STROKE:
No references available",Adult and Pediatric,Assessments and Examinations.Vital Signs and Other Body Measures,NA,NA,Assessments and Examinations.Vital Signs and Other Body Measures,Assessments and Examinations.Vital Signs and Other Body Measures,Assessments and Examinations.Vital Signs and Other Body Measures,NA,Assessments and Examinations.Vital Signs and Other Body Measures,Assessments and Examinations.Vital Signs and Other Body Measures,Assessments and Examinations.Vital Signs and Other Body Measures,Assessments and Examinations.Vital Signs and Other Body Measures,Assessments and Examinations.Vital Signs and Other Body Measures,NA,N/A.N/A,Assessments and Examinations.Vital Signs and Other Body Measures,Assessments and Examinations.Vital Signs and Other Body Measures,Supplemental,NA,NA,NA,NA,NA,Core,Core,Core,NA,Supplemental,Core,Core,Core,Core,NA,Supplemental,Supplemental,Supplemental,Vital signs date and time,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2014-04-01,2014-04-01,Published,NA,NA
WgtMeasr,Vital Signs,Weight measurement,Common Data Element,1.5,Measurement of participant's/subject's weight,Measurement of participant's/subject's weight,Numeric Values,NA,Free-Form Entry,0,1000,NA,NA,NA,NA,NA,Kilogram,"ALS/GENERAL/TBI/SCI/STROKE: Record the weight of the participant/subject. To be collected at the visit, not self-reported. Indicate whether weight was measured in  kilograms (kg) preferably,  or pounds (lbs.). Height and weight are commonly collected at the baseline visit. Depending on the study population and study intervention it may be appropriate to collect height and weight at subsequent study visits.  The suggested range is 0-500 kg or 0-1000 lbs. Add date stamp for when assessed. Recommend collection at least on date of TBI. Documentation of height and weight is motivated by two reasons: 1. the risk of (systemic) complications is greater in the presence of obesity; 2. body weight is important for calculating required doses of (study) medications.
","CDISC variable: Vital Signs Test Code (VSTESTCD), Units for Vital Signs Results (VSRESU), Vital Signs Test Name (VSTEST), WEIGHT",Weight measurement,Injury_History;CDISC;TRACK_TBI,No references available,Adult and Pediatric,Assessments and Examinations.Vital Signs and Other Body Measures,Assessments and Examinations.Vital Signs and Other Body Measures,Assessments and Examinations.Imaging Diagnostics,Assessments and Examinations.Vital Signs and Other Body Measures,Assessments and Examinations.Vital Signs and Other Body Measures,Assessments and Examinations.Vital Signs and Other Body Measures,NA,Assessments and Examinations.Vital Signs and Other Body Measures,Assessments and Examinations.Vital Signs and Other Body Measures,Assessments and Examinations.Vital Signs and Other Body Measures,Assessments and Examinations.Vital Signs and Other Body Measures,Assessments and Examinations.Vital Signs and Other Body Measures,NA,N/A.N/A,Assessments and Examinations.Vital Signs and Other Body Measures,Assessments and Examinations.Vital Signs and Other Body Measures;Outcomes and End Points.Assessing Comorbidities,Supplemental,Supplemental,Supplemental,Supplemental,Supplemental,Supplemental,Core,Core,Core,NA,Supplemental,Core,Core,Core,Core,NA,Supplemental,Core,Supplemental,Weight measurement. SCI Variable: WEIGHT,NA,NA,NIH/NINDS,NINDSCDE,NINDSCDE@emmes.com,NA,NA,NIH/NINDS,NINDSCDE,NINDSCDE@emmes.com,2014-04-01,2020-02-05,Published,NA,NA
